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Summary 
Huntington’s Disease (HD) is an autosomal dominant neurodegenerative disease 
caused by a CAG expansion on the HD gene on chromosome 4, which gives rise to an 
expanded polyglutamine (polyQ) tract in the huntingtin protein. HD is characterised 
primarily by motor abnormalities, but is also commonly associated with cognitive 
impairments and psychiatric disturbances.  
Huntingtin (HTT) dynamically shuttles between subcellular compartments, however 
the mutant huntingtin protein (mHTT) is mislocalised to cell nuclei, where it may 
interfere with nuclear functions, such as transcription. The phosphorylation of HTT has 
been implicated with the regulation of its subcellular localisation; however the 
mechanism by which the mislocalisation of mHTT occurs is currently unknown.  
The localisation of HTT in an immortalised embryonic striatal cell model of HD 
(StHdhQ111) was identified as being more nuclear with a longer polyQ length. 
Additionally, stimulation of StHdhQ111 lines with a panel of growth factors alters the 
apparent subcellular localisation of HTT in a polyQ length-dependent manner. 
Aberrant kinase responses to growth factor stimulation were identified by ELISA assay. 
Inhibition of AKT1 and MEK1 phosphorylation indicated that their activation may be 
involved in mHTT mislocalisation and immediate-early gene expression. 
Transcriptional dysregulation is a characteristic feature of HD pathogenesis that may 
be directly influenced by HTT localisation. Microarray analysis of differential gene 
expression responses to growth factor stimulation uncovered a potential role for 
SMAD transcription factor activity and the transforming growth factor-β pathway in HD 
pathogenesis. Primary embryonic striatal cells from the HdhQ111 and HdhQ150 mouse 
models of HD showed similarities to the StHdhQ111 cell model in terms of HTT 
localisation, kinase signalling and gene expression.  
Cellular dysfunction may therefore be an early HD phenotype that is present from 
embryogenesis, and potentially alters HD development and progression; aberrant 
control of kinase signalling may regulate mHTT mislocalisation, which in turn 
modulates transcriptional dysregulation and contributes to HD pathogenesis. 
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Chapter 1: General introduction 
 
1.1 Background to HD 
 1.1.1      Historical background 
In 1872, George Huntington provided the first comprehensive description of a 
‘hereditary chorea’; his detailed and vivid description meant that this disorder would 
later become known as ‘Huntington’s Disease’ (HD). The inheritance of HD was 
subsequently found to be autosomal dominant (Hayden 1981), and the disease gene 
was localised to chromosome 4p16.3 (Gusella et al. 1983). However, it wasn’t until 
1993 that the HD gene itself (IT15) was identified, and the polymorphic expansion of a 
trinucleotide ‘CAG’ repeat on the 5’ end of the gene was recognised as the genetic 
cause of HD (HDCRG 1993). CAG repeat lengths found in the unaffected general 
population are between 9 - 39, although individuals suffering from HD have been 
found to have CAG expansions of between 35 – 86 repeats with a median repeat size 
of around 46. However, expansions over 100 CAG repeats have also been identified in 
rare cases (De Rooij, De Koning Gans, Skraastas et al. 1993; Duyao et al. 1993; HDCRG 
1993; Nørremølle et al 1993; Read 1993; Snell et al.1993; Rubinsztein et al. 1996).  
The detection of the gene was largely aided by the discovery of large HD-affected 
families in the Lake Maracaibo region of Venezuela by Dr. Americo Negrette in 1955 
(Okun & Thommi 2004), who were consequently a rich source of genetic information 
following a sustained and intensive collaborative research effort (Wexler 1995; Wexler 
2012). Since its discovery, there has been a plethora of research that has aimed to fully 
characterise the HD gene and its function, and to develop effective interventions and 
treatments for HD. However, despite knowing the genetic basis for HD, the causal 
sequence leading to manifestation of the disease still remains unclear. 
 1.1.2 Clinical phenotypes 
HD is characterised primarily by motor disturbances, but is commonly accompanied by 
cognitive impairments and psychiatric abnormalities (Buckley et al. 2010; Myers et al. 
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1985; Martin et al. 1986; Folstein 1989; Vonsattel & DiFiglia 1998; Novak & Tabrizi 
2010; Wexler 2012). HD noticeably manifests in the third to fourth decades of life, with 
the average age of onset being around 40 years (Novak & Tabrizi 2010). However, 
there is a substantial spread in the age of onset; this ranges from 2 to over 80 years 
old, with CAG repeat length accounting for only 40-70% of this variability (Hayden 
1981; HDCRG 1993; Kremer et al. 1993; Novak & Tabrizi 2010; Wexler 2012). Despite 
being a monogenic, autosomal dominant disease, there is a wide range of severity and 
rates of progression following disease onset (MacMillan et al. 1993), and individuals 
may live with HD for 10-20 years before death (Vonsattel & DiFiglia 1998). 
  1.1.2.1 Motor symptoms 
Involuntary choreiform movements are among the most common motor abnormalities 
that occur in HD, and become progressively more severe with time (Myers et al. 1985; 
Vonsattel & DiFiglia 1998; Bates & Murphy 2002; Buckley et al. 2010). This may also be 
accompanied by incoordination, motor impersistence and slow saccadic eye 
movements (Reiner et al. 1988; Reilmann et al. 2001; Walker 2007), as well as difficulty 
maintaining gaze and a lack of balance (Bates & Murphy 2002). Despite the prevalence 
of chorea in HD patients, it may not be a suitable marker for the severity of 
progression (Young et al. 1986; Mahant et al. 2003); in many cases, the incidence of 
chorea may be transient, or it may not develop in patients at all. In later stages of the 
disease, patients can also develop rigidity and dystonia, which make the chorea appear 
less prominent (Berardelli et al. 1999; Squitieri et al. 2000). In addition, some 
individuals experience an atypical onset of HD motor phenotypes, such as 
Parkinsonism, ataxia and dystonia, as well as bradykinesia and rigidity (Berardelli et al. 
1999; Squitieri et al. 2000); these patients tend to have larger CAG repeat lengths and 
an earlier age of onset, and these atypical onsets have been associated with a more 
severe course of progression (Squitieri et al. 2000).   
  1.1.2.2 Cognitive symptoms 
Cognitive impairments may also be present as early as during the prodromal stages of 
HD (Kirkwood et al. 2000; Ho et al. 2003; Holl et al. 2013), and tend to worsen 
following motor symptom onset (Stout et al. 2001; Campbell et al. 2004; Buckley et al. 
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2010; Novak & Tabrizi 2010).  For example, individuals with HD often experience a 
deficit in executive function, such as a decreased ability for organisation and planning, 
and have delayed acquisition of learning new tasks (Crauford & Snowden 2002; 
Folstein 1989; Novak & Tabrizi 2010). In addition, their performance on the Stroop test 
(a measure of prepotent response inhibition) and verbal fluency are impaired from 
early disease development (Holl et al. 2013), and impairments of risky decision making, 
as measured by the Iowa gambling task, may also worsen with disease progression 
(Stout et al. 2001; Campbell et al. 2004). Many individuals may also develop problems 
with working memory and emotion recognition (Tabrizi et al. 2009; Duff et al. 2010; 
Stout et al. 2011; Labuschagne et al. 2013). These cognitive and emotional deficits can 
be some of the most concerning for patients, and can be highly disruptive to their 
general ability to function, independent of motor impairments (Rothlind et al. 1993).  
  1.1.2.3 Psychiatric symptoms 
Emotional, behavioural and psychiatric disturbances are common in HD, and their 
development often precedes, and are more distressing than, motor symptoms (Myers 
et al. 1985; Martin et al. 1986; Dimaio et al. 1993; Rothlind et al. 1993; Klöppel et al. 
2010; Novak & Tabrizi 2010; Labuschagne et al. 2013). These changes typically include 
increased irritability, forgetfulness, and anxiety (Folstein 1989; Klöppel et al. 2010).  
Depressive symptoms are estimated as affecting as many as 33-69% of HD sufferers 
(Paulsen et al. 2008; Novak & Tabrizi 2010; Wexler 2012; Chisholm et al. 2013), and 
this has been associated with an increased suicide rate in individuals with HD; suicide 
was identified as a major feature of the illness by George Huntington in 1872, and the 
risk of attempting suicide in HD populations has been estimated to be between 5-10 
times higher than in the general population (Schoenfeld et al. 1984; Dimaio et al. 1993; 
Robins Wahlin et al. 2000; Baliko et al. 2004). The largest proportion of those either 
attempting suicide or with suicidal ideation in the HD population were in the very early 
stages of the disease, or were gene carriers approaching the threshold for diagnosis 
(Schoenfeld et al. 1984; Paulsen et al. 2005). Other severe psychiatric conditions that 
may also develop in HD-affected individuals include hallucinations, delusions, paranoia 
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and obsessive-compulsive behaviour, although these are less common (Novak & 
Tabrizi 2010; Wexler 2012).  
  1.1.2.4 Monitoring progression 
In order to monitor the progression of HD in individuals, both prior to and following 
diagnosis, the Unified Huntington’s Disease Rating Scale (UHDRS) was developed to 
assess the clinical features of HD (Huntington Study Group 1996). The scale includes 
quantifiable measures of motor, cognitive, behavioural and functional components 
within the HD phenotype; further details of which can be found in Table 1.1.  
Motor Assessment 
 
Cognitive Assessment 
 
Behavioural Assessment 
  Ocular pursuit 
 
Verbal fluency test 
 
Sad/Mood 
Saccade initiation 
 
Symbol digit modalities test 
 
Low self esteem 
Saccade velocity 
 
Stroop interference test 
 
Anxiety 
Dysarthria 
   
Suicidal thoughts 
Tongue protrusion 
 
Functional Capacity 
 
Disruptive or aggressive 
behaviour 
Maximal dystonia (trunk 
and extremities) 
  
Irritable behaviour 
Maximal chorea (face, 
mouth, trunk and 
extremities) 
 
Occupation 
 
Obsessions 
Retropulsion pull test 
 
Finances 
 
Compulsions 
Finger taps 
 
Domestic chores 
 
Delusions 
Pronate/supinate hands 
(right and left) 
 
Activities of daily living 
 
Hallucinations 
Luria (fist-hand-palm test) 
 
Care level 
 
I: Confused? 
Rigidity (arms) 
   
I: Demented? 
Bradykinesia (body) 
   
I: Depressed 
Tandem walking 
   
I: Require 
pharmacotherapy for 
depression? 
Gait 
    
 
     
 
Table 1.1 Continued on next page 
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Functional Assessment  Independence Scale 
 
Can the subject… 
 
100 No special care needed 
Engage in gainful employment 
in accustomed work? 
 
90 
No physical care needed if difficult tasks are 
avoided 
Engage in any gainful 
employment? 
 
80 
Pre-disease level of employment changes or 
ends, cannot perform chores to pre-disease 
level, may need help with finances 
Engage in any volunteer work? 
 
70 
Self-care maintained for bathing, limited 
household duties, driving terminates, unable 
to manage finances 
Manage finances? 
 
60 
Needs minor assistance in dressing, 
toileting, bathing, food must be cut 
Shop for groceries without 
help? 
 
50 
24-hour supervision, assistance required for 
bathing, eating, toileting 
Handle money in cash 
transactions? 
 
40 
Chronic care facility needed, limited self-
feeding, liquefied diet 
Supervise children without 
help? 
 
30 
Patient provides minimal assistance in own 
feeding, bathing, toileting 
Operate an automobile safely? 
 
20 No speech, must be fed 
Do housework without help? 
 
10 Tube fed & bed care 
Do laundry without help? 
   Prepare meals without help? 
   Use the telephone without 
help? 
   Take medication without help? 
   Feed themselves without help? 
   Dress themselves without 
help? 
   Bathe themselves without 
help? 
 
  Use public transportation 
without help? 
   Walk within neighbourhood 
without help? 
   Walk without falling? 
   Walk without help? 
   Comb hair without help? 
   Transfer between chairs 
without help? 
   Get in and out of bed without 
help? 
   Use the toilet without help? 
   Care still be provided at home? 
    
Table 1.1 The unified Huntington’s disease rating 
scale (UHDRS) (Huntington Study Group 1996). 
Motor assessments are graded from 0 (normal) to 
4 (unable to complete task). The cognitive 
assessments are based on the raw scores from 
each test, and each point within the behavioural 
assessment is graded for severity (0 = Absent – 4 = 
severe) and frequency (0 = almost never – 4 = 
almost always).  The last four points prefixed ‘I:’ 
are based on the investigator’s opinion of the 
subject’s behaviour. Functional capacity is graded 
from 0 (unable/total care) to 3 (normal), and 
functional assessment requires yes/no responses. 
The most accurate level reflecting the subject’s 
independence is selected from the independence 
scale. 
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More recently, a battery of tests has been assembled that is more sensitive to the 
development of subtle HD phenotypes in the prodromal stages of the disease prior to 
a formal diagnosis, and in early stages of progression, in order to provide reliable 
measures for clinical trial end points (Tabrizi et al. 2012; Tabrizi et al. 2013). 
Progression can be ascertained by the monitoring of fine motor skills, such as speeded 
finger tapping (Bechtel et al. 2010), as well as several measures of cognitive 
performance and the use of imaging techniques to assess brain atrophy; Table 1.2 
outlines the array of tests sensitive to early HD progression in this study (Tabrizi et al. 
2009; Tabrizi et al. 2011; Tabrizi et al. 2012; Tabrizi et al. 2013).  
 
Prodromal Early-HD 
Neuroimaging measures 
Whole brain atrophy     
Ventricular expansion    
Caudate atrophy     
Putamen atrophy     
White matter atrophy     
Grey matter atrophy     
Cognitive measures 
Symbol digit modality 
test     
Stroop test     
Emotion recognition     
UHDRS 
Motor assessment     
Functional capacity    
Quantitative motor measures 
Chorea position index     
Chorea orientation 
index     
Grip force variability     
Speed-tapping tap 
duration     
Speed-tapping inter-tap 
interval     
Psychiatric measures 
Problem behaviours 
assessment, Apathy     
 
   
Table 1.2 HD assessment measures utilised in the TRACK-HD study (Tabrizi et al. 
2012; Tabrizi et al. 2013) that exhibited significant progression compared to controls 
in prodromal and/or early stage HD individuals over a period of 24-36 months. 
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  1.1.2.5 Peripheral symptoms 
The progression of HD is also associated with a variety of peripheral effects; one of the 
most marked is weight loss, often despite an increased appetite and an increase in 
calorie intake (Farrer & Meaney 1985; Morales et al. 1989; Pratley et al. 2000; Robbins 
et al. 2006; Aziz et al. 2008; van der Burg et al. 2009). A higher body weight has been 
associated with slower progression (Myers et al. 1991), and the extent of weight loss 
has been correlated with CAG repeat length (Aziz et al. 2008). Even in the very early 
stages of disease, the body mass index (BMI) of HD patients tends to be lower than in 
matched controls (Djoussé et al. 2002). This weight loss has been attributed to 
metabolic effects (Mochel et al. 2007; Goodman et al. 2008), including higher 
sedentary energy expenditure (Pratley et al. 2000). Many other peripheral symptoms 
are also characteristic of HD, including osteoporosis (Bonelli et al. 2002), skeletal 
muscle wasting (Ribchester et al. 2004), cardiac failure (Lanska et al. 1988), 
gastrointestinal abnormalities (van der Burg et al. 2009), and increased immune 
activation (Dalrymple et al. 2007; Bjorkqvist et al. 2008); all of which significantly 
contribute to the poor quality of life of individuals with HD, as well as to morbidity and 
mortality (van der Burg et al. 2009).  
  1.1.2.6 CAG repeat length and age of onset 
A correlation between CAG repeat length and age of onset has been consistently 
identified in the literature (Andrew et al. 1993; De Rooij, De Koning Gans, Skraastas et 
al. 1993; Telenius et al. 1993; Lee et al. 2013), however for any repeat number there is 
a wide range of associated onset ages (MacMillan et al. 1993). However, under-
representative sampling, such as the omission of individuals with 36-39 repeats who 
don’t develop HD within their lifetime, and the use of inappropriate statistical analyses 
may have biased the current literature to over-estimate the risk associated with lower 
CAG expansions (Langbehn et al. 2010), making this correlation of limited clinical 
relevance. For repeat lengths of 40-50 CAGs, which is the range in which 90% of the 
world wide HD population lie, CAG repeat size accounts for only 40% of the variation of 
the age of onset (Wexler 2012). However, for juvenile HD, which is associated with 
much larger repeat sizes, this increases to 73%  of the variation (Kremer et al. 1993). In 
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contrast, when the age of onset is higher than 60 years of age, there is no correlation 
with CAG repeat length (Kremer et al. 1993). In some cases, individuals with only 34 
CAG repeats have developed HD, whereas other individuals have been found to have 
up to 39 repeats and remain unaffected (Rubinsztein et al. 1996; DiFiglia & Lombroso 
2000); although the exact mechanisms contributing to the differences in penetrance 
are unknown, much of the variance has been found to be heritable, supporting the 
existence of genetic modifiers (Langbehn et al. 2010; Lee et al. 2012). However, the 
contribution of several of these modifying genes has failed to be replicated in large HD 
cohorts (Ramos et al. 2013; Lee et al. 2012), although population stratification and 
differences in genetic ancestry may be critical factors that contribute to the 
investigation of disease modifying genes, and that influence age of onset (Ramos et al. 
2012). 
  1.1.2.7 Juvenile HD 
In 1-10% of cases, HD can manifest before 20 years of age (Hayden 1981), which is 
known as juvenile HD. Juvenile HD is associated with considerably longer CAG repeat 
lengths, typically of around 60 or more (Douglas et al. 2013), although it has been 
found to manifest with a repeat expansion as low as 48 (Ribai et al. 2007); the largest 
expansion that has been identified was 250 CAG repeats, with an age of onset of just 
2.5 years of age (Nance et al. 1999). Similar to adult HD, it is often behavioural and 
psychiatric disturbances that manifest prior to motor abnormalities, sometimes by a 
matter of years (Duesterhus et al. 2004). This can include depression, changes in 
conduct and personality, school performance decline, as well as isolation and 
aggression (Hayden 1981; Rasmussen et al. 2000; Duesterhus et al. 2004). Unlike adult 
HD, juvenile HD does not usually manifest with chorea, and has a higher incidence of 
bradykinesia, dystonia and rigidity as the initial motor manifestations (Jervis 1963; 
Vandjik et al. 1986; Rasmussen et al. 2000; Ribai et al. 2007). There is an increased 
incidence of seizures, myoclonus and epilepsy (Rasmussen et al. 2000; Douglas et al. 
2013). In addition, juvenile HD may have a more rapid and severe rate of progression 
than adult HD (Hayden 1981).  
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  1.1.2.8 Late onset HD 
In contrast, 10-25% of HD cases are considered as ‘late onset’ HD (Davenport & 
Muncey 1916; Kremer et al. 1993), in whom symptom onset does not occur until after 
50 years of age (Kremer et al. 1993). The progression of symptoms tends to be slower, 
with milder chorea and less prominent intellectual decline (Hayden 1981; Faught et al. 
1983; Myers et al. 1985; Kremer et al. 1993). In cases where there is a CAG repeat 
length >39, it is unknown what the protective mechanism may be that delays symptom 
onset. However, there are limited cases of individuals who develop HD as late as 65 
years of age, but carry only intermediate CAG repeat lengths of 30 - 31 (Groen et al. 
2010); late symptom development at these lengths is consistent with the negative 
correlation of CAG repeat size and age of onset. As the HD gene is not fully penetrant 
at these lengths, there must be additional contributing factors that lead to the 
development of the HD phenotype in these individuals. For these rare cases, there are 
therefore implications for the diagnosis and management of HD, as well as 
requirements for family genetic counselling in case of CAG instability and expansion 
(Groen et al. 2010). 
  1.1.2.9 Homozygous HD carriers 
The majority of HD cases are heterozygous for the HD gene, and therefore individuals 
carry one allele with a CAG repeat in the non-pathogenic range. However, there are 
some very rare cases of individuals that are homozygous for the HD gene. No 
difference in the age of onset has been identified in these people compared to those 
carrying a single expanded CAG repeat. However, despite initial reports suggesting no 
HD gene dosage effect (Wexler et al. 1987), it has been suggested that there may be a 
more rapid decline in motor, cognitive and behavioural symptoms in HD homozygotes 
compared to heterozygous individuals, and they may reach severe disability in a 
shorter time frame (Squitieri 2003). In concordance with the more severely 
progressing heterozygote phenotypes, 50% of homozygous individuals present with 
non-choreiform motor abnormalities at symptom onset (Squitieri et al. 2000; Squitieri 
2003). 
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 1.1.3 Neuropathological features 
  1.1.3.1 Gross neuropathology 
There is evidence for widespread neuropathology in HD brain, by both post-mortem 
examination and in vivo imaging techniques (Scahill et al. 2013). The areas that exhibit 
the most prominent cell loss and astrogliosis are the caudate and putamen (Lange et 
al. 1976; Vonsattel et al. 1985; Roos et al. 1986; Vonsattel & DiFiglia 1998), which was 
the basis for the original 5 stage grading system of HD progression (Vonsattel et al. 
1985); the extent of this atrophy has been found to be a function of CAG repeat length 
and age of death (Furtado et al. 1996; Penney et al. 1997). Atrophy of the striatum has 
also been found to begin prior to overt symptom onset by magnetic resonance imaging 
(MRI) (Harris et al. 1999; Aylward et al. 2004; Ciarmiello et al. 2006). In addition to 
caudate and putaminal atrophy, there is also widespread degeneration of cortical 
structures (Rosas et al. 2003; Rosas et al. 2005; Rosas et al. 2008) such as the angular 
gyrus in the parietal lobe (Macdonald et al. 1997; MacDonald & Halliday 2002), as well 
as of subcortical brain regions such as the hypothalamus (Kremer et al. 1991; Heinsen 
et al. 1999; Politis et al. 2008), globus pallidus, subthalamic nucleus, substantia nigra 
and hippocampus (Spargo et al. 1993; Vonsattel & DiFiglia 1998). 
The development of imaging techniques, such as functional magnetic resonance 
imaging (fMRI) and diffusion tensor imaging (DTI) has allowed the development of in 
vivo quantitative measurement of HD brain atrophy, which can also be associated with 
disease progression and symptom severity. Imaging data has confirmed that there is a 
loss of striatal volume, and a consequent increase in the volume of the lateral 
ventricles (Aylward et al. 1997; Aylward et al. 2004; Hobbs et al. 2009; Tabrizi et al. 
2009; Tabrizi et al. 2011; Tabrizi et al. 2012; Tabrizi et al. 2013), and that this atrophy 
can begin up to 11 years prior to estimated symptom onset in the caudate, and 9 years 
in the putamen (Aylward et al. 2004; Paulsen et al. 2004; Kipps et al. 2005; Tabrizi et al. 
2012). In addition to striatal volume loss, there is also global brain atrophy (Thieben et 
al. 2002; Henley et al. 2009; Squitieri et al. 2009; Tabrizi et al. 2012) and cortical 
thinning (Rosas et al. 2002; Rosas et al. 2005; Nopoulos et al. 2010); these structural 
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losses have consequently been correlated with the clinical phenotype (Rosas et al. 
2005; Henley et al. 2008; Rosas et al. 2008).  
Global grey and white matter loss has also been identified in HD patient brains, and 
this atrophy has been correlated with performance on motor, oculomotor and 
emotion recognition tasks (Scahill et al. 2013). For example, the extent of the loss in 
the occipital and frontal lobes is correlated with anti-saccadic error rates (Scahill et al. 
2013); cortical thinning is associated with visuomotor impairment (Rosas et al. 2008); a 
reduction in white matter integrity is correlated with tongue force coordination 
(Dumas et al. 2012), and bilateral atrophy of the caudate and putamen can be 
associated with worsened tapping precision (Scahill et al. 2013). The use of white and 
grey matter measures as markers for disease progression has also been proposed; the 
atrophy of each follows distinct patterns leading up to the estimated age of onset 
(Squitieri et al. 2009). However, the volume of cerebral spinal fluid (CSF) has also been 
suggested as a useful biomarker due to the linear increase in volume with disease 
progression, which strongly relates to age of onset predictions (Squitieri et al. 2009). 
  1.1.3.2 Cellular pathogenesis 
The GABAergic medium spiny neurons (MSNs) within the striatum are most vulnerable 
to degeneration in HD, whereas cholinergic medium aspiny interneurons are relatively 
spared until the late stages of disease (Ferrante et al. 1985; Ferrante et al. 1987; Reiner 
et al. 1988; Vonsattel et al. 2008). Within the MSN population, there also appears to 
be certain subsets of neurons that are more vulnerable to degeneration than others 
(Figure 1.1); enkephalin containing neurons that project to the external segment of the 
globus pallidus showed increased cell death compared to substance-P containing 
neurons projecting to the internal pallidal segment (Reiner et al. 1988). However, 
substance-P containing neurons with afferents to the substantia nigra pars compacta 
were more resistant to cell death than those with afferents to the substantia nigra pars 
reticular until the late stages of disease (Reiner et al. 1988).  
Within the cortex, loss of volume initially develops in posterior cortical regions during 
early stages of the disease, such as the middle occipital and middle temporal lobes, as 
well as the angular and supramarginal gyri (Rosas et al. 2002). With disease 
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progression, loss of volume extends to more anterior cortical regions, until the frontal 
lobes are also severely affected (Rosas et al. 2002). Cortical pyramidal neurons within 
the middle to deep layers (layers III, V and VI) are the most susceptible to degeneration 
(Cudkowicz & Kowall 1990; Hedreen et al. 1991; MacDonald & Halliday 2002).  Brain 
derived neurotrophic factor (BDNF) production occurs largely within cortical cells, and 
is transported to striatal cells via corticostriatal afferents (Baquet et al. 2004); 
degeneration of both cortical cells and corticostriatal afferents during HD progression 
therefore reduces the amount of BDNF available in the striatum and contributes to 
striatal cell death (Zuccato & Cattaneo 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Globus pallidus 
Internal 
external 
Substantia nigra 
Pars compacta 
Pars reticular 
Caudate & 
Putamen 
 Cortex 
Figure 1.1 Simplified cartoon showing the differentially affected MSNs in HD 
pathogenesis. The orange arrow depicts enkephalin-containing neurons, and the 
blue arrows represent substance-P containing neurons. In early and middle stages 
of HD, MSNs projecting to the external segment of the globus pallidus and 
substantia nigra pars reticular are lost at a greater rate (dashed arrows). MSNs 
projecting to the substantia nigra pars compacta and internal globus pallidus are 
most resistant to degeneration (solid arrows) (Reiner et al. 1988). 
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  1.1.3.3 Molecular pathogenesis 
It is highly likely that dysfunction occurs before death in HD-affected neuronal cells 
(Levine et al. 2004). Neuronal intranuclear inclusions (NIIs) are a characteristic feature 
of HD that are apparent prior to symptom onset (Gomez-Tortosa et al. 2001); N-
terminal fragments of the huntingtin protein (HTT) containing the expanded 
polyglutamine (polyQ) stretch is translated from the elongated CAG repeat and 
aggregates within cell nuclei. However, these have been found to occur in only 3-6% of 
cortical neurons in post-mortem adult HD brain, although they are more frequent (38-
52% neurons) in juvenile HD brain (DiFiglia 1997). These inclusions are also present in 
MSNs, but not in the globus pallidus or cerebellum (DiFiglia 1997). NII presence has 
been correlated with neuropathological severity (Davies et al. 1997; DiFiglia 1997); for 
example, preventing the clearance of the mutant protein may enhance cellular toxicity 
(Tsvetkov et al. 2013). However, it has also been asserted that NIIs may be protective 
against mutant HTT (mHTT) toxicity and cell death (Saudou et al. 1998; Gutekunst et al. 
1999; Kuemmerle et al. 1999; Arrasate et al. 2004); the concentration of the diffuse 
form of mHTT has been found to more closely correlate with cell death than NII 
formation (Arrasate et al. 2004), and thus sequestration into aggregates may be a 
compensatory strategy to reduce the availability of soluble toxic mHTT species within 
the cell. 
NIIs were found to be disproportionately present in interneurons that tend to be 
spared during striatal degeneration, compared to the more vulnerable MSN population 
(Kuemmerle et al. 1999). In addition, smaller neuropil and cytoplasmic inclusions were 
present in more than 50% of the striatal cell population that are resistant to mHTT 
insult, whereas they were present in only 4% of MSNs (Kuemmerle et al. 1999), 
supporting the assertion that aggregation pathology does not correspond to disease 
severity (Gutekunst et al. 1999; Kuemmerle et al. 1999; Arrasate et al. 2004).  
In addition to NII pathology, early stages of HD progression exhibit a diphasic pattern 
of dendritic alterations (Ferrante et al. 1991); initially, MSNs show proliferative 
dendritic activity, such as an increase in the number and size of dendritic spines, which 
may be indicative of a compensatory response in order to remodel degenerating 
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contacts (Ferrante et al. 1991). However by the severe grades of HD, there is dendritic 
swelling and marked spine loss, which is indicative of degenerative processes (Ferrante 
et al. 1991). Dystrophic neurites are also present in an uneven distribution throughout 
cortical layers V and VI, and are more prevalent in adult HD brain than juvenile (DiFiglia 
1997; Sapp et al. 1999). 
 1.1.4 Epidemiology and inheritance 
The incidence of HD is highest in European populations, where it affects 5-10 in 
100,000 people (Reiner et al. 1988; Sackley et al. 2011), although more recent 
estimates suggest an incidence as high as 12.3 per 100,000 people in the UK (Evans et 
al. 2013). The prevalence of HD is considerably lower in African and Asian populations, 
at 0.5 per 100,000 people (Takano et al. 1998; Harper 2002; Warby et al. 2011). This 
may be due to a higher frequency of larger CAG repeat alleles in white European 
populations that are more predisposed to expansion (Harper 2002). Additionally, 
European and East-Asian populations can be characterised by different HTT haplotypes 
that confer differential HD risk; cis-acting elements within each haplotype may 
therefore contribute to the instability of the CAG repeat and help to explain variations 
in HD prevalence between populations (Warby et al. 2011). 
Despite the dominant inheritance of the HD gene, there is a window of CAG repeat 
lengths where there is not complete penetrance of the HD phenotype; unaffected 
individuals up to the age of 95 years old with 36 - 39 CAG repeats have been identified 
(De Rooij, De Koning Gans, Losekoot et al. 1993; Goldberg et al. 1993; Rubinsztein et 
al. 1996); in contrast, there are also limited cases of individuals exhibiting HD 
phenotypes with CAG repeat lengths as low as 31-34 (Andrich et al. 2008; Groen et al. 
2010). In these cases, known HD phenocopies have been ruled out, although post-
mortem neuropathological examination has not yet been possible to confirm the HD 
diagnosis. Together, these cases suggest that within this intermediate repeat size 
range, there may be additional factors modulating HD penetrance, and may therefore 
also alter disease severity in the presence of longer repeats; these factors may also 
contribute to the variation in age of onset observed for all CAG repeat lengths. Over 39 
repeats, there appears to be complete penetrance (DiFiglia & Lombroso 2000).  
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The expanded CAG repeat has been found to be particularly unstable during parental 
transmission, with around 80% of inherited alleles undergoing an alteration in CAG 
repeat length (Duyao et al. 1993; Myers et al. 1993; Wheeler et al. 2007; Gonitel et al. 
2008). This instability is subject to both expansions (about 73% of events) and 
contractions (about 23% of events) (Djoussé et al. 2004; Wheeler et al. 2007). The 
more common CAG expansion events have contributed to the occurrence of 
‘anticipation’ in HD families; offspring inheriting the HD gene tend to have a lower age 
of onset in comparison to the affected parent (Ridley et al. 1988).  However, there is 
not a clear association between the degree of expansion and the extent of anticipation 
(Andrew et al. 1993). The majority of CAG expansions are paternally transmitted, and 
are associated with larger increases in CAG repeat length (Andrew et al. 1993; Duyao 
et al. 1993; Cannella et al. 2004). This expansion most likely occurs during 
spermatogenesis (MacDonald et al. 1993; Kremer et al. 1995; Ranen et al. 1995), as 
there is a high degree of CAG length mosaicism within patient spermatocytes, and 
repeats much larger than those found in patient lymphocytes have been identified in 
these cells (Duyao et al. 1993; MacDonald et al. 1993; Wheeler et al. 2007).  
It has been suggested that paternal transmission of the HD allele therefore also leads 
to a stronger anticipation effect, and therefore an earlier age of onset in offspring 
(Ridley et al. 1988; Roos et al. 1991; Farrer et al. 1992; Snell et al. 1993); in a Welsh 
cohort of HD-affected families, the anticipation of maternally transmitted HD alleles 
was on average 2.75 years, whereas for paternally transmitted alleles, this was 
significantly earlier at 9.11 years (Snell et al. 1993). However, this was not replicated in 
an Italian population, despite also identifying larger CAG expansions in paternally 
transmitted HD alleles (Cannella et al. 2004). Nevertheless, this supports the 
supposition that there are additional mechanisms contributing to the age of onset 
other than CAG repeat length. 
Due to the increased incidence of CAG expansion during gametogenesis in male 
germlines, both juvenile and sporadic forms of HD are also more highly associated with 
transmission of a paternal allele rather than with a maternal allele (Ridley et al. 1988; 
De Rooij, De Koning Gans, Skraastas et al. 1993; Goldberg et al. 1993; HDCRG 1993; 
Telenius et al. 1993; Cannella et al. 2004). Juvenile HD is associated with very large 
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CAG repeats, and age of onset can occur from as young as 2 years old (Hayden 1981; 
HDCRG 1993); 70-80% of juvenile HD cases are paternally transmitted, and this figure 
increases to 90% when considering an age of onset below 10 years (Telenius et al. 
1993; Cannella et al. 2004). Similarly, sporadic cases of HD have been found to arise 
from expansions in the paternal allele (Goldberg et al. 1993); in several families 
experiencing sporadic HD, the paternal allele was found to lie within the intermediate 
allele range of 36-39 CAG repeats in unaffected fathers (Goldberg et al. 1993), which 
had been expanded to the fully penetrant 41-42 repeats in their offspring (Myers et al. 
1993). The frequency of a new HD mutation is rare, but may be as high as 10% in some 
populations (Warby et al. 2011).  In European populations, the majority of HD cases 
share the same haplotype, of which two variants are most highly associated with CAG 
length instability (Warby et al. 2011), these particular ‘HD-haplotypes’ are therefore 
more prone to expansion, and account for many sporadic cases of HD (Myers et al. 
1993; Goldberg et al. 1995; Warby et al. 2011). 
 
1.2 The HTT gene 
 1.2.1 Expression  
The HTT gene is expressed widely throughout the body (Strong et al. 1993; DiFiglia et 
al. 1995; Sharp et al. 1995; Cattaneo et al. 2005), and is particularly enriched in 
neurons and testes (Strong et al. 1993; DiFiglia et al. 1995; Sharp et al. 1995; Ferrante 
et al. 1997; Cattaneo et al. 2005). Within the brain, HTT expression is higher in neurons 
than glial cells, and is most strongly expressed in the pyramidal neurons of cortical 
layers III and V that project to the striatum (Strong et al. 1993; Fusco et al. 1999), 
although there is no enrichment of its expression in the striatum itself (Sharp et al. 
1995). In peripheral tissues, although there is high HTT expression in testes, which is 
highest in immature spermatogonia (Strong et al. 1993), there are also high levels of 
expression in the liver, heart and lungs (Li et al. 1993; Landwehrmeyer et al. 1995). 
Two different HTT mRNA species have been identified; one is a 10.3kb transcript, 
which is expressed throughout peripheral tissues, and the other is a longer 13.7kb 
transcript with an extended untranslated region at the 3’ end of the mRNA sequence, 
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and is expressed in brain (Lin et al. 1993). These alternate transcripts are thought to be 
produced by differential polyadenylation sites on the 3’ end of the HTT mRNA, 
although the reason for this is yet to be elucidated (Lin et al. 1993). However, the 
presence of alternate transcripts may be a mechanism for the tissue specific 
degeneration observed in HD.  More recently, an alternatively spliced variant of HTT 
was also identified; in the presence of the expanded CAG repeat, serine/arginine-rich 
splicing factor 6 (SRSF6) binds to HTT and leads to a small polyadenylated exon1-
intron1 mRNA transcript, which is then translated into a small polyQ-containing N-
terminal fragment of the HTT protein (Sathasivam et al. 2013). This alternate 
processing of HTT expression may account for some of the observed differences in the 
subcellular localisation of the HTT protein. 
The expression of HTT has also been found to be altered by the presence of the 
expanded CAG; in lymphoblast cultures from heterozygote juvenile HD patients, the 
expression of the mutant HD gene was found to be relatively reduced in comparison to 
the ‘normal’ gene (Gutekunst et al. 1995; Persichetti et al. 1996). A similar observation 
has also been made in an immortalised embryonic striatal cell line model of HD 
(Pouladi et al. 2010) and in expanded CAG-transfected rat striatal cultures (J. Miller et 
al. 2010); however it has not been fully elucidated whether this reduction is truly a 
result of reduced transcription and mRNA processing, or to altered processing of the 
subsequent HTT protein.  
 1.2.2 Somatic mosaicism  
There is increasing evidence for the presence of somatic mosaicism in both models of 
HD, and in human HD tissues. Somatic expansion of the CAG repeat has been noted in 
liver, kidneys, stomach, blood and brain (Wheeler 1999; Ishiguro et al. 2001; 
Nørremølle et al. 2004); however, CAG repeat length exhibits the greatest variability in 
brain tissues (Telenius et al. 1994; Aronin et al. 1995; Giovannone et al. 1997; Kennedy 
et al. 2003; Shelbourne et al. 2007; Cannella et al. 2009). Although expansion of the 
CAG repeat has been observed in cortical neurons, the largest expansions have 
occurred within the striatum; expansions of up to 100 additional CAG repeats have 
been found in human HD striatal cells in comparison to other neuronal cells (Kennedy 
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et al. 2003; Shelbourne et al. 2007), and in pre-symptomatic HD gene carriers 
expansions of up to 200 CAG repeats were present (Kennedy et al. 2003). In contrast, 
late stage HD brain exhibits higher CAG instability in the cortex, implying that the early 
instability in striatal neurons is likely to lead to cell death before the end stage of the 
disease (Shelbourne et al. 2007). Somatic CAG instability has not been found to occur 
in the cerebellum (Ishiguro et al. 2001; Kennedy et al. 2003), and occurs to a larger 
extent in neurons than in glia (Shelbourne et al. 2007). CAG instability also has a 
greater tendency for expansion in the presence of initially larger CAG repeat lengths 
(Cannella et al. 2009).  Instability of the CAG repeat in somatic cells, particularly large 
expansions in striata that accumulate with disease progression (Shelbourne et al. 
2007), may be a mechanism by which cell-specific neurodegeneration occurs in HD, 
and therefore inhibiting CAG instability may be a therapeutic target. 
 
1.3 The HTT protein 
 1.3.1 Structure 
The HTT gene encodes for the ~348kDa protein HTT; to date, the high molecular 
weight of HTT has prevented the elucidation of a detailed structure of the full length 
protein, although it has been asserted that HTT forms a large α-helical solenoid (Seong 
et al. 2010). Therefore, much of the current work has focused on the structure and 
function of the polyQ containing N-terminus of HTT. Due to the wide variety of 
potential cellular functions with which HTT is associated, the polyQ stretch is thought 
to assume several dynamic and flexible conformations in a manner dependent on the 
required protein binding partners available, its subcellular localisation and cell type in 
order to regulate its many functions (Trettel et al. 2000; Wheeler 2000; Kim et al. 2009; 
Lotz et al. 2010; Seong et al. 2010; Zuccato et al. 2010; Długosz & Trylska 2011). N-
terminus HTT was first described as having a ‘polar zipper’ structure; a motif that 
promotes binding with transcription factors, which suggested HTT may play a role in 
transcriptional regulation (Perutz et al. 1994).  The N-terminus of HTT is considered to 
form an α-helical structure (Kim et al. 2009; Długosz & Trylska 2011), which can be 
altered by mutations to amino acids 1-17 (Atwal et al. 2007), post-translational 
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modifications such as phosphorylation events (Aiken et al. 2009; Atwal et al. 2011), 
and by a pathogenic expanded polyQ tract (Legleiter et al. 2009; Długosz & Trylska 
2011; Peters-Libeu et al. 2012; Vachharajani et al. 2012). Alternate epitopes can be 
detected by using different antibodies against HTT; a more thorough discussion of this 
can be found in Chapter 3. 
The alteration in its N-terminal structure is considered one of the pathogenic 
mechanisms for mHTT aggregate formation and cellular toxicity; increasing the length 
of the polyQ substantially reduces the stability of HTT and promotes aggregation 
(Vachharajani et al. 2012). One mechanism by which this may occur is by increasing the 
exposure of amino acids 1-17; the α-helical structure of non-pathogenic HTT is 
stabilised by interactions between amino acids 1-17 and the polyproline rich region 
that follows the polyQ tract (Długosz & Trylska 2011). When the polyQ tract is 
expanded in the context of mHTT, the structure is ‘loosened’ by preventing this 
interaction, and the N-terminus is more able to form aberrant associations and 
structures (Li et al. 2007; Długosz & Trylska 2011). Alterations to the structure of HTT 
by the expanded polyQ may also lead to specific conformations that are toxic in 
soluble monomeric and oligomeric forms, which may be particularly dynamic and 
heterogeneous in their structure (Lotz et al. 2010; Długosz & Trylska 2011).  
The HTT protein also contains several huntingtin, elongation factor 3, protein 
phosphatase 2A, and Tor1 (HEAT) repeats; 16 repeats arranged into four clusters along 
the length of the protein have been identified (Tartari et al. 2008), although up to 36 
putative HEAT repeats have been identified on HTT (Takano & Gusella 2002). HEAT 
repeats are binding regions that promote protein-protein interactions, therefore their 
multiple appearances may support a multi-functional role for HTT (Andrade & Bork 
1995).  
 1.3.2 Cleavage and proteolysis 
Caspases and calpains have been identified as potential regulators of HTT proteolysis, 
which plays a role in modulating HTT binding partner interactions, subcellular 
localisation, degradation, as well as mHTT aggregation in models of HD (Ehrnhoefer et 
al. 2011). Several caspase and calpain proteolytic cleavage sites have been identified 
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within HTT, which all lie between amino acids 469 and 586 (Figure 1.2) (Goldberg et al. 
1996; Wellington et al. 1998; Kim et al. 2001; Gafni & Ellerby 2002; Graham, Deng, et 
al. 2006; Landles et al. 2010). 70-80kDa N-terminal fragments of HTT have been 
identified in several mouse and cell models, as well as in human brain (DiFiglia 1997; 
Wellington et al. 1998; Gafni & Ellerby 2002; Gafni et al. 2004; Sawa et al. 2005; 
Thompson et al. 2009; Warby et al. 2009; Landles et al.2010), which may be a result of 
these cleavage events. Although the cleavage of mHTT has been associated with 
increased cellular toxicity and neurodegeneration (DiFiglia 1997; Wellington et al. 
2000; Graham, Deng et al. 2006; Schilling et al. 2006; Warby et al. 2009), whether 
mHTT has an increased affinity for either caspase or calpain binding, or may modulate 
cleavage activity, is still under debate. Several authors suggest that mHTT is more 
readily cleaved (Goldberg et al. 1996; Gafni & Ellerby 2002; Gafni et al. 2004), and 
neuronal cells containing mHTT have enhanced caspase and calpain activity (Gafni & 
Ellerby 2002; Gafni et al. 2004; Graham et al. 2010). In contrast, others suggest that 
mHTT is either more resistant to cleavage and caspase binding than wild type HTT 
(Dyer & McMurray 2001; Zhang et al. 2006), or no association with polyQ length has 
been identified at all (Wellington et al. 1998; Kim et al. 2001; Sawa et al. 2005; Landles 
et al. 2010).  
The cleavage of HTT is regulated by its phosphorylation, and this in turn may alter the 
toxicity of mHTT and aggregation kinetics (Luo et al. 2005; Schilling et al. 2006; 
Thompson et al. 2009; Warby et al. 2009). For example, phosphorylation of serine 421 
(S421) prevents caspase-6 cleavage of mHTT, thus reducing the availability of shorter 
N-terminal fragments that may translocate to cell nuclei, consequently reducing mHTT 
toxicity (Warby et al. 2009). In addition, enhanced phosphorylation of serine 434 
(S434) prevents caspase-3 cleavage (Luo et al. 2005), and a phosphomimetic mutation 
of serine 536 (S536) prevents calpain cleavage (Schilling et al. 2006); both of which 
reduced mHTT toxicity and associated cell death. The cleavage-associated toxicity of 
mHTT is likely to act through the increased availability of smaller N-terminal fragments 
that can more readily translocate to cell nuclei and can more rapidly form aggregates 
(Sawa et al. 2005; Tanaka et al. 2006; Warby et al. 2009). 
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Figure 1.2 Simplified cartoon of cleavage sites on the HTT protein. a.a. = amino acid 
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HTT cleavage may also occur via the action of matrix metalloproteinases (MMPs); 
specifically, a cleavage site for MMP10 has been identified at amino acid 402 (J. P. 
Miller et al. 2010). MMP10 activity has been found to be increased in mouse models of 
HD, and the knock down of its activation reduced cell death (J. P. Miller et al. 2010). N-
terminal fragments that are smaller than the predicted caspase, calpain and MMP 
cleavage products have also been identified in human HD brain, as well as in cell and 
mouse models, with the smallest fragment terminating at amino acid 90 (DiFiglia 1997; 
Ratovitski et al. 2009; Landles et al. 2010). The mechanism for the generation of these 
fragments has not yet been fully elucidated, however they may be a result of the 
action of aspartyl proteases (Lunkes et al. 2002; Kim et al. 2006), which may cleave HTT 
between amino acids 104-114, and 205-214 (Kim et al. 2006). This process has been 
found to be most efficient on smaller HTT fragments that have been previously cleaved 
by calpains, caspases and MMPs, rather than full length HTT (Tebbenkamp et al. 2012); 
this suggests that the proteolysis of HTT may be a series of sequential cleavage events 
(Lunkes et al. 2002; Ratovitski et al. 2009; Tebbenkamp et al. 2012). In contrast, only a 
single 180kDa N-terminal fragment of mHTT was detectable from human HD brain 
lysates when investigated by native gel electrophoresis (Sapp et al. 2012); therefore 
the extent and relevance of cleavage events in HD pathogenesis remains under debate.  
 
1.4 Animal models of HD 
The discovery of the HD gene has permitted the development of genetic models of HD, 
each with features that mimic the human disease. Although no single model is able to 
fully recapitulate human HD, they have provided invaluable insights into the both the 
developmental and degenerative mechanisms of the disease; for example, the 
characterisation and significance of NII formation, and the manipulation of Htt gene 
expression as a potential therapeutic target. 
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 1.4.1 Transgenic and knock-in mouse models 
Many mouse models of HD are now available, and are suited to different applications, 
depending on their patterns of neuropathology, motor abnormalities and disease 
progression. The models are generally grouped depending on their genetic 
manipulation; transgenic models were created using either truncated or full length 
HTT inserted randomly into the genome, whereas ‘knock-in’ models consist of a CAG 
expansion inserted into the mouse genome at the appropriate location on the HTT 
gene, which is expressed under the endogenous mouse promoter. Further details 
regarding the most commonly used mouse models of HD can be found in Table 1.3. 
  1.4.1.1 Behavioural phenotypes 
Several tests and measures are used to assess the motor performance of HD mouse 
models, including gait abnormalities, basal activity, balance beam traversing time, 
swim speed, limb clasping following tail suspension, and latency to fall on the rotarod, 
which has proved to be one of the most robust measures of motor impairment in 
these models (Crook & Housman 2011).  
 
Background 
strain 
Transgene Promoter 
CAG 
repeat 
length 
Life 
span 
Reference 
N-Terminal transgenic models 
R6/2 
CBA x 
C57Bl/6 
Exon 1 human 
HTT 
Human 
HTT 
150 
10-13 
weeks 
Mangiarini et al.1996; Carter et 
al. 1999 
R6/1 
CBA x 
C57Bl/6 
Exon 1 human 
HTT 
Human 
HTT 
116 
32-40 
weeks 
Mangiarini et al. 1996; Hodges 
et al. 2008 
N171-82Q 
C3H/HEJ x 
C57Bl/6 
First 171 amino 
acids human 
HTT 
Mouse 
prion 
promoter  
82 
16-22 
weeks 
Schilling et al. 1999; Schilling et 
al. 2004 
Inducible models 
HD94 
CBA x 
C57Bl/6 
Chimeric 
human/mouse 
exon 1 HTT 
TetO + tTA 94 Normal Yamamoto et al. 2000 
Inducible-
148Q 
C57BL/6 
First 171 amino 
acids human 
HTT 
PrP + tTA 148 
28-40 
weeks 
Tanaka et al. 2006 
Full-length transgenic models 
YAC72 FVB/N Human HTT 
Human 
HTT 
72 Normal Hodgson et al. 1999 
YAC128 FVB/N Human HTT 
Human 
HTT 
120 Normal Slow et al. 2003 
BACHD FVB/N Human HTT 
Human 
HTT 
97 Normal Gray et al. 2008 
Table 1.3 Continued on next page  
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Knock-in models 
HdhQ72-80 
129Sv x 
C57Bl/6 
Expanded CAG 
inserted in 
endogenous 
mouse Htt 
Mouse Htt 72, 80 Normal Shelbourne 1999 
HdhQ92 
CD1 × 
129SvEv 
Endogenous 
mouse Htt with 
chimeric 
human/mouse 
exon 1 
Mouse Htt 90 Normal Wheeler et al. 1999 
HdhQ94 C57BL/6 
Endogenous 
mouse Htt with 
chimeric 
human/mouse 
exon 1 
Mouse Htt 94 Normal Menalled et al. 2002 
HdhQ111 
CD1 × 
129SvEv 
Endogenous 
mouse Htt with 
chimeric 
human/mouse 
exon 1 
Mouse Htt 109 Normal 
Wheeler et al. 1999; Wheeler et 
al. 2002 
HdhQ140 C57BL/6 
Endogenous 
mouse Htt with 
chimeric 
human/mouse 
exon 1 
Mouse Htt 140 Normal Menalled et al. 2003 
HdhQ150 
129/Ola × 
C57BL/J6 
Expanded CAG 
inserted in 
endogenous 
mouse Htt 
Mouse Htt 150 Normal 
Lin et al. 2001; Woodman et al. 
2007 
HdhQ200 C57BL/6J 
Expanded CAG 
inserted in 
endogenous 
mouse Htt 
Mouse Htt 200 
Euthan-
ised at 
80 
weeks 
Heng et al. 2010 
 
 
   1.4.1.1a Transgenic models 
The transgenic N-terminal fragment mouse models develop overt behavioural 
abnormalities at an earlier age than the full length knock in models; the R6/2 mouse 
model exhibits deficits in rotarod performance by 6 weeks of age (Carter et al. 1999; 
Rattray et al. 2013), whereas the R6/1 and N171-82Q models develop deficits at 18 
weeks and 3 months, respectively (Schilling et al. 2006; Hodges et al. 2008). Both R6 
models develop a progressive motor phenotype, including choreiform movements, 
tremor, involuntary stereotyped movements, and handling induced seizures; these 
behaviours emerge at 9-11 weeks for the R6/2 mice, and 4-5 months for the R6/1 
mice, followed by premature death at 10-16 weeks and 32-40 weeks, respectively 
Table 1.3 Key features of the most commonly used mouse models of HD  
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(Mangiarini et al. 1996; Rattray et al. 2013). N171-82Q mice also develop progressive 
motor abnormalities, such as loss of co-ordination, tremor, hypokinesis and abnormal 
gait from 3 months, and die prematurely after 16-22 weeks (Schilling et al. 1999; 
Schilling et al. 2004). Both inducible transgenic models, HD94 and Inducible 148Q, 
develop a progressive behavioural phenotype similar to the other transgenic models; 
this is apparent from 4 weeks with a mild clasping phenotype in HD94 mice 
(Yamamoto et al. 2000), and rotarod deficits and progressive ataxia in Inducible 148Q 
mice becoming apparent from 6 months (Tanaka et al. 2006). Despite a progressive 
tremor and hypoactivity in HD94 mice, these animals survive for a normal life span 
(Yamamoto et al. 2000). However, phenotypic progression is more severe in the 
Inducible 148Q mice, leading to premature death at 7-8 months (Tanaka et al. 2006).  
YAC72, YAC128 and BACHD mouse models all contain a full length human HTT 
transgene; these mice exhibit similar behavioural abnormalities as the N-terminal 
transgenic models, but in contrast to the R6/2 mice, their onset is delayed. Motor 
abnormalities are not apparent in YAC72 mice until 9 months (Hodgson et al. 1999), 
and in YAC128 mice, mild deficits can be seen from 3 months (Slow 2003; Van 
Raamsdonk et al. 2005), although not all of these progressively worsen with time 
(Brooks, Jones, et al. 2012).  A mild deficit in rotarod ability can be seen in BACHD mice 
from 1-2 months, but there is no continuous decline in performance until 28 weeks of 
age (Gray et al. 2008; Menalled et al. 2009). In addition to deficits in a standard battery 
of tests for motor function, these mice also display an initial hyperkinesia, followed by 
the development of hypokinesia (Hodgson et al. 1999; Slow 2003; Slow et al. 2005; Van 
Raamsdonk et al. 2005).  
Increasingly, mouse models of HD are being assessed for cognitive and emotional 
abnormalities, such as procedural learning and anxiety behaviours, as in the human 
disease these subtle phenotypes often develop prior to any overt motor symptoms 
(Kirkwood et al. 2000; Ho et al. 2003; Holl et al. 2013). R6/2 mice have been found to 
have deficits in special memory from 4-5 weeks of age, as well as an increase in 
anxious behaviour from 8-10 weeks (Cowin et al. 2011). In addition, there is a gender 
effect in these mice for an aberrant startle response; female mice show reduced 
startle from 4 weeks of age, whereas male mice exhibit a loss of pre-pulse inhibition 
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(PPI) from 10 weeks (Cowin et al. 2011). R6/2 mice also have deficits in task reversal 
from 6 weeks, which develops into a more widespread deficit in learning by 10-11 
weeks (Lione et al. 1999). R6/1 mice have been less thoroughly characterised, however 
they also exhibit deficits in procedural learning, a reduced startle response and PPI, as 
well as special memory impairments from 3 months (Cayzac et al. 2011; Brooks, 
Janghra, et al. 2012).  
YAC128 mice also have impaired spatial memory from 8 months, as well as a learning 
deficiency; by 12 months they can no longer learn the rotarod task (Van Raamsdonk et 
al. 2005). They also exhibit perseveration during learning tasks (Slow 2003) and similar 
to both R6 models, have a reduced startle response and PPI from 12 months of age. 
BACHD mice have similar impairments with reversal learning and set shifting, and also 
have increased anxiety and an increased fear response during conditioning tasks 
(Abada et al. 2013).  
   1.4.1.1b Knock-in models 
Knock-in mouse models tend to show a slower and more mildly progressive motor 
phenotype than transgenic models, and all have a normal life span, despite expressing 
CAG repeats much larger than those in the rapidly progressing transgenic models 
(Ferrante 2009). Models with repeats lower than 111 CAGs only exhibit very modest 
behavioural phenotypes; for example, HdhQ72-80 mice have no reported motor 
abnormalities (Shelbourne 1999), and HdhQ94 mice exhibit aberrant rearing behaviour 
at 2 months of age, followed by hypokinesia by 4-6 months (Menalled et al. 2002), but 
no other overt phenotypes. HdhQ111 mice, however, develop a gait deficit by 24 
months, consisting of a shortened stride and imprecise paw placement (Wheeler et al. 
2002). However there are no observable differences in paw clasping behaviour, and 
there is only a very late impairment in rotarod performance in female mice at 100 
weeks of age (Menalled et al. 2009).  
In contrast, knock-in models exhibiting longer CAG repeats develop more overt 
behavioural abnormalities, although in comparison to transgenic models their onset is 
considerably later. HdhQ140 mice have a similar behavioural phenotype to the HdhQ94 
model, although the expanded CAG repeat has hastened the age of onset; aberrant 
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rearing behaviour occurs at only 1 month of age, and hypokinesia occurs closer to 4 
months (Menalled et al. 2003). In addition, these mice have uncoordinated gait and 
resting tremor from 20-26 months (Hickey et al. 2008), a progressive deficit in climbing 
ability from 1.5 months, and subtle balance and rotarod impairments from 4-6 months 
(Hickey et al. 2008). The HdhQ150 model has an earlier onset of more severe observable 
motor impairments at 70 weeks, including rotarod deficits, balance impairments, and 
clasping behaviour from 40 weeks (Heng et al. 2007; Woodman et al. 2007; Brooks, 
Higgs, et al. 2012). Similar to the HdhQ140 mice, a resting tremor and an unsteady gait is 
also apparent from 100 weeks, although a reduction in grip strength has also been 
reported at just 1.5 months in this model (Woodman et al. 2007). Finally, HdhQ200 mice 
have the earliest onset and most severe phenotype of the knock-in models, but is 
currently one of the least thoroughly characterised; these mice display imbalance and 
poor motor co-ordination from 50 weeks, which progresses to deficits in gait by 60 
weeks, and gross motor impairment by 80 weeks (Heng et al. 2010).  
Due to their delayed and more subtle motor phenotypes, there is increasing interest in 
cognitive and emotional abnormalities in knock-in mice that may be apparent prior to 
motor symptom onset, and may be useful markers for disease progression and 
potential interventions. Long term spatial and recognition memory has been found to 
be impaired in HdhQ111 mice at 8 months, which is considerably earlier than the 
appearance of any motor phenotype (Giralt et al. 2012). Consistent with several of the 
transgenic models, HdhQ140 mice exhibit increased anxiety in the open field test, and 
increased freezing following fear conditioning tasks that occur from 1 month of age, as 
well as impaired motor learning (Hickey et al. 2008). HdhQ150 and HdhQ200 mice have 
not yet been as well characterised in their cognitive abilities, however HdhQ150 mice 
display difficulty in set-shifting tasks (Brooks et al. 2006) and also have some spatial 
memory deficits (Brooks, Higgs, et al. 2012).  
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  1.4.1.2 Neuropathology 
   1.4.1.2a Transgenic models 
N-terminal transgenic mice display an earlier manifestation of neuropathological 
features in contrast to full length models. Brain atrophy is detectable in R6/2 mice 
from just 3 weeks using MRI (Zhang et al. 2010), and a 20% reduction in brain weight 
has been observed from a month of age (Mangiarini et al. 1996; Stack et al. 2005). It 
was initially suggested that this model also had a reduction in striatal volume caused 
by neuronal atrophy and death from 12 weeks (Stack et al. 2005), however more 
recent investigations reveal that rather than a loss in volume, growth of the striatum 
no longer occurs after 8 weeks, and neuronal loss is minimal (Rattray et al. 2013). HTT 
aggregates have been identified from postnatal day 1, which increase in both number 
and size throughout the entire brain during disease progression (Sathasivam et al. 
1999; Meade et al. 2002; Yu et al. 2003; Stack et al. 2005; Rattray et al. 2013). The 
R6/1 model has a similar neuropathological phenotype that develops at a later time 
point; HTT nuclear inclusions are apparent from 9 weeks, and a reduction in brain 
volume is detectable from 18 weeks, including striatal atrophy (Naver et al. 2003). This 
atrophy has been attributed to cellular dysfunction rather than neuronal death (Yu et 
al. 2003). N171-82Q mice also share a similar pathology of striatal atrophy and 
ventricular enlargement, which was initially attributed to neuronal loss by 3 months 
(Yu et al. 2003; Gardian et al. 2005), however more recent reports propose that any 
neurodegeneration in this model is subtle, and atrophy is associated with neuronal 
dysfunction rather than apoptosis (Cheng et al. 2011). N171-82Q mice also have 
widespread neuronal HTT inclusions from 16 weeks that increase in size and number 
with disease progression (Schilling et al. 1999; Yu et al. 2003). 
Neither inducible HD mouse model has been as thoroughly characterised as the N-
terminal transgenic models, however both have mild to moderate entire brain 
atrophy, including a reduction in striatal volume and ventricular enlargement 
(Yamamoto et al. 2000; Tanaka et al. 2006). They also have widespread HTT nuclear 
inclusions, as well as evidence for some extranuclear aggregates in several brain 
regions (Yamamoto et al. 2000; Tanaka et al. 2006).  YAC72 mice have a milder, more 
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specific neuropathological phenotype; at 12 months, there is striatal degeneration and 
the nuclear translocation of HTT in MSNs, and some rare microaggregates (Hodgson et 
al. 1999). YAC128 mice also do not develop dense and progressive HTT inclusions, 
although they have an increased presence of microaggregates at 12 months that 
increase in number over time (Slow 2003). In contrast to the YAC72 model, there is a 
reduction in both striatal and cortical volume by 12 months in YAC128 mice (Van 
Raamsdonk et al. 2007). Finally, the BACHD model exhibits a more severe 
neuropathological phenotype in comparison to the YAC mice; there is gross brain 
atrophy by 12 months, including significantly reduced cortical and striatal volume, 
which is due to neuronal dysfunction rather than death (Gray et al. 2008; Ferrante 
2009). HTT inclusions are also apparent from 12 months, however these are mostly 
extranuclear and appear primarily in the cortex (Gray et al. 2008; Ferrante 2009). 
   1.4.1.2b Knock-in models 
Despite their later onset and milder behavioural phenotypes, knock-in models develop 
several progressive neuropathological features that are present in transgenic models 
of HD. HdhQ72-80 mice, despite no overt behavioural phenotype, develop neuropil HTT 
aggregates, and have a 10-15% reduction in brain weight by 4-6 months; however 
there is no evidence of reactive gliosis or neuronal loss (Shelbourne 1999). Similarly, 
HdhQ94 mice exhibit no neuronal loss, although there are widely distributed 
microaggregates from 4-6 months, and some nuclear HTT inclusions by 18 months 
(Menalled et al. 2002; Hickey et al. 2008). Both HdhQ92 and HdhQ111 mice have a 
progressive nuclear phenotype that exhibits striatal specificity; HTT becomes 
increasingly localised in striatal neuronal nuclei by 6 weeks, which appears punctate 
and forms nuclear inclusions by 4 months in both models (Wheeler 2000; Bayram-
Weston et al. 2012). There is also evidence of late onset neurodegeneration in the 
HdhQ111 model (Wheeler et al. 2002). 
In concordance with the association observed between CAG repeat length and motor 
phenotype severity in knock-in mouse models, there is also more severe and 
progressive neuropathology in models with longer CAG repeats. There is evidence for 
the formation of HTT aggregates from only 1 month in HdhQ140 mice, which initially 
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form in the striatum and progressively become more widespread throughout the brain 
(Hickey et al. 2008). Striatal nuclear inclusions and neuropil aggregates are also 
apparent from 4 months, and spread to the cortex, nucleus accumbens, and olfactory 
tubercle (Menalled et al. 2003). By one year, there is substantial neuronal loss within 
the striatum (Menalled et al. 2003; Hickey et al. 2008). Progressive nuclear staining 
and nuclear inclusions have also been reported in HdhQ150 striatum from 5 months 
(Woodman et al. 2007; Weiss et al. 2008; Bayram-Weston et al. 2012), accompanied 
by neuronal loss at 100 weeks, and a 40% loss in striatal volume by 23 months (Lin 
2001; Yu et al. 2003; Tallaksen-Greene et al. 2005; Heng et al. 2007). Similarly, HdhQ200 
mice develop nuclear inclusions in the striatum and cortex by 20 weeks, although 
neuronal dysfunction rather than neuronal loss is reported (Heng et al. 2010). By 40-50 
weeks, this model develops cytoplasmic and perinuclear HTT aggregates and exhibits a 
40% reduction in cerebellar purkinje cells (Heng et al. 2010; Dougherty et al. 2013). By 
80 weeks, there is substantial striatal and cortical astrogliosis (Heng et al. 2010). 
 1.4.2 Large animal models of HD 
Large mammalian models are currently in development, including sheep (Jacobsen et 
al. 2010; Morton & Avanzo 2011), miniature pig (Uchida et al. 2001; Yang et al. 2010) 
and Rhesus macaque models (Yang et al. 2008). These are being developed with an 
aim to more faithfully reproduce human HD, as greater similarities in brain 
development and longer life spans in these animals allows for the more thorough 
investigation of the chronic effects of HD, as well as pre-clinical testing of new 
therapeutic compounds. In addition, it has been observed that species differences 
have a large impact on neuropathology; larger animals appear to be more susceptible 
to the toxicity of larger CAG repeats than rodents, and in some models, suffer a greater 
extent of neurodegeneration and neuronal apoptosis (Li & Li 2012). 
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1.5  The dynamic shuttling of HTT 
Although HTT was initially considered to be a cytoplasmic protein (DiFiglia et al. 1995; 
Gutekunst et al. 1995), its nuclear presence has now been well characterised (Hilditch-
Maguire et al. 2000; Trettel et al. 2000; Kegel et al. 2002; Truant 2003; Truant et al. 
2007; Benn et al. 2008). HTT has been associated with a wide range of cellular 
functions, both within the cytoplasm and the nucleus; the dynamic shuttling between 
these compartments is therefore likely to be a mechanism by which the complex 
variety of HTT activities can be regulated (Truant 2003; Truant et al. 2007). 
 1.5.1 Subcellular localisation 
HTT is primarily cytoplasmic in the majority of somatic cells, however within neurons, 
spermatocytes and lymphoblasts, its localisation is both nuclear and cytoplasmic 
(Hoogeveen et al. 1993), suggesting a differential role of HTT dependent on cell type 
that can be regulated by its localisation. HTT has been associated with a variety of 
organelles within the cytoplasm (De Rooij et al. 1996; DiFiglia 1997), such as the 
endoplasmic reticulum, Golgi body, the plasma membrane and cytoskeleton (Hilditch-
Maguire et al. 2000; Ko et al. 2001; Atwal et al. 2007; Rockabrand et al. 2007). Within 
the cytoplasm, HTT is also associated with the regulation of vesicular transport; the 
palmitoylation of HTT targets it to membranes (Suopanki et al. 2006), and it is enriched 
in compartments containing vesicle associated proteins (DiFiglia et al. 1995), where it 
has been found to associate with vesicles and their interacting proteins (BlockGalarza 
et al. 1997; Qin et al. 2004; Atwal et al. 2007). Specifically, HTT may mediate the axonal 
transport of BDNF by mediating the interaction with vesicular motor proteins 
(Gauthier et al. 2004); a process which is disrupted in the presence of mHTT 
(Gunawardena et al. 2003). Furthermore, cytoplasmic HTT is thought to play a role in 
mediating protein-protein interactions (Bauer & Nukina 2009; Ehrnhoefer et al. 2011), 
as well as regulating gene expression; HTT sequesters repressor element 1-silencing 
transcription factor/neuron-restrictive silencing factor (REST/NRSF) in the cytoplasm, 
thus preventing its binding to the repressor element 1/neuron-restrictive silencing 
element (RE1/NRSE) on the promoter region of the BDNF gene, therefore ensuring 
BDNF expression (Zuccato et al. 2001; Zuccato et al. 2003; Zajac et al. 2010). HTT with 
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an expanded polyQ is unable to interact with REST/NRSF, and therefore BDNF 
expression is suppressed (Zuccato et al. 2003; Zuccato et al. 2010). Around 1900 
RE1/NRSE sites have been identified on both mouse and human genomes (Bruce et al. 
2004), suggesting that HTT is likely to be implicated in the expression of many genes 
other than BDNF. 
Within cell nuclei, HTT has been found to localise to speckles, promyelocytic leukaemia 
(PML) bodies, and the nucleous (Hilditch-Maguire et al. 2000; Tao & Tartakoff 2001; 
Kegel et al. 2002), as well as associating with a variety of transcription factors and 
being able to target DNA directly; all of which are modified by the presence of the 
expanded polyQ repeat within mHTT (Boutell et al. 1999; McCampbell et al. 2000; 
Shimohata et al. 2000; Steffan et al. 2000; Dunah et al. 2002; Li et al. 2002; Kegel et al. 
2002; Bae et al. 2005; Benn et al. 2008; Johnson et al. 2008). These interactions 
implicate HTT as having a necessary role in transcription and RNA processing within 
the nucleus, as well as in the assembly of nuclear matrix bound protein complexes 
(Kegel et al. 2002; Sun et al. 2007).  
 1.5.2 Nuclear import 
HTT is present in cell nuclei in both truncated and full length forms (Hilditch-Maguire 
et al. 2000; Trettel et al. 2000; Kegel et al. 2002; Truant 2003; Truant et al. 2007; Benn 
et al. 2008), however the mechanism by which such a large protein is able to 
translocate between subcellular compartments has not yet been fully elucidated. Small 
proteins between 20-40kDa, such as truncated N-terminal fragments, are easily able to 
cross the nuclear pore by passive diffusion (Figure 1.3) (Truant 2003; Terry et al. 2007; 
Bauer & Nukina 2009), which may account for the global nuclear inclusion phenotype 
observed in N-terminal HD mouse models (Sathasivam et al. 1999; Schilling et al. 1999; 
Meade et al. 2002; Yu et al. 2003; Stack et al. 2005; Rattray et al. 2013).  
However, this mechanism does not explain how longer epitopes of HTT may traverse 
the nuclear pore. Larger proteins must be accompanied through the nuclear pore via 
one of several transport pathways that require active diffusion; these pathways 
therefore exert stricter control of nuclear import and export than passive diffusion. 
Nuclear localisation signals (NLS) and nuclear export signals (NES) on a peptide act as 
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recognition sequences for an interaction with nuclear pore transporter molecules in 
order to regulate nuclear localisation via these pathways (Bessert et al. 1995; Desmond 
et al. 2013). It has been under debate whether HTT contains an endogenous NLS or not 
(Bessert et al. 1995; Xia 2003; Desmond et al. 2013). A consensus sequence for a 
typical NLS was initially identified between amino acids 1182-1190 on HTT, which 
when cloned into the cytoplasmic enzyme β-galactosidase, enhanced its nuclear 
localisation (Bessert et al. 1995). However, the NLS properties of this region were not 
replicated upon further investigation (Xia 2003).  It has been proposed that the series 
of HEAT repeats on HTT may interact with the nuclear pore associated proteins, 
nucleoporins, which may mediate nuclear localisation (Suhr et al. 2001; Truant et al. 
2007); the HEAT repeats on nuclear proteins importin-β and exportin have been shown 
to perform this function (Bayliss et al. 2002). In addition, mHTT nuclear inclusions 
sequester nucleoporins (Suhr et al. 2001), therefore suggesting that they may interact 
with either wild type or mutant HTT. 
More recently, HTT has been associated with the karyopherin β2/transportin pathway 
(Desmond et al. 2012; Desmond et al. 2013). The three consensus components 
required for the formation of a karyopherin β2 –dependent proline tyrosine (PY)-NLS 
were identified between amino acids 174-207 of HTT, which may modulate the nuclear 
localisation of HTT (Desmond et al. 2013). The PY-NLS is typically unstructured, and 
forms the correct conformation upon binding to the HEAT-repeat rich region of 
karyopherin β2; the structure of the HTT PY-NLS does not adhere to the same 
mechanism utilised by other PY-NLS containing proteins, as the three consensus 
sequences are separated by a β-sheet structured region, which may provide a 
mechanism for regulating the action of the NLS in different cellular contexts (Desmond 
et al. 2013).  
 1.5.3 Nuclear export 
A leucine-rich consensus sequence for a chromosome region maintenance 1 (CRM1) 
NES has been identified on the C-terminus end of HTT (Figure 1.3) (Xia 2003); as this 
region is often cleaved away during HTT proteolysis (Section 1.6.2), this may be a 
mechanism by which there is an enrichment of N-terminal HTT fragments present in 
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the nucleus compared to the cytoplasm (Wellington et al. 1998; Kim et al. 2003; 
Landles et al. 2010).  The N-terminus of HTT has been found to bind to the nuclear 
pore protein translocated promoter region (TPR), which is associated with nuclear 
export, and this association declines in the presence of an expanded polyQ (Cornett et 
al. 2005). However, the association between HTT and TPR also diminished in the 
context of full length HTT (Cornett et al. 2005), therefore indicating that this may be a 
mechanism primarily for the nuclear export of truncated N-terminal fragments. In 
addition, post translational modifications of N-terminal HTT may reduce its association 
with the TPR, and therefore promote the nuclear localisation of phosphorylated HTT 
(Cornett et al. 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Cartoon representing the mechanisms of HTT subcellular localisation; 
small fragments can traverse the nuclear pore via passive diffusion. Grey triangles 
depict the interaction between nuclear pore- associated TPR proteins and N-terminus 
HTT. Black triangles represent the putative association between nucleoporins with 
HTT HEAT repeats.  Red and orange circles depict NLS and NES sequences, 
respectively. 
HEAT 
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It has been suggested that amino acids 1-18 form an amphipathic alpha helical 
structure that act as a cytoplasmic retention signal, which targets HTT to the 
endoplasmic reticulum and vesicles; an association that can be disrupted by cellular 
stress or mutation of the region in order to alter its conformation, thus increasing the 
nuclear localisation of HTT (Atwal et al. 2007). As the structure of this region is thought 
to be disrupted in the presence of an expanded polyQ (Li et al. 2007; Długosz & Trylska 
2011), this may be an additional mechanism for the increased nuclear localisation 
observed in HD models and human HD brain (DiFiglia 1997; Gomez-Tortosa et al. 
2001). The first 17 amino acids of HTT have also been identified as a potential NES 
(Maiuri et al. 2013; Zheng et al. 2013); N17 of HTT is a leucine rich sequence, which is 
roughly a consensus sequence for exportin 1 and CRM1 mediated nuclear export 
(Maiuri et al. 2013; Zheng et al. 2013). By using mutations to leucines 4, 7 and 14, as 
well as to phenylalanine 11, to alter the NES sequence, the nuclear localisation of HTT 
was increased; however, alterations to other residues in this region had no effect 
(Zheng et al. 2013). In contrast, the phosphorylation of serines 13 (S13) and 16 (S16) 
have been found to reduce the association between HTT N17 and CRM1, possibly by 
altering the alpha-helical structure, and therefore increasing nuclear phosphorylated 
HTT epitopes (Maiuri et al. 2013). 
 
1.6  Cellular signalling transduction pathways in HD 
The expanded polyQ repeat within mHTT not only alters the regulation of its 
subcellular localisation, but may also initiate aberrant protein-protein interactions. In 
turn, this is likely to disrupt the complex balance between pro- and anti-apoptotic 
signalling transduction mechanisms that regulate cell growth and survival.  Attention 
has therefore been given to the alterations of these pathways by mHTT, and the role 
they may play in HD pathogenesis; a depiction of the associations between several of 
these pathways can be found in Figure 4.1. 
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 1.6.1 Anti-apoptotic and compensatory mechanisms 
Anti-apoptotic pathways have been found to be important for prolonging neuronal 
survival during pathogenesis in HD models, as they may counter toxic metabolic 
changes elicited by mHTT (Ginés 2003). The most thoroughly characterised survival 
pathway in HD is the protein kinase B (AKT) pathway; baseline levels of AKT are 
relatively low in adult brain (Owada et al. 1997), however its activation rises following 
cellular stress and injury (Chong et al. 2005). AKT exerts its protective effects by 
phosphorylating and inactivating components of the cell death machinery, such as B-
cell lymphoma-2 associated death promoter (BAD), caspase-9, forkhead box proteins 
(FOXOs) and inhibitor of kappa-β kinase (IKK) (Humbert et al. 2002; Humbert 2003).  
The enhanced activation of AKT in HD models has been attributed to the reduced 
expression of its inhibitor, PH domain leucine-rich repeat protein phosphatase 1 
(PHLPP1), which is suppressed in HdhQ111, R6/1, R6/2 and HD94 striata, as well as in 
human putamen (Saavedra et al. 2010). It has also been suggested that by interacting 
with growth factor receptor bound protein 2 (GRB2), mHTT may directly activate 
growth factor signalling cascades that are upstream of AKT activation, thus enhancing 
AKT phosphorylation (Liu et al. 1997). In contrast, the aberrant interaction between 
mHTT and GRB2 at the epidermal growth factor receptor (EGFR) and the receptor 
tyrosine kinase A (TRKA) has also been found to inhibit the downstream activation of 
AKT, mitogen activated protein kinase (MAPK) and c-jun N-terminal kinase (JNK) (Song 
et al. 2002). Therefore, although increasing AKT phosphorylation is a neuroprotective 
mechanism in HD pathogenesis, the nature of its activation in relation to mHTT 
requires further elucidation. 
The activation of mitogen activated protein kinase kinase (MEK) and extracellular 
signal-regulated kinase (ERK) is required for BDNF-induced transcriptional regulation 
(Gokce et al. 2009), and as such, both are considered as pro-survival signalling 
pathways. In cell models of HD, compounds that inhibit cell death have been identified 
as acting via ERK phosphorylation (Varma et al. 2007; Scotter et al. 2010), and 
increasing ERK activity confers a protective effect by reducing the activation of 
caspase-3 (Apostol et al. 2006). However, in contrast to AKT activity, ERK 
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phosphorylation is consistently found to be either suppressed, which may increase 
cellular sensitivity to oxidative stress, or unchanged in models of HD (Apostol et al. 
2006; Roze et al. 2008; Ginés et al. 2010; Taylor et al. 2013). This reduction is thought 
to be mediated by alterations in the upstream receptor tyrosine kinase B (TRKB); there 
is a reduction in the presence of TRKB receptors in HD models, as well as in human 
caudate (Ginés et al. 2006; Brito et al. 2013), which may be due to the inhibition of the 
retrograde transport of TRKB-containing vesicles as a result of aberrant interactions 
with mHTT (Liot et al. 2013). MEK has been less thoroughly investigated in the context 
of HD, however as it is upstream of ERK, it may be expected to regulate the protective 
effects of ERK activity in HD models. It has been found that MEK1 activation may 
enhance the phosphorylation of HTT (Schilling et al. 2006), which is generally 
considered to reduce mHTT toxicity (Bauer & Nukina 2009; Gu et al. 2009; Thompson 
et al. 2009; Warby et al. 2009; Atwal et al. 2011; Maiuri et al. 2013), and the 
overexpression of MEK1 in a PC12 model of HD enhanced ERK phosphorylation and 
reduced cell death (Apostol et al. 2006).  However, in a Drosophila model of HD, MEK 
overexpression had no effect on survival (Iijima-ando et al. 2005). 
 1.6.2 Pro-apoptotic and inflammatory mechanisms 
Hyperactivation of the two pro-apoptotic members of the MAPK family, JNK and P38 
MAPK, has also been associated with HD (Taylor et al. 2013). The JNK pathway 
regulates transcription associated with the cell death response (Weston & Davis 2002), 
and can be activated by endoplasmic reticular stress; the stress response is initiated 
due to the accumulation of unfolded proteins, which leads to activation of apoptosis 
signal-regulating kinase 1 (ASK1) that induces JNK (Humbert 2003). Alternatively, JNK 
activation may be induced by the mixed lineage kinase 2 - MAP kinase kinase 7 - MAP 
kinase kinase 4 (MLK2-MKK7-MKK4) kinase cascade in response to growth factor 
signalling (Humbert 2003). The expanded polyQ has been suggested to enhance cell 
stress via activation of ASK1 (Nishitoh et al. 2002), and has been found to reduce the 
inhibitory association of wild type HTT with MLK2 (Humbert 2003), thus increasing JNK 
activation and supporting apoptosis. Increased JNK activation in response to mHTT has 
been noted in various cell and animal models of HD (Liu et al. 2000; Apostol et al. 
2006; Perrin et al. 2009), where it has been found to enhance cellular toxicity and 
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increase the activation of caspase-3 (Apostol et al. 2006). P38 MAPK phosphorylation is 
increased in the striatum of R6/1, R6/2 and YAC128 mouse models of HD (Gianfriddo 
et al. 2004; Saavedra et al. 2011; Fan et al. 2012), and it has been suggested that its 
activity correlates with striatal damage (Gianfriddo et al. 2004). Additionally, 
suppressing P38 MAPK increases neuronal survival in a rat model, and primary 
neuronal model of HD (Wang et al. 2010; Taylor et al. 2013), implicating this kinase as 
a pro-apoptotic response to mHTT; however the co-ordination with other pro- and 
anti-apoptotic signalling networks will contribute towards determining cell fate. 
Tumour suppressor protein 53 (P53) has also been associated with increased pro-
apoptotic signalling in HD pathogenesis; P53 mediates tumour suppression by initiating 
cell cycle arrest, apoptosis and cellular senescence, and is increased in response to 
cellular stress (Chang et al. 2012). Levels of P53 are enhanced in HD patient 
lymphoblasts, N171-82Q mouse brain and in cell models of HD (Trettel et al. 2000; Bae 
et al. 2005); mHTT is also able to bind to P53 and has been shown to increase both its 
expression and nuclear localisation (Steffan et al. 2000). The aberrant regulation of P53 
in models of HD is therefore a mechanism by which neuronal death is enhanced via 
pro-apoptotic signalling in response to mHTT. 
The inhibitor of kappaB kinase beta/ nuclear factor kappa-light-chain-enhancer of 
activated B-cells (IKKβ/NFκβ) pathway is a prominent regulator of neuroinflammation, 
and its activation has been found to be increased both in models of HD, and in human 
HD patient serum and central nervous system (Khoshnan et al. 2004; Bjorkqvist et al. 
2008; Khoshnan & Patterson 2011; Hsiao et al. 2013). Chronic elevation of IKKβ has 
been associated with increased neurodegeneration (Mattson 2006); one mechanism 
for this may be that an excessive inflammatory response in astrocytes confers 
additional damage to the adjacent neurons (Hsiao et al. 2013). Additionally, mHTT has 
been found to directly interact with the inhibitor of kappaB kinase gamma (IKKγ) 
subunit of IKKβ via the polyQ repeat and adjacent proline-rich region (Khoshnan et al. 
2004). This interaction increases the activation of IKKβ, and subsequent activation of 
NFκβ (Khoshnan & Patterson 2011); in turn, activated IKKβ inactivates anti-apoptotic 
protein B-cell lymphoma – extra-large (BCL-XL) and activates caspase activity 
(Khoshnan et al. 2009). As well as promoting the expression of genes associated with 
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inflammation, NFκB activation may also promote AKT phosphorylation (Meng et al. 
2002), which is compatible with the increased AKT phosphorylation observed in HD 
models, as described previously (Section 1.6.1). 
IKKβ may also regulate HTT proteolysis, however the manner in which this occurs is 
under debate; increased IKKβ has been found to phosphorylate HTT on S13 and S16, 
which initiates HTT proteolysis and clearance by the proteasome and lysosome 
(Thompson et al. 2009). This may initially be a protective mechanism to enhance the 
clearance of mHTT, however with age related degradation of the proteasome system, 
this may lead to pathogenic accumulation of phosphorylated mHTT fragments 
(Thompson et al. 2009). In concordance with this, the reduction of IKKβ was found to 
prevent HTT proteolysis and increase cellular resistance to DNA damage, which 
improved neuronal survival (Khoshnan et al. 2009). Paradoxically, on another occasion 
the inhibition of IKKβ could also elicit the phosphorylation of HTT, which despite 
promoting proteolysis and targeting HTT to nuclear and subnuclear puncta, was 
neuroprotective (Atwal et al. 2011). Typically, the inhibition of IKKβ or NFκβ exerts 
neuroprotective effects in models of HD (Khoshnan et al. 2004; Khoshnan et al. 2009; 
Hsiao et al. 2013), implying that the enhanced IKKβ pathway in HD is likely to confer 
cellular toxicity. The paradoxical findings of HTT phosphorylation in response to IKKβ 
activation suggest that relationship between inflammatory kinases and the 
neuroprotective mechanisms of HTT phosphorylation are likely to be complex, and rely 
on cellular context and synergistic associations with multiple signal transduction 
pathways. 
 
1.7  Gene expression in HD 
Transcriptional dysregulation is one of the most central mechanisms contributing to 
HD pathogenesis (Ross et al. 2002; Zucker et al. 2005; Crocker et al. 2006; Crook & 
Housman 2011; Bowles et al. 2012; Seredenina & Luthi-Carter 2012), and is apparent 
from pre-symptomatic stages in mouse models of the disease (Crocker et al. 2006; 
Carnemolla et al. 2009; Becanovic et al. 2010), as well as in human HD embryonic stem 
cells (Feyeux et al. 2012) and in the blood of pre-symptomatic HD patients (Borovecki 
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et al. 2005). As such, there is currently a large volume of gene expression studies 
investigating the effect of mHTT- associated transcriptional dysregulation in a variety 
of HD models and tissues (Cha 2007; Seredenina & Luthi-Carter 2012).  
 1.7.1 Transcriptional profiles of HD and HD models 
Despite variation in polyQ length, HTT gene dosage and expression context, there is a 
good correlation between the gene expression changes observed in post-mortem 
human HD caudate and mouse models of HD (Kuhn et al. 2007; Hodges et al. 2008), as 
well as with the immortalised embryonic striatal cell model (StHdhQ111) of HD (Lee et 
al. 2007). The investigation of transcriptional dysregulation in human HD is limited to 
post-mortem caudate, which only allows for the transcriptional profiles of end-stage 
HD to be determined. However, the similarity of expression changes in mouse and cell 
models of the disease permits the characterisation of developmental mechanisms of 
dysregulation, and the exploration of potentially disease-modifying factors. The gene 
expression changes observed in different studies are reproducibly associated with 
similar biological pathways, including; neurotransmitter and neurotrophin receptors, 
transcription and chromatin remodelling, homeostasis, synaptic organisation, and 
regulation of metabolism (Luthi-Carter 2000; Hodges et al. 2006; Seredenina & Luthi-
Carter 2012).  
Although the downregulation of gene expression is most consistently observed in 
models of HD, upregulated genes are also present (Carnemolla et al. 2009; Crook & 
Housman 2011). However, the pattern of gene expression changes in response to 
mHTT is likely to be complex, and may not necessarily be stable over time; micro-RNA 
(miRNA) expression was initially upregulated in pre-symptomatic YAC128 mice, 
however at 12 months of age, miRNA expression was downregulated in comparison to 
control animals (Lee et al. 2011), which may reflect an initial compensatory mechanism 
for transcriptional control, followed by mHTT mediated disruption of miRNA 
regulation.  
Additional autocompensatory mechanisms that serve to counter mHTT toxicity are also 
likely to be present in transcriptional profiles of HD and HD models, and the regulation 
of these genes aren’t necessarily directly modulated by mHTT (Seredenina & Luthi-
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Carter 2012). For example, the activity of the ETS-domain containing protein (ELK1) 
transcription factor has been found to be increased in mouse and cell models of HD , 
without any direct association with mHTT (Anglada-Huguet et al. 2012), and several 
ELK1 downstream target genes have also been observed to be dysregulated in these 
models (Spektor 2002; Roze et al. 2008). Consequently, inhibiting ELK1 activation or 
expression promoted cell death and enhanced caspase-3 cleavage (Anglada-Huguet et 
al. 2012). Therefore the transcriptional dysregulation observed in models of HD is 
unlikely to be universally due to direct mHTT interference with transcriptional 
machinery, so care must be taken when interpreting gene expression profiles.  
 1.7.2 Mechanisms of transcriptional dysregulation 
Due to the extent of transcriptional dysregulation that is observed in HD, several 
different mechanisms have been identified by which mHTT may alter gene expression. 
  1.7.2.1 Protein-protein interactions 
The sequestration of transcription factors (TFs) into mHTT aggregates is one of the 
most commonly described pathways for the alteration of transcriptional machinery; 
several TFs have been found to interact with mHTT neuronal aggregates, including 
CREB-binding protein (CBP), binding protein 300 (P300), P53, specificity protein 1 (SP1) 
and TATA-binding protein (TBP) (Kazantsev et al. 1999; Steffan et al. 2000; Nucifora et 
al. 2001). Sequestration into aggregates is predicted to prevent the normal 
associations of TFs with DNA, thus altering gene expression. The inhibition of positive 
regulators and loss of negative regulators of transcription mean that TF sequestration 
may lead to aberrant up- and down-regulations of gene expression. However, 
transcriptional dysregulation is observed in R6/2 neurons that do not contain 
intranuclear inclusions (Sadri-Vakili et al. 2006), and in StHdhQ111 cells that do not form 
mHTT aggregates (Trettel et al. 2000); therefore TF sequestration is unlikely to be a 
major contributor to transcriptional dysregulation in models of HD. 
Soluble mHTT has been found to interact abnormally with TFs in a manner that may 
modify gene expression patterns. For example, wild type HTT has been shown to 
interact with SP1, and this association is stronger with mHTT due to the expanded 
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polyQ repeat; (Shimohata et al. 2000; Dunah et al. 2002; Li et al. 2002). The association 
with mHTT inhibits SP1 binding to DNA in both pre-symptomatic and symptomatic 
post-mortem HD brain (Dunah et al. 2002), and has also been found to inhibit the 
interaction between SP1 and the general TF TFII130, therefore further altering 
transcriptional activation (Shimohata et al. 2000; Dunah et al. 2002). In addition to 
direct TF interactions, mHTT has also been found to inhibit TF activity by altering their 
clearance by the proteasome; CBP clearance is enhanced in the presence of mHTT, 
therefore reducing its availability for DNA binding (Cong et al. 2005), whereas in 
contrast, mHTT has been found to impair the clearance of β-catenin by aberrant 
interactions with its destruction complex (Godin et al. 2010). β-catenin accumulates in 
its phosphorylated form that marks it for proteasomal degradation, which results in 
increased cellular toxicity, but does not increase the expression of β-catenin target 
genes (Godin et al. 2010). Aberrant interactions with members of cellular kinase signal 
transduction pathways, as described previously (Section 1.6), may also be a 
mechanism by which mHTT alters the transcriptional regulation of downstream genes. 
  1.7.2.2 Chromatin remodelling 
The architecture of chromatin significantly contributes to the regulation of 
transcription, and can be regulated by the post-translational modifications of histones. 
Histone marks have been found to be altered in several models of HD, including R6/2 
and N171-82Q mice (Ferrante et al. 2003; Hockly et al. 2003; Gardian et al. 2005; Ryu 
et al. 2006; McFarland et al. 2012; Valor et al. 2013) and StHdhQ111 cells (Sadri-Vakili et 
al. 2007; Ng et al. 2013).  Histone acetyltransferases, such as CBP, may be sequestered 
by mHTT, therefore reducing histone acetylation in models of HD (Seredenina & Luthi-
Carter 2012). However, despite hundreds of hypoacetylated loci for histones H3 and 
H4 in the N171-82Q mouse model, very few genes with altered transcript levels 
showed significant changes in histone acetylation (Valor et al. 2013). There may 
therefore be little concordance between hypoacetylation and transcriptional 
dysregulation in HD (McFarland et al. 2012), and the two alterations may be 
independent manifestations of the effect of mHTT (Valor et al. 2013). However there 
was a small subset of genes where hypoacetylation of H3 –lysine 9 (K9) and H3-lysine 
14 (K14) at the transcriptional start site was associated with transcriptional 
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dysregulation, and these genes were consistent between brain regions, mouse models 
and in HD patient tissue (Valor et al. 2013), and histone deacetylation inhibitors have 
proven to be neuroprotective (Ferrante et al. 2003; Hockly et al. 2003; Sadri-Vakili et 
al. 2007; Thomas et al. 2008; McFarland et al. 2012). Although the role of 
hypoacetylation in HD remains to be elucidated, additional epigenetic modifications 
are likely to contribute to the widespread transcriptional dysregulation in these 
models. 
In contrast to acetylation, a large proportion of dysregulated genes have been 
associated with significant changes in methylation (Ng et al. 2013). Regions with a low 
cytosine-phosphate-guanine (CpG) content were particularly affected by increased 
DNA methylation, and were associated with activator protein 1 (AP1) and sex-
determining region Y-box 2 (SOX2) TF activity (Ng et al. 2013). As DNA bound TFs can 
alter methylation patterns (Hogart et al. 2012; Stadler & Allis 2012), mHTT may alter 
histone methylation status by TF interactions; mHTT interacts with SET-domain, 
bifurcated 1 (SETDB1), a regulator of H3K9 trimethylation (Ryu et al. 2006). The activity 
of this methyltransferase is increased in human HD caudate and R6/2 brain (Ryu et al. 
2006), and knocking down its expression reduces hypertrimethylation and ameliorates 
the R6/2 phenotype (Ryu et al. 2006). As methylation has been associated with a range 
of cognitive abilities, such as learning and memory (Liu et al. 2009; Day & Sweatt 
2010), the modification of histone methylation may have significant implications for 
the daily functioning of HD patients. 
  1.7.2.3 Direct associations 
In addition to the indirect modification of transcriptional regulation via sequestration 
and interactions with TFs, kinases, acetyltransferases and methyltransferases, mHTT 
can also bind directly to DNA in a manner that alters genomic DNA structure (Benn et 
al. 2008). mHTT has been identified as having increased DNA binding capacity in R6/2 
striatum and in StHdhQ111 cells, having a higher binding occupancy at gene promoter 
regions than the wild type protein, and interfering with normal TF binding (Benn et al. 
2008). Gene expression changes have also been observed in HTT-deficient cells 
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(Boudreau et al. 2009), therefore suggesting that HTT plays a normal, direct role in 
transcriptional control, which may be altered by the presence of mHTT. 
 
1.8 Aims of this project 
This project aims to investigate and characterise the mechanisms for transcriptional 
dysregulation associated with HTT localisation in the immortalised embryonic striatal 
cell model (StHdhQ111) of HD. The model was derived from primary striatal neurons 
cultured from the HdhQ111 knock-in mouse model of HD (Trettel et al. 2000); as such, 
wild type cells (StHdhQ7/7) carry two alleles each containing 7 CAG repeats, and 
heterozygote (StHdhQ7/111) and homozygote (StHdhQ111/111) cells carry either one or two 
mutant alleles carrying 111 CAG repeats, respectively.  
Since its development, the StHdhQ111 cell line has been widely utilised.  Comparisons 
between wild type and mutant cells have revealed phenotypes that mirror those also 
identified in mouse and human models of HD, such as mHTT mislocalisation (Trettel et 
al. 2000), transcriptional dysregulation (Benn et al. 2008; Saavedra et al. 2010), an 
augmented endoplasmic reticulum stress response (Trettel et al. 2000; Carnemolla et 
al. 2009), and altered kinase signalling (Ginés et al. 2003; Battaglia et al. 2011). The 
StHdhQ111 cell model is therefore considered an appropriate model for the preliminary 
investigation of early cellular HD phenotypes.     
By creating a dynamic model, it is possible to examine CAG repeat length-associated 
differential responses to cellular stimulation. This will be achieved by; 
 Characterisation of the localisation of phosphorylated and non-phosphorylated 
N-terminal HTT epitopes in StHdhQ111 cell lines prior to, and following 
stimulation with brain derived neurotrophic factor (BDNF), nerve growth factor 
(NGF) or epidermal growth factor (EGF), 
 Identification of kinase signalling pathways elicited by growth factor 
stimulation, and of those that are aberrantly responding in the presence of 
mHTT, 
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 Inhibition of dysregulated kinase signalling pathways in order to determine the 
downstream effects on immediate-early gene transcription and HTT 
localisation,  
 Analysis of differential gene expression changes following growth factor 
stimulation in order to determine additional signalling and transcriptional 
pathways that may be altered by mHTT, 
 Replication of results from StHdhQ111 cell lines in primary cell cultures from 
HdhQ111 and HdhQ150 E14 striata to determine whether any observed effects are 
model or CAG length specific. 
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Chapter 2:  Materials and methods 
 
2.1 Materials 
Addresses of all suppliers whose products were used in this study are listed below in 
alphabetical order: 
Abcam plc, Cambridge, UK; Affymetrix, Santa Clara, California, USA; Bioline reagents 
Ltd, London, UK; Bio-Rad laboratories Inc, Hercules, California, USA; Developmental 
Studies Hybridoma Bank, Iowa City, Iowa, USA; Fisher Scientific UK Ltd, 
Loughborough, UK; Jax®, Bar Harbor, Maine, USA; Leica Microsystems, Wetzlar, 
Germany; Life Technologies Corporation, Carlsbad, California, USA; Lorne Laboratories 
Ltd, Reading, UK; Merck Millipore, Billerica, Massachusetts, USA;  New England 
Biolabs, Hitchin, UK; PAA laboratories, Yeovil, UK; Qiagen, Manchester, UK; Santa Cruz 
Biotechnology Inc, Dallas, Texas, USA; Sigma Aldrich Company Ltd, Dorset, UK; VWR 
international, Lutterworth, UK. 
 2.1.2Chemicals 
All analytical grade chemicals were supplied by Sigma-Aldrich, unless otherwise stated.  
 2.1.3 Buffers and general reagents 
Below are details of the buffers and reagents commonly used throughout this project, 
listed in alphabetical order: 
Cell Lysis buffer 
1 x Cell lysis buffer (New England Biolabs), containing: 
 20 mM Tris-Hydrochloride (Tris-HCl), pH 7.5  
 150 mM Sodium Chloride (NaCl)  
 1 mM Disodium-EDTA (Na2EDTA)  
 1 mM Ethylene Glycol Tetraacetic Acid (EGTA)  
 1% Triton  
 2.5 mM Sodium Pyrophosphate (Na4P2O7) 
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 1 mM Beta-glycerophosphate (BGP) 
 1 mM Sodium Orthovanadate (Na3VO4)  
 1 µg/ml Leupeptin 
1mM phenylmethanesulfonylfluoride (PMSF) 
Distilled water (dH2O) 
 
DNA extraction buffer 
1M Tris-HCl, pH8.0 
0.5M Ethylenediaminetetraacetic acid (EDTA), pH8.0 
10% Sodium Dodecyl Sulfate (SDS) 
dH2O 
 
DNA Orange Loading Dye 
70% dH2O 
30% Glycerol 
Orange G 
 
Fractionation Buffer 
250mM Sucrose 
3mM Imidazole 
1mM EDTA, pH8.0 
1% Protease inhibitor 
 dH2O 
 
PBS Tween (PBS-T)  
1ml Tween®20 dissolved in 1L PBS. 
 
Phosphate Buffered Saline (PBS) 
Made by dissolving 5 PBS tablets in 1 litre dH2O, giving a final yield of: 
100nM phosphate buffer 
27nM Potassium Chloride (KCl) 
137nM NaCl, pH 7.4 
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Radioimmunoprecipitation assay (RIPA) buffer 
Acquired ready-made, containing: 
150nM NaCl 
1.0% IGEPAL® CA-630 
0.5% Sodium Deoxycholate 
0.1% SDS 
50 mM Trisaminomethane (Tris), pH8.0. 
 
Tris/Borate/EDTA (TBE) buffer 
44.5mM Tris 
44.5mM Boric acid (H3BO3) 
1mM EDTA, pH8.0 
dH2O 
 
 2.1.4 Cell lines 
StHdhQ7/7, StHdhQ7/111 and StHdhQ111/111 immortalised embryonic striatal cells were a 
kind gift from Marcy MacDonald (Molecular Neurogenetics Unit, Massachusetts 
General Hospital, Massachusetts, USA). The MW1 hybridoma cell line was provided by 
the Developmental Studies Hybridoma Bank, (University of Iowa, Iowa, USA).  
 2.1.5 Animals 
HdhQ150 mice bred on a C57/Bl6 background were obtained from Jax® (The Jackson 
laboratory, Bar Harbor, Maine, USA), and HdhQ111 mice were from the Wheeler 
laboratory (Molecular Neurogenetics Unit, Massachusetts General Hospital, 
Massachusetts, USA). Both lines were housed under project licence PPL: 30/3036 on a 
12 hour light-dark cycle from 6am to 6pm in a temperature controlled environment 
(20-22°C), with water freely available and environmental enrichment. The CAG repeat 
length in HdhQ150 mice varied between 125-160 repeats, but was maintained at around 
150. In HdhQ111 mice, the repeat length ranged between 125-145, but was maintained 
at around 135. Timed mating was carried out by pairing heterozygote males and 
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females at 4pm, and leaving overnight until 9am, when they were then separated. 
Females were checked for plugs, and after 14 days the pregnant dams were killed by 
cervical dislocation, and the embryos were harvested for striatal dissections. 
 2.1.6 Cell culture  
Penicillin-Streptomycin solution, Trypan Blue, Fetal Bovine Serum (FBS) for primary cell 
culture, and DMSO and the Nalgene® Mr.Frosty for cryogenic preservation of cell lines 
were all purchased from Sigma-Aldrich. FBS for immortalised and hybridoma cell lines 
was supplied by PAA, and the Trypsin for primary cell culture was purchased from 
Lorne Laboratories. T75 and T160 flasks and Nalgene cryovials were purchased from 
Fisher Scientific. All other culture media reagents were purchased from Life 
Technologies Incorporated.   
 2.1.7 Immunofluorescence materials 
Chance Propper Ltd Blue Star glass microscopy slides, 6 well and 24 well plates were 
supplied by Fisher Scientific. 1cm and 24mm diameter coverslips were both purchased 
from VWR International Ltd. Poly-L-lysine and Poly-D-lysine for coating coverslips and 
Formalin to fix cells were all obtained from Sigma-Aldrich. For mounting coverslips, 
ProLong® Gold antifade reagent with DAPI was purchased from Life Technologies 
Incorporated.  
 2.1.8 Electrophoresis of proteins and protein transfer 
SDS-PAGE gel electrophoresis was carried out in the XCell SureLock™Mini-Cell 
Electrophoresis system, and wet blotting was carried out in the XCell II Blot Module, 
both from Life Technologies Incorporated. Immobilon™-P Transfer membrane was 
purchased from Merck Millipore, and chromatography paper was from Fisher 
Scientific. The Precision Plus Protein™ molecular weight standard was supplied by 
BioRad, bovine serum albumen (BSA) was from Sigma Aldrich, and Marvel dried semi-
skimmed milk was used as a blocking agent. All precast 4-12% NuPage® Bis-Tris gels 
and other protein electrophoresis and transfer materials were supplied by Life 
Technologies Incorporated. 
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 2.1.9 Antibodies and labelling reagents 
A table of all antibodies and labelling reagents used during this project can be found in 
Table 2.1, and details of the epitopes detected by the N-terminal antibodies against 
HTT and mHTT are depicted in Figure 2.1. 
 
Antibody Source 
IF 
dilution 
WB 
dilution 
Preferred 
blocking 
reagent 
Supplier 
Primaries   
    
  
Huntingtin Mab2166 Mouse 
monoclonal 1:1000 1:1000 Milk Millipore 
  Ab109115 Rabbit 
polyclonal 1:100 1:1000 Milk Abcam 
  Ab675 Rabbit 
polyclonal 1:200 1:500 Milk Covalab 
  MW1 
Mouse 
monoclonal 
hybridoma 
- 1:1000 Milk 
Developmental Studies 
Hybridoma Bank, 
University of Iowa 
  Anti-pS13 Rabbit 
polyclonal 1:500 - Milk Kind gifts from Joan 
Steffan, University of 
California, Irvine, USA 
  Anti-pS13S16 Rabbit 
polyclonal 1:1000 1:1000 Milk 
  N17 Rabbit 
polyclonal 1:250 1:5000 Milk Kind gifts from Ray 
Truant, McMaster 
University, Canada 
  
N17 pS13S16 Rabbit 
polyclonal 1:250 1:5000 Milk 
 
            
Cell Markers Anti-MEK Rabbit 
monoclonal - 1:1000 BSA New England Biolabs 
  
Anti-Lamin 
A/C 
Mouse 
monoclonal - 1:2000 Milk New England Biolabs 
 
            
Receptors Anti-EGFR Rabbit 
monoclonal 1:50 1:1000 BSA New England Biolabs 
  
Anti-TRKA Rabbit 
monoclonal 1:100 - Milk Abcam 
Table 2.1 Continued on next page 
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Anti-TRKA Rabbit 
monoclonal 
- 1:1000 Milk  New England Biolabs 
  
Anti-TRKB Rabbit 
polyclonal 1:100 1:100 Milk Abcam 
  
Anti-P75 NTR Rabbit 
polyclonal 1:500 1:500 Milk Abcam 
 
            
Loading 
Control Anti-α-tubulin 
Mouse 
monoclonal - 1:10,000 
Milk or 
BSA Abcam 
 
            
Striatal Cell 
markers Anti-CTIP2 Rat monoclonal 1:500 - BSA Abcam 
  
Anti-DARPP-
32 
Rabbit 
polyclonal 1:200 - BSA 
Santa Cruz 
Biotechnology Inc 
 
      
SMADs SMAD1 Rabbit 
monoclonal - 1:1000 Milk New England Biolabs 
 
Phospho-
SMAD1 
(ser465) 
Rabbit 
polyclonal - 1:1000 Milk Abcam 
 
Phospho-
SMAD1/5 
(ser463/465) 
Rabbit 
monoclonal - 1:1000 Milk New England Biolabs 
 
SMAD2 Rabbit 
monoclonal - 1:1000 Milk New England Biolabs 
 
Phospho-
SMAD2 
(ser465/467) 
Rabbit 
monoclonal - 1:1000 Milk New England Biolabs 
 
SMAD3 Rabbit 
monoclonal - 1:1000 Milk New England Biolabs 
 
Phospho-
SMAD3 
(ser423/425) 
Rabbit 
monoclonal - 1:1000 Milk New England Biolabs 
 
SMAD4 Rabbit 
polyclonal - 1:1000 Milk New England Biolabs 
Table 2.1 Continued on next page 
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SMAD5 Rabbit 
polyclonal - 1:1000 Milk New England Biolabs 
 
Phospho-
SMAD5 
(ser463/465) 
Rabbit 
monoclonal - 1:500 Milk Abcam 
 
SMAD6 Rabbit 
polyclonal - 1:1000 Milk New England Biolabs 
 
TGFBI Goat polyclonal - 1:1000 Milk Abcam 
 
      
Secondaries       
  
Goat α Rabbit 
568   1:100 - 
Milk or 
BSA Life Technologies Inc 
  
Donkey α 
Mouse 488  
1:100 - Milk or 
BSA Life Technologies Inc 
  
Chicken α Rat 
647  
1:100 - Milk or 
BSA Life Technologies Inc 
  
Goat α Mouse 
DyLight™ 800  
- 1:20,000 Milk or 
BSA Fisher Scientific 
 
Rabbit α Goat 
680  
- 1:10,000 Milk Life Technologies Inc 
  
Goat α Rabbit 
680  
- 1:10,000 Milk or 
BSA Life Technologies Inc 
  
ProLong Gold 
Antifade with 
DAPI 
  1 drop - Milk or 
BSA Life Technologies Inc 
 
 
 
 
Table 2.1 Primary and secondary antibodies utilised throughout this project for 
both immunofluorescence (IF) and western blot (WB). 
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 2.1.10 Confocal microscopy 
A Leica TCS SP5 confocal microscope was used to image all immunofluorescence 
experiments, using the Leica Suite Application Advanced Fluorescence 3 microscope 
software version 2.6.0 (copyright 1997-2011 Leica Microsystems CMS GmbH). Type F 
immersion oil was also from Leica. 
 2.1.11 ELISA kits 
The following Cell Signalling Technology PathScan® Sandwich ELISA kits were all 
purchased from New England Biolabs: 
Signalling Nodes Multi-Target kit, Cleaved PARP (Asp 214) kit, Phospho-BAD (Ser112) 
kit, Phospho-SAPK/JNK (Thr183/Tyr185) kit, Phospho-AKT (Ser473) kit, Phospho-MEK1 
(Ser217/221) kit, Phospho-SMAD2 (ser 465/467), Total SMAD2, Total SMAD3 and 
Phospho-SMAD3 (Ser423/425).  
 2.1.12 General protein biochemistry materials 
10cm round dishes used to grow cells for protein extraction, cell scrapers, lysing matrix 
D tubes and the 1ml glass Dounce homogeniser were all from Fisher Scientific, as was 
the protein assay kit for protein quantitation. Chromatography columns for 
Anti-pS13S16 
 
Ab675 
N17 
Ab109115 
1 2 17  PolyQ 181 810 
Mab2166 MW1 
13 16 
P 
P P 
Anti-pS13 
N17 pS13S16 P P 
Figure 2.1 Cartoon of N-terminal Huntingtin, depicting the epitopes detected by 
the panel of anti-HTT primary antibodies used throughout this project. Red ‘P’ 
denotes a phosphorylation site at either serine 13 or 16. 
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purification of antibodies from hybridoma cell lines were from BioRad, which used 
protein G sepharose beads from Sigma Aldrich. Ponceau S was also purchased from 
Sigma Aldrich, and SimplyBlue™ Safe Stain was from Life Technologies. 
 2.1.13 Oligonucleotides 
Primers and assays for DNA and cDNA amplification were purchased from Life 
Technologies Incorporated. Details of the oligonucleotide sequences and 
identifications can be found in Table 2.2. 
 2.1.14 Preparation of nucleic acids 
All reagents used for the extraction of RNA and DNA were purchased from Sigma 
Aldrich, with the exception of RNaseZap® and diethylpyrocarbonate (DEPC)-treated 
water, which were both from Life Technologies. 
 
 
Gene Forward 5'-3' Reverse 5'-3' 
Ubc GAGTTCCGTCTGCTGTGTGA CCTCCAGGGTGATGGTCTTA 
      
C-fos AGAAGGGGCAAAGTAGAGCA GCAGCCATCTTATTCCGTTC 
Egr1 CCTATGAGCACCTGACCACA GGGATAACTCGTCTCCACCA 
Ngfib CAATGCTTCGTGTCAGCACT TGGCGCTTTTCTGTACTGTG 
Arc GAGAGCTGAAAGGGTTGCAC ACGTAGCCGTCCAAGTTGTT 
 
Gene Forward 5'-3' Reverse 5'-3' 
Htt CCCATTCATTGCCTTGCT GCGGCTGAGGGGGTTGA 
 
B 
A 
Table 2.2 Continued on next page 
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Gene ID 
 
Gene ID 
18s Mm03928990_g1 
 
Smad1  Mm00484723_m1 
Atf3 Mm00476032_m1 
 
Smad3  Mm01170760_m1 
Cdc42ep3 Mm00518245_m1 
 
Smad6  Mm00484738_m1 
Egr1 Mm00656724_m1 
 
Smad9  Mm00649885_m1 
Etv5 Mm00465816_m1 
 
Tgfb2  Mm00436955_m1 
Fgf2 Mm00433287_m1 
 
Tgfbr2  Mm00436977_m1 
Fosl1 Mm04207958_m1 
 
Tgfb3  Mm00436960_m1 
Gadd45g  Mm01352550_g1 
 
Tgfbr3  Mm00803538_m1 
Id3 Mm01188138_g1 
 
Tgfbi  Mm00493634_m1 
Junb  Mm04243546_s1 
 
Smurf2  Mm03024086_m1 
Myc  Mm00487804_m1 
 
Csf1  Mm00432686_m1 
Ngf  Mm00443039_m1 
 
Ctgf  Mm01192932_g1 
Rasa1 Mm00520858_m1 
 
Ereg  Mm00514794_m1 
Smad7 Mm00484742_m1 
 
Rgs16  Mm00803317_m1 
Sox9 
Mm00448840_m1 
 
Ppargc1α  Mm01208835_m1 
C 
Table 2.2 Continued on next page 
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Usp43 Mm00620499_m1 
 
Nr4a2  Mm00443060_m1 
Rnd3  Mm00512162_m1 
 
Mybl1  Mm00485327_m1 
Id2  Mm00711781_m1 
 
Prl2c2  Mm04208104_gH 
Ccng2  Mm00432394_m1 
 
Gapdh Mm99999915_g1 
Htt Mm01213820_m1 
   
  
 
 
 2.1.15 Polymerase chain reaction reagents  
The BioTaq™ DNA polymerase kit was purchased from Bioline, Proteinase K was from 
Life Technologies, and Betaine solution was provided by Sigma-Aldrich. All PCR 
reactions were carried out on a MJ research PTC-225 thermal cycler 
 2.1.16 Electrophoresis of DNA for Genotyping 
Agarose was purchased from Sigma Aldrich, HyperLadder™50bp was from Bioline and 
Ethidium bromide was from Sigma Aldrich. All other materials and reagents were 
supplied by Life Technologies.  
 2.1.17 Quantitative reverse transcription polymerase chain reaction materials 
All qRTPCR reagents and materials were from Life Technologies, although the RNeasy 
MinElute Cleanup Kit for purifying RNA extractions was purchased from Qiagen. 
 2.1.18 Small Interfering RNA reagents 
Apart from cell culture reagents previously mentioned, all Dharmacon siRNA reagents 
were supplied by Fisher Scientific. 
Table 2.2 Oligonucleotides designed and used for A. Sybr® Green qRTPCR, B. 
genotyping PCR and C. Identification codes for TaqMan® oligonucleotides used 
throughout this project. 
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 2.1.19 Microarray chips and analysis 
Affymetrix GeneChip® Mouse Genome 430A 2.0 and Affymetrix GeneChip® Mouse 
Gene 1.0 ST arrays were utilised. Microarray data was analysed in the Partek® 
Genomics Suite™ 6.6beta (copyright 1993-2011 Partek Incorporated). 
 2.1.20 Growth factors and kinase inhibitors  
EGF and NGF were purchased from Life Technologies, and BDNF was from Promega. 
Both AKT inhibitor VIII and MEK 1/2 inhibitor were supplied by Merck Millipore, and 
transforming growth factor-β 1 (TGFβ1) and 20mM citrate were from New England 
Biolabs. 
 
2.2 Methods 
 2.2.1 General cell culture protocols 
  2.2.1.1 Maintenance of immortalised striatal cell lines 
The StHdhQ111 cell line was derived from knock-in HdhQ111 embryonic day 14 (E14) 
striatal cells by infection with the mouse adenovirus simian vacuolating 40 (SV40) large 
T antigen containing a temperature sensitive tsA58/U19 mutation (Trettel et al. 2000). 
StHdhQ7/7, StHdhQ7/111 and StHdhQ111/111 cell lines were grown and maintained in high 
glucose Dulbecco’s Modified Eagle Medium (DMEM) containing L-glutamine, sodium 
pyruvate, 1% Penicillin-Streptomycin solution, 1% 40mg/ml Geneticin and 10% FBS in 
T-75 flasks . These cells were grown in a humid environment at 33°C with 5% C02. Cells 
were split every 2-3 days. To passage adherent cells, monolayers were trypsinised in 
2ml 0.25% Trypsin/EDTA for 5 minutes at 33°C. Flasks were then gently rocked to 
dislodge the cells, which were then resuspended in fresh complete medium and plated 
into new flasks.   
  2.2.1.2 Cell counting with a haemocytometer 
To count cells for seeding onto coverslips or for cryogenic preservation, 10µl of cell 
suspension was applied to a haemocytometer. A haemocytometer is a modified glass 
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slide with two counting grids; each grid is made up of 9 squares, the volume of each 
square being 0.1mm3. Five of these squares are used for cell counting. The number of 
cells in each of the 5 squares is averaged to give the mean number of cells per 0.1mm3 
(N). This is then used to determine the number of cells per 1ml suspension. The 
number of cells per 1cm3 is equal to N x 104. 
  2.2.1.3 Seeding immortalised striatal cell lines onto coverslips and  
  culture dishes 
To prepare a 6-well plate for seeding, 24mm diameter coverslips were washed in 
ethanol then left to dry in the wells of a 6-well plate. Cells were seeded at a 
concentration of 1x105 per 1 ml on each coverslip. Each coverslip was then flooded 
with a further 1ml of complete media. For seeding into 10cm dishes, cells were 
trypsinised and resuspended into complete DMEM as previously described. A portion 
of the cell suspension was re-plated into a 10cm dish and flooded with 10ml complete 
DMEM. Cells were grown for 1-2 days before being serum starved overnight prior to 
processing. 
  2.2.1.4 Embryonic striatal microdissection 
Pregnant mice were taken when at embryonic day 14 (E14), and killed by cervical 
dislocation. Both uterine horns were then removed and placed in Hank’s balanced salt 
solution (BSS). The embryos were then removed and kept moist in a petri dish, also 
containing Hank’s BSS. Individual embryos were moved to a separate petri dish, where 
they were killed by decapitation. All dissections were carried out using a dissection 
microscope with fibre optic light source and a transmitted light base. The brain was 
dissected by an incision at its base with a fine scalpel, the skin and meninges were 
peeled away with forceps, then the brain was freed by pinching at the base of the hind 
brain. The whole brain was then moved to an eyeglass well with a little Hank’s BSS for 
striatal microdissection, while the rest of the body was kept and stored at -80°C. 
In the eyeglass well, the brain was laid on its ventral surface. Using iridectomy scissors, 
a cut was made longitudinally through the medial cortex, which was then folded aside. 
This exposes the ganglionic eminence in the floor of the lateral ventricle. A superficial 
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cut was made either side of the ganglionic eminence, and then both lateral and medial 
sections of the striatum were removed and placed in DMEM/F-12 prior to processing. 
Figure 2.2 illustrates this process. The rest of the brain was kept and stored at -80°C. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
A B 
C 
D E F 
 
Figure 2.2 Microdissection of the ganglionic eminence from an E14 mouse embryo. 
A. The embryo is killed by decapitation, and B-C. the brain is dissected and 
removed. D-F. show the embryonic brain laying on its ventral surface. D. The medial 
cortex is cut to expose the ganglionic eminence (E), which is then removed with 
microspring scissors (F). Figure adapted from Dunnett & Bjorklund (1999). 
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2.2.1.5 Seeding primary striatal neurons from microdissections       
To culture primary cells from HdhQ111 and HdhQ150 embryonic microdissections, each 
sample was washed in DMEM/F-12, then digested with 50µl 0.1 % Trypsin in 0.01% 
DNase in Hank’s BSS, and incubated for 20 minutes at 37°C. Following trypsinisation, 
samples were incubated with an additional 150µl 0.01% DNAse in Hank’s BSS for a 
further 5 minutes at 37°C. After this time, the supernatant was removed and the 
remaining sample was titrated 10-12 times with a pipette in 50µl DMEM/F-12 to create 
a cell suspension. Viable cells were identified using Trypan Blue and counted using a 
haemocytometer. 
For immunofluorescence, primary cell suspensions were grown at 1x105 per well on 
1cm diameter Poly-L-lysine treated coverslips in a 24 well plate. The entire cell 
suspension from each embryo was divided into two wells of a Poly-L-lysine treated 6-
well plate for protein and RNA extraction experiments. To prepare coverslips for 
seeding, they were autoclaved then individually placed in wells. Coverslips and wells 
were then incubated for 1 hour with 100µg/ml Poly-L-lysine in dH2O at room 
temperature. If the plates were being prepared for future use, they were then 
wrapped in cling film and stored at 4°C. Otherwise, they were washed three times with 
distilled water, and left to dry for 45 minutes in the culture hood with the UV light 
turned on. Cell suspensions were then pipetted directly on to the coverslips or into 
wells, and left to set down for 2-3 hours at 37°C. They were then flooded with 
complete DMEM/F-12, containing 1% antibiotic-antimycotic solution, 2% B-27 
supplement, and 10% FBS, and grown in a humid environment at 37°C with 5% C02. 
Cells were fed with fresh complete DMEM/F-12 after 3 days, and were processed after 
7 days. 
  2.2.1.6 Hybridoma cell culture 
The MW1 hybridoma cell line was grown in T160 flasks with high glucose DMEM 
containing 1% Penicillin-Streptomycin solution and 20% FBS in a humid environment at 
37°C with 5% CO2. Hybridomas were passaged every 4 – 5 days by knocking the semi-
adherent cells back into suspension within the flask. This suspension was then split 
into new T160 flasks and flooded with 50ml fresh complete DMEM. 
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  2.2.1.7 Cryogenic preservation of cell lines 
Following trypsinisation, cells were resuspended in complete media containing 10% 
DMSO at a concentration of 1-3 x 106 cells per 1ml and transferred to cryovials. The 
cryovials were placed in a Nalgene® Mr.Frosty containing isopropanol at -80°C. After 
24 hours, the cryovials were either transferred to storage in liquid Nitrogen (-196°C), 
or kept at -80°C for short term storage. Cells were thawed for use by suspension in a 
water bath at 37°C for 90 seconds, before being transferred to complete DMEM, 
excluding Geneticin. The media was replaced the following day to ensure removal of 
any DMSO. After 2-3 days, Geneticin was added to the growth media, and cells were 
maintained as previously described (Section 2.2.1.1). 
  2.2.1.8 Sample preparation for immunofluorescence 
Both primary and immortalised cells were prepared in the same manner for 
immunofluorescence. The media was removed from each well, and coverslips were 
then washed twice with sterile 1xPBS pH7.2, before being incubated with Formalin 
solution (containing 10% paraformaldehyde) for 20 minutes at room temperature. The 
Formalin solution was then removed, and the coverslips were washed a further three 
times with 1x PBS. Fixed cells were then stored in 1xPBS at 4°C until use.  
  2.2.1.9 Fluorescence microscopy  
All coverslips were imaged on a Leica SP5 confocal microscope, using a x63 oil 
immersion objective lens. Images were captured with a 1024 x 1024 frame at a speed 
of 400Hz, a pinhole of 1 airy unit, with the line average and frame average both set at 
4, and a 1.5x zoom. Table 2.3 displays the lasers and detection bandwidths for each 
photomultiplier tube (PMT) used for each secondary antibody. The level of smart gain 
for each antibody was kept at the same voltage across coverslips. 
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Secondary Antibody AlexaFluor 488 AlexaFluor 568 AlexaFluor 647 DAPI 
Laser Argon (30%) HeNe 543 HeNe 633 405 diode (UV)  
Bandwidth 
Start (nm) 510 550 640 411 
Finish (nm) 540 630 690 436 
 
 
  
  2.2.1.10 Statistical analysis of confocal images  
Images from confocal microscopy were analysed using the GNU Image Manipulation 
Program 2.6.11, Copyright 1995-2008. Images were initially converted to greyscale, 
and then the mean pixel intensities of particular cellular regions were determined. The 
ratio of intensity between the cytoplasm, perinuclear region and nucleus were then 
calculated for each individual cell in order to determine whether there was a change in 
protein localisation. An illustration of this process can be seen in Figure 2.3. 
The resulting nuclear/cytoplasmic (N/C), nuclear/perinuclear (N/P) and 
perinuclear/cytoplasmic (P/C) ratios were then used for statistical analysis, using SPSS 
v.18 (SPSS Inc. Released 2009. PASW Statistics for Windows, Version 18.0. Chicago: 
SPSS Inc).  
 
 
 
 
 
 
Table 2.3 Confocal microscopy settings used for imaging immunofluorescence 
experiments  
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 2.2.2 Protein biochemistry methods 
  2.2.2.1 Preparing protein lysates from immortalised striatal cells for 
  ELISA 
Immortalised cell lines were grown on 10cm culture dishes for 2 days in complete 
DMEM and then serum starved overnight prior to protein extraction. Cells were 
washed twice with 1xPBS, then incubated with 1xLysis Buffer (provided with the ELISA 
kits) containing 1mM phenylmethanesulfonylfluoride (PMSF) for 10 minutes on ice 
prior to scraping and collection into a 2ml tube. Lysates were briefly sonicated on ice 
then centrifuged for 10 minutes at 13,000xg at 4°C. The supernatant was retained as 
the protein lysate and the pellet was discarded. 
Figure 2.3 An example of immunofluorescence image quantification. For every cell, 
a circular region within the nucleus (N), perinuclear area (P) and cytoplasm (C) were 
selected, and a histogram displaying the mean pixel intensity for that region was 
given. Within each cell, an N/C, N/P and P/C pixel intensity ratio was calculated in 
order to control for variance in background staining across coverslips and images. 
This also allowed the determination of localisation change between these regions in 
response to treatment rather than intensity alterations for each region. 
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  2.2.2.2 Protein extraction from primary embryonic tissue and cells 
Tissue was placed in a lysing matrix D tube along with cold RIPA buffer containing 1% 
protease inhibitor.  The samples were then homogenised in a FastPrep® instrument for 
20 seconds at a speed of 4.5 m/sec, then put straight back on ice. The lysate was then 
moved from the beads to a fresh tube, before being briefly sonicated on ice.  
Protein was extracted from cultured primary striatal preparations in the same manner 
as described in Section 2.2.2.1. 
  2.2.2.3 Subcellular fractionations from immortalised striatal cell lines 
Cells were seeded into 10cm culture dishes and grown for two days in complete 
DMEM and then serum starved overnight prior to subcellular fractionation. Cells were 
washed twice with 1xPBS before the addition of Fractionation Buffer (Section 2.1.3). 
Cells and buffer were then scraped into a 2ml tube and kept on ice for 10 minutes. 
Lysates were then subject to 30 strokes of a 1ml dounce homogeniser on ice. A portion 
of the resulting lysate was retained as a whole-cell fraction and was briefly sonicated 
on ice. The remaining lysate was centrifuged for 5 minutes at 500xg at 4°C. The 
supernatant was removed to a separate tube, and the pellet was resuspended in RIPA 
buffer, briefly sonicated on ice, and retained as the nuclear fraction. The supernatant 
was then centrifuged for a further 20 minutes at 10,000xg at 4°C. The new supernatant 
was retained as the cytoplasmic fraction, and the resulting pellet was discarded. 
  2.2.2.4 Antibody extraction and purification from hybridoma cell lines 
The antibody supernatant was extracted from the hybridoma cell line by centrifuging 
the cell suspension in complete DMEM for 5 minutes at 500xg to pellet the cells. The 
supernatant was removed and either frozen for future use or purified on a 
chromatography column. 
To purify the antibody supernatant, a chromatography column was loaded with 1ml 
Protein G Sepharose beads and washed with 1xPBS. The hybridoma supernatant was 
then loaded, collected, and re-loaded on to the column before washing with 1XPBS to 
remove any bed volume serum from the beads. To prevent the beads drying out 
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quickly, a frit disc was floated on the PBS while it was still in the column, and carefully 
pushed through the tube until it sat evenly 1mm above the beads. 
Four eluates were collected from the column by loading volumes of IgG Elution Buffer 
to the column. Eluate 2 was the main antibody fraction. To store the column for future 
use, 10ml IgG Elution Buffer was added to the column and allowed to run through to 
waste, followed by a wash with 1xPBS, then 10ml 0.05% Sodium Azide in PBS. The 
column was then capped, wrapped in parafilm and stored at 4°C. Antibody 
concentrations were determined by Bradford Assay, and IgG bands were checked by 
subjecting the eluates to SDS-PAGE gel Electrophoresis for 1.5 hours at 150V on a 
NuPage® Bis-Tris 4-12% gel. The gel was then washed three times for 5 minutes with 
gentle agitation in dH2O, and incubated for 1 hour in SimplyBlue
TM Safe Stain on a 
shaker. The gel was then washed for a further hour in dH2O to reduce background 
staining, and was imaged on the Licor® Odyssey® quantitative fluorescent imaging 
system. 
  2.2.2.5 Protein quantification 
Protein concentrations were determined by bicinchoninic acid assay (BCA)(based on a 
procedure described by Bradford (1976)), using the BCA protein assay kit from Thermo 
Fisher Scientific. 2 x 10µl replicates of each sample and of 9 Bovine Serum Albumin 
standards were added to a 96-well flat bottomed microwell plate. The wells were then 
flooded with 200µl working reagent solution (50:1, Reagent A:B), the plate was sealed 
and incubated for 30 minutes at 37°C. Following the incubation period, the plate was 
allowed to come to room temperature, and the absorbance was measured at 562nm in 
a BioTek® µQuant™ microplate spectrophotometer. 
  2.2.2.6 Acetone precipitation of protein 
Acetone precipitation was performed when the protein concentration in cell lysates 
was low. Acetone was first cooled to -20°C, then 4x volume of the sample was added 
to each lysate. Samples were then vortexed and incubated at -20°C for 1 hour. They 
were then centrifuged for 10 minutes at 14,000xg at 4°C. The supernatant was 
discarded, and the pellets left to dry at room temperature for 30 minutes. After drying, 
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pellets were resuspended in a smaller volume of RIPA buffer, and protein 
quantification was repeated.  
  2.2.2.7 SDS-PAGE gel electrophoresis  
Sodium dodecyl sulphate - polyacrylamide gel electrophoresis (SDS-PAGE) was carried 
out using the XCell SureLock™Mini-Cell Electrophoresis system. Pre-cast mini (8cm x 
8cm) Novex® NuPage® gels were used with a 4-12% polyacrylamide gradient, in order 
to optimise the separation between wild type and polyglutamine expanded huntingtin 
bands. These gels are Bis-Tris-HCl buffered (pH6.4) and were designed to be used for 
denaturing gel electrophoresis. 
20µg protein was loaded per lane, unless otherwise stated. Protein samples were 
denatured by heating for 10 minutes at 70°C with NuPage® 4x lithium dodecyl sulphate 
(LDS) sample buffer and NuPage® 10x sample reducing agent. Electrophoresis was 
carried out in 1x NuPage® 3-(N-morpholino)propanesulfonic acid (MOPS) SDS running 
buffer (50mM MOPS, 50mM Tris base, 0.1% SDS, 1mM EDTA) containing 1ml NuPage® 
antioxidant in order to maintain reducing conditions. Electrophoresis was carried out 
at 150V for 2 hours, until the tracking dye ran off the bottom of the gel. Precision Plus 
Protein™ standard from Bio-Rad was used as the molecular weight marker. 
  2.2.2.8 Western blotting 
Resolved proteins in NuPage® gels were blotted onto an Immobilon-P polyvinylidene 
difluoride (PVDF) membrane. Prior to transfer in the XCell II Blot Module, the PVDF 
membrane (8.5 x 7.5cm) was wet in methanol and rinsed with dH2O. The PVDF 
membrane, two sheets of chromatography paper (8.5 x 7.5cm) and 6 blotting sponges 
were then soaked in 1x NuPage® Transfer buffer (25mM Bicine, 25mM Bis-Tris, 1mM 
EDTA), with 0.01% SDS added in order to aid the blotting of larger proteins by 
maintaining reducing conditions. Methanol was not added as this strips SDS from 
proteins and aids the transfer of smaller proteins only. Transfer of higher molecular 
weight proteins was found to be increased with 0% methanol during optimisation of 
this protocol (Section 2.2.2.9). The blot was assembled as illustrated in Figure 2.4. The 
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inner chamber was flooded with transfer buffer, and the outer chamber was filled with 
dH2O. 
 
 
 
 
 
 
 
 
 
For the detection of high molecular weight proteins, gels were blotted at 15V 
overnight, and kept at 4°C to prevent overheating; otherwise, blotting was carried out 
at 30V for 1 hour at room temperature. Blots were then dissembled, and the 
membrane was blocked in either 5% Marvel dried milk powder in PBS-T or 5% BSA in 
PBS-T, depending on supplier recommendations for each antibody, for 30 minutes at 
room temperature on a shaker, or overnight at 4°C. Primary antibodies were diluted in 
the appropriate blocking buffer (Table 2.1), and incubated either for 1 hour at room 
temperature, or overnight at 4°C on a roller. Unbound antibody was then removed by 
3 x 5 minute washes with PBS-T and 1 x 5 minute wash with PBS. The secondary 
antibody was then diluted in the same buffer used for the primary antibody, and was 
incubated with the membrane for 1 hour at room temperature on a roller before being 
washed as detailed above. Protein bands were imaged on the Licor® Odyssey® 
quantitative fluorescent imaging system. 
In order to strip away previously bound antibodies from blots, membranes were 
incubated for 15 minutes at room temperature in Restore™ Plus Western Blot 
Stripping Buffer, followed by another 15 minutes incubation with Restore™ Western 
SDS gel 
Whatman 
paper 
Whatman 
paper 
Sponges 
Sponges 
PVDF 
membrane 
Cathode core 
Anode lid 
 
 
Figure 2.4 Blot assembly. The SDS gel and PVDF membrane are sandwiched 
between two sheets of chromatography paper  and several sponges, all soaked in 
NuPage® Transfer buffer  with 0.01% SDS.  
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Blot Stripping Buffer, and a 5 minute wash in PBS, all with gentle shaking. Membranes 
were then re-blocked and probed with a new antibody as previously described. 
  2.2.2.9 Optimisation of blotting technique 
As HTT and mHTT are high molecular weight proteins, optimisation of the blotting 
protocol was carried out to improve protein transfer onto the PVDF membrane. This 
included varying methanol and SDS concentrations in the transfer buffer, as well as 
varying the voltage and length of time for which the blotting occurred. To test protein 
transfer efficiency, following blotting the PVDF membrane was washed twice for 5 
minutes with dH2O at room temperature. To visualise the protein that had been 
blotted to the PVDF, the membrane was then incubated with Ponceau S solution for 1 
hour at room temperature on a shaker. After this time, the solution was discarded and 
the membrane was given 3 x 5 minute washes in dH2O.  
To visualise the protein that remained on the gel following blotting, the gel was initially 
given 3 x 5 minute washes with dH2O, followed by incubation for 1 hour with 
SimplyBlue™ SafeStain at room temperature on a shaker, then a 1 hour wash in dH2O 
for an hour on the shaker. The gel was then imaged on the Licor® Odyssey® 
quantitative fluorescent imaging system. 
  2.2.2.10 ELISA protocol 
Following the protein extraction protocol outlined in Section 2.2.2.1, lysates were 
diluted in the diluent buffer provided with the ELISA kit (Section 2.1.11) to the required 
protein concentration. The ELISA protocol was then carried out according to 
manufacturer’s instructions, and absorbance was read on a Biotek® µQuant™ 
microplate spectrophotometer at 450nm. 
  2.2.2.11 Immunofluorescence 
To permeabilise cells, fixed coverslips were first incubated with 1% Triton x-100 in 
1xPBS for 30 minutes on a shaker at room temperature, and were then washed 3 times 
with PBS to ensure the detergent was fully removed. Cells were then blocked with 1% 
(w/v) BSA in PBS for 30 minutes on a shaker at room temperature. After this time, the 
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BSA solution was removed and the primary antibody at the relevant dilution (Table 
2.1) was applied. Coverslips were then either incubated for 1 hour at 37°C, or 
overnight at 4°C with the primary antibody, depending on supplier recommendations.  
The primary antibody was then removed, and coverslips were washed with PBS for 3 x 
10 minutes, followed by a 30 minute wash on a shaker at room temperature. Cells 
were then incubated with the relevant secondary antibody (Table 2.1) for 1 hour at 
37°C, while covered in tin foil to block out light. The wash process was then repeated. 
Coverslips were then mounted onto glass microscope slides using a drop of ProLong® 
Gold antifade reagent with DAPI. Coverslips were stored in the dark at 4°C for 24 hours 
to allow the mountant to dry and the DAPI to develop, before sealing with clear nail 
varnish and imaging. 
To control for non-specific binding of the secondary antibodies, secondary-only 
controls were carried out on both immortalised StHdhQ111 embryonic striatal cell lines, 
and primary HdhQ111 and HdhQ150 embryonic cell cultures (Figure 2.5). 
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Goat α Rabbit 568 Donkey α Mouse 488 Chicken α Rat 647 
Hdh
Q111
  
Hdh
Q150
  
B 
Goat α Rabbit 568 Donkey α Mouse 488 
StHdh
Q111
  
A 
Figure 2.5 AlexaFluor secondary antibody-only immunofluorescence controls for A. 
StHdh
Q111
 cell lines and B. primary embryonic Hdh
Q111
 and Hdh
Q150
 cell cultures. 
Cells were treated in the same manner as previously described (Section 2.2.2.11) 
with the exclusion of the primary antibody incubation stage. Coverslips were then 
imaged in the same manner as previously described (Section 2.2.1.9).  
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 2.2.3 Nucleic acid manipulation techniques 
  2.2.3.1 Phenol/chloroform RNA extraction 
For total RNA extraction, both immortalised and primary cells were grown in 6 well 
plates. Media was removed, and the cells were washed twice with PBS. All surfaces 
were treated with RNaseZAP® to destroy RNases. The cells were then lysed and 
dissociated from the wells by the addition of TRIzol® (a phenol and guanidine 
isothiocyanate solution), and were then transferred to a centrifuge tube, and left to 
incubate at room temperature for 5 minutes. Chloroform was added to each sample, 
and was vortexed for 15 seconds to mix the solutions.  
The samples were then spun at 12,000xg for 15 minutes at 4°C in a Beckman Coulter 
Avanti J-E centrifuge. The resulting upper aqueous phase was then transferred to a 
fresh 2ml eppendorf. To precipitate the RNA, isopropanol was added and gently 
shaken into the sample by hand, then left to precipitate at room temperature for 10 
minutes. To pellet the RNA, samples were then spun at 12,000xg for 10 minutes at 4°C 
in a Biofuge. The supernatant was then gently removed and the pellet was washed 
with 75% ethanol, made with nuclease free water. To re-pellet the RNA, it was spun 
again at 9,500xg for 10 minutes at 4°C. This wash step was repeated again, and all of 
the remaining supernatant was removed and discarded. To aid with drying the pellets, 
tubes were kept in a 45°C oven for 15 minutes.  
Following this, the remaining pellets were resuspended in 100µl diethylpyrocarbonate 
DEPC-treated water by vortexing, heating at 65°C on a block for 5 minutes, and then 
vortexing again.    
  2.2.3.2 Purification of RNA samples 
Resuspended RNA samples were purified by silica membrane spin columns, by using 
the RNeasy MinElute Cleanup kit (Section 2.1.13) according to manufacturer’s 
instructions.  
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To degrade any DNA contaminants in the RNA samples, they were treated with 
TURBO™DNase according to manufacturer’s instructions. The resulting purified RNA 
was then stored at -80°C. 
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  2.2.3.3 Quantitation of nucleic acids 
Both DNA and RNA were quantified on a Nanodrop spectrophotometer, and the 
260/280 and 260/230 ratios were utilised as a rough determination of nucleic acid 
quality. 
  2.2.3.4 Quantitative reverse-transcription polymerase chain reaction 
Both SYBR® Green and TaqMan® qRTPCR technologies were used in this project in a 
two-step protocol. For both methods, 1µg RNA per sample underwent reverse 
transcription (RT) using the High Capacity RNA-to-cDNA™ kit from Life Technologies, 
according to manufacturer’s instructions. This concentration of RNA was determined 
by carrying out an RT reaction efficiency curve. This was done by performing the 
reaction with 250ng, 500ng and 1µg RNA, followed by qPCR using an example primer 
pair. If the RT reaction is efficient, the threshold cycle (Ct) values will decrease with 
increased RNA load.  
Similarly, amplification efficiencies were determined for every primer pair for SYBR® 
Green and TaqMan® assays by loading a serial dilution of cDNA into the qRTPCR 
reaction. If the reaction is efficient, there will be a linear relationship between the 
concentration of cDNA put into the reaction, and the resulting Ct value. The R
2 and 
slope of this relationship were then identified from the Sequence Detection Systems 
(SDS) Version 2.3 programme (copyright 2005, Applied Biosystems), and the PCR 
efficiency can be determined from these (see formulae below). Probe efficiencies 
relevant to this project can be found in Table 2.4.  
Efficiency: 
((10ˆ(-1/slope)) -1) x 100 
 
For SYBR® Green qRTPCR, the resulting cDNA from the RT reaction was diluted 1:5 with 
nuclease free water before use. A mastermix was created for each primer pair that was 
to be used (Table 2.2), which per 20µl sample, consisted of: 
10µl  SYBR® Green 
0.6µl  each oligonucleotide primer at 100µM concentration 
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4.8µl  nuclease free water 
4µl  cDNA template 
 
The mastermix and cDNA samples were loaded into Fast Optical 96 well plates, and 
sealed with optical adhesive film. The plate was then briefly centrifuged at 10,000xg 
before being loaded into the Applied Biosystems 7900HT Real Time PCR machine. The 
thermal cycler protocol was as follows: 
 
Stage 1 
95°C  10 minutes (Initialisation) 
Stage 2 (x40 cycles) 
95°C  15 seconds (Denaturation) 
55°C 1 minute (Annealing/extension) 
Stage 3 (Dissociation curve) 
95°C  15 seconds  (following gradual ramp) 
 
A thermal ramp was included at the end of the cycle in order to create a dissociation 
curve to determine the specificity of cDNA amplification to each particular primer pair. 
In order to ensure there was no contamination of samples at each stage of the 2-step 
process, each plate also included an RT- control (where no RT reaction was carried 
out), a water RT control (where the RT reaction was performed, but with no RNA 
template), and a No Template control (where cDNA was replaced with dH2O).  
 
For Taqman® qRTPCR, 200ng of cDNA template was loaded into each reaction, and 
made up to a total volume of 9µl with nuclease free water. This was added to a 
mastermix of 10µl Taqman® Fast Advanced master mix and 1µl of the relevant 
Taqman® gene expression assay per well, which was then loaded into Fast Optical 96 
well plates, then sealed with optical adhesive film. The plate was then briefly 
centrifuged at 10,000xg before being loaded into the Applied Biosystems 7900HT Real 
Time PCR machine. The thermal cycler protocol was as follows: 
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Stage 1 
50°C  2 minutes  (UNG activation) 
95°C 20 seconds (Polymerase activation) 
Stage 2 (x40 cycles) 
95°C 1 second  (Denaturation) 
60°C 20 seconds  (Annealing/extension) 
 
All qRTPCR protocols were controlled and analysed by Sequence Detection Systems 
(SDS) Version 2.3 programme from Applied Biosystems. Taqman® data were also 
analysed using SDS RQ Manager Version 1.2, also by Applied Biosystems. 
  2.2.3.5 DNA extraction from primary tissue 
For the purpose of genotyping, the remaining mouse embryo brain was digested 
overnight in a shaking incubator at 40°C in DNA extraction buffer (Section 2.1.3), plus 
10µl Proteinase K per sample. The next day, 6M Sodium Chloride was added, the 
samples vortexed and centrifuged for 10 minutes at 13,000xg. The resulting 
supernatant was retained and the pellet discarded. To precipitate the DNA, 
Isopropanol was added to the supernatant, and put in a -80°C freezer for 15 minutes. 
Samples were centrifuged again at 13,000xg for 10 minutes to pellet the DNA, and the 
supernatant discarded.  
The pellet was then washed in 70% ethanol, and centrifuged again to remove all the 
remaining ethanol. The pellet was then placed on a heating block at 80°C for 2 
minutes, and then resuspended in nuclease free water at room temperature for an 
hour. The DNA was then quantified as described in Section 2.2.3.3. 
  2.2.3.6 Genotyping polymerase chain reaction 
Reactions were performed in a 25µl final volume, containing 5M Betaine, 50mM 
Magnesium Chloride (MgCl2), 10mM deoxyribonucleotide triphosphate (dNTP) mix, 
ammonium (NH4) reaction buffer, 100µM each forward and reverse primers (Table 
2.2), and BioTaq™ DNA polymerase, with 50ng DNA per reaction. PCR reactions were 
all performed with the following protocol: 
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Stage 1 
94°C 5 minutes  (Initialisation) 
Stage 2 (x 34) 
94°C 30 seconds (Denaturation) 
50°C 30 seconds (Annealing) 
72°C 3 minutes (Extension) 
Stage 3 
72°C 5 minutes (Final extension) 
 
Completed reactions were then stored at 4°C until use. 
  2.2.3.7 Oligonucleotide primer design 
Primers used for SYBR® Green qRTPCR were designed over gene exon boundaries using 
the program Primer 3 (V.0.4.0), which is available on the internet 
(http://frodo.wi.mit.edu/). All primers were synthesised to a scale of 25nM, and were 
provided in a desalted lyophilised form, and were then resuspended to a 100µM stock 
solution using nuclease free water, and then stored at -20°C. TaqMan® gene 
expression assays were pre-designed by Life Technologies. 
  2.2.3.8 Agarose gel electrophoresis of DNA 
PCR products were run on 1% agarose gels made with TBE; agarose was dissolved in 
TBE buffer by heating in a microwave, and was then cooled before adding 3µl ethidium 
bromide. The liquid was poured into a mould and allowed to set for at least 30 
minutes. 
Following PCR amplification, 6µl of DNA orange loading dye was added to each PCR 
product and gently mixed by pipetting. HyperLadder™50bp was loaded into the first 
and last lanes of each gel, and 15µl of PCR product containing loading dye was loaded 
into each lane. The gels were electrophoresed at 100V for 1 hour, before being 
visualised using a 3UV™ Transilluminator and imaged on the UVP AutoChemi™ 
BioImaging system, where it was then analysed in Labworks Image Acquisition and 
Analysis Software version 4.5.0 (copyright 1996-2003, Media Cybernetics Inc). 
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  2.2.3.9 Microarray  
Microarray experiments were kindly carried out by Megan Musson in Cardiff 
University’s Central Biotechnology Services (CBS) department.  
  2.2.3.10 siRNA transfection for antibody validation 
ON-TARGETplus SMARTpool siRNA oligonucleotides were purchased at 5nmol, and 
were resuspended into a stock solution of 20µM by mixing with 250µl 1 x siRNA buffer 
(diluted from 5x stock solution with nuclease free water) on a shaker for 30 minutes at 
room temperature. siRNA experiments were carried out with a final siRNA 
concentration of 25nM, with 1µl DharmaFECT transfection reagent no.1 per well (using 
a 6 well plate). Details of the siRNA oligonucleotides and the relevant TaqMan® primer 
efficiencies can be found in Table 2.5. 
To prepare the siRNA for transfection, 20µM stock siRNA was first diluted to a 5µM 
working solution using 1x siRNA buffer. 10µl/well was then gently mixed with 
190µl/well serum free media, and left to incubate at room temperature for 5 minutes. 
1µl/well DharmaFECT transfection reagent was mixed with 199µl serum free media in 
a separate tube and also incubated for 5 minutes at room temperature. Following the 
incubation time, 200µl/well of the DharmaFECT media was transferred to the siRNA 
media, mixed gently and incubated for 20 minutes at room temperature. 1600µl/well 
of antibiotic free media was then added to the transfection media and mixed; this was 
now the complete transfection reagent. Old media was removed from the cells and 
replaced with 2ml of the appropriate transfection reagent.  
StHdhQ7/7 cells were seeded at 0.25x105/well, and StHdhQ7/111 and StHdhQ111/111 cells 
were seeded at 0.5x105/well in 6 well plates in 5% FBS antibiotic free media. For RNA 
analysis, siRNA was applied 24 hours after seeding, and RNA was extracted following 
48 hours of incubation. For protein analysis, siRNA was applied 24 hours after seeding, 
applied again 48 hours later, and either protein lysates were extracted or cells were 
fixed after a further 48 hours. 
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Huntingtin 
Target sequence Exon 
GAACGUACCCAGUUUGAAA 60 
AUACAGAUGUGUGGAGUAA 62-63 
GGCCUUACCUGGUGAAUCU 5-6 
GAAUGGUGCUCCUCGAAGU 5 
 
Gapdh 
Target sequence Exon 
GUGUGAACCACGAGAAAUA 1 
GGAGAAACCUGCCAAGUAU 1 
UCAAGAAGGUGGUGAAGCA 1 
UGGUGAAGCAGGCAUCUGA 1 
 
 
Huntingtin Gapdh 
R
2
 0.96 1 
Slope -2.91 -3.66 
Efficiency (%) 120.6 87.7 
 
 
  
 
Table 2.5 ON-TARGETplus SMARTpool siRNA target sequences for mouse A. Htt and 
B. Gapdh. Each siRNA that was utilised consisted of a pool of four separate 
oligonucleotides for increased gene coverage. C. TaqMan® probe efficiencies for the 
primers used to assess siRNA knockdown. 
A 
B 
C 
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 2.2.4 Growth factor stimulation and pathway inhibition 
  2.2.4.1 Growth factors 
EGF, NGF and BDNF were reconstituted and diluted to a stock solution of 100µg/ml in 
PBS and stored at -20°C. TGFβ1 was also reconstituted to a stock solution of 100µg/ml, 
but in 20mM citrate, pH 3.0, and stored at -20°C. 24 hours prior to growth factor 
treatment, the present media was removed from the cell cultures and replaced with 
the same volume of serum free media. The following day, the appropriate growth 
factor was diluted to 100ng/ml in fresh serum free media; the previous serum free 
media was removed from the cells and replaced with the growth factor media for the 
appropriate length of time before subsequent processing. 
  2.2.4.2 Kinase inhibition 
AKT inhibitor VIII was reconstituted in DMSO to a stock solution of 0.1mM, and MEK 
1/2 inhibitor was initially reconstituted in DMSO, before being diluted to a 0.05mM 
stock solution in serum free media.  Aliquots of both inhibitors were stored at -20°C. 
Cells were serum starved for 24 hours (as described in Section 2.2.4.1) prior to 
treatment with either kinase inhibitor. Each inhibitor was diluted to the appropriate 
concentration in serum free media, and was incubated with the cells for 2 hours prior 
to EGF stimulation. Serum free media containing the equivalent volume of just DMSO 
was used as a control. EGF was diluted to 100ng/ml in fresh serum free media that also 
contained the appropriate concentration of each kinase inhibitor or DMSO before 
incubation with the cells. 
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Chapter 3:  The localisation and phosphorylation of huntingtin in immortalised 
  murine knock-in embryonic striatal cell lines 
 
3.1 Introduction 
Early immunofluorescence studies detected the localisation of the HTT protein as 
primarily cytoplasmic (DiFiglia et al. 1995; Gutekunst et al. 1995), and nuclear 
localisation was thought to be indicative of a pathogenic process of mHTT (Reddy et al. 
1999). Specifically, HTT has been found to localise with the endoplasmic reticulum and 
presynaptic vesicles (Atwal et al. 2007), as well as the Golgi body, dendritic plasma 
membrane and cytoskeleton (Ko et al. 2001; Rockabrand et al. 2007). However, it is 
now accepted that both HTT and mHTT localise to nuclei in cell and mouse models of 
HD, as well as in human HD brain (De Rooij et al. 1996; Hilditch-Maguire et al. 2000; 
Trettel et al. 2000; Wheeler 2000; Ko et al. 2001; Tao & Tartakoff 2001; Kegel et al. 
2002; Truant 2003; Benn et al. 2008). 
HTT is thought to perform several necessary roles within the nucleus (Hilditch-Maguire 
et al. 2000; Trettel et al. 2000; Kegel et al. 2002; Benn et al. 2008), and as such, 
shuttling dynamically between the cytoplasm and the nucleus may be a means by 
which its function is regulated (Truant 2003; Truant et al. 2007), although the 
mechanism by which this occurs is not fully understood. Full length HTT has been 
found to be present in cell nuclei (De Rooij et al. 1996; Dorsman et al. 1999; Trettel et 
al. 2000; Kegel et al. 2002), although to a lesser extent than in the cytoplasm; however 
there is an enrichment of N-terminal fragments of HTT in the nucleus compared to the 
cytoplasm (Hilditch-Maguire et al. 2000; Tao & Tartakoff 2001; Kegel et al. 2002). 
These fragments may be created by proteolytic cleavage of HTT by caspases (Bauer & 
Nukina 2009); in the case of mHTT, N-terminal fragments containing the expanded 
polyglutamine repeat are able to translocate to the nucleus (Hackam et al. 1998), 
where their presence may be detrimental due to aggregation and aberrant function. 
However, in YAC128 mice resistant to HTT cleavage by caspase-6, there was delayed 
nuclear localisation of HTT, as there were fewer small fragments available for passive 
diffusion across the nuclear pore (Graham, Slow, et al. 2006).  
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The majority of HTT and mHTT N-terminal fragments have had the putative C-terminal 
NES cleaved away (Wellington et al. 1998; Kim et al. 2003; Xia 2003; Landles et al. 
2010), which may explain why a larger proportion of truncated HTT and mHTT remain 
in cell nuclei. Mutations of the first 17 amino acids, including the presence of an 
expanded polyglutamine repeat,  may impair the cytoplasmic retention signal activity 
of this region by altering its structure, and impair the CRM1 dependent NES, thus 
leading to increased nuclear localisation of HTT (Steffan et al. 2004; Cornett et al. 
2005; Atwal et al. 2007; Rockabrand et al. 2007; Gu et al. 2009; Maiuri et al. 2013).   
There is some uncertainty over how full length HTT and mHTT are able to localise to 
the nucleus, given how large the protein is. In addition to the potential NLS sites 
identified on HTT (Bessert et al. 1995; Xia 2003; Truant et al. 2007; Desmond et al. 
2013), the HTT protein may also require an exogenous NLS in order to traverse the 
nuclear pore, and this mechanism may be specific to cortical and striatal neurons 
(Truant 2003; Truant et al. 2007). Indeed, there are several HTT-interacting proteins, 
including transcription factors that may act as potential chaperones (Li et al. 1995; 
Faber et al. 1998). The presence and activation of these chaperone proteins have also 
been identified as a moderating factor of nuclear inclusion formation and toxicity of 
mHTT in Drosophila, yeast and mammalian models of HD (Ferrigno & Silver 2000). 
Post-translational modification of HTT by phosphorylation has been identified as a 
mechanism by which the subcellular localisation of HTT may be regulated. For 
example, phosphorylation of S421 can inhibit proteolytic cleavage and reduce the 
amount of HTT transported to the nucleus (Bauer & Nukina 2009; Warby et al. 2009); 
as such, phosphorylation of S421 has a protective effect in models of HD by reducing 
the levels of nuclear toxic fragments available. Phosphorylation of both S13 and S16 
have also been found to influence HTT cellular localisation (Gu et al. 2009; Thompson 
et al. 2009; Atwal et al. 2011; Havel et al. 2011). Phosphomimetic mutations of both 
S13 and S16 to aspartate have been found to increase the nuclear localisation of full 
length and fragmented HTT and mHTT in immortalised murine embryonic striatal cells 
(Thompson et al. 2009) as well as in a bacterial artificial chromosome mouse model 
(BACHD) of HD containing 97 glutamine repeats (Gu et al. 2009). In both models, this 
modification was found to be protective by enhancing clearance of the mutant protein 
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(Thompson et al. 2009), and by preventing aggregate formation and 
neurodegeneration (Gu et al. 2009). In the BACHD model, it was suggested that 
phosphorylation of S16 was more important for the nuclear localisation of HTT, as a 
phosphomimetic mutation of S16 had effects similar to that of a double mutant; 
whereas mutation of S13 alone did not elicit the same protection (Gu et al. 2009). 
Atwal et al. 2011 also found that phosphomimetic mutation of S16 alone increased the 
nuclear localisation of HTT in immortalised striatal neurons, but mutation of S13 did 
not. 
Havel et al. 2011 proposed that phosphorylation of S16 is key for generating N-
terminal fragments of HTT that localise to the nucleus, but rather than this being a 
protective effect, they found that it enhanced the formation of nuclear aggregates in 
primary rat striatal neurons transfected with N-terminal mHTT containing 143 
glutamine repeats. It was also found that phosphorylated mHTT in the nucleus was less 
able to interact with the nuclear pore complex protein TPR, which is implicated in the 
nuclear export of HTT, as well as other proteins (Bangs et al. 1998; Frosst et al. 2002; 
Cornett et al. 2005). In addition, phosphomimetic mutations of HTT S13 and S16 
reduced the interaction of HTT with the nuclear export factor CRM1, thus retaining it 
in the nucleus (Maiuri et al. 2013). Smaller fragments of phosphorylated HTT and 
mHTT may therefore translocate to the nucleus via passive diffusion, but 
phosphorylated forms of mHTT are less able to leave the nucleus and therefore 
gradually accumulate over time and may form aggregates. 
The phosphorylation of S13 and S16 may influence the shuttling of HTT and mHTT 
between cellular compartments, but whether this is a protective effect or not is still 
unknown. However, if increased phosphorylation and nuclear localisation of mHTT is 
initially protective, gradual nuclear accumulation is likely to be damaging. Striatal cells 
from knock-in HdhQ140 mice showed increased staining for phosphorylated S16 
compared to wild type (WT) cells at 6 months of age, and this increased further by 24 
months of age (Havel et al. 2011). However, immortalised murine embryonic striatal 
neurons carrying an expanded polyglutamine repeat have been found to be 
hypophosphorylated on these two serines (Atwal et al. 2011). mHTT has been 
identified as being phosphorylated less efficiently than wild type HTT (Thompson et al. 
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2009), so  these results may reflect the transient nature of phosphorylation in early, 
non-symptomatic stages of disease prior to gradual accumulation of this modification 
on mHTT due to a  reduced ability to translocate between cellular compartments.  
HTT and its phosphorylation have been implicated in various neurotrophin associated 
signalling pathways; for example, the phosphorylation of HTT has been related to the 
activity of various cellular kinases such as IKK, AKT and casein kinase 2 (CK2), which can 
influence the phosphorylation of S13 and S16, and subsequently the localisation of HTT 
(Thompson et al. 2009; Atwal et al. 2011; Khoshnan & Patterson 2011; Desmond et al. 
2013). Here, we aim to characterise the localisation and phosphorylation of HTT and 
mHTT epitopes in the StHdhQ111 immortalised murine embryonic striatal cell model of 
HD in response to stimulation with a panel of different growth factors, in order to 
determine whether HTT localisation may be regulated by kinase signalling pathway 
activation, and if this is disrupted in the context of mHTT. 
 
3.2 Identifying the appropriate growth factor receptors   
The presence of the appropriate growth factor receptors in StHdhQ7/7, StHdhQ7/111 and 
StHdhQ111/111 cell lines was checked to ensure that these cells were capable of 
responding to stimulation with either BDNF, NGF or EGF.  
 3.2.1 The TRKB receptor 
The receptor for BDNF, TRKB, was found to be present in StHdhQ7/7, StHdhQ7/111 and 
StHdhQ111/111 cells (Figure 3.1). It appeared to be localised in the same manner between 
genotypes, and although quantification of its detection by western blot suggested 
slightly lower levels of TRKB in StHdhQ7/111 and StHdhQ111/111 cells, this was not 
statistically significant (p>0.05).  
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 3.2.2 The TRKA and P75 NTR receptors 
NGF stimulates both TRKA and the low affinity P75 neurotrophin receptor (P75 NTR). 
Both NGF receptors were found to be present in all three genotypes (Figure 3.2); there 
were no apparent differences in localisation by immunofluorescence for P75 NTR, 
although for the TRKA receptor, the localisation is slightly more diffuse in StHdhQ7/111 
and StHdhQ111/111 cells compared to StHdhQ7/7 cells, and isn’t detected in such large 
clusters. However, there is no significant difference in the detection of each receptor 
by western blot between genotypes. 
Figure 3.1 A. Immunofluorescence images of StHdh
Q7/7
, StHdh
Q7/111
 and 
StHdh
Q111/111
 cells, stained using an Anti-TRKB antibody. Scale bar = 20µm. B. 
Western blot indicating similar expression of the TRKB protein in all three cell lines 
using the same antibody as in A. (TRKB 92kDa, α-tubulin 50kDa). C. Licor Odyssey 
quantification of fluorescence intensity (FI) of B; TRKB normalised to α-tubulin 
loading control. There are no significant differences in the levels of the TRKB 
receptor between StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111
 cells (Error bars = SEM, 
n=3).  
StHdh
Q7/7 StHdh
Q7/111 
StHdh
Q111/111 
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B C 
D E 
Figure 3.2 A. Immunofluorescence images of StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111
 
cells, stained using antibodies against P75 NTR and TRKA. Scale bar = 20µm. B-C. 
Western blots indicating similar expression of the P75 NTR (60-75kDa) and TRKA 
(140kDa) proteins in all three cell lines using the same antibody as in A, using α-
tubulin (50kDa) as a loading control. D-E. Licor Odyssey quantification of B and C, 
normalising receptor fluorescence intensity (FI) levels to α-tubulin loading control; 
there are no significant differences in the levels of the P75 NTR or TRKA receptors 
between StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111
 cells (Error bars = SEM, n=3). 
A 
P75 NTR 
TRKA 
StHdh
Q7/7
 StHdh
Q7/111
 StHdh
Q111/111
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 3.2.3 The EGF receptor 
The EGFR was found to be present in StHdhQ7/7, StHdhQ7/111 and StHdhQ111/111 cells, and 
there were no differences in its subcellular localisation between genotypes, as 
identified by immunofluorescence and western blot (Figure 3.3), which has been 
observed previously in the same cell line (Ginés et al. 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 A. Immunofluorescence images of StHdh
Q7/7
, StHdh
Q7/111
 and 
StHdh
Q111/111
 cells, stained using an Anti-EGFR antibody. Scale bar = 20µm B. 
Western blot indicating similar expression of the EGFR protein (175kDa) in all three 
cell lines using the same antibody as in A, and α-tubulin (50kDa) as a loading 
control. C. Licor Odyssey quantification of fluorescence intensity (FI) of B normalised 
to loading control; there are no significant differences in the levels of EGFR between 
StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111
 cells (Error bars = SEM, n=3). 
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3.3 Localisation of HTT epitopes in response to growth factor stimulation 
StHdhQ7/7, StHdhQ7/111 and StHdhQ111/111 cells were stimulated with one of three growth 
factors at 100ng/ml for 0, 5, 15 and 30 minutes following overnight serum starvation, 
before being fixed and probed with a panel of antibodies against different HTT 
epitopes. A summary of these antibodies can be found in Table 2.1 and Figure 2.1.  
 3.3.2 Characterisation of HTT N-terminal antibodies 
The specificity of several antibodies against N-terminal HTT utilised in these 
experiments was validated by knocking down the expression of Htt in StHdhQ7/7, 
StHdhQ7/111 and StHdhQ111/111 cells. 
  3.3.2.1 Gene expression 
The expression of Htt was analysed by qRTPCR in response to incubation with Htt 
siRNA, in comparison to incubation with Gapdh siRNA, non-coding siRNA and 
transfection reagent only controls. Further details of the protocol and the siRNA 
oligonucleotides utilised can be found in Section 2.2.3.11 and Table 2.5. There was a 
significant reduction in Htt expression in StHdhQ7/7 cells (Figure 3.4) following 48 hours 
of incubation with 25nM Htt siRNA as compared to all three control conditions (all 
p<0.025).  
Gapdh control siRNA was able to significantly reduce the expression of Gapdh in these 
cells compared to all other conditions (all p<0.001) without significantly reducing Htt 
expression. The relative quantification (RQ) score for Htt expression in StHdhQ7/111 and 
StHdhQ111/111 cells was lower than the control conditions, although due to high 
variability, possibly due to the mutant expansion, and low statistical power, this 
difference did not reach significance for individual control conditions. However, there 
is a trend that Htt is being knocked down in these cells, as the expression of Htt is 
significantly lower following Htt siRNA treatment in StHdhQ7/111 cells when the control 
conditions are pooled (p=0.038), and there is a trend towards a significant difference in 
StHdhQ111/111 cells (P=0.069). Conversely, Gapdh expression was significantly reduced 
compared to all controls in StHdhQ7/111 cells (p<0.001) and compared to the non-coding 
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siRNA control in StHdhQ111/111 cells (p=0.028), indicating that these cells are capable of 
being transfected with the same efficiency as StHdhQ7/7 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
Figure 3.4 A. qRTPCR relative quantification (RQ) values representing the expression 
of Htt in StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111
 cells when treated with either the 
DharmaFECT transfection reagent alone, a non-coding siRNA, Gapdh siRNA, or Htt 
siRNA for 48 hours prior to RNA extraction. B. The expression of Gapdh under the 
same conditions. Differences in cycle threshold (Ct) values were statistically 
analysed by genotype individually using a one-way ANOVA and post-hoc Tukey tests 
(Error bars = SEM, n=3). ‘*’ indicates a significant difference to DharmaFect only 
control. 
*p<0.05 **p<0.01 ***p<0.001  
R
Q
 
Gapdh expression 
StHdh
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Q111/111
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  3.3.2.2 Western blot analysis 
In order to validate whether the high molecular weight ~350kDa band on western blot 
analyses detected by our panel of anti-HTT antibodies was in fact the HTT protein, cells 
were incubated for 48 hours with the appropriate siRNA or control oligonucleotides, 
followed by another 48 hour incubation with fresh oligonucleotides prior to collection 
of protein lysates. The extension of the siRNA protocol was due to the longer 
degradation time of proteins compared to mRNAs. The experiment was carried out 
with triplicate samples, and after the initial detection, each blotted membrane was 
stripped and re-probed with the panel of HTT antibodies. 
There was a visible reduction in the strength of the high molecular weight band in all 
three genotypes following Htt siRNA treatment compared to the control conditions 
(Figure 3.5), however due to noise and a lack of power, quantification of the HTT band 
intensity was not significantly different to quantification of the transfection reagent 
only control. Despite this, qualitatively, Htt siRNA treatment reduces the strength of 
the high molecular weight band detected by all anti-HTT antibodies, and therefore 
these antibodies are likely to be picking up full length HTT by western blot. The 
concentration of the protein lysate for StHdhQ7/7 cells treated with Htt siRNA was lower 
than the other lysates, and as such less could be loaded onto the gel, however 
normalisation to the α-tubulin loading control reveals that there is still a relative 
reduction in the strength of detection of the HTT band.  
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Figure 3.5 Continued on next page 
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Figure 3.5 A. Western blots of StHdh
Q7/7
, StHdh
Q7/111 
and StHdh
Q111/111 
cells treated 
with either 25nM Htt siRNA, 25nM Gapdh siRNA, 25nM non-coding (N-C) siRNA or 
transfection reagent only control for 48 hours, followed by a second 48 hour 
incubation with the same treatment.  Blots were double-probed for Ab675 and 
Mab2166 before being stripped and re-probed sequentially with the rest of the 
panel of N-terminal HTT antibodies, and α-tubulin as a loading control. B. Licor 
Odyssey quantification of fluorescence intensities in A. Intensities were normalised 
to α-tubulin loading control, then expressed as a percentage of the transfection-
only control intensity (%C)  (Error bars = SEM, n=3). 
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  3.3.2.3 Immunofluorescence 
As there was no effect on the expression of Htt or presence of its protein product 
when cells were treated with Gapdh or non-coding siRNA oligonucleotides, only the 
transfection reagent control was used for the immunofluorescence experiments in 
order to preserve antibody stocks. For all antibodies investigated, there was little 
visible reduction of signal in StHdhQ7/7 cells that had been treated with Htt siRNA 
compared to the transfection reagent only control (Figure 3.6). However, there was a 
visible reduction when looking at Ab109115, N17 and N17 s1316p; this is particularly 
evident for the two non-phosphorylated HTT antibodies, where there is a visible 
reduction in the detection of nuclear HTT. There is a larger apparent difference in 
StHdhQ7/111 and StHdhQ111/111 cells for all antibodies when Htt is knocked down; similar 
to StHdhQ7/7 cells, the most obvious difference is the reduction of a nuclear signal. It 
has previously been observed that the expression of the mutant HTT protein is lower 
than the wild type protein (Gutekunst et al. 1995; Persichetti et al. 1996; J. Miller et al. 
2010; Pouladi et al. 2010), and that this may be due to reduced stability (Sapp et al. 
2012) and a shorter half-life of mHTT (J. Miller et al. 2010); both of which may 
contribute to a greater reduction in HTT detection following siRNA treatment in 
StHdhQ7/111 and StHdhQ111/111 cells compared to StHdhQ7/7 line. 
The knock down of Htt in these cells appears to have also had an effect on cell 
morphology, particularly in StHdhQ7/111 and StHdhQ111/111 cells; qualitatively, cell soma 
became considerably smaller, and there was a reduction in cell number. Whether this 
was due to increased cell death or was a suppression of growth was not investigated as 
this was not the primary aim of this experiment. However, as it has been previously 
noted that in the developing cortical neuroepithelium, knocking out Htt disturbs cell 
migration and proliferation, and increases cell death (Tong et al. 2011), it is not 
unexpected that reducing Htt expression in an embryonic striatal cell model has 
detrimental effects on cell survival.   
 
 
94 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
Figure 3.6 Continued on next page 
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Figure 3.6 Continued on next page 
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Ab675 
Mab2166 
Ab109115 
N17 
N17 s1316p 
DharmaFECT only Htt siRNA 
 
StHdh
Q111/111
 
Figure 3.6. Immunofluorescence images of A. StHdh
Q7/7
, B. StHdh
Q7/111
 and C. 
StHdh
Q111/111 
cells treated with either 25nM Htt siRNA or transfection reagent-only 
for 48 hours followed by a second 48 hour incubation with the same treatment, 
then probed with a panel of N-terminal HTT antibodies. Scale bar = 20µm.  
C 
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Despite the knock down of the HTT protein not being entirely successful, we have 
shown evidence that suggests each of the N-terminal HTT antibodies that were 
analysed are likely to be detecting the HTT protein, particularly in cell nuclei. However, 
the extent of any non-specific binding could not be assessed due to incomplete protein 
knock down. Several other models may have been particularly useful for anti-HTT 
antibody validation, such as HTT knock-out mouse neural stem cell lines (Conforti et al. 
2013) and conditional Htt null mutation mouse fibroblast cells (Zhang et al. 2008; 
Dragatsis et al. 2000). However, these were not available to us, and as they were not 
derived from the same mouse model utilised here, may have had the extra confound 
of additional or alternative HTT epitopes that are not apparent in StHdhQ111 cell lines 
when using the same antibodies. 
 3.3.3 Immunostaining with antibody 675 
  3.3.3.1 BDNF stimulation 
At baseline, the N-terminal epitope of HTT as detected by Ab675 is primarily 
cytoplasmic in StHdhQ7/7 cells, although it becomes increasingly nuclear with increased 
mHTT load (Figures 3.7 and 3.8). Statistical analysis of quantitative measures (for 
further details, see Section 2.2.1.10  and Figure 2.3)  of the nuclear/cytoplasmic (N/C) 
pixel intensity ratio showed that there was a significant main effect of cell type (F (2, 
664) = 22.56, p<0.001) and time of growth factor stimulation (F (3, 664) = 19.79, 
p<0.001) on the localisation of HTT epitopes, as well as a significant interaction 
between the two (F (6, 664) = 2.27, p=0.035). Simple main effects analysis showed that 
StHdhQ7/7 had significantly lower N/C intensity ratios than both the StHdhQ7/111 and 
StHdhQ111/111 cell lines (P<0.001), which did not differ from each other (P=0.17). Post-
hoc Tukey HSD tests revealed that following 5 minutes of BDNF stimulation, there was 
a significant reduction in the nuclear/cytoplasmic (N/C) intensity ratio for all three cell 
lines (StHdhQ7/7 p=0.011, StHdhQ7/111 p=0.044, StHdhQ111/111 p<0.001); the effect of 
which was persistent for up to 30 minutes of stimulation (StHdhQ7/7 p=0.011, 
StHdhQ7/111 p<0.001, StHdhQ111/111 p<0.001). In StHdhQ7/7 cells, there was also a 
significant reduction in the nuclear/perinuclear (N/P) ratio (F (3,664) = 16.78, p<0.001) 
and perinuclear/cytoplasmic (P/C) ratio following BDNF stimulation (F (3,664) = 19.72, 
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p<0.001), both of which significantly interacted with cell type (N/P F(6,664) = 10.88, 
p<0.001, N/C F(6,664) = 3.03, p=0.006). This suggests that there is reduction of the N-
terminal epitope of HTT and mHTT in the nucleus and a concordant increase in the 
cytoplasm following BDNF stimulation, but that this effect is influenced by cell type.  
In both StHdhQ7/111 and StHdhQ111/111 cells, there was a significant reduction in the N/P 
ratio for N-terminal HTT and mHTT epitopes over time. In StHdhQ7/111 cells, there is 
significant reduction in the N/P ratio by 30mins (Tukey HSD p<0.001), but no difference 
in the P/C ratio (p=0.076), suggesting that although there may be some movement out 
of the nucleus, there doesn’t appear to be relocalisation to the cytoplasm. In contrast, 
StHdhQ111/111 cells show reduced N/C and P/C ratios after only 5 minutes (p<0.001), but 
there is no significant change in the N/P ratio itself at any time point (p>0.05). 
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Figure 3.8 Quantitative analysis of immunofluorescence images in Figure 3.7. 
Nuclear/Cytoplasmic (N/C),  Nuclear/Perinuclear (N/P) and Perinuclear/Cytoplasmic 
(P/C) mean pixel intensity ratios for StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111 
cells 
following 0, 5, 15 and 30 minutes of stimulation with 100ng/ml BDNF. Mean pixel 
intensities were calculated from confocal microscopy images using GNU Image 
Manipulator (further details of the analysis can be found in Section 2.2.1.10). All 
images were randomised and analysed blind to genotype and length of time 
stimulated with BDNF. Each condition consisted of 9 confocal microscopy images 
taken from 3 separate coverslips. A two-way ANOVA was carried out for main 
effects analysis, followed by planned one way ANOVAs and post-hoc Tukey tests.  
Error bars = SEM 
* p<0.05  ** p<0.01 *** p<0.001 
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  3.3.3.2 NGF stimulation 
In contrast to BDNF stimulation, NGF stimulation of immortalised embryonic cell lines 
prompted a significant nuclear increase of the N-terminal HTT epitope (F (3,826) =5.38, 
p=0.001), but there was also a significant interaction between length of stimulation 
and cell type (F (6,826) = 12.50, p<0.001) (Figures 3.9 & 3.10). This occurs as early as 
after 5 minutes in StHdhQ7/7 cells (p=0.039), although the effect is delayed to 30 and 15 
minutes in both the StHdhQ7/111 and StHdhQ111/111 cell lines, respectively (StHdhQ7/111 
30mins p<0.001, StHdhQ111/111 15mins p=0.002). Statistical analysis of the N/P ratio for 
StHdhQ7/7 and StHdhQ7/111 cells shows a significant reduction by 15 minutes, when the 
N/P intensity ratio returns to baseline following the 5 minute increase (StHdhQ7/7 
p<0.001, StHdhQ7/111 p<0.001). There is no significant change in the P/C ratio for any 
genotype at these times, suggesting that detection of HTT epitopes is changing largely 
between the nucleus and the perinuclear region rather than between the nucleus and 
cytoplasm. However, StHdhQ111/111 cells show a significant increase in the P/C ratio 
following NGF stimulation by 15 minutes (p=0.002), with no significant N/P change, 
suggesting that the N-terminal epitope of mHTT may be recruited from the cytoplasm, 
and becomes condensed in the nuclear and perinuclear regions of the cell. 
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Figure 3.10 Quantitative analysis of immunofluorescence images in Figure 3.9. 
Nuclear/Cytoplasmic (N/C),  Nuclear/Perinuclear (N/P) and Perinuclear/Cytoplasmic 
(P/C) mean pixel intensity ratios for StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111 
cells 
following 0, 5, 15 and 30 minutes of stimulation with 100ng/ml NGF. Mean pixel 
intensities were calculated from confocal microscopy images using GNU Image 
Manipulator (further details of the analysis can be found in Section 2.2.1.10). All 
images were randomised and analysed blind to genotype and length of time 
stimulated with NGF. Each condition consisted of 9 confocal microscopy images taken 
from 3 separate coverslips. A two-way ANOVA was carried out for main effects 
analysis, followed by planned one way ANOVAs and post-hoc Tukey tests.  Error bars = 
SEM. 
* Denotes a significant difference from 0mins 
# Denotes a significant difference from 5mins 
* p<0.05  ** p<0.01  *** p<0.001 
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  3.3.3.3 EGF stimulation 
Although there is a significant effect of both time (F (3,797) = 6.15, p<0.001) and cell 
type (F (2, 797) = 77.25, p<0.001) on the N/C ratio following EGF stimulation there was 
no significant interaction (F (6,797) = 0.38, p=0.89). However, the interaction was 
significant for the N/P ratio (F (6, 797) = 6.42, p<0.001). Similar to BDNF stimulation, 
EGF prompted a reduction of the N-terminal epitope of HTT in the nucleus by 5 
minutes of stimulation in both StHdhQ7/7 and StHdhQ7/111 cell lines (p=0.021, p=0.001 
respectively), although the effect is not persistent beyond this time point (Figure 3.11 
& 3.12). There was a trend towards the same effect in the StHdhQ111/111 cells, although 
this was not significant (p=0.702). Analogous to the effect seen following NGF, there 
were significant differences in the N/P ratio for the StHdhQ7/7 and StHdhQ7/111 cell lines 
by 5 minutes (p=0.021, p=0.001 respectively), but there was no significant change in 
the P/C ratio at any time point. StHdhQ111/111 cells don’t show any significant 
differences in N/C or N/P pixel intensity ratios over time, suggesting reduced 
movement of the N-terminal epitope of mHTT in response to EGF.  However, there is a 
statistically significant increase of the P/C ratio at 30 minutes following a non-
significant trend away from the perinuclear region at 5 minutes (p=0.023). 
 
 
 
 
 
 
 
 
 
 
105 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
St
H
d
h
Q
7
/7
 
St
H
d
h
Q
7
/1
1
1  
St
H
d
h
Q
1
1
1
/1
1
1  
0
 m
in
u
te
s 
5
 m
in
u
te
s 
1
5
 m
in
u
te
s
 
3
0
 m
in
u
te
s 
Fi
gu
re
 3
.1
1
 S
u
b
ce
llu
la
r 
lo
ca
lis
at
io
n
 o
f 
an
 N
-t
er
m
in
al
  
ep
it
o
p
e 
o
f 
H
TT
 a
n
d
 m
H
TT
 in
 S
tH
d
h
Q
7
/7
, 
St
H
d
h
Q
7
/1
1
1
 a
n
d
 S
tH
d
h
Q
1
1
1
/1
11
 c
el
l 
lin
es
. 
C
el
ls
 w
er
e 
fi
xe
d
 f
o
llo
w
in
g 
0
, 
5
, 
1
5
 a
n
d
 3
0
 m
in
u
te
s 
o
f 
st
im
u
la
ti
o
n
 w
it
h
 1
0
0n
g/
m
l E
G
F,
 la
b
el
le
d
 w
it
h
 A
b
67
5
 a
ga
in
st
 a
m
in
o
 a
ci
d
s 
1
-1
7
 o
f 
H
TT
, 
th
en
 a
n
al
ys
ed
 
b
y 
co
n
fo
ca
l m
ic
ro
sc
o
p
y 
(s
ee
 S
ec
ti
o
n
s 
2
.2
.1
.8
 a
n
d
 2
.2
.1
.9
 f
o
r 
fu
rt
h
er
 d
et
ai
ls
).
 S
ca
le
 b
ar
 =
 2
0
µ
m
 
106 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P/
C
 p
ix
el
 in
te
n
si
ty
 r
at
io
 
StHdh
Q7/7
 StHdh
Q7/111
 StHdh
Q111/111
 
# 
N
/C
 p
ix
e
l 
in
te
n
si
ty
 r
a
ti
o
 
StHdh
Q7/7
 StHdh
Q7/111
 StHdh
Q111/111
 
* 
**
* 
N
/P
 p
ix
el
 in
te
n
si
ty
 r
at
io
 
StHdh
Q7/7
 StHdh
Q7/111
 StHdh
Q111/111
 
**
* 
**
* 
Figure 3.12 Quantitative analysis of immunofluorescence images in Figure 3.11. 
Nuclear/Cytoplasmic (N/C),  Nuclear/Perinuclear (N/P) and Perinuclear/Cytoplasmic 
(P/C) mean pixel intensity ratios for StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111 
cells 
following 0, 5, 15 and 30 minutes of stimulation with 100ng/ml EGF. Mean pixel 
intensities were calculated from confocal microscopy images using GNU Image 
Manipulator (further details of the analysis can be found in Section 2.2.1.10). All 
images were randomised and analysed blind to genotype and length of time 
stimulated with EGF. Each condition consisted of 9 confocal microscopy images taken 
from 3 separate coverslips. A two-way ANOVA was carried out for main effects 
analysis, followed by planned one way ANOVAs and post-hoc Tukey tests.  Error bars = 
SEM. 
* Denotes a significant difference from 0mins 
# Denotes  a significant difference from 5mins 
* p<0.05  ** p<0.01  *** p<0.001 
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 3.3.4 Immunostaining with Mab2166 
Like Ab675, Mab2166 also detects an N-terminal epitope of HTT and mHTT, although it 
has been raised against amino acids 181-810, which are located downstream of the 
polyglutamine expansion. It shows a different pattern of localisation at baseline than 
Ab675, as it is primarily perinuclear, particularly in the StHdhQ7/7 cells. Similar to Ab675, 
as the genetic load of mHTT increases, this epitope becomes more densely nuclear and 
perinuclear in its localisation (Figures 3.13 and 3.14). 
  3.3.4.1 BDNF stimulation 
Similar to the effect observed with Ab675, there is a significant interaction between 
cell line and length of growth factor stimulation in the N/C ratio (F (6, 688) = 7.18, 
p<0.001). In both StHdhQ7/7 and StHdhQ7/111 cells, there is also a significant reduction in 
the N/C ratio (StHdhQ7/7 p= 0.003, StHdhQ7/111 p=0.03), although this is observed at 15 
minutes of stimulation rather than 5. In contrast, there is no significant effect in the 
StHdhQ111/111  cells in the N/C ratio (p >0.05), although the N/P ratio suggests an 
increase in nuclear mHTT compared to the perinuclear area in these cells, and in 
StHdhQ7/7 cells as early as 5 minutes following stimulation (both p<0.001). StHdhQ7/7 
then have a significant increase in both the N/C (p=0.007) and N/P (p<0.001) ratios at 
30 minutes, indicating a return of this epitope to the nucleus above baseline levels. 
The majority of significant alterations in pixel intensity lie within N/C and N/P ratios, 
while the P/C ratio shows no significant effects in either the StHdhQ7/111 or StHdhQ111/111 
cell lines (p>0.05). However in StHdhQ7/7 cells, the pattern of the P/C ratio reflects the 
possible movement of HTT between the cytoplasm and perinuclear area. 
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Figure 3.14 Quantitative analysis of immunofluorescence images in Figure 3.13. 
Nuclear/Cytoplasmic (N/C),  Nuclear/Perinuclear (N/P) and Perinuclear/Cytoplasmic 
(P/C) mean pixel intensity ratios for StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111 
cells 
following 0, 5, 15 and 30 minutes of stimulation with 100ng/ml BDNF. Mean pixel 
intensities were calculated from confocal microscopy images using GNU Image 
Manipulator (further details of the analysis can be found in Section 2.2.1.10). All images 
were randomised and analysed blind to genotype and length of time stimulated with 
BDNF. Each condition consisted of 9 confocal microscopy images taken from 3 separate 
coverslips. A two-way ANOVA was carried out for main effects analysis, followed by 
planned one way ANOVAs and post-hoc Tukey tests.  Error bars = SEM 
* p<0.05  ** p<0.01 *** p<0.001 
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  3.3.4.2 NGF stimulation 
Mab2166 detects a nuclear increase of HTT and mHTT following NGF stimulation, 
although this effect is statistically significant in the N/P ratio (F (3, 757) = 23.85, 
p<0.001), not in the N/C ratio (F (3,757) = 2.54, p= 0.056) (Figures 3.15 & 3.16).  Post-
hoc Tukey HSD tests indicate that for StHdhQ7/7 and StHdhQ7/111 cells, this increase in 
nuclear intensity occurs at 15 minutes (StHdhQ7/7 p<0.001, StHdhQ7/111 p<0.001). 
Analysis of the individual intensity ratios suggests that these changes could be due to 
relocalisation of HTT and mHTT between the perinuclear region and the nucleus, 
rather than movement between the cytoplasm and nucleus. Interestingly, StHdhQ111/111 
cells indicate the opposite effect; there is a reduction of the N/P ratio from 15 minutes 
of NGF stimulation (p=0.005). The StHdhQ7/7 cells show the formation of discrete 
nuclear foci of N-terminal HTT at 15 minutes following NGF stimulation, which is not 
observed in either the StHdhQ7/111 or StHdhQ111/111 cell lines.  
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Figure 3.16 Quantitative analysis of immunofluorescence images in Figure 3.15. 
Nuclear/Cytoplasmic (N/C),  Nuclear/Perinuclear (N/P) and Perinuclear/Cytoplasmic 
(P/C) mean pixel intensity ratios for StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111 
cells 
following 0, 5, 15 and 30 minutes of stimulation with 100ng/ml NGF. Mean pixel 
intensities were calculated from confocal microscopy images using GNU Image 
Manipulator (further details of the analysis can be found in Section 2.2.1.10). All 
images were randomised and analysed blind to genotype and length of time 
stimulated with NGF. Each condition consisted of 9 confocal microscopy images taken 
from 3 separate coverslips. A two-way ANOVA was carried out for main effects 
analysis, followed by planned one way ANOVAs and post-hoc Tukey tests.  Error bars = 
SEM.  
* p<0.05  ** p<0.01  *** p<0.001 
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  3.3.4.3 EGF stimulation 
Mab2166 shows the same pattern of localisation following EGF stimulation in all three 
cell lines as Ab675 (Figures 3.17 & 3.18). For the N/C ratio, there was a significant 
effect of cell type (F (2, 847) = 46.93, p<0.001) and growth factor stimulation (F (3,847) 
= 26.43, p<0.001), but there was no interaction between the two (F (6, 847) = 1.37, 
p=0.225). However, there was no longer a significant interaction in the N/P ratio as 
there was previously (F (6, 847) = 1.56, p=0.16), which is likely due to the N/P ratio in 
StHdhQ111/111 cells now reaching significance by 5 minutes of EGF stimulation (p<0.001). 
Again, significant effects are predominantly found between the nuclear and 
perinuclear regions, although the same pattern of movement within the cell is 
reflected in the P/C ratio. This reaches significance at 30 minutes of stimulation in 
StHdhQ7/7 cells (p=0.009), and at 5 minutes in the StHdhQ7/111 cells (p=0.044). 
  3.3.5 Immunostaining with other N-terminal HTT antibodies  
In order to more thoroughly characterise the localisation of HTT and mHTT, as well as 
support the results from Ab675 and Mab2166, both another rabbit polyclonal antibody 
created in a different lab against the same epitope as Ab675 (N17), and a commercial 
equivalent of Ab675 (Ab109115) that was raised against a slighter longer epitope of 
HTT (amino acids 1-30), were also utilised. Only EGF stimulation was selected to be 
followed up using these antibodies, as it produced the most consistent results and 
clear effect of genotype.   
In concordance with Ab675, there was a similar pattern of HTT localisation following 
EGF stimulation when cells were immunostained with Ab109115; details of these 
results can be found in Appendix I. There was not enough of the N17 antibody 
available to immunostain sufficient cell numbers for quantification and statistical 
analysis. However, in comparison with the other N-terminal antibodies, there was no 
effect of EGF stimulation on the localisation of HTT epitopes detected by N17 in any of 
the genotypes; further details and images from this experiment can be found in 
Appendix II. A comparison of the differential effects of growth factor stimulation on 
the nuclear localisation of HTT detected by the panel of N-terminal HTT antibodies can 
be found in Table 3.1.   
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Figure 3.18 Quantitative analysis of immunofluorescence images in Figure 3.17. 
Nuclear/Cytoplasmic (N/C),  Nuclear/Perinuclear (N/P) and Perinuclear/Cytoplasmic 
(P/C) mean pixel intensity ratios for StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111 
cells 
following 0, 5, 15 and 30 minutes of stimulation with 100ng/ml EGF. Mean pixel 
intensities were calculated from confocal microscopy images using GNU Image 
Manipulator (further details of the analysis can be found in Section 2.2.1.10). All 
images were randomised and analysed blind to genotype and length of time 
stimulated with EGF. Each condition consisted of 9 confocal microscopy images taken 
from 3 separate coverslips. A two-way ANOVA was carried out for main effects 
analysis, followed by planned one way ANOVAs and post-hoc Tukey tests.  Error bars = 
SEM. 
* Denotes a significant difference from 0mins 
# Denotes  a significant difference from 5mins 
* p<0.05  ** p<0.01  *** p<0.001 
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 3.3.6 Using subcellular fractionation to determine cellular localisation of HTT 
 epitopes 
In order to further investigate the subcellular localisation of HTT and mHTT, protein 
extraction and subcellular fractionation were performed following growth factor 
stimulation, and were followed by SDS-PAGE gel electrophoresis and western blotting 
(for further details, see Section 2.2.2.3). Nuclear fractions were confirmed by the 
presence of nuclear protein Lamin A/C, and cytoplasmic fractions were confirmed by 
the presence of MEK. In addition to Ab109115 and Mab2166, blots were also probed 
with MW1; a mouse monoclonal antibody that only detects mHTT. Ab675 and N17 
were also used to visualise full length HTT on these blots, but due to limited antibody 
availability, these were not able to be replicated and quantified. 
All five antibodies detected full length HTT and mHTT in both nuclear and cytoplasmic 
fractions (example blots and quantifications following BDNF and EGF stimulation can 
be found in Figures 3.19 - 3.21. The remaining blots can be found in Appendix III). 
Lysates from StHdhQ111/111 cells showed fainter bands as compared to both StHdhQ7/7 
and StHdhQ7/111 cell lysates when detected by the four N-terminal antibodies, Ab675, 
Ab109115, Mab2166 and N17. This may be partly due to a lower affinity of these 
antibodies to the mutant protein, as there was strong detection of mHTT when the 
blots were probed with MW1. However, the larger protein may fail to blot as 
efficiently as wild type HTT, or this may reflect a reduction in mHTT protein levels, as 
has been observed in other HD models (Gutekunst et al. 1995; Persichetti et al. 1996; J. 
Miller et al. 2010; Pouladi et al. 2010). 
Following stimulation with any of the three growth factors, there was no change in the 
quantification of full length HTT or mHTT between nuclear and cytoplasmic fractions 
with any of the antibodies used for detection.  
 
 
 
118 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.19 A. Western blots of cytoplasmic fractions of StHdh
Q7/7
, StHdh
Q7/111 
and 
StHdh
Q111/111
 cells  stimulated with 100ng/ml BDNF for 0, 5, 15 and 30 minutes 
before cell lysis and subcellular fractionation (see Section 2.2.2.3 for more details), 
and a whole cell lysate control (W). Blots were probed with Mab2166, stripped and 
re-probed with Ab109115, followed by MW1. Fractions were normalised to  α-
tubulin loading control, and purity of the fraction was assessed by the presence of 
cytoplasmic marker MEK (40kDa) and lack of the nuclear marker Lamin A/C (70-
75kDa). B. Licor Odyssey quantification of fluorescence intensities (FI) in A 
normalised to the loading control, and expressed as a percentage of 0 mins BDNF 
stimulation (%0). Percentages were analysed by genotype individually using a one 
way ANOVA due to differences in band intensity between cell types, followed by 
post-hoc Tukey tests. (Error bars = SEM, n=3). 
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Figure 3.20 A. Western blots of nuclear fractions of StHdh
Q7/7
, StHdh
Q7/111 
and 
StHdh
Q111/111
 cells  stimulated with 100ng/ml BDNF for 0, 5, 15 and 30 minutes 
before cell lysis and subcellular fractionation (see Section 2.2.2.3 for more details), 
and a whole cell lysate control (W). Blots were probed with Mab2166, stripped and 
re-probed with Ab109115, followed by MW1. Fractions were normalised to α-
tubulin loading control, and purity of the fraction was assessed by the presence of 
nuclear marker Lamin A/C (70-75kDa) and lack of the cytoplasmic marker MEK 
(40kDa). B. Licor Odyssey quantification of fluorescence intensities (FI) in A 
normalised to the loading control, and expressed as a percentage of 0 mins BDNF 
stimulation (%0). Percentages were analysed by genotype individually  using a one 
way ANOVA due to differences in band intensity  between cell types, followed by 
post-hoc Tukey tests (Error bars = SEM, n=3).  
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3.4 The localisation of phosphorylated HTT in response to growth factor stimulation 
Anti-S13p and Anti-S1316p were both kind gifts from Joan Steffan (University of 
California, Irvine, USA), and were raised against the first 17 amino acids of HTT, 
including phosphorylation on either serine 13 (Anti-S13p) or both serines 13 and 16 
(Anti-S1316p). A similar antibody, N17 s1316p, which was raised in Ray Truant’s 
laboratory against the same immunogen, was also utilised to support the changes in 
the localisation of the double phosphorylated epitope of HTT identified with the Anti-
S1316p antibody following EGF stimulation. 
 3.4.1 Immunostaining with anti-phosphorylated S13 antibody 
  3.4.1.1 BDNF stimulation 
HTT phosphorylated on S13 is detected predominantly in the cytoplasm of StHdhQ7/7 
cells, although there is denser accumulation around the perinucleus (Figures 3.22 & 
3.23). With increasing mHTT load, there is a higher nuclear presence of phosphorylated 
HTT, and stronger staining of perinuclear regions. Contrary to previous reports that 
mHTT is hypophosphorylated in these cells (Atwal et al. 2011), there is no indication of 
reduced S13 phosphorylation in this case.  
Following BDNF stimulation, there is a significant effect of cell type in the N/C ratio (F 
(2, 681) = 16.28, p<0.001) and of time stimulated (F (3, 681) = 72.38, p<0.001), as well 
as a significant interaction between the two (F (6, 681) = 6.69, p<0.001). Simple main 
effects analysis shows that significant changes in the N/C ratio are at 5 minutes 
(p<0.001) and 30 minutes (p<0.001) of BDNF stimulation, and that localisation of 
phosphorylated S13 HTT in StHdhQ7/7 cells differs significantly from StHdhQ111/111 cells 
(p<0.001), but not StHdhQ7/111 cells (p=0.089). Post-hoc analysis of the N/C ratio shows 
that BDNF stimulation led to a nuclear increase of phosphorylated S13 HTT in StHdhQ7/7 
and StHdhQ111/111 cell lines. This occurred twice; once at 5 minutes (both p<0.001), and 
again at 30 minutes (both p<0.001), however there was a significant decrease in the 
N/C ratio at 15 minutes of stimulation in the StHdhQ7/111 cell lines (p<0.001). The effect 
seen in the N/C ratio is mirrored in the N/P ratio. However, although there is a 
122 
 
significant effect of cell type in the P/C ratio (F (2, 681) = 24.58, p<0.001), there is no 
effect of BDNF stimulation (F (3, 681) = 2.28, p=0.078). 
  3.4.1.2 NGF stimulation 
There was a significant effect of cell type (F (2, 755) = 97.75, p<0.001) and of NGF 
stimulation (F (3, 755) = 21.66, p<0.001) on the N/C ratio of HTT and mHTT 
phosphorylated on S13 (Figures 3.24 & 3.25), as well as a significant interaction 
between the two (F (6, 755) = 3.03, p=0.006). Tukey HSD tests show that there was a 
significant reduction in the N/C ratio at 15 minutes for StHdhQ7/7 cells (p<0.001). In 
StHdhQ7/111 cells, however, there was a significant increase in the N/C ratio at 5 
minutes of stimulation (p<0.001), which was followed by a return to baseline. There 
was no significant effect of NGF stimulation on the N/C ratio of StHdhQ111/111 cells. The 
N/P ratio of StHdhQ7/7 cells mirrors the effect seen in the N/C ratio; there is a reduction 
at 5 minutes (p=0.018), which is persistent for the full 30 minutes of stimulation (15 
and 30 minutes, p<0.001). This effect is also seen in the N/P ratio for StHdhQ111/111 cells, 
although the reduction becomes significant at 15 minutes (P=0.001). Again, there is a 
significant increase in this ratio for the StHdhQ7/111 cells, which is significant at 30 
minutes (p=0.038). Despite a significant main effect of cell type (F (2, 755) = 73.31, 
p<0.001) and NGF stimulation (F (3, 755) = 5.18, p=0.002) in the P/C ratio, there is only 
a small significant increase in the P/C ratio for StHdhQ7/7 cells at 5 minutes (p=0.029), 
but no other significant post-hoc effects. To summarise, NGF stimulation appears to 
elicit a movement of nuclear S13 phosphorylated epitopes of HTT in StHdhQ7/7 and 
StHdhQ111/111 cells to the perinuclear region. Interestingly, it prompts a nuclear increase 
of this HTT epitope in StHdhQ7/111 cells, although the effect remains primarily between 
the nuclear and perinuclear areas. 
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Figure 3.23 Quantitative analysis of immunofluorescence images in Figure 3.22. 
Nuclear/Cytoplasmic (N/C),  Nuclear/Perinuclear (N/P) and Perinuclear/Cytoplasmic 
(P/C) mean pixel intensity ratios for StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111 
cells 
following 0, 5, 15 and 30 minutes of stimulation with 100ng/ml BDNF. Mean pixel 
intensities were calculated from confocal microscopy images using GNU Image 
Manipulator (further details of the analysis can be found in Section 2.2.1.10). All 
images were randomised and analysed blind to genotype and length of time 
stimulated with BDNF. Each condition consisted of 9 confocal microscopy images 
taken from 3 separate coverslips. A two-way ANOVA was carried out for main 
effects analysis, followed by planned one way ANOVAs and post-hoc Tukey tests.  
Error bars = SEM 
* p<0.05  ** p<0.01 *** p<0.001 
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Figure 3.25 Quantitative analysis of immunofluorescence images in Figure 3.24. 
Nuclear/Cytoplasmic (N/C),  Nuclear/Perinuclear (N/P) and Perinuclear/Cytoplasmic 
(P/C) mean pixel intensity ratios for StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111 
cells 
following 0, 5, 15 and 30 minutes of stimulation with 100ng/ml NGF. Mean pixel 
intensities were calculated from confocal microscopy images using GNU Image 
Manipulator (further details of the analysis can be found in Section 2.2.1.10). All 
images were randomised and analysed blind to genotype and length of time 
stimulated with NGF. Each condition consisted of 9 confocal microscopy images 
taken from 3 separate coverslips. A two-way ANOVA was carried out for main 
effects analysis, followed by planned one way ANOVAs and post-hoc Tukey tests.  
Error bars = SEM.  
* p<0.05  ** p<0.01  *** p<0.001 
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  3.4.1.3 EGF stimulation 
There was again a significant main effect of cell type in the N/C ratio (F (2, 673) = 9.08, 
p<0.001), but there was not a significant effect of time of EGF stimulation (F (3, 673) = 
2.42, p=0.065) (Figures 3.26 & 3.27). However, there was a significant interaction 
between the two (F (6, 673) = 7.38), p<0.001). Simple main effects analysis showed 
that significant differences in the N/C ratio lay between the StHdhQ7/7 and StHdhQ111/111 
cells (p<0.001) rather than the StHdhQ7/111 cells (p=0.944). Tukey HSD post-hoc tests 
reveal that there is a significant reduction in the N/C ratio in both StHdhQ7/7 and 
StHdhQ7/111 cells, which is significant at 5 minutes (p<0.001) and at 15 minutes 
(p<0.001), respectively, suggesting a reduction of S13 phosphorylated HTT epitopes in 
the nucleus. In contrast, there is a significant increase in the N/C ratio in StHdhQ111/111 
cells at 15 minutes of EGF stimulation (p=0.008). The increase in nuclear staining for 
S13 phosphorylated mHTT in these cells appears in discrete foci in some of these cells 
rather than in the diffuse pattern previously seen.  Analysis of the N/P ratio shows that 
there was no effect of cell type (F (2, 673) = 1.36, p=0.258), but there was a significant 
effect of EGF stimulation over time (F (3, 673) = 11.08, p<0.001), and a significant 
interaction between the two (F (6, 673) = 10.62, p<0.001). Post-hoc analysis shows that 
there is no significant difference from baseline in StHdhQ7/7 cells in this ratio, but both 
the StHdhQ7/111 and StHdhQ111/111 cells show a significant increase following 5 minutes 
of EGF stimulation (StHdhQ7/111 p<0.000, StHdhQ111/111 p<0.031), which was followed by 
a significant reduction in the N/P ratio below baseline by 15 minutes in StHdhQ7/111 cells 
(p=0.002). The P/C ratio for both StHdhQ7/7 and StHdhQ111/111 cell lines reflect the 
pattern of nuclear and perinuclear S13 phosphorylated HTT and mHTT observed in the 
N/C and N/P ratios, although there are no significant effects in the StHdhQ7/111 cells.  
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Figure 3.27 Quantitative analysis of immunofluorescence images in Figure 3.26. 
Nuclear/Cytoplasmic (N/C),  Nuclear/Perinuclear (N/P) and Perinuclear/Cytoplasmic 
(P/C) mean pixel intensity ratios for StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111 
cells 
following 0, 5, 15 and 30 minutes of stimulation with 100ng/ml EGF. Mean pixel 
intensities were calculated from confocal microscopy images using GNU Image 
Manipulator (further details of the analysis can be found in Section 2.2.1.10). All 
images were randomised and analysed blind to genotype and length of time 
stimulated with EGF. Each condition consisted of 9 confocal microscopy images taken 
from 3 separate coverslips. A two-way ANOVA was carried out for main effects 
analysis, followed by planned one way ANOVAs and post-hoc Tukey tests.  Error bars = 
SEM. * Denotes a significant difference from 0mins, # Denotes a significant difference 
from 5mins.  * p<0.05  ** p<0.01  *** p<0.001 
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 3.4.2 Immunostaining with anti-phosphorylated s1316 antibody 
  3.4.2.1 BDNF stimulation 
Similar to previously observed patterns of localisation in this chapter, the epitope of 
HTT detected by the anti-phosphorylated s1316p antibody was more nuclear with 
increased mutant HTT load (Figures 3.28 & 3.29). This is reflected in the significant 
main effects of cell type found for the N/C (F (2, 661) = 9409.292, p<0.001), N/P (F (2, 
661) = 43.22, p<0.001) and P/C ratios (F (2, 661) = 27.84, p<0.001). For the N/C and P/C 
ratios, there were significant simple main effects between all three genotypes 
(p<0.01), however for the N/P ratio, there was a significant difference between 
StHdhQ7/7 cells and both StHdhQ7/111 (p<0.001) and StHdhQ111/111 cells (p<0.001), but 
there was no difference between the StHdhQ7/111 and StHdhQ111/111 lines (p>0.05). This 
suggests that when mHTT is present, there is mislocalisation of phosphorylated mHTT 
to nuclear and perinuclear areas, regardless of the extent of mHTT load. 
There was no significant effect of BDNF stimulation in the N/C ratio (p=0.08) or in the 
P/C ratio (p=0.333) across all three genotypes, and post-hoc analyses of the genotypes 
individually support this finding (p>0.05 in all cases). There was, however, a significant 
effect of BDNF in the N/P ratio (F (3, 661) = 7.04, p<0.001); simple main effects analysis 
indicated that this was due to a reduction in this epitope of HTT in the nucleus and a 
perinuclear increase after 30 minutes of stimulation (p<0.05). Post-hoc analysis reveals 
that this is due to a significant reduction in nuclear phosphorylated HTT at 30 minutes 
in the StHdhQ7/7 (p<0.001) and StHdhQ7/111 (p<0.01) cells only; there was no effect of 
BDNF stimulation in StHdhQ111/111 cells (p=0.286). Similar to the HTT epitope 
phosphorylated on S13 alone, there was an increase in the nuclear presence of the 
double phosphorylated epitope at 5 minutes in both StHdhQ7/7 and StHdhQ7/111 cells, 
although this does not reach significance, and does not appear again at 30 minutes. 
The localisation of this epitope of HTT following BDNF stimulation shows a slightly 
delayed pattern to the non-phosphorylated epitopes; previously it was observed that 
there was a reduction in nuclear HTT at 15 minutes (Sections 3.3.3.1 & 3.3.4.1), but in 
this case the reduction is only apparent at 30 minutes. 
  
131 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
St
H
d
h
Q
7
/7
 
St
H
d
h
Q
7
/1
1
1  
St
H
d
h
Q
1
1
1
/1
1
1  
0
 m
in
u
te
s 
5
 m
in
u
te
s 
1
5
 m
in
u
te
s 
3
0
 m
in
u
te
s 
Fi
gu
re
 3
.2
8
 S
u
b
ce
llu
la
r 
lo
ca
lis
at
io
n
 o
f 
an
 N
-t
er
m
in
al
 e
p
it
o
p
e 
o
f 
H
TT
 a
n
d
 m
H
TT
 p
h
o
sp
h
o
ry
la
te
d
 o
n
 s
er
in
es
 1
3
 a
n
d
 1
6
 i
n
 S
tH
d
h
Q
7
/7
, 
St
H
d
h
Q
7
/1
11
 
an
d
 S
tH
d
h
Q
1
1
1
/1
1
1
 c
el
l 
lin
es
. 
C
el
ls
 w
er
e 
fi
xe
d
 f
o
llo
w
in
g 
0
, 
5
, 
15
 a
n
d
 3
0
 m
in
u
te
s 
o
f 
st
im
u
la
ti
o
n
 w
it
h
 1
0
0n
g
/m
l 
B
D
N
F,
 l
ab
el
le
d
 w
it
h
 A
n
ti
-S
1
31
6
p
, 
th
en
 a
n
al
ys
ed
 b
y 
co
n
fo
ca
l m
ic
ro
sc
o
p
y 
(s
ee
 S
e
ct
io
n
s 
2
.2
.1
.8
 a
n
d
 2
.2
.1
.9
  f
o
r 
fu
rt
h
er
 d
et
ai
ls
).
  S
ca
le
 b
ar
 =
 2
0
µ
m
 
132 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
/C
 p
ix
el
 in
te
n
si
ty
 r
at
io
 
StHdh
Q7/7
 StHdh
Q7/111
 StHdh
Q111/111
 
StHdh
Q7/7
 StHdh
Q7/111
 StHdh
Q111/111
 
N
/P
 p
ix
el
 in
te
n
si
ty
 r
at
io
 
# 
#
#
#
 
**
 
P/
C
 p
ix
el
 in
te
n
si
ty
 r
at
io
 
StHdh
Q7/7
 StHdh
Q7/111
 StHdh
Q111/111
 
Figure 3.29 Quantitative analysis of immunofluorescence images in Figure 3.28. 
Nuclear/Cytoplasmic (N/C),  Nuclear/Perinuclear (N/P) and Perinuclear/Cytoplasmic 
(P/C) mean pixel intensity ratios for StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111 
cells 
following 0, 5, 15 and 30 minutes of stimulation with 100ng/ml BDNF. Mean pixel 
intensities were calculated from confocal microscopy images using GNU Image 
Manipulator (further details of the analysis can be found in Section 2.2.1.10). All 
images were randomised and analysed blind to genotype and length of time 
stimulated with BDNF. Each condition consisted of 9 confocal microscopy images 
taken from 3 separate coverslips. A two-way ANOVA was carried out for main effects 
analysis, followed by planned one way ANOVAs and post-hoc Tukey tests.  Error bars = 
SEM 
* Denotes a significant difference from 0mins 
# Denotes a significant difference from 5mins 
* p<0.05  ** p<0.01 *** p<0.001 
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  3.4.2.2 NGF stimulation 
There was again a significant main effect of genotype in the N/C (F (3,655) = 27, 
p<0.001), N/P (F (3, 655) = 15.69, p<0.001) and P/C ratios (F (3, 655) = 10.75, p<0.001), 
as well as a significant effect of time of NGF stimulation for all three ratios (p<0.003). 
Similar to the findings following BDNF stimulation, simple main effects analysis showed 
significant differences between StHdhQ7/7 cells and both StHdhQ7/111 and StHdhQ111/111 
cells (p<0.002) for all three ratios, but no significant differences in localisation of the 
double phosphorylated HTT epitope were found between StHdhQ7/111 and StHdhQ111/111 
cells (Figures 3.30 & 3.31). In all three ratios, there was also a significant interaction 
between genotype and time of NGF stimulation (N/C p=0.027, N/P p=0.028, P/C 
p=0.018). 
Post hoc analyses reveal that in StHdhQ7/7 cells following NGF stimulation, there is an 
increase in the perinuclear localisation of the double phosphorylated epitope of HTT at 
15 minutes,  which is reflected in the N/P ratio (p=0.006). There is also a reduction in 
the N/C ratio at 15 minutes, as well as an increase in the P/C ratio from 5 minutes of 
stimulation, suggesting movement out of the nucleus into a perinuclear ring, although 
these don’t reach significance due to larger variability than was seen in the N/P ratio. 
By 30 minutes, the localisation of this epitope had returned to baseline. This is the 
same pattern that was observed with the single phospho-S13 epitope, although the 
nuclear reduction persisted up to 30 minutes (Section 3.4.1.2). Double phosphorylation 
of both S13 and S16 may therefore be more variable and transitory in response to NGF 
stimulation compared to the phosphorylation of S13 alone.  
StHdhQ7/111 cells, although exhibiting a significantly different phospho-S13S16 HTT 
localisation to StHdhQ7/7 cells, show a similar response to NGF. There is a significant 
reduction in the N/P ratio at 15 minutes (p=0.001) in these cells, as well as a reduction 
in the N/C ratio at the same time point, which is significantly lower than at 5 minutes 
of NGF stimulation (p=0.024). However, both ratios remain consistently higher than in 
StHdhQ7/7 cells, reflecting the increased nuclear and perinuclear localisation of 
previously investigated HTT epitopes in the presence of mHTT. There is an unexpected 
increase in the P/C ratio in StHdhQ7/111 cells at 30 minutes (p=0.004), and the N/P ratio 
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does not quite return to baseline by this time point as it did in StHdhQ7/7 cells. It is 
therefore possible that although there is the same pattern of response to NGF in 
StHdhQ7/111 cells as in wild type cells, the increased perinuclear localisation of this 
phosphorylated epitope is more persistent. This pattern is quite different to the effect 
seen with the single phospho-S13 antibody, which had a significant nuclear increase at 
5 minutes in these cells (Section 3.4.1.2). This may be due to the phosphorylation of 
S13 occurring prior to the phosphorylation of S16 (Thompson 2009); the latter event 
promoting perinuclear, rather than nuclear, localisation of this epitope. 
Perhaps surprisingly, StHdhQ111/111 cells show a similar response to NGF stimulation in 
both the N/C and N/P ratios. In both cases, there is a significant nuclear reduction at 
15 minutes of stimulation (p<0.001), although similar to the effect seen in StHdhQ7/111 
cells, this effect is persistent for up to 30 minutes in the N/P ratio (p=0.001), suggesting 
a reduced capacity for mHTT to return to its baseline localisation. There is also an 
increase in the P/C ratio at 30 minutes that supports increased perinuclear localisation 
of this epitope, although this is only significantly different from 5 minutes of NGF 
stimulation (p=0.012). This is the same pattern that was observed with the single 
phospho-S13 antibody, which suggests that the localisation of both phosphorylated 
epitopes is very similar following NGF stimulation 
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Figure 3.31 Quantitative analysis of immunofluorescence images in Figure 3.30. 
Nuclear/Cytoplasmic (N/C),  Nuclear/Perinuclear (N/P) and Perinuclear/Cytoplasmic 
(P/C) mean pixel intensity ratios for StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111 
cells 
following 0, 5, 15 and 30 minutes of stimulation with 100ng/ml NGF. Mean pixel 
intensities were calculated from confocal microscopy images using GNU Image 
Manipulator (further details of the analysis can be found in Section 2.2.1.10). All 
images were randomised and analysed blind to genotype and length of time 
stimulated with NGF. Each condition consisted of 9 confocal microscopy images taken 
from 3 separate coverslips. A two-way ANOVA was carried out for main effects 
analysis, followed by planned one way ANOVAs and post-hoc Tukey tests.  Error bars = 
SEM.  
* Denotes a significant difference from 0mins 
# Denotes a significant difference from 5mins 
* p<0.05  ** p<0.01  *** p<0.001 
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  3.4.2.3 EGF stimulation 
There was a significant main effect of genotype for the N/C (F(2, 723) = 51.7, p<0.001), 
N/P (F(2, 723) = 27.19, p<0.00) and P/C (F(2,723) = 19.59, p<0.001) following EGF 
stimulation (Figures 3.32 & 3.33). However, unlike the observations following BDNF 
and NGF stimulation, simple main effects analysis showed a significant difference 
between all three genotypes for all three ratios (p<0.008). There was only a main 
effect of time for the N/C and P/C ratios (F(3, 723) =6.36, p<0.001, F(3, 723)=8.59, 
p<0.001, respectively), with no effect of EGF stimulation in the N/P ratio. All three 
ratios showed a significant genotype x EGF stimulation interaction (all p<0.01). 
In StHdhQ7/7 cells, there was an increase in nuclear HTT at 15 minutes, which appeared 
as focal loci in the centre of the nucleus and persisted up to 30 minutes of stimulation, 
which was reflected as a significant increase in the N/C ratio (p=0.001.  There was also 
a significant increase in the P/C ratio at both 15 and 30 minutes (p=0.004, p=0.041 
respectively), although there is not a visible increase in perinuclear localisation as seen 
following BDNF and NGF stimulation (Sections 3.4.2.1 & 3.4.2.2). This may reflect 
reduced cytoplasmic localisation of this epitope due to recruitment to the nucleus. In 
StHdhQ7/111 cells, no significant effects were observed at any time point, although as 
previously noted for other antibodies investigated in this chapter, localisation of this 
epitope of HTT was more nuclear than in StHdhQ7/7 cells. The lack of effect seen in 
these cells may be due to a suppressed response to EGF stimulation, or large variability 
in the localisation of phosphorylated HTT in these cells. StHdhQ111/111 cells show a large 
increase in the N/C (p=0.006) and P/C (p<0.001) ratios at 30 minutes. This is due to 
formation of discrete loci of this epitope of HTT being detected in the nucleus, rather 
than a generalised nuclear increase. These are similar to the loci seen in StHdhQ7/7 cells, 
although they are not formed as early or to the same extent.  
These findings are contrary to those observed with the single phospho-S13 antibody, 
where there was a reduction in nuclear detection in both StHdhQ7/7 and StHdhQ7/111 
cells, but an increase in the StHdhQ111/111 (Section 3.4.1.3). This may be due to differing 
regulatory effects of phosphorylation of either S13 alone or both S13 and S16 
together. This also demonstrates that the phosphorylation of HTT does not have a 
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single universal response to growth factor stimulation, but differences in signalling 
pathways may modulate its phosphorylation and localisation, which therefore lead to 
alternate downstream cellular effects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
139 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
St
H
d
h
Q
7
/7
 
S
tH
d
h
Q
7
/1
1
1
 
St
H
d
h
Q
1
1
1
/1
1
1
 
0
 m
in
u
te
s 
5
 m
in
u
te
s 
1
5
 m
in
u
te
s 
3
0
 m
in
u
te
s 
Fi
gu
re
 3
.3
2
 S
u
b
ce
llu
la
r 
lo
ca
lis
at
io
n
 o
f 
an
 N
-t
er
m
in
al
 e
p
it
o
p
e 
o
f 
H
TT
 a
n
d
 m
H
TT
 p
h
o
sp
h
o
ry
la
te
d
 o
n
 s
er
in
es
 1
3
 a
n
d
 1
6
 in
 S
tH
d
h
Q
7
/7
, S
tH
d
h
Q
7
/1
1
1 
an
d
 S
tH
d
h
Q
1
1
1
/1
1
1
 c
el
l 
lin
es
. 
C
el
ls
 w
er
e 
fi
xe
d
 f
o
llo
w
in
g 
0
, 
5
, 
15
 a
n
d
 3
0
 m
in
u
te
s 
o
f 
st
im
u
la
ti
o
n
 w
it
h
 1
0
0
n
g
/m
l 
EG
F,
 l
ab
el
le
d
 w
it
h
 A
n
ti
-S
1
3
16
p
, 
th
en
 a
n
al
ys
ed
 b
y 
co
n
fo
ca
l m
ic
ro
sc
o
p
y 
(s
ee
 S
ec
ti
o
n
s 
2
.2
.1
.8
 a
n
d
 2
.2
.1
.9
 f
o
r 
fu
rt
h
er
 d
et
ai
ls
).
  S
ca
le
 b
ar
 =
 2
0
µ
m
 
140 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
/C
 p
ix
el
 in
te
n
si
ty
 r
at
io
 
StHdh
Q7/7
 StHdh
Q7/111
 StHdh
Q111/111
 
**
* 
**
 
N
/P
 p
ix
el
 in
te
n
si
ty
 r
at
io
 
StHdh
Q7/7
 StHdh
Q7/111
 StHdh
Q111/111
 
P/
C
 p
ix
el
 in
te
n
si
ty
 r
at
io
 
StHdh
Q7/7
 StHdh
Q7/111
 StHdh
Q111/111
 
**
 
* 
**
* 
Figure 3.33 Quantitative analysis of immunofluorescence images in Figure 3.32. 
Nuclear/Cytoplasmic (N/C),  Nuclear/Perinuclear (N/P) and Perinuclear/Cytoplasmic 
(P/C) mean pixel intensity ratios for StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111 
cells 
following 0, 5, 15 and 30 minutes of stimulation with 100ng/ml EGF. Mean pixel 
intensities were calculated from confocal microscopy images using GNU Image 
Manipulator (further details of the analysis can be found in Section 2.2.1.10). All 
images were randomised and analysed blind to genotype and length of time 
stimulated with EGF. Each condition consisted of 9 confocal microscopy images 
taken from 3 separate coverslips. A two-way ANOVA was carried out for main 
effects analysis, followed by planned one way ANOVAs and post-hoc Tukey tests.  
Error bars = SEM. 
* p<0.05  ** p<0.01  *** p<0.001 
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 3.4.3 Immunostaining with the N17 s1316p antibody 
As it was not possible to validate the anti-phosphorylated s1316 antibody, another 
antibody that was raised against a similar immunogen but produced in a different 
laboratory was also tested. However, cells were only probed with this antibody 
following EGF stimulation. 
Immunostaining with the N17 s1316p antibody showed a similar localisation of HTT as 
immunostaining with the previous anti-phosphorylated s1316 antibody (Section 3.4.2). 
As with the other antibodies analysed, there is increasing nuclear intensity with mHTT 
load (Figure 3.34 & 3.35). This is reflected in the significant main effect of genotype for 
all three ratios (N/C F(2, 983) =6.323, p=0.002, N/P F(2, 983) =33.193, p<0.001, P/C 
F(2,983) = 29.655, p<0.001). There is also a significant effect of EGF stimulation in all 
three ratios (all p<0.006), and a significant genotype x EGF interaction (all p<0.003). 
However, contrary to the previous anti-phosphorylated s1316 antibody (Section 
3.4.2.3), for both the N/C and P/C ratios, there was no effect between StHdhQ7/7 and 
StHdhQ7/111 cells, but there was a significant difference between both of these 
genotypes and the StHdhQ111/111 cells (p<0.003). This suggests that with this antibody, 
StHdhQ7/111 cells appear more similar to StHdhQ7/7 cells than their homozygote 
counterparts, despite the mutant gene. However, in the N/P ratio, there is a significant 
difference between all three genotypes (p<0.001), thus indicating there is still a 
discernible effect of genotype on the localisation of phosphorylated HTT.    
There is increased nuclear detection of phosphorylated HTT in StHdhQ7/7 cells after 15 
minutes of stimulation with EGF (N/C p=0.006, N/P p<0.001), which persisted up to 30 
minutes of stimulation. This is the same as the effect observed with the previous anti-
phosphorylated s1316 antibody (Section 3.4.2.3), although in this case, no discrete loci 
are detected, and nuclear staining is more diffuse. In StHdhQ7/111 cells, however, the 
pattern of localisation differed to the previous antibody. Using the N17 s1316p 
antibody, there was a significant reduction in the detection of nuclear HTT at 5 
minutes (N/C p=0.001) and 30 minutes (N/C p<0.001), while there was a return to the 
N/C baseline at 15 minutes, and an increase in the N/P ratio at the same time point 
(p=0.029). StHdhQ111/111 cells showed the same pattern of localisation in response to 
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EGF stimulation as StHdhQ7/111 cells, although due to higher variability, none of the time 
points reached significance. This increased variability and altered pattern of 
localisation in both StHdhQ7/111 and StHdhQ111/111 cell lines may be due to the expanded 
polyQ preventing stable phosphorylation of serines 13 and 16, which as a 
consequence, alters the localisation of this epitope of HTT.  
As a similar pattern of localisation is observed in the StHdhQ7/7 cells using both 
phospho-antibodies, it is likely that both antibodies are detecting phosphorylated HTT. 
However, the differences in the pattern of nuclear staining, and the response to EGF in 
StHdhQ7/111 and StHdhQ111/111   cells suggests that different epitopes of phosphorylated 
HTT are possibly being detected. A summary of the pattern of phosphorylated HTT 
nuclear localisation in response to stimulation with different growth factors can be 
seen in Table 3.2.  
 3.4.4 Characterising the cellular localisation of phosphorylated epitopes of HTT 
 by subcellular fractionation  
Consistent with the findings from western blots probed with non-phosphorylated N-
terminal HTT antibodies in Section 3.3.6, there was no apparent change in the 
cytoplasmic or nuclear localisation of phosphorylated HTT as detected by N17 s1316p 
(Figure 3.21). Unfortunately, the other two phospho-antibodies were not available for 
this experiment, and there was only one replicate of each blot probed with N17 
s1316p, so quantification was not possible. However, as described previously (Section 
3.3.6), this method may not be the most sensitive way to characterise transient 
changes in protein localisation. 
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Figure 3.35 Quantitative analysis of immunofluorescence images in Figure 3.34. 
Nuclear/Cytoplasmic (N/C),  Nuclear/Perinuclear (N/P) and Perinuclear/Cytoplasmic 
(P/C) mean pixel intensity ratios for StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111 
cells 
following 0, 5, 15 and 30 minutes of stimulation with 100ng/ml EGF. Mean pixel 
intensities were calculated from confocal microscopy images using GNU Image 
Manipulator (further details of the analysis can be found in Section 2.2.1.10). All 
images were randomised and analysed blind to genotype and length of time 
stimulated with EGF. Each condition consisted of 9 confocal microscopy images 
taken from 3 separate coverslips. A two-way ANOVA was carried out for main 
effects analysis, followed by planned one way ANOVAs and post-hoc Tukey tests.  
Error bars = SEM. 
* p<0.05  ** p<0.01  *** p<0.001 
145 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ta
b
le
 3
.2
 A
 s
u
m
m
ar
y 
o
f 
th
e 
co
m
p
ar
is
o
n
 o
f 
ap
p
ar
en
t 
p
h
o
sp
h
o
ry
la
te
d
 H
TT
 n
u
cl
ea
r 
lo
ca
lis
at
io
n
 i
n
 r
es
p
o
n
se
 t
o
 B
D
N
F,
 N
G
F 
an
d
 E
G
F 
st
im
u
la
ti
o
n
 i
n
 S
tH
d
h
Q
7
/7
, 
St
H
d
h
Q
7
/1
1
1  
an
d
 S
tH
d
h
Q
11
1
/1
1
1
 c
el
ls
 a
s 
d
et
ec
te
d
 b
y 
a 
p
an
el
 o
f 
A
n
ti
-p
h
o
sp
h
o
ry
la
te
d
 N
-t
er
m
in
al
 H
TT
 a
n
ti
b
o
d
ie
s.
 ‘
↓
’ 
in
d
ic
at
es
 a
 r
ed
u
ct
io
n
 i
n
 n
u
cl
ea
r 
st
ai
n
in
g 
in
te
n
si
ty
 a
n
d
 ‘
 ↑
 ‘
 i
n
d
ic
at
es
 a
n
 i
n
cr
ea
se
 a
t 
th
e 
ti
m
e 
p
o
in
t 
o
f 
gr
o
w
th
 f
ac
to
r 
st
im
u
la
ti
o
n
 t
h
at
 i
s 
st
at
ed
.  
‘X
’ r
ep
re
se
n
ts
 n
o
 c
h
an
ge
 in
 H
TT
 n
u
cl
ea
r 
lo
ca
lis
at
io
n
 a
t 
an
y 
ti
m
e 
p
o
in
t.
 
146 
 
3.5 Discussion  
 3.5.1 N-terminal HTT localisation 
We demonstrate an apparent differential subcellular localisation of HTT and mHTT 
using a panel of several antibodies against N-terminal epitopes of HTT following 
growth factor stimulation, suggesting that the regulation of HTT localisation may be 
downstream of kinase signalling pathways. As different batches of polyclonal antibody 
stocks can exhibit variability in detection, which can alter the apparent localisation of 
HTT, this experiment therefore focused on the pattern of subcellular ratio changes 
rather than absolute fluorescence intensities. The presence of HTT in the nucleus is 
increased in the context of the expanded polyQ; a phenotype that has been previously 
described in this cell model (Trettel et al. 2000; Truant 2003; Atwal et al. 2007; Atwal 
et al. 2011) and in other models of HD (Hoogeveen et al. 1993; Dorsman et al. 1999; 
Hilditch-Maguire et al. 2000; Wheeler 2000; Kegel et al. 2002; Wheeler et al. 2002; 
Rockabrand et al. 2007; Seong et al. 2010). By using a panel of different antibodies, we 
have also observed that the detection of HTT localisation is modulated by the epitope 
against which the antibody was raised; Ab675 and N17 were both raised against amino 
acids 1-17, and they both demonstrate a strong nuclear presence. In contrast, 
Ab109115 was raised against a longer epitope of amino acids 1-30, and Mab2166 was 
raised against an epitope downstream of the polyQ repeat. Their pattern of detection 
appears considerably less nuclear than the amino acid 1-17 antibodies, suggesting that 
these antibodies may be detecting either a different epitope or a different 
conformation of HTT in these cells.  Short N-terminal fragments of HTT have been 
identified as being enriched in cell nuclei (Hilditch-Maguire et al. 2000; Tao & Tartakoff 
2001; Kegel et al. 2002), and aberrant splicing and subsequent translation of exon 1 of 
mHTT has been found in the HdhQ150 mouse model (Sathasivam et al. 2013), thus more 
short N-terminal mHTT fragments may be aberrantly available in the presence of the 
expanded polyQ. Therefore the difference in localisation between Ab109115 and 
Mab2166 compared to the amino acid 1-17 antibodies may reflect the increased 
presence of shorter HTT fragments in the nuclei of these cells, and the increased 
nuclear intensity in StHdhQ7/111 and StHdhQ111/111 cells may reflect increased availability 
of this epitope.   
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Mab2166 and Ab109115 detect primarily perinuclear and cytoplasmic forms of HTT 
and mHTT, although in StHdhQ7/111 and StHdhQ111/111 cells, there is also a stronger 
nuclear presence. This may be a more open conformation of mHTT in cell nuclei due to 
the polyQ expansion leaving N-terminal epitopes more accessible (Wheeler 2000), it 
may be increased nuclear accumulation of mHTT (Truant 2003; Cornett et al. 2005; 
Atwal et al. 2007; Truant et al. 2007; Benn et al. 2008; Bauer & Nukina 2009) or there 
could be increased non-specific binding in mHTT carrying cells.  HTT is thought to play 
a role in the formation of perinuclear organelles, such as mitochondria, the Golgi 
complex and the endoplasmic reticulum (Hilditch-Maguire et al. 2000), which may 
explain the clustering of detection of these epitopes to this region. Distinct versions of 
full length HTT have also been identified as being differentially localised between the 
nucleus and cytoplasm, which alter epitope accessibility and can create different 
patterns of antibody reactivity (Trettel et al. 2000; Wheeler 2000). Typically, the 
nuclear forms of full length HTT were found to be ‘amino-terminal accessible,’ whereas 
internal portions of the protein were inaccessible, and cytoplasmic forms that 
associated with membrane organelles close to the nucleus were ‘internal accessible’ 
(Trettel et al. 2000; Wheeler 2000). Therefore all of the antibodies investigated here 
may be detecting full length HTT, but the pattern of localisation that is elicited may be 
dependent upon HTT conformation; amino acid 1-17 antibodies Ab675 and N17 may 
be more able to detect amino accessible forms present in the nucleus, but Ab109115 
and MW1 may be more sensitive to the internal accessible form present in the 
cytoplasm and associated with perinuclear organelles. 
 3.5.2 BDNF stimulation 
The different epitopes of HTT in StHdhQ111 cell lines exhibited differential responses to 
stimulation with each growth factor. Following BDNF stimulation, there was a dramatic 
reduction in nuclear HTT, as detected by both Ab675 and Mab2166, although this 
effect was more variable when visualising the epitope probed by Mab2166. 
Furthermore, this effect was suppressed in the presence of the polyQ repeat; although 
there was still a reduction of nuclear HTT in both StHdhQ7/111 and StHdhQ111/111 cells 
following BDNF stimulation, it occurred to a lesser extent and at a later time point, 
suggesting that the response to BDNF stimulation is impaired in mutant cell types, 
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despite similar levels of the TRKB receptor between genotypes. This is perhaps 
unsurprising, as a loss of BDNF signalling in models of HD and in human HD brain have 
been well characterised (Canals et al. 2001; Reilly 2001; Zuccato et al. 2003; Baquet et 
al. 2004; Canals et al. 2004; Zuccato & Cattaneo 2007). As well as a reduction in BDNF 
available to striatal cells from cortical afferent inputs (Ferrer et al. 2000; Zuccato et al. 
2001; Gauthier et al. 2004; Strand et al. 2007), one mechanism that may contribute to 
reduced BDNF responsive signalling in HD models may be the impairment of 
retrograde transport of TRKB containing vesicles in response to BDNF activation (Liot 
et al. 2013). In the HdhQ111 mouse model of HD, it was found that HTT co-localises with 
these vesicles, and upon BDNF stimulation, aids their binding to microtubules for 
transport from the dendrites to the cell body, but that this process was impaired due 
to the mutant polyQ repeat (Liot et al. 2013). Therefore, it is possible that the 
localisation of HTT in response to BDNF stimulation in StHdhQ7/111 and StHdhQ111/111 
cells may be a result of impaired TRKB trafficking and activation, despite a lack of 
impairment in its expression.   
This suppressed response to BDNF stimulation has been observed previously; BDNF-
mediated phosphorylation of ERK1/2 was found to be diminished in the same cell line, 
and although stimulation with BDNF protected StHdhQ7/7 cells from oxidative stress, it 
failed to exert the same protection in cells carrying mHTT (Ginés et al. 2010). Similarly, 
in primary cell cultures from R6/1 and HdhQ111 mice, BDNF stimulation also failed to 
protect against N-methyl-D-aspartate (NMDA) excitotoxicity (Brito et al. 2013). Despite 
this, BDNF is generally considered a protective factor, as its overexpression prevents 
striatal neuron loss and motor dysfunction in the YAC128 model (Xie et al. 2010), and it 
can block polyQ mediated cell death in an in vitro model of HD (Saudou et al. 1998). Its 
expression was also enhanced in response to voluntary running in R6/1 hippocampus, 
which delayed motor symptom onset (Zajac et al. 2010).  
The localisation of HTT may be altered in response to BDNF stimulation, as BDNF is a 
major regulator of excitatory pathways, which may elicit transcriptional activity as well 
as synaptic transmission and plasticity (Soulé et al. 2006). It has been postulated that 
HTT acts as a TF, and its activity is regulated by its localisation (Truant 2003; Truant et 
al. 2007). For example, the expression of Bdnf is regulated by HTT localisation; HTT 
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sequesters the Bdnf expression repressors NRSF/REST in the cytoplasm, therefore 
allowing the expression of Bdnf (Zuccato et al. 2001). However, mislocalisation of 
mHTT to cell nuclei and aberrant protein interactions due to the expanded polyQ 
prevent this sequestration, and Bdnf expression is suppressed (Zuccato et al. 2003). 
REST also regulates other genes associated with growth factors, neurotransmitters and 
vesicular trafficking (Zuccato & Cattaneo 2007), the transcription of which were 
recently found to be dysregulated in primary cells from HdhQ109 mice; a phenotype that 
was rescued with REST knock-down (Soldati et al. 2013). Therefore, movement of HTT 
into the cytoplasm following BDNF stimulation may be a mechanism by which REST is 
further sequestered by HTT in order to enhance transcriptional activity, but this 
cytoplasmic localisation in response to stimulation is aberrant in StHdhQ7/111 and 
StHdhQ111/111 cells, thus contributing to disrupted transcriptional regulation. 
 3.5.3 NGF stimulation 
NGF stimulation elicited the opposite response in StHdhQ111 cell lines compared with 
BDNF stimulation, and there was a clear difference in the detection and localisation of 
different HTT epitopes. NGF stimulation led to an increase in nuclear HTT in StHdhQ7/7 
cells, which appeared at 5 minutes and was diffuse when probed with Ab675, but 
demonstrated aggregated foci from 15 minutes of stimulation when visualised with 
Mab2166. NGF is required for neuronal survival, growth and maintenance of neuronal 
function (Allen et al. 2013), and as such is associated with mechanisms such as 
transcription, neurite outgrowth and differentiation (Song et al. 2002; Humbert 2003; 
Chen et al. 2012). However, NGF has been found to be reduced in HD patient plasma 
(Tasset et al. 2012), and phosphorylation of its receptor, TRKA, was suppressed in PC12 
cells carrying mHTT (Song et al. 2002). Similarly, in PC12 cell models of HD, MAPK and 
JNK signalling pathways in response to NGF stimulation have previously been found to 
be suppressed (Humbert 2003), plus NGF-mediated neurite outgrowth is blocked (Song 
et al. 2002). These effects are thought to be due to either an aberrant interaction 
between mHTT and TRKA (Song et al. 2002), or interference with huntingtin associated 
protein 1 (HAP1), a stabiliser for TRKA activation (Rong et al. 2006).This suggests that 
as well as levels of endogenous NGF being lowered due to the presence of mHTT, the 
sensitivity of cells in HD models may also be suppressed due to interference at the 
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receptor. This is observed here in the StHdhQ7/111 and StHdhQ111/111 cell lines; similar to 
the effect seen following BDNF stimulation, there is still an effect of NGF stimulation 
on these cells, but it is delayed to a later time point compared with the StHdhQ7/7 cells. 
In addition, StHdhQ111/111 cells exhibit a much more variable localisation of the HTT 
epitope detected by Mab2166, and neither mHTT line exhibit the nuclear foci that 
develop in StHdhQ7/7 cells, suggesting aberrant activity of HTT in these cells. 
N-terminal HTT has been found to aggregate in the perinuclear region prior to 
translocation to the nucleus, particularly in response to cellular stress (Sawa et al. 
2005). The epitope of HTT labelled with Mab2166 exhibits a strong perinuclear signal 
in StHdhQ7/7 cells, and this may have primed the transport of this epitope into the 
nucleus following NGF stimulation, whereas StHdhQ7/111 and StHdhQ111/111 cells already 
demonstrate increased nuclear presence of this epitope, so increased nuclear 
translocation in response to NGF stimulation may be less efficient. It remains to be 
elucidated what the nuclear foci seen in StHdhQ7/7 cells are, but it is possible that they 
appear within the cell nucleoli; it has previously been observed that invaginations of 
the nuclear membrane can make contact with the nucleolus (Fricker et al. 1997), 
providing a potential mechanism for entry of N-terminal HTT to the nucleus. 
Association with the nucleolus may implicate HTT in ribosomal synthesis, which has 
been found to be dysregulated in models of HD (Trettel et al. 2000; Kegel et al. 2002) 
and can be modulated by NGF stimulation (Angelastro et al. 2002). In addition, the 
internal-accessible epitope of HTT that we postulate may be detected by Mab2166 in 
these cells, and is associated with perinuclear organelles, has also been identified in 
the nucleolus (Trettel et al. 2000).  
Alternatively, HTT has also been associated with subnuclear speckles and 
promyelocytic leukaemia (PML) bodies, where it may play a role in transcription and 
RNA processing (Kegel et al. 2002). This suggests that stimulation with NGF may be 
eliciting transcriptional activity, and the localisation of HTT is modulated in response 
(Kegel et al. 2002). The lack of foci formation in StHdhQ7/111 and StHdhQ111/111 cells 
suggests that there may be dysregulation of normal HTT nuclear processes in these 
cells in response to stimulation with NGF due to mislocalisation of the mutant protein 
and disorganisation of nuclear structures.   
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The differences in localisation and time of response between Ab675 and Mab2166 may 
reflect a change in HTT conformation within the nucleus, thus allowing for differential 
antibody detection. For example, the diffuse nuclear filling with Ab675 is less apparent 
at 15 minutes of NGF stimulation, which is when the Mab2166 labelled foci appear. 
However, the perinuclear labelling with Mab2166 also disappears at this time point, 
which may be more indicative of a change in localisation rather than change in 
conformation.   
There have been mixed reports as to whether enhancing NGF availability in affected 
striatal cells is beneficial in models of HD. Bone marrow mesenchymal stem cells 
overexpressing NGF had little therapeutic effect when transplanted into YAC128 striata 
(Dey et al. 2010), although enhanced NGF via an astrocytic NGF enhancer proved to be 
protective against neuronal death in response to the mitochondrial toxin 3-
nitropropionic acid (3-NP) (Almeida et al. 2010; Chen et al. 2012). However, if cells 
carrying mHTT have a suppressed response to stimulation by NGF, as observed here, 
then a more efficacious therapeutic target may be the TRKA receptor, or downstream 
targets associated with nuclear processes. 
 3.5.4 EGF stimulation 
EGF stimulation is known to elicit the transcription of immediate-early genes (Lin et al. 
2001; Cabodi et al. 2009), and is associated with a range of essential cellular functions 
such as development, differentiation and survival (Liévens et al. 2008), and is 
implicated in the inflammatory and immune response (Cabodi et al. 2009). It has also 
been suggested that the EGFR may act as a transcriptional regulator itself (Lin et al. 
2001); therefore incubating StHdhQ111 cell lines with EGF is likely to elicit a 
transcriptional response. Stimulation of StHdhQ7/7 cells with EGF led to a reduction in 
nuclear HTT for three of the N-terminal antibodies utilised, although alterations in 
localisation remained primarily between the nucleus and perinuclear regions of the 
cell, rather than diffusing out into the cytoplasm. This change in localisation may be a 
mechanism by which to regulate the transcriptional response that occurs following 
EGF stimulation. Similar to the effect seen following stimulation with either BDNF or 
NGF, there was a suppressed response to EGF in both StHdhQ7/111 and StHdhQ111/111 
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cells, which would be consistent with transcriptional dysregulation seen in models of 
HD (Ross et al. 2002; Zucker et al. 2005; Crocker et al. 2006; Crook & Housman 2011).  
How the localisation of HTT may be regulating the transcriptional response to growth 
factor stimulation remains to be elucidated. However, HTT has previously been found 
to associate with the EGFR via its SRC-homology 3 (SH3) domain, and in turn this can 
regulate the RAS-dependent signalling pathway by competitive inhibition of Ras 
GTPase activating protein (RasGAP); mechanisms that have both been found to be 
disrupted by an extended polyQ repeat (Liu et al. 1997; Song et al. 2002). A reduction 
in nuclear HTT may therefore reflect localisation with the EGFR and downstream 
kinases that regulate transcription in response to EGF stimulation. However, there 
have been mixed findings with regards to the effect of mHTT on the activation of the 
downstream kinase ERK 1/2. In some models, EGF-mediated activation of ERK 1/2 is 
suppressed in the presence of mHTT (Song et al. 2002; Liévens et al. 2008; Melone et 
al. 2013), although in StHdhQ111/111 cells, ERK 1/2 activation by EGF stimulation was not 
found to differ from StHdhQ7/7 cells (Ginés et al. 2010). 
Alternatively, as HTT is known to localise to the Golgi and endosomes (Pal et al. 2006; 
del Toro et al. 2009), it may be playing a role in the recycling and degradation of the 
EGFR following stimulation with EGF, thus its increased perinuclear localisation may 
reflect translocation to the Golgi body and late endosomes in order to process the 
EGFR, or to assist with its nuclear localisation. Indeed, delayed EGFR degradation and 
altered trafficking has been observed in human HD fibroblasts (Melone et al. 2013). Of 
course, the role of HTT on the downstream effects of EGF may be more direct; HTT is 
able to bind directly to DNA and chromatin in order to act as a transcription factor 
(Benn et al. 2008), or can bind to other transcription factors to regulate their activity 
(Bauer & Nukina 2009). Therefore the reduction in nuclear HTT that is observed 
following EGF stimulation may be reflective of this process, and may be either  a true 
change in localisation, or a conformational change that alters the availability of the N-
terminal epitope. Evidence for the latter may be the effect of EGF on the epitope 
detected by the N17 antibody; this was much more nuclear than the other N-terminal 
antibodies, and showed no response to EGF stimulation. As there was a reduction in its 
signal following Htt siRNA treatment, it is unlikely that N17 is detecting entirely non-
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specific products. Therefore it may be detecting an alternative epitope of HTT that 
remains detectable despite a potential change in HTT conformation.  
 3.5.5 Western blot analysis of HTT subcellular localisation 
Western blot analysis also provided support that there may not necessarily be changes 
in the localisation of HTT following growth factor stimulation, as none of the three 
growth factors or five antibodies utilised elicited any visible change in the presence of 
full length HTT in either nuclear or cytoplasmic fractions. The lack of localisation 
change identified by western blot may indicate that there is a conformational change 
in nuclear HTT in response to growth factor stimulation rather than a translocation. In 
contrast, this may be a methodological issue, in that the process by which subcellular 
fractionation was carried out is not sensitive enough to retain the transient alterations 
in HTT localisation observed by immunofluorescence. 
 3.5.6 HTT shuttling mechanisms  
Despite sharing some downstream kinase signalling pathways, each growth factor had 
a separate effect on the localisation of HTT; this may be due to be different 
interactions of HTT with each growth factor receptor, but also to the different kinetics 
of activation in response to each growth factor. For example, NGF stimulation elicits 
sustained activation of MAPK in PC12 cells, whereas EGF stimulation elicits only 
transient activation (Ji et al. 2010). In addition, it has been found previously that only 
BDNF-mediated ERK 1/2 activation was suppressed in StHdhQ111/111 cells, but EGF-
mediated ERK 1/2 activation showed no difference to StHdhQ7/7 cells (Ginés et al. 
2010), suggesting that upstream mediators alter the effect of different stimuli on 
shared signalling pathways. These alterations in signalling kinetics and mediators 
appear to be enough to regulate the localisation and/or the conformation of HTT in 
order to mediate different cellular functions, the natures of which are yet to be 
elucidated.  
Various mechanisms have been described that can explain the ability of full length HTT 
to shuttle between the nucleus and cytoplasm, as it is too large to passively diffuse 
across the nuclear pore (Terry et al. 2007). For example, the ability of the first 17 
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amino acids to act as a cytoplasmic retention signal (Xia 2003), including the CRM1-
dependent NES (Maiuri et al. 2013), both act to target HTT to the cytoplasm. In 
addition, several HEAT repeats along HTT have been described as being similar to other 
nuclear import factors (Atwal et al. 2007; Truant et al. 2007), and an NLS that binds to 
nuclear import receptors importin beta 1 and transportin has been identified between 
amino acid residues 174 - 207, which can be activated by cellular stress (Desmond et 
al. 2012; Desmond et al. 2013). The availability of these sequences in the different 
conformations of HTT, as well as binding to exogenous chaperones to traverse the 
nuclear pore (Li et al. 1995; Faber et al. 1998; Ferrigno & Silver 2000; Truant et al. 
2007) may be a mechanism by which growth factor stimulation can alter the 
localisation of HTT. It has also been observed that the phosphorylation of HTT can alter 
the action of its NES and NLS sequences, and can regulate its subcellular localisation 
(Gu et al. 2009; Thompson et al. 2009; Atwal et al. 2011; Havel et al. 2011; Maiuri et al. 
2013).  
 3.5.7 The localisation of phosphorylated HTT 
We therefore also investigated the localisation of phosphorylated epitopes of HTT 
both prior to, and in response to growth factor stimulation. As observed for non-
phosphorylated N-terminal epitopes of HTT, there was increased nuclear and 
perinuclear localisation at baseline in StHdhQ7/111 and StHdhQ111/111 cells, and there 
were differential growth factor effects on the localisation of phosphorylated HTT. 
Following BDNF stimulation, there was initially a reduction in nuclear HTT 
phosphorylated on S13, followed by a nuclear increase again and a subsequent second 
reduction in StHdhQ7/7 cells. StHdhQ7/111 and StHdhQ111/111 cells showed a similar pattern 
of response, but this was much more variable. There was the same pattern of 
localisation as detected by Ab675 and Mab2166, suggesting that the alterations in 
subcellular HTT detection following BDNF may be due to alterations in its localisation 
rather than a conformational change. In contrast, there was little effect of BDNF 
stimulation on the localisation of the double S1316 phosphorylated epitope in any 
genotype; therefore the pathways activated by BDNF stimulation may be capable of 
S13 phosphorylation, but do not elicit S16 phosphorylation.  
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In contrast, there is a reduction in the detection of nuclear single S13 and double 
S1316 phosphorylated HTT epitopes following NGF stimulation in StHdhQ7/7 cells. 
However, this is also more variable for StHdhQ7/111 and StHdhQ111/111 cell types, 
suggesting dysregulation in the control of mHTT localisation and phosphorylation. The 
phosphorylation of HTT on S13 and S16 tends to be associated with increased nuclear 
localisation of HTT (Atwal et al. 2007; Thompson et al. 2009; Atwal et al. 2011; Havel et 
al. 2011; Desmond et al. 2013; Maiuri et al. 2013), suggesting that NGF stimulation is 
either not having an effect on the phosphorylation of HTT on S13 or S16, or it is 
dephosphorylating these epitopes. The pattern of localisation is similar to that 
detected by Ab675, but is the opposite of that displayed by Mab2166; nuclear foci are 
detected by Mab2166 at the same 15 minute time point following NGF stimulation 
when a reduction in nuclear phosphorylated epitopes occurs. Therefore, this may be 
indicative of a conformational change in nuclear HTT that reduces the ability of anti-
phosphorylated S13 and S1316 antibodies to detect HTT; the detection of HTT by the 
phosphorylated S13 antibody has been found to alter detection by Mab2166 before 
(Wheeler 2000; Thompson et al. 2009; Di Pardo et al. 2012).  
Following EGF stimulation, there was a reduction in phosphorylated S13 apparent in 
cell nuclei in StHdhQ7/7 and StHdhQ7/111 cells, but an increase in StHdhQ111/111 cells. In 
contrast, there was an increase in the double phosphorylated epitope in the nuclei of 
StHdhQ7/7 cells for both anti-phosphorylated S1316 HTT antibodies that were analysed, 
but there was a more variable response in StHdhQ7/111 and StHdhQ111/111 cells. This 
suggests that EGF stimulation may elicit the phosphorylation of both S13 and S16, but 
that the double phosphorylation event is more relevant to the nuclear localisation of 
HTT; an effect that has been described previously (Gu et al. 2009; Atwal et al. 2011; 
Havel et al. 2011).  This effect is in contrast to the localisation of HTT detected by 
Ab675, Mab2166 and Ab109115 following EGF stimulation, where there was a 
reduction in nuclear HTT. Therefore, these results may reflect either an alteration in 
HTT conformation; i.e the phosphorylation of HTT epitopes in the nucleus reduces the 
binding capacity of non-phosphorylated N-terminal antibodies, or there is a 
bidirectional shuttling of HTT epitopes between the nucleus and perinuclear region 
dependent upon phosphorylation status. Phosphorylation at S13 and S16 can reduce 
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the interaction of HTT with the nuclear export factors CRM1 (Maiuri et al. 2013) and 
TPR (Cornett et al. 2005), therefore non-phosphorylated epitopes could still be capable 
of leaving cell nuclei at the same time as phosphorylated epitopes are imported. The 
S1316 phosphorylated epitopes form nuclear speckles in StHdhQ7/7 cells following 15 
minutes of EGF stimulation, which may be areas associated with transcription; Atwal et 
al. 2011 previously noted that phosphorylation on these two serines in response to 
stress targeted full length HTT to chromatin subregions of the nucleus in StHdhQ111 cell 
lines.  
 3.5.8 The role of phosphorylated HTT subcellular localisation 
All three growth factors investigated altered the detection of the subcellular 
localisation of phosphorylated HTT epitopes, however whether this is due to nuclear-
cytoplasmic shuttling, changes in conformation within cellular compartments, or a 
more complex combination of these two processes remains to be elucidated. 
However, different patterns of responses in combination with our findings from non-
phosphorylated N-terminal epitope antibodies suggests that different stimulations are 
likely to be eliciting different processes. The majority of the localisation changes 
occurred between the nucleus and the perinucleus, rather than any large alterations 
within the cytoplasm. This is consistent with perinuclear aggregation of HTT prior to 
nuclear translocation (Sawa et al. 2005), and the role of phosphorylation in the 
subcellular shuttling of HTT (Atwal et al. 2007; Thompson et al. 2009; Atwal et al. 2011; 
Ehrnhoefer et al. 2011; Greiner & Yang 2011; Havel et al. 2011; Khoshnan & Patterson 
2011; Desmond et al. 2013; Maiuri et al. 2013).  
The nuclear localisation of HTT is thought to be able to alter gene expression (Zoghbi & 
Orr 2000; Kegel et al. 2002) and can also affect nuclear organisation and function (Sun 
et al. 2007), and the phosphorylation of HTT is one mechanism by which this may be 
regulated (Holmberg et al. 2002; Ehrnhoefer et al. 2011). Phosphorylation at S13 and 
S16 is known to be a protective mechanism, despite inducing an increase in nuclear 
HTT, which is typically associated with enhanced toxicity (Gu et al. 2009; Thompson et 
al. 2009; Atwal et al. 2011; Khoshnan & Patterson 2011; Di Pardo et al. 2012; Mishra et 
al. 2012). Typically, alterations in the phosphorylation of HTT have been investigated in 
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cells and mouse models carrying the mutant protein, and have looked at alterations in 
aggregation pathology and clearance of mHTT via the ubiquitin proteasome system 
(Gu et al. 2009; Thompson et al. 2009; Di Pardo et al. 2012). However, we have 
identified that the localisation and phosphorylation of endogenous wild type HTT can 
be altered by growth factor stimulation, and therefore nuclear translocation of 
phosphorylated epitopes may be a mechanism by which cell signalling responses are 
regulated, as well having a role as a protective mechanism following cell stress and for 
modifying mHTT toxicity (Gu et al. 2009; Thompson et al. 2009; Atwal et al. 2011; 
Mishra et al. 2012; Di Pardo et al. 2012). However, it was observed that alterations in 
localisation and phosphorylation in response to growth factor stimulation are 
suppressed in the cell lines carrying mHTT, suggesting there may be polyQ dependent 
hypophosphorylation of mHTT, as has previously been identified in these cells and 
other models of HD (Thompson et al. 2009; Atwal et al. 2011). Whether this is due to 
interference in kinase signalling pathways upstream of HTT phosphorylation or to less 
efficient phosphorylation of mHTT due to physical disruption from the expanded polyQ 
remains to be elucidated.  
 3.5.9 Other post-translational modifications of HTT 
There are many other post-translational modifications of HTT that may also be 
occurring in response to growth factor stimulation, and that may also modulate the 
localisation of HTT. One of the most well characterised phosphorylation sites on HTT is 
at S421, which has been associated with the regulation of proteolysis and clearance 
(Warby et al. 2009), as well as BDNF vesicle transport (Gauthier et al. 2004; Zala et al. 
2008), and can be elicited by AKT or serine/threonine protein kinase (SGK) activity 
(Warby et al. 2005; Zala et al. 2008; Bauer & Nukina 2009; Warby et al. 2009). In 
accordance with the phosphorylation of S13 and S16, S421 phosphorylation has also 
been found to be protective in models of HD (Warby et al. 2005; Zala et al. 2008; Bauer 
& Nukina 2009; Warby et al. 2009), but in contrast to S13 and S16, has been found to 
reduce the nuclear localisation of HTT (Bauer & Nukina 2009; Warby et al. 2009). We 
were unfortunately unable to utilise an anti-phosphorylated S421 antibody in this 
experiment, however it may have provided additional information on the regulation of 
HTT localisation; for example, when a nuclear reduction in HTT was observed, such as 
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following BDNF and EGF stimulation, it would have been informative to investigate 
whether this may have been relocalisation of HTT epitopes towards the cytoplasm to 
aid with vesicular transport.  
HTT is also phosphorylated on Threonine 3 (T3) in a polyQ dependent manner (Aiken 
et al. 2009), with mHTT being hypophosphorylated. T3 phosphorylation is considered 
to be neuroprotective by regulating the secondary structure of N-terminal HTT, thus 
altering its availability for further modification and clearance (Aiken et al. 2009); 
therefore the baseline phosphorylation of T3 in this model may be modulating the 
phosphorylation responses to growth factor stimulation. In addition, it has been 
postulated that phosphorylation at S13 and S16 may interact with nearby 
ubiquitination and small ubiquitin like modifier (SUMO)-ylation sites on lysines 6 (K6), 
9 (K9) and 15 (K15) (Steffan et al. 2004; Ehrnhoefer et al. 2011). Ubiquitin and SUMO 
modifiers compete for these sites (Steffan et al. 2004), and tend to have opposing 
effects on the toxicity of mHTT in HD models; ubiquitination has been associated with 
increasing mHTT clearance and therefore reducing toxicity (Kalchman et al. 1996; 
Steffan et al. 2004; Jana et al. 2005), whereas SUMOylation stabilises the mHTT 
protein, thereby increasing its nuclear localisation and worsening transcriptional 
dysregulation, thus enhancing toxicity (Steffan et al. 2004). As most SUMO modifiers 
are in the nucleus (Steffan et al. 2004), this may contribute to the reduced export of 
nuclear forms of mHTT in StHdhQ7/111 and StHdhQ111/111 cells following growth factor 
stimulation. There are also several acetylation and palmitoylation sites on HTT 
(Pennuto et al. 2009; Ehrnhoefer et al. 2011), but these have not been directly 
associated with the shuttling of HTT between cellular compartments, although any 
post-translational modifications of HTT are likely to affect its regulation in response to 
cellular stimulation. Proteolytic cleavage of HTT by caspases and calpains are a 
modification of HTT that can alter its subcellular localisation due to the exclusion of 
NES or NLS sequences on the protein, and the generation of small fragments that can 
passively diffuse across the nuclear pore (Wellington et al. 1998; Toneff et al. 2002; 
Kim et al. 2003; Terry et al. 2007; Bauer & Nukina 2009; Landles et al. 2010; 
Ehrnhoefer et al. 2011). However, analysis of HTT localisation by subcellular 
fractionation and western blot did not reveal any HTT fragments smaller than the full 
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length protein (examples of full blots can be found in Appendix IV), indicating that 
either proteolytic cleavage of HTT does not occur in the StHdhQ111 cell model of HTT, 
the abundance of cleaved fragments was too low for detection, or the method by 
which fractionation occurred was too harsh in order to retain the integrity of cleaved 
products. Regardless of the mechanism, we were unable to assess the contribution of 
cleaved HTT products to our localisation and phosphorylation observations.  
 3.5.10 Conclusion 
In conclusion, different growth factors elicit differential subcellular localisation and 
phosphorylation of N-terminal epitopes of HTT, which may be due to different 
signalling pathways and kinetics downstream of the growth factor receptors. This 
process is suppressed in cells carrying the mutant protein, although it remains to be 
determined at what stage of the cell signalling process this disruption occurs, i.e. at the 
receptor, during kinase phosphorylation, or at mHTT itself. Post-translational 
modifications and the shuttling of HTT between cellular compartments are both 
associated with the regulation of its function (Truant 2003; Truant et al. 2007), such as 
the control of gene expression (Atwal et al. 2011), regulating protein-protein 
interactions (Bauer & Nukina 2009; Ehrnhoefer et al. 2011) and interactions with 
organelles (Hilditch-Maguire et al. 2000; Kegel et al. 2002; Tao & Tartakoff 2001; Atwal 
et al. 2007). However, investigation of these processes is confounded by the ability of 
HTT to undergo dramatic conformational switches (Seong et al. 2010), particularly 
following post-translational modifications such as phosphorylation (Aiken et al. 2009; 
Gu et al. 2009; Atwal et al. 2011; Mishra et al. 2012) that alter its binding capacity to N-
terminal antibodies. As such, we were unable to determine whether the alterations in 
localisation and phosphorylation of HTT that we observe were due to changes in either 
its conformation or nuclear translocation in response to growth factor stimulation. 
However, by comparing results from the localisation patterns of several different 
antibodies, a mechanism can be hypothesised; this appears to differ between growth 
factors, with BDNF perhaps eliciting translocation, NGF leading to a conformation 
change, and both events occurring following EGF stimulation (a summary can be found 
in Table 3.3). The investigation of the identity of the nuclear foci that co-localised with 
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HTT in response to growth factor stimulation would have been advantageous; 
however, there was not the opportunity within this project.  
Although validation of the antibodies used by siRNA was not unequivocally successful, 
the antibodies used to detect N-terminal HTT tend to show the same pattern of 
localisation and response to stimulation that suggests they are detecting similar 
proteins, likely to be HTT-related. It is therefore reasonable to infer that our 
immunofluorescence findings are not heavily confounded by non-specific binding. 
Despite demonstrating differential HTT localisation and phosphorylation responses 
due to genotype and growth factor stimulation, we have not yet elucidated what 
signalling pathways may be leading to these responses. Therefore we next aimed to 
discover which signalling pathways were most relevant to our panel of growth factors 
in this cell line, and whether aberrant upstream activity may be responsible for the 
altered mHTT localisation and phosphorylation responses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.3 A comparison of the general effects of growth factor (GF) stimulation on 
the apparent nuclear localisation of HTT and phosphorylated HTT epitopes in 
StHdhQ7/7 and StHdhQ111/111 cells. Arrows indicate an increase or decrease in the 
intensity of nuclear HTT detection, and a cross indicates no observable change. 
Where more than one direction is present, findings were mixed between 
antibodies. The presence of an expanded CAG repeat in StHdhQ111/111 cells inhibited 
the HTT localisation and phosphorylation responses to GF stimulation. A 
comparison of non-phosphorylated and phosphorylated HTT localisation patterns 
allows for conclusions about the potential mechanisms underlying the differential 
observable effects for each GF to be drawn.   
161 
 
Chapter 4: Characterisation of the signalling pathways induced by growth factor 
  stimulation in immortalised embryonic striatal cells 
 
4.1 Introduction 
Patients with HD have been reported as having a low incidence of tumour formation, 
as well as a lower glucose metabolism (Kuwert et al. 1990; Grafton et al. 1992), 
suggesting that growth factor responsive kinase pathways may play a role in the 
pathogenic mechanism of the disease. A cartoon depicting several of the overlapping 
signalling pathways investigated in this chapter can be found in Figure 4.1. The EGFR is 
involved with cell development, differentiation and survival (Liévens et al. 2008), and 
its signalling complex has been found to interact with both HTT and mHTT (Liu et al. 
1997; Song et al. 2002; Apostol et al. 2006; Liévens et al. 2008). Specifically, the proline 
rich motifs in HTT appear to associate with SH3 domain-containing molecules within 
the EGFR complex, and this association is strengthened with EGFR stimulation (Liu et 
al. 1997). It is unknown exactly what role HTT may have at the EGFR, but it may 
regulate the consequent RAS-dependent pathway by competitive inhibition (Liu et al. 
1997).  
There have been inconsistent findings regarding the effect of mHTT at the EGFR and 
the consequences for downstream signalling. It has generally been found that mHTT 
attenuates signalling pathways downstream of the EGFR by its association with GRB2 
(Liu et al. 1997; Song et al. 2002), and as a result, activation of AKT and ERK is 
antagonised (Song et al. 2002; Humbert 2003). However, this effect may be model 
specific; attenuated AKT and ERK were identified in PC12 cells expressing the mutant 
protein (Song et al. 2002; Humbert 2003), in Drosophila (Liévens et al. 2008), and in 
R6/1 hippocampus (Ransome & Hannan 2013). In contrast, increased AKT 
phosphorylation has been identified in the StHdhQ111 immortalised cell line of HD 
(Ginés et al. 2003; Kong et al. 2009; Atwal et al. 2011), in HdhQ111 mice (Ginés et al. 
2003), and in the striata of R6/1 mice (Saavedra et al. 2010). Conversely, in YAC128 
and R6/2 mice, no difference in active AKT was found between wild type and mutant 
mice (Warby et al. 2005; Xie et al. 2010). 
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GRB2 has also been implicated with the NGF-responsive TRKA receptor; subsequently, 
phosphorylation of this receptor was found to be repressed in PC12 cells expressing 
mHTT (Song et al. 2002). The NGF pathway shares several of the same signalling 
pathways as EGF downstream of stimulation of its receptor, such as MAPK (Torcia et 
al. 2001; Rosini et al. 2004; Ji et al. 2010) and AKT (Rong et al. 2002). Regulation of the 
MEK/ERK cascade is also thought to mediate the effect of NGF on neurite outgrowth 
(Levkovitz & Baraban 2002). In the presence of mHTT, the phosphorylation and 
activation of these pathways following NGF stimulation have been found to be 
substantially suppressed (Song et al. 2002; Humbert 2003; Rong et al. 2006) despite 
evidence that suggests the level of NGF secretion does not change with overexpression 
of mHTT (Zuccato et al. 2001). This suggests that in the context of NGF signalling, the 
mutant protein may be exerting its effects at the TRKA receptor rather than disrupting 
NGF itself.  
The P75 NTR also acts as a receptor for NGF stimulation, but in contrast to evidence 
that suggests downregulation of TRKA activity in HD models, P75 ntr mRNA was found 
to be significantly increased in the caudate of human HD brain (Zuccato et al. 2008), as 
well as in HdhQ111 and R6/1 mouse striata (Brito et al. 2013). In addition to regulating 
the NGF response, the P75 NTR also modulates TRKB activity (Brito et al. 2013), which 
has consistently been identified as being downregulated in mouse models of HD, as 
well as in human HD brain (Ginés et al. 2006; Brito et al. 2013). Reduced BDNF in HD 
models and human HD brain is also a well characterised phenotype (Baquet et al. 
2004; Xie et al. 2010; Zajac et al. 2010), which is thought to be due to reduced 
transcription of the Bdnf gene in response to aberrant regulation of NRSF/REST 
signalling (Zuccato et al. 2001; Zuccato et al. 2003; Zajac et al. 2010), coupled with 
reduced BDNF vesicle transport efficiency (Gunawardena et al. 2003). The BDNF 
signalling pathway also overlaps with both NGF and EGF pathways; specifically, BDNF is 
known to activate the MAPK (Altar et al. 2004; Ji et al. 2010) and AKT pathways (Kaplan 
& Miller 2000). A reduction in MAPK activation has been observed in the StHdhQ111 
immortalised cell line following BDNF stimulation, but there was no difference in the 
effect on the downstream AKT pathway (Ginés et al. 2010). It was therefore suggested 
that despite reduced levels of the TRKB receptor, a diminished presence and binding of 
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adaptor proteins may be an additional mechanism that leads to dysregulation of kinase 
signalling (Ginés et al. 2010). Inhibition of MEK also abrogated the protective effect of 
BDNF stimulation in StHdhQ111 cells, implicating this pathway as a downstream 
modulator of BDNF activity (Ginés et al. 2010). However, despite substantial 
disruptions identified at the receptors of various growth factors, mHTT may also be 
exerting an effect on signalling cascades downstream of growth factor receptors. 
HTT and mHTT have been implicated in MAPK signalling pathways; HTT binds to the 
SH3 domain of MLK2, which prevents activation of the pro-apoptotic JNK pathway. 
However, in PC12 cells, mHTT is unable to bind to MLK2, therefore increasing 
activation of the JNK pathway that leads to cell death (Humbert 2003). However, 
similar to the lack of consensus over AKT activation, there have been mixed findings 
about the effect of mHTT on MAPK signalling pathways. For example, an 80-90% 
reduction in MAPK and JNK activation has been reported in PC12 cells (Song et al. 
2002), but an increase in sustained ERK activation and alterations in the genes 
associated with this pathway have also been identified in the same cell line (Apostol et 
al. 2006). Unfortunately, there has so far been little work investigating the role of P38 
MAPK signalling in HD mouse models and immortalised cell lines. 
The effect of HTT and mHTT on growth factor signalling pathways has implications for 
the regulation of transcription; both the AKT pathway and MAPKs are known to play a 
role in transcription, either by direct regulation or through the phosphorylation of 
other proteins (Lin et al. 2001; Apostol et al. 2006; Cabodi et al. 2009; Kong et al. 2009; 
Ro et al. 2010). Therefore it is possible that mHTT may disrupt transcriptional 
regulation via interruption of growth factor signalling pathways. AKT can directly 
phosphorylate HTT on S421 (Humbert 2003) and potentially on S13 and S16 
(Thompson et al. 2009), which may affect mHTT toxicity by modulating its localisation,  
and therefore regulation of transcription.  The overall phosphorylation of HTT has also 
been found to be repressed by inhibiting MEK1 activation in 293T cells expressing 
either 23Q or 148Q (Schilling et al. 2006), suggesting a role of MEK stimulation in the 
phosphorylation of HTT and mHTT.  The effect of disrupted growth factor signalling 
pathways may therefore alter the phosphorylation of HTT and mHTT, and may also be 
an indirect mechanism by which transcription is dysregulated in models of HD. 
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Here, we aim to identify the signalling pathways that are aberrantly controlled in the 
StHdhQ111 cell model of HD in response to a panel of growth factors, and to ascertain 
whether these pathways are likely to influence the transcription of a panel of 
immediate-early (IE) genes we have identified as being differentially expressed 
between genotypes in response to growth factor stimulation. We also aim to 
determine whether AKT and MEK activity in these cells may be regulating the 
phosphorylation and nuclear localisation of HTT, and if this may be a mechanism for 
transcriptional regulation in response to EGF stimulation.  
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4.2 Signalling pathways downstream of BDNF receptor stimulation 
A panel of sandwich ELISA assays was used to investigate the activity within several 
kinase signalling pathways in StHdhQ111 cell lines (see Section 2.2.2.10 for further 
details). In addition to investigating common cellular signalling pathways, three 
apoptosis-associated signalling markers were also examined; markers of cell stress 
have previously been identified as being enhanced in models of HD (Liu et al. 1997; 
Trettel et al. 2000; Humbert 2003; Bae et al. 2005; Apostol et al. 2006; Carnemolla et 
al. 2009), and dysregulation within these pathways may therefore be an additional 
mechanism contributing to gene expression changes in the StHdhQ111 cell model of HD. 
4.2.1 Cell signalling pathways  
There was a significant interaction effect of BDNF stimulation on the level of AKT1 
phosphorylated on serine 473 in StHdhQ111 cells (Figure 4.2) (F (1, 12) = 10.79, 
p=0.006).  Simple main effects analysis showed that there was no effect of BDNF in 
StHdhQ7/7 cells (p=0.798), but there was a small reduction in StHdhQ111/111 cells 
(p=0.013); this reduction lead to a significant difference in the extent of 
phosphorylated AKT1 change following EGF stimulation between genotypes (t(6) 
=7.312, p<0.001). However, there were significantly higher levels of phosphorylated 
AKT1 detected in StHdhQ111/111 cells at baseline compared to StHdhQ7/7 cells (p<0.001), 
as well as following BDNF stimulation (P= 0.004).  
There was also a significant difference in the level of MEK1 phosphorylated on serines 
217/221 between StHdhQ7/7 and StHdhQ111/111 cells at baseline (p<0.001) and following 
BDNF treatment (P< 0.001) (Figure 4.2). Overall, there was a significant effect of both 
cell type (F (1, 12) = 121.6, p<0.001) and BDNF stimulation (F (1, 12) = 27.23, p<0.001) 
on the level of phosphorylated MEK1, but there was no significant interaction between 
the two (P=0.185). Both cell types showed increased phosphorylated MEK1 following 
BDNF stimulation, but this was only significant in StHdhQ7/7 cells (P=0.003).  
P38 MAPK phosphorylated on threonine 180 and tyrosine 182 was not different 
between genotypes (P=0.115), and there was no effect of BDNF stimulation (P=0.501), 
plus there was no significant interaction between the two (P=0.523) (Figure 4.2). There 
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was also no effect of BDNF on phosphorylated signal transducer and activator of 
transcription 3 (STAT3) (tyrosine 705) (P=0.844), but there was a significant effect of 
genotype (F (1, 12) = 25.5, p<0.001). Simple main effects analysis showed that this was 
due to increased phosphorylated STAT3 in StHdhQ111/111 cells at baseline compared to 
SthdhQ7/7 (P=0.006). BDNF stimulation also had no effect on NFκβ p65, phosphorylated 
on serine 536 (P=0.152).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Mean absorbance (Abs) read at 450nm following a sandwich ELISA 
protocol for the detection of a panel of cell signalling markers in StHdh
Q7/7
 and 
StHdh
Q111/111
 cells at 0 and 10 minutes of 100ng/ml BDNF stimulation. Absorbance 
values were statistically analysed by two-way ANOVAs for main effects analysis, 
followed by a priori one-way ANOVAs to determine simple main effects and post-
hoc Tukey tests. Differences between the extent of phosphorylation change 
following growth factor stimulation were determined by subtracting the absorbance 
values from 0 mins from 10 mins for each genotype, and were submitted to 
independent-samples T-tests for analysis. (Error bars = SEM, n=4). 
* P<0.05 **P<0.01 ***P<0.001 
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 4.2.2 Apoptotic pathways 
To investigate whether different responses to BDNF stimulation between genotypes 
were a result of differing apoptotic pathways, a series of further sandwich ELISA assays 
were performed on typical cell death signalling markers (Figure 4.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There was no effect of either genotype or BDNF on the levels of phosphorylated BAD 
(serine 112) (P= 0.098 and P=0.463, respectively), or cleaved Poly (ADP-ribose) 
polymerase (PARP) (aspartate 214) (genotype p= 0.229, BDNF p= 0.217), and there 
were no significant baseline differences between StHdhQ7/7 and StHdhQ111/111 cells for 
either of these markers (phosphorylated BAD p= 0.125, cleaved PARP p= 0.979). 
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Figure 4.3 Mean absorbance read at 450nm following sandwich ELISA protocol for a 
panel of cellular apoptotic markers in StHdh
Q7/7
 and StHdh
Q111/111
 cells following 0 
and 10 minutes 100ng/ml BDNF stimulation. Absorbance values were statistically 
analysed by two-way ANOVAs for main effects analysis, followed by a priori one-
way ANOVAs to determine simple main effects and post-hoc Tukey tests. 
Differences between the extent of phosphorylation change following growth factor 
stimulation were determined by subtracting the absorbance values from 0 mins 
from 10 mins for each genotype, and were submitted to independent-samples T-
tests for analysis. (Error bars = SEM, n=4). 
* P<0.05 **P<0.01 ***P<0.001 
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However, there was a significant effect of BDNF stimulation on phosphorylated stress 
activated kinase (SAPK)/JNK (threonine 183/tyrosine 185) (F (1, 12) = 7.59, p= 0.017), 
although there was no effect of genotype (p= 0.063) and no significant interaction 
between the two (p=0.139). Post Hoc Tukey tests revealed that the effect of BDNF was 
in StHdhQ7/7 cells only, where it initiated a slight increase in phosphorylated SAPK/JNK 
(P= 0.042), but there was no effect in StHdhQ111/111 cells.  
 
4.3 Signalling pathways downstream of NGF receptor stimulation  
4.3.1 Cell signalling pathways 
There were no significant effects of NGF on any of the cell signalling markers that were 
tested (Figure 4.4). However, the differences found previously between StHdhQ7/7 and 
StHdhQ111/111 cells at baseline were replicated in these samples.  There was a significant 
effect of genotype for phosphorylated AKT1 (F (1, 12) = 71.57, p< 0.001), 
phosphorylated MEK1 (F (1, 12) = 52.23), p< 0.001) and phosphorylated STAT3 (F (1, 
12) = 29.5, p< 0.001), but no interaction with NGF stimulation in any case (p> 0.05). 
These differences were found to be significant between the genotypes at both baseline 
and following NGF stimulation. 
There was a significant main effect of genotype for phosphorylated P38 MAPK (F (1, 
12) = 20.96, p= 0.001), but simple main effects analysis showed that there was no 
significant difference between the genotypes at baseline (p= 0.68). The effect was 
found to be from a small, yet significant difference (p= 0.008) between genotypes 
following NGF stimulation due to a non-significant increase in P38 MAPK 
phosphorylation in StHdhQ7/7 cells. However, there was no significant genotype x NGF 
interaction (p= 0.303). This was also the case for phosphorylated NFκβ; there was a 
significant effect of genotype (F (1, 12) = 14, p= 0.003), which was found to be from an 
increase in StHdhQ7/7 cells following NGF stimulation (p= 0.014) rather than a difference 
between genotypes at baseline (p= 0.552).  
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Figure 4.4 Mean absorbance (Abs) read at 450nm following a sandwich ELISA 
protocol for the detection of a panel of cell signalling markers in StHdh
Q7/7
 and 
StHdh
Q111/111
 cells at 0 and 10 minutes of 100ng/ml NGF stimulation. Absorbance 
values were statistically analysed by two-way ANOVAs for main effects analysis, 
followed by a priori one-way ANOVAs to determine simple main effects and post-
hoc Tukey tests. Differences between the extent of phosphorylation change 
following growth factor stimulation were determined by subtracting the absorbance 
values from 0 mins from 10 mins for each genotype, and were submitted to 
independent-samples T-tests for analysis. (Error bars = SEM, n=4). 
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4.3.2 Apoptotic pathways 
In contrast to previous findings when looking at BDNF stimulation, there was a 
significant effect of genotype when looking at phosphorylated BAD in these samples (F 
(1, 12) = 30.86, p< 0.001); this difference was due to significantly decreased 
phosphorylated BAD in StHdhQ111/111 cells at baseline (p= 0.019) and following NGF 
stimulation (p= 0.009). However, the BDNF samples also showed a reduction in 
phosphorylated BAD in StHdhQ111/111 cells, but this failed to reach significance. There 
was no significant effect of NGF stimulation or a significant interaction with genotype 
(P= 0.33 and P= 0.48, respectively) (Figure 4.5). 
Cleaved PARP also showed a significant effect of genotype (F (1, 12) = 19.33, P= 0.001), 
but no significant effect of NGF (P= 0.179) or a significant interaction (P= 0.345). 
Similar to the pattern of activation described in section 4.2.1 following BDNF 
stimulation, simple main effects analysis shows that the observed genotype effect is 
due to a slight increase in cleaved PARP in StHdhQ7/7 cells following NGF stimulation, 
causing a significant difference between genotypes (P = 0.012). Finally, there was a 
significant effect of genotype for phosphorylated SAPK/JNK (F (1, 12) = 8.84, p= 0.012), 
but this effect failed to remain significant when looking at the simple main effect of 
genotype at baseline (P= 0.295) or following NGF stimulation (P= 0.142). There was 
also no effect of NGF stimulation (P= 0.06) or a significant genotype x NGF interaction 
(P= 0.736). 
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4.4 Signalling pathways downstream of EGF receptor stimulation 
 4.4.1 Cell signalling pathways 
EGF stimulation appears to have had the most striking effect on the activated kinases 
investigated in these cell lines compared to both NGF and BDNF stimulation. For 
phosphorylated AKT1, there was a significant effect of genotype (F (1, 12) = 12.75, p= 
0.004), EGF (F (1, 12) = 756.23, p<0.001), and a significant interaction between the two 
(F (1,12) = 5.8, p= 0.033). Although the difference between genotypes that was 
previously observed at baseline was not replicated here, the level of phosphorylated 
AKT1 following EGF stimulation was significantly higher in StHdhQ111/111 cells than in 
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Figure 4.5 Mean absorbance read at 450nm following sandwich ELISA protocol for a 
panel of cellular apoptotic markers in StHdh
Q7/7
 and StHdh
Q111/111
 cells following 0 
and 10 minutes 100ng/ml NGF stimulation. Absorbance values were statistically 
analysed by two-way ANOVAs for main effects analysis, followed by a priori one-
way ANOVAs to determine simple main effects and post-hoc Tukey tests. 
Differences between the extent of phosphorylation change following growth factor 
stimulation were determined by subtracting the absorbance values from 0 mins 
from 10 mins for each genotype, and were submitted to independent-samples T-
tests for analysis. (Error bars = SEM, n=4). 
* P<0.05 **P<0.01 ***P<0.001 
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StHdhQ7/7 cells (P= 0.006), thus supporting the notion that there is increased active 
AKT1 in these cells. In this case, there is a significant increase in phosphorylated AKT1 
for both StHdhQ7/7 (P<0.001) and StHdhQ111/111 cells (P<0.001), but this response is 
augmented in the latter cell type (t(6) = -2.465, p=0.049) (Figure 4.6). 
The same pattern is observed for phosphorylated MEK1; there is a significant effect of 
genotype (F (1,12) = 98, p<0.001), EGF (F (1,12) = 3082.28, p<0.001), and a significant 
interaction between the two (F (1,12) = 81.33, p<0.001). However, although both 
genotypes have increased phosphorylated MEK1 following EGF stimulation (both 
p<0.001), the effect is suppressed in StHdhQ111/111 cells (t(6) = 8.107, p<0.001), which 
have significantly lower phosphorylated MEK1 following EGF than StHdhQ7/7 cells 
(p<0.001). Contrary to previous observations (Sections 4.2.1 & 4.3.1), there was no 
significant difference between genotypes at baseline in these samples. 
In accordance with previous findings, there was a significant effect of genotype for 
phosphorylated STAT3 (F (1, 12) = 759.78, p<0.001), which was due to increased levels 
in StHdhQ111/111 cells at baseline (p<0.001) and following EGF stimulation (p<0.001). 
There was also a significant effect of EGF (F (1, 12) = 33.75, p<0.001) and a significant 
interaction (F (1, 12) = 43.03, p<0.001), both due to a large increase in phosphorylated 
STAT3 in StHdhQ111/111 cells following EGF stimulation (p<0.001), but no effect in 
StHdhQ7/7 cells. The difference in the extent of phosphorylation change following EGF 
stimulation was therefore significantly higher in StHdhQ111/111 cells (t(6) = -12.821, 
p<0.001). The same pattern was observed for phosphorylated P38 MAPK. 
Finally, there was a significant effect of genotype for phosphorylated NFκβ (F (1, 12) = 
6.43, p= 0.026), which was due to higher activation in StHdhQ111/111 cells at baseline (P= 
0.012). Previously, this had not reached significance; however there was a trend 
towards this in Section 4.2.1 (BDNF stimulation).  This difference disappeared following 
EGF stimulation due to a small, non-significant reduction in StHdhQ111/111 cells.  There 
was no effect of EGF stimulation (P= 0.347) on phosphorylated NFκβ, however there 
was a significant genotype x EGF interaction (F (1, 12) = 8.07, p= 0.015). 
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 4.4.2 Apoptotic pathways 
In contrast with BDNF and NGF stimulation, there was a significant effect of EGF on 
phosphorylated BAD in both cell lines (Figure 4.7) (F (1, 12) = 111.62, p<0.001), as 
levels of phosphorylated BAD increased in both StHdhQ7/7 (P= 0.002) and StHdhQ111/111 
(P<0.001) cells. However, there was also a significant interaction with genotype (F (1, 
Figure 4.6 Mean absorbance (Abs) read at 450nm following a sandwich ELISA 
protocol for the detection of a panel of cell signalling markers in StHdh
Q7/7
 and 
StHdh
Q111/111
 cells at 0 and 10 minutes of 100ng/ml EGF stimulation. Absorbance 
values were statistically analysed by two-way ANOVAs for main effects analysis, 
followed by a priori one-way ANOVAs to determine simple main effects and post-
hoc Tukey tests. Differences between the extent of phosphorylation change 
following growth factor stimulation were determined by subtracting the absorbance 
values from 0 mins from 10 mins for each genotype, and were submitted to 
independent-samples T-tests for analysis. (Error bars = SEM, n=4). 
* P<0.05 **P<0.01 ***P<0.001 
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12) = 10.98, p= 0.008), as phosphorylation was enhanced in StHdhQ111/111 cells 
(p<0.001), which was to a significantly larger extent than in StHdhQ7/7 cells (t(4) = -3.81, 
p=0.019). In contrast to the BDNF and NGF results reported here, there was no 
difference at baseline between genotypes (P= 0.194).  
There was no effect of genotype, EGF, or an interaction between the two for either 
cleaved PARP or phosphorylated SAPK/JNK (P>0.05). 
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Figure 4.7 Mean absorbance read at 450nm following sandwich ELISA protocol for a 
panel of cellular apoptotic markers in StHdh
Q7/7
 and StHdh
Q111/111
 cells following 0 
and 10 minutes 100ng/ml EGF stimulation. Absorbance values were statistically 
analysed by two-way ANOVAs for main effects analysis, followed by a priori one-
way ANOVAs to determine simple main effects and post-hoc Tukey tests. 
Differences between the extent of phosphorylation change following growth factor 
stimulation were determined by subtracting the absorbance values from 0 mins 
from 10 mins for each genotype, and were submitted to independent-samples T-
tests for analysis. (Error bars = SEM, n=4). 
* P<0.05 **P<0.01 ***P<0.001 
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4.5 Inhibition of EGF signalling pathways 
As EGF stimulation elicited the greatest response in StHdhQ111 cells, we utilised this 
growth factor in order to further investigate aberrant cell signalling pathways due to 
the presence of mHTT. EGF had the largest effect on AKT1 and MEK1 phosphorylation 
in a differential manner between genotypes, so these pathways were chosen for 
further investigation.  
4.5.1 AKT inhibition 
  4.5.1.1 Inhibitor concentration 
AKT inhibitor VIII is a reversible quinoxaline compound that can selectively inhibit the 
phosphorylation of AKT1 and 2; its structure and mode of action are described in 
Figure 4.8. In order to determine the optimum concentration of AKT inhibitor VIII 
required to efficiently inhibit phosphorylated AKT1 in StHdhQ111 cells, a concentration 
curve experiment was carried out (Figure 4.9). 
Although 250nM of AKT inhibitor VIII reduced the level of phosphorylated AKT1 
measured by ELISA assay to levels that were comparable to baseline in StHdhQ7/7 cells 
(p= 0.054), phosphorylated AKT1 in both StHdhQ7/111 and StHdhQ111/111 cells, remained 
significantly higher than baseline (P<0.001, P=0.004 respectively). At 500nM of 
inhibitor, although there was still significantly more phosphorylated AKT1 in 
StHdhQ7/111 cells than at baseline (p= 0.006), it was still significantly lower than when 
the cells were stimulated with EGF without any inhibitor present (p<0.001). At this 
molarity, levels in StHdhQ111/111 cells were brought back down to baseline (p= 0.124), 
and in StHdhQ7/7 cells AKT1 phosphorylation was slightly suppressed below baseline 
levels (p= 0.041). There was no significant effect of AKT inhibitor VIII on the activation 
of MEK1, suggesting that this compound is targeting a separate pathway. It was 
therefore decided that 500nM AKT inhibitor VIII would be used for the following 
experiments. 
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Figure 4.9 Mean absorbance read at 450nm following a sandwich ELISA protocol in 
StHdh
Q111
 cells to determination  the optimum concentration of AKT inhibitor VIII in 
order to prevent phosphorylation of AKT1 on serine 473 following 5 minutes 
stimulation with 100ng/ml EGF. The inhibitor was tested at 50, 250 and 500nM, 
prepared in DMSO solution for 2 hours prior to EGF stimulation.  Inhibitor-free time 
points included the equivalent volume of DMSO in the media for the same length of 
time prior to EGF stimulation and sample collection.  A. Effect of AKT inhibitor VIII 
on the phosphorylation of AKT1 (serine 473). B. Effect of AKT Inhibitor VIII on the 
phosphorylation of MEK1 (serines 217/221). Absorbance values were statistically 
analysed by two-way ANOVAs for main effects analysis, followed by a priori one-
way ANOVAs to determine simple main effects and post-hoc Tukey tests. (Error bars 
= SEM, n=3). 
*p<0.05  ** p<0.01 ***p<0.001 
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4.5.1.2 Localisation of HTT and mHTT following EGF stimulation when    
AKT is inhibited 
To investigate whether AKT signalling following EGF stimulation may play a role in the 
control of HTT and mHTT localisation, StHdhQ7/7, StHdhQ7/111 and StHdhQ111/111 cells 
were serum starved overnight, then cells were treated with either DMSO or AKT 
inhibitor VIII for 2 hours prior to stimulation with EGF for 0, 5, 15 and 30 minutes. The 
cells were then fixed, stained, imaged and analysed in the same manner as described 
in Chapter 3.  
   4.5.1.2a Ab109115 
Once fixed, the cells were double stained with HTT N-terminal antibodies Ab109115 
and Mab2166. It was previously found that the nuclear detection of HTT decreased in 
StHdhQ7/7 cells for both of these antibodies following EGF stimulation when no inhibitor 
was present, but there was a slight increase in nuclear detection in StHdhQ111/111 cells 
(Sections 3.3.4.3 & 3.3.5).  
When AKT activation was inhibited during stimulation with EGF, there was a significant 
increase in the N/C ratio after 5 (p=0.014) and 15 minutes (p=0.03) in StHdhQ7/7 cells, 
which was also apparent in the N/P ratio at 15 minutes (p<0.001), indicating an 
increase in detection of this epitope of HTT in the nucleus (Figures 4.10 and 4.11). 
There is also a significant reduction in the P/C ratio from 15 minutes of EGF stimulation 
(p=0.016), which supports the relocalisation of HTT from the perinuclear area into the 
nucleus. The increase in nuclear HTT appears in a speckled pattern rather than as a 
diffuse stain, and is most apparent at 5 minutes of stimulation. In comparison, when 
StHdhQ7/7 cells are stimulated with EGF for 5 minutes without AKT inhibition, there is 
no difference in the localisation of HTT. 
In StHdhQ111/111 cells, there was the converse effect of inhibiting AKT activation by EGF 
stimulation. In Chapter 3, there was very little effect of EGF stimulation on the 
localisation of mHTT in these cells. However, when AKT was inhibited, there was a 
significant reduction in nuclear mHTT at all three time points when looking at the N/P 
ratio (p<0.001 in all cases). The reduction was also apparent in the N/C ratio, but this 
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did not reach significance. There was also an increase in the P/C ratio at 5 minutes, 
which would mirror movement of mHTT from the nucleus into the perinucleus, but this 
did not reach significance due to high variability among cells. When AKT was not 
inhibited, EGF stimulation had no effect on the localisation of mHTT in these cells. This 
suggests that HTT and mHTT may interact very differently with the AKT pathway in a 
manner that may regulate its localisation. There was no effect of AKT inhibition or EGF 
stimulation on the detection of this epitope of HTT in StHdhQ7/111 cells at any time point 
in the N/C, N/P or P/C ratios; it is possible that this reflects the opposing effects of AKT 
inhibition on HTT and mHTT, both of which are present in these cells. 
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Figure 4.11 Quantitative analysis of immunofluorescence images in Figure 4.10. 
Nuclear/Cytoplasmic,   Nuclear/Perinuclear and Perinuclear/Cytoplasmic mean pixel 
intensity ratios for StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111 
cells following 0, 5, 15 and 
30 minutes of stimulation with 100ng/ml EGF following 2 hours incubation with either 
500nM AKT inhibitor VIII or the equivalent volume of DMSO. Mean pixel intensities 
were calculated from confocal microscopy images using GNU Image Manipulator 
(further details of the analysis can be found in Section 2.2.1.10). All images were 
randomised and analysed blind to genotype, AKT inhibition and length of time 
stimulated with EGF. Each condition consisted of 9 confocal microscopy images taken 
from 3 separate coverslips. A two-way ANOVA was carried out for main effects 
analysis, followed by planned one-way ANOVAs and post-hoc Tukey tests. Error bars = 
SEM 
* Denotes difference from 0. # Denotes difference from 5 mins + DMSO   
*p<0.05, ** p<0.01, *** p<0.001 
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4.5.1.2b Mab2166 
StHdhQ111 cells stained with Ab109115 were double-labelled with Mab2166, however 
as this antibody detects a different epitope of HTT, the patterns of localisation differed 
slightly. In StHdhQ7/7 cells, there was still a significant increase in the nuclear detection 
of HTT at 5 minutes of EGF stimulation when AKT was inhibited, which was most 
apparent in the N/P ratio (p=0.001), but was also present in the N/C ratio (p=0.026). 
However, this did not persist beyond 5 minutes (Figures 4.12 & 4.13). The epitope of 
HTT that was detected in the nucleus by Mab2166 was more diffuse and subtle than 
the epitope detected by Ab109115. There was no difference in the P/C ratio in 
StHdhQ7/7 cells, although there was a trend towards a perinuclear accumulation of this 
epitope, which may reflect the movement of nuclear HTT out of the nucleus following 
its initial increase at 5 minutes. 
In contrast to Ab109115, there was a significant increase in the N/P ratio for 
StHdhQ7/111 cells from 5 minutes of EGF stimulation when AKT was inhibited (p<0.001) 
as compared to both 0 and 5 minutes of EGF stimulation without inhibition. The N/P 
ratio decreased by 15 minutes, but remained significantly higher than the non-
inhibited 5 minute time point for the entire 30 minutes of stimulation (p<0.001). There 
was no significant effect in the N/C ratio, but there was a decrease in the P/C ratio at 5 
minutes (p=0.03), which is concordant with an increased N/P ratio. Taken together, 
this suggests that any movement of HTT in this model occurs mostly between the 
nuclear and perinuclear regions of the cell, which is consistent with previous findings 
(Section 3.3.4.3). These findings also suggest that although the effect is smaller, for this 
epitope of HTT the StHdhQ7/111 cells respond more similarly to StHdhQ7/7 cells than the 
StHdhQ111/111 cells. 
The epitope of mHTT detected by Mab2166 appears to be less responsive to the effect 
of AKT inhibition in StHdhQ111/111 cells than the epitope detected by Ab109115, 
however the N/P ratio is still significantly reduced at 15 minutes (p<0.001), indicating a 
reduction in nuclear mHTT. In contrast, both the N/C and P/C ratios are significantly 
increased at 30 minutes (p=0.015, p=0.004 respectively), which isn’t apparent with 
Ab109115. In addition to the likely detection of alternate mHTT epitopes by these two 
184 
 
antibodies, this effect may be due to a delayed response of potentially longer mHTT 
epitopes to AKT inhibition in these cells, or may be a homeostatic reaction in response 
to the prior reduction in nuclear mHTT. 
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Figure 4.13 Quantitative analysis of immunofluorescence images in Figure 4.12. 
Nuclear/Cytoplasmic,   Nuclear/Perinuclear and Perinuclear/Cytoplasmic mean pixel 
intensity ratios for StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111 
cells following 0, 5, 15 and 
30 minutes of stimulation with 100ng/ml EGF following 2 hours incubation with either 
500nM AKT inhibitor VIII or the equivalent volume of DMSO. Mean pixel intensities 
were calculated from confocal microscopy images using GNU Image Manipulator 
(further details of the analysis can be found in Section 2.2.1.10). All images were 
randomised and analysed blind to genotype, AKT inhibition and length of time 
stimulated with EGF. Each condition consisted of 9 confocal microscopy images taken 
from 3 separate coverslips. . A two-way ANOVA was carried out for main effects 
analysis, followed by planned one-way ANOVAs and post-hoc Tukey tests. Error bars = 
SEM 
* Denotes difference from 0. # Denotes difference from 5 mins + DMSO   
*p<0.05, ** p<0.01, *** p<0.001 
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4.5.1.2c Ab675 and N17 
In order to determine the reproducibility of these findings, the experiment was 
repeated and cells were labelled with either Ab675 or N17; both N-terminal HTT 
antibodies that detect a similar epitope to Ab109115. In Chapter 3, cells stained with 
Ab675 exhibited the same pattern of response following EGF stimulation as those 
stained with Ab109115, but there was no effect of EGF on the epitope detected by 
N17. In contrast to the previous experiment, these images were not quantitatively 
analysed. 
Ab675 detected a similar pattern of localisation as Ab109115 when AKT activity was 
inhibited (Figure 4.14); there is a visible increase in nuclear staining in StHdhQ7/7 cells 
following incubation with the AKT inhibitor, and a contrasting reduction in nuclear 
detection in StHdhQ111/111 cells from 5 to 15 minutes of EGF stimulation is also seen. 
StHdhQ7/111 cells exhibit less of an effect, as they did with Ab109115, supporting a gene 
dosage effect. However, there is a slight reduction in nuclear HTT from 15 minutes, 
suggesting that in terms of the response of this epitope to inhibited AKT activity, they 
may be more similar to StHdhQ111/111 cells than StHdhQ7/7. 
In general, the N17 antibody supported the results from the previous N-terminal 
antibodies, however consistent with the different pattern of detection in Chapter 3 
following EGF stimulation, the findings also differed slightly when AKT was inhibited. In 
StHdhQ7/7 cells, there was again an increase in the detection of nuclear HTT that was 
apparent from 5 minutes of stimulation (Figure 4.15). However, there was also a visible 
reduction in the nuclei of StHdhQ111/111 cells, but this did not occur until 15 minutes of 
stimulation, and did not persist up to 30 minutes. Similarly, StHdhQ7/111 cells also had a 
reduction in detection of nuclear HTT at 15 minutes, which was more like the detection 
by Ab675, but in contrast to Mab2166. This suggests that generally the localisation 
response of HTT and mHTT to EGF stimulation when AKT is inhibited is reproducible 
and similar between different epitopes of HTT; inhibiting AKT in StHdhQ7/7 cells 
prompts localisation of HTT towards the nucleus, whereas it elicits a reduction of 
mHTT in StHdhQ111/111 cells. The findings in StHdhQ7/111 are a lot more variable, most 
likely due to a gene dosage effect and the expression of both HTT and mHTT epitopes. 
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4.5.1.3 Localisation of phosphorylated HTT epitopes following EGF 
stimulation when AKT is inhibited.  
The same experiment was repeated, and cells were labelled with the N17 S1316p 
phospho-antibody. This was the only remaining phospho-antibody available, so we 
were unable to look at the effect on S13 phosphorylation alone or compare double 
phosphorylation antibodies.  In this instance, StHdhQ7/111 cells were not utilised as the 
staining and imaging was of insufficient quality. 
There was a significant nuclear increase of phosphorylated HTT in StHdhQ7/7 cells at 5 
minutes of stimulation with EGF when AKT was inhibited (p<0.001 in both N/C and N/P 
ratios), compared to no significant change at 5 minutes when AKT phosphorylation was 
not inhibited. This effect appeared to fluctuate; at 15 minutes the amount of 
phosphorylated HTT detected in the nucleus returned to baseline, but there was again 
a significant increase in both N/C and N/P ratios (p<0.05) at 30 minutes (Figures 4.16 
and 4.17). An increase in these ratios was also apparent in the previous chapter when 
these cells were stimulated with EGF, although this did not become significant until 
after 15 minutes of stimulation, and the effect persisted. It may therefore be possible 
that by inhibiting AKT activation downstream of EGF stimulation, the stability of HTT 
phosphorylation is reduced.  
Despite this epitope of phosphorylated mHTT already being primarily nuclear in 
StHdhQ111/111 cells at baseline, inhibition of AKT lead to a significant increase of its 
nuclear presence in these cells by 5 minutes of EGF stimulation, although this was only 
apparent in the N/P ratio (p<0.001), and persisted for 15 minutes (p<0.001) until a 
return to baseline by 30 minutes of stimulation. In contrast to previous observations 
(Section 3.4.3), there was initially more nuclear phosphorylated mHTT in this 
experiment at baseline, and there was a significant increase in the N/P ratio at 5 
minutes of stimulation with EGF without AKT inhibition (p=0.01), whereas there was 
no effect of EGF in the prior experiment. This may be due to the addition of DMSO to 
the media in this instance, or could reflect that the phosphorylation of mHTT may be 
more unstable and transient in comparison to wild type HTT. 
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Figure 4.17 Quantitative analysis of immunofluorescence images in Figure 4.16. 
Nuclear/Cytoplasmic,   Nuclear/Perinuclear and Perinuclear/Cytoplasmic mean pixel 
intensity ratios for StHdh
Q7/7
 and StHdh
Q111/111 
cells following 0, 5, 15 and 30 minutes of 
stimulation with 100ng/ml EGF following 2 hours incubation with either 500nM AKT 
inhibitor VIII or the equivalent volume of DMSO. Mean pixel intensities were calculated 
from confocal microscopy images using GNU Image Manipulator (further details of the 
analysis can be found in Section 2.2.1.10). All images were randomised and analysed 
blind to genotype, AKT inhibition and length of time stimulated with EGF. Each 
condition consisted of 9 confocal microscopy images taken from 3 separate coverslips. 
A two-way ANOVA was carried out for main effects analysis, followed by planned one-
way ANOVAs and post-hoc Tukey tests. Error bars = SEM 
* Denotes difference from 0. # Denotes difference from 5 mins + DMSO   
*p<0.05, ** p<0.01, *** p<0.001 
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4.5.1.4 Immediate-early gene expression changes 
In order to determine whether the AKT signalling pathway is relevant to gene 
expression changes in these cells, both due to disruption by mHTT and in response to 
EGF stimulation, qRTPCR on a selection of IE genes was carried out following AKT 
inhibition. This panel of genes was selected as they have been identified as being 
downstream of growth factor signalling pathways, particularly AKT and/or MEK 
pathways (Cosgaya & Aranda 1999; Levkovitz & Baraban 2002; Fuentes et al. 2008; 
Cabodi et al. 2009; Gokce et al. 2009; Ji et al. 2010; Liot et al. 2013). Generally, the 
transcriptional response of IE genes in StHdhQ111/111 cells was more sensitive to EGF 
stimulation, which elicited much larger gene expression fold changes than in StHdhQ7/7 
cells. Therefore, there was a stronger ability for kinase inhibition to have a significant 
effect on IE gene expression (Figure 4.18).  
There was no difference in the level of C-fos expression between StHdhQ7/7 and 
StHdhQ111/111 cells, and although EGF stimulation reduced the expression in both 
genotypes, this did not reach significance. AKT inhibition did not have any significant 
effect on the expression of C-fos following EGF stimulation in either genotype.  
There was a significant increase in Egr1 expression in response to EGF stimulation in 
both StHdhQ7/7 and StHdhQ111/111 cells (F (3, 24) = 17.95, p<0.001), the effect of which 
was augmented in the StHdhQ111/111 cell line (p<0.001) as compared to the StHdhQ7/7s 
(p= 0.035). In the StHdhQ7/7 cells, there was no effect of AKT inhibition on Egr1 
expression (p= 0.82), and its expression remained significantly increased compared to 
0 minutes EGF (p= 0.029). In StHdhQ111/111 cells, there was a reduction of Egr1 
expression following AKT inhibition, although this did not reach significance (p= 0.167), 
and in parallel with StHdhQ7/7 cells, expression remained significantly higher than at 0 
minutes EGF (p= 0.002).  
Similarly, for the expression of Arc, there was a significant increase following EGF 
stimulation when looking at the main effect of treatment (p = 0.004). However in post-
hoc Tukey HSD testing, this increase of expression failed to reach significance in 
StHdhQ7/7 cells (p= 0.507), but was highly significant due to a larger response in 
StHdhQ111/111 cells, thus providing more signal compared to background noise (p= 
194 
 
0.001). Although there was a reduction in Arc expression due to AKT inhibition in the 
StHdhQ111/111 cells, this was not significant (p= 0.636), and there was no effect in 
StHdhQ7/7 cells. 
Finally, EGF stimulation elicited a significant increase in Ngfib expression in both 
genotypes (F (3, 24) = 8.07, p= 0.001). AKT inhibition led to a slight decrease in Ngfib 
expression in both cases; although this was not a significant reduction compared to 
EGF stimulation alone, expression was no longer significantly higher than baseline 
(p>0.05). Therefore for this panel of IE genes, stimulation of the AKT pathway is not 
likely to be the main contributor to gene expression regulation, despite regulatory 
effects on the localisation and phosphorylation of HTT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18 Relative quantitation (RQ) values representing gene expression fold 
changes in StHdh
Q7/7
 and StHdh
Q111/111
 cells following inhibition with either 500nM 
AKT inhibitor VIII, 1uM MEK 1/2 inhibitor or the equivalent volume of DMSO, followed 
by 0 or 2 hours of 100ng/ml EGF stimulation for A. C-fos, B. Egr1 C. Arc and D. Ngfib. 
Statistical analysis was conducted on ΔCt values using a two-way ANOVA followed by 
post-hoc Tukey tests.  (Error bars = SEM, n = 5) 
‘*’ denotes a significant difference from 0.  
* p<0.05  ** p<0.01 ***p<0.001 
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4.5.2 MEK 1/2 inhibition 
  4.5.2.1 Inhibitor concentration 
MEK 1/2 inhibitor is a vinylogous cyanamide that is a potent inhibitor of MEK1 and 2; 
its structure and mode of action are described in Figure 4.19. A concentration curve 
experiment was carried out for this inhibitor (Figure 4.20); all three concentrations of 
the inhibitor significantly reduced phosphorylated MEK1 as compared to stimulation 
with EGF with no inhibitor present (p<0.001 in all cases). However, even at the highest 
concentration, this inhibitor failed to reduce levels of activated MEK1 to the equivalent 
of baseline. At all concentrations of MEK 1/2 inhibitor that were tested, there was no 
significant reduction in phosphorylated AKT1, indicating that these inhibitors are 
targeting different cellular signalling pathways. As the largest reduction of 
phosphorylated MEK1 was at 1µM of inhibitor, this concentration was used for the 
following experiments.  
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Figure 4.20 Mean absorbance (Abs) read at 450nm following sandwich ELISA 
protocol in StHdh
Q111 
cells to determination  the optimum concentration of MEK 1/2 
inhibitor in order to prevent phosphorylation of MEK1 on serines 217/221 following 
5 minutes stimulation with 100ng/ml EGF. The inhibitor was tested at 0.25, 0.5 and 
1μM, prepared in DMSO solution for 2 hours prior to EGF stimulation.  Inhibitor-free 
time points included the equivalent volume of DMSO in the media for the same 
length of time prior to EGF stimulation and sample collection. A. The effect of MEK 
1/2 inhibitor on phosphorylated MEK1. B. The effect of MEK 1/2 inhibitor on 
phosphorylated AKT1 (serine 473). (Error bars = SEM, n=3). 
‘*’ denotes a significant difference from 0. 
* p<0.05  ** p<0.01 ***p<0.001 
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4.5.2.2 Localisation of HTT and mHTT following EGF stimulation when 
MEK 1/2 is inhibited 
This series of experiments was carried out at the same time as the AKT inhibition 
experiments in Section 4.5.1.2, and therefore share the same baseline ‘0 mins + DMSO’ 
and ‘5 mins + DMSO’ time points. They were treated in the same manner as previously 
described, but with the use of 1µM MEK 1/2 inhibitor for 2 hours prior to stimulation 
with 100ng/ml EGF. 
4.5.2.2a Ab109115 
MEK inhibition appears to have had a similar effect on the localisation of the HTT 
epitope detected by Ab109115 as AKT inhibition, although the effect is more 
pronounced and less persistent with time (Figures 4.21 and 4.22). In StHdhQ7/7 cells, 
there was a significant increase in the N/C and P/C ratios at 5 minutes of EGF 
stimulation when MEK was inhibited (p<0.001 and p=0.043, respectively). Similar to 
the observations following AKT inhibition, this did not present as a diffuse nuclear 
stain, but appeared as particular foci within nuclei (Figure 5.20). There was also an 
increase in the P/C ratio at this time point, suggesting movement from the entire cell 
towards the nucleus rather than shuttling between the nucleus and perinucleus, but 
this did not reach significance. In contrast to AKT inhibition, the effect did not persist 
past 5 minutes. However, there was a second significant increase in the N/P ratio 
(p=0.007) and a reduction in the P/C ratio (p=0.012) at 30 minutes; there was no visible 
nuclear increase in the immunofluorescent images, so this may be reflecting a 
reduction of HTT that had accumulated in the perinuclear region back towards the 
cytoplasm.  
When MEK was inhibited, StHdhQ111/111 cells had a dramatic reduction in the detection 
of nuclear mHTT at 5 minutes after stimulation with EGF; this was apparent in both the 
N/C (p<0.001) and N/P (p<0.001) ratios. However, despite this reduction, there were 
still discrete foci of mHTT that remained in the nuclei of some of these cells. As 
StHdhQ111/111 cells do not form aggregates of mHTT, the function of these discrete foci 
requires elucidation; they may represent the interaction of mHTT with areas of 
transcription, or may be a result of impaired nuclear-cytoplasmic trafficking in these 
199 
 
cells. Similar to the effect in StHdhQ7/7 cells, the reduction in nuclear mHTT was not 
persistent in StHdhQ111/111 cells, and returned to baseline by 15-30 minutes of EGF 
stimulation.  
Similar to Ab109115 detection following AKT inhibition in StHdhQ7/111 cells, there was 
very little effect of MEK inhibition in these cells. There was a slight nuclear increase at 
5 minutes when MEK was inhibited in the N/C ratio (p=0.003), which reflects the 
nuclear increase observed in StHdhQ7/7 cells. However, as previously noted, this lack of 
effect may be due to the balancing of opposing effects of inhibition on HTT and mHTT. 
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Figure 4.22 Quantitative analysis of immunofluorescence images in Figure 4.21. 
Nuclear/Cytoplasmic,   Nuclear/Perinuclear and Perinuclear/Cytoplasmic mean pixel 
intensity ratios for StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111 
cells following 0, 5, 15 and 30 
minutes of stimulation with 100ng/ml EGF following 2 hours incubation with either 
1µM MEK1/2 inhibitor or the equivalent volume of DMSO. Mean pixel intensities were 
calculated from confocal microscopy images using GNU Image Manipulator (further 
details of the analysis can be found in Section 2.2.1.10). All images were randomised 
and analysed blind to genotype, MEK inhibition and length of time stimulated with EGF. 
Each condition consisted of 9 confocal microscopy images taken from 3 separate 
coverslips. A two-way ANOVA was carried out for main effects analysis, followed by 
planned one-way ANOVAs and post-hoc Tukey tests. Error bars = SEM 
* Denotes difference from 0. # Denotes difference from 5 mins + DMSO   
*p<0.05, ** p<0.01, *** p<0.001 
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   4.5.2.2b Mab2166 
StHdhQ7/7, StHdhQ7/111 and StHdhQ111/111 cells that were stained with Ab109115 were 
also double labelled with Mab2166. There was the same increase in the N/C and N/P 
ratios at 5 minutes of stimulation when MEK was inhibited in StHdhQ7/7 cells (p=0.008 
and p<0.001, respectively), but this was followed by a significant reduction in the N/P 
ratio below baseline at 15 and 30 minutes of stimulation (both p=0.002), and a 
consequent increase in the P/C ratio that reached significance at 30 minutes (p=0.015) 
(Figures 4.23 and 4.24). Due to the more transient nature of the effect of MEK 
inhibition on HTT localisation, this may be an effect of the movement of this epitope of 
HTT that accumulated in the nucleus back out into the perinuclear area. As has 
previously been observed when labelling these cells with Mab2166, the increase in 
nuclear detection is more diffuse than the Ab109115 signal, which may be reflective of 
the detection of different HTT epitopes, which are nevertheless responding in a similar 
manner.  
StHdhQ111/111 cells stained with Mab2166 show the same pattern of effect as 
Ab109115; there was a significant reduction in both the N/C and N/P ratios from 5 
minutes of EGF stimulation when MEK was inhibited (N/C p=0.032, N/P p<0.001), 
although no localised foci were left behind in the nucleus as previously seen; this may 
be due to Mab2166 detecting potentially longer N-terminal epitope than Ab109115, 
suggesting the foci that are seen with Ab109115 may include shorter fragments of 
mHTT. The nuclear reduction is still apparent at 15 minutes in StHdhQ111/111 cells, but 
the ratios return to baseline by 30 minutes.  
In contrast to detection by Ab109115, there was a significant increase in the N/C 
(p<0.001) and N/P (p<0.001) ratios for StHdhQ7/111 cells from 5 minutes of EGF 
stimulation when MEK was inhibited. In concordance with the data following AKT 
inhibition, this suggests that this epitope of HTT behaves more similarly to the epitope 
detected in StHdhQ7/7 cells than mHTT in StHdhQ111/111 cells. However, the effect 
appears to be less transient in StHdhQ7/111 cells than the other two genotypes, as 
nuclear detection of this epitope remained higher than baseline at both 15 and 30 
minutes of stimulation (p<0.001 for both N/C and N/P ratios for both time points). 
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Figure 4.24 Quantitative analysis of immunofluorescence images in Figure 4.23. 
Nuclear/Cytoplasmic,   Nuclear/Perinuclear and Perinuclear/Cytoplasmic mean pixel 
intensity ratios for StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111 
cells following 0, 5, 15 and 30 
minutes of stimulation with 100ng/ml EGF following 2 hours incubation with either 
1µM MEK 1/2 inhibitor or the equivalent volume of DMSO. Mean pixel intensities were 
calculated from confocal microscopy images using GNU Image Manipulator (further 
details of the analysis can be found in Section 2.2.1.10). All images were randomised 
and analysed blind to genotype, MEK inhibition and length of time stimulated with EGF. 
Each condition consisted of 9 confocal microscopy images taken from 3 separate 
coverslips. A two-way ANOVA was carried out for main effects analysis, followed by 
planned one-way ANOVAs and post-hoc Tukey tests. Error bars = SEM 
* Denotes difference from 0. # Denotes difference from 5 mins + DMSO   
*p<0.05, ** p<0.01, *** p<0.001 
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   4.5.2.2c Ab675 and N17 
Cells labelled with Ab675 appear to support the effects of MEK inhibition in StHdhQ111 
cells labelled with the other N-terminal antibodies Ab109115 and Mab2166 (Figure 
4.25). Although HTT localisation appears much more nuclear in all three genotypes, 
there is a small increase in nuclear intensity in both StHdhQ7/7 and StHdhQ7/111 cells 
following EGF stimulation when the MEK 1/2 inhibitor is applied. In addition, there is 
also a dramatic reduction of this epitope of mHTT detected in the majority of 
StHdhQ111/111 nuclei from 5 minutes of stimulation that returns to baseline by 30 
minutes, which is concordant with the findings from the other N-terminal antibodies 
used here.  
There is a similar effect when looking at the N17 antibody; there is little difference in 
StHdhQ7/7 and StHdhQ7/111 cells over time, however there is a noticeable reduction in 
nuclear mHTT detected by this antibody in StHdhQ111/111 cells, although there is not 
complete emptying of nuclei as seen when using Ab675 (Figure 4.26). Overall, four 
different HTT N-terminal antibodies that each detect slightly different epitopes of HTT 
and mHTT exhibit the same response to EGF stimulation on the localisation of HTT 
when MEK is inhibited in StHdhQ111 cells. 
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4.5.2.3 Localisation of phosphorylated HTT epitopes following EGF 
stimulation when MEK 1/2 is inhibited. 
As this experiment was carried out at the same time as the AKT inhibition experiment, 
the quality of StHdhQ7/111 cell staining with the N17 s1316p was also too poor for 
inclusion, so only StHdhQ7/7 and StHdhQ111/111 cells are reported here. 
MEK inhibition had a similar effect on the localisation of phosphorylated HTT in 
StHdhQ7/7 cells as AKT inhibition did (Figures 4.27 and 4.28). There was also a significant 
increase in nuclear detection at 5 minutes of stimulation when MEK was inhibited 
(both N/C and N/P ratios p<0.001). However, in contrast to AKT inhibition and to non-
phospho-antibodies following MEK inhibition, this effect remained more stable for the 
entire 30 minutes; the N/P ratio remained significantly higher than baseline at both 15 
(p<0.001) and 30 minutes (p=0.005) of EGF stimulation. There was no significant effect 
in the P/C ratio, indicating that relocalisation of this epitope of phosphorylated HTT 
occurs mostly between the nucleus and perinucleus.  
After an initial increase in nuclear phosphorylated mHTT in StHdhQ111/111 cells following 
EGF stimulation, inhibiting MEK led to a small reduction in nuclear detection. However, 
this doesn’t reach significance until 30 minutes in the N/C ratio (p=0.02), but the 
reduction is visible in the immunofluorescence images. This reduction is not apparent 
in every cell, which may account for the lack of any quantifiable differences. The 
reduction of nuclear phospho-HTT following MEK inhibition in StHdhQ111/111 cells is in 
contrast to the effect of AKT inhibition; this may be due to different mechanisms 
downstream of either signalling pathway having differential interactions with mHTT. 
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Figure 4.28 Quantitative analysis of immunofluorescence images in Figure 4.27. 
Nuclear/Cytoplasmic,  Nuclear/Perinuclear and Perinuclear/Cytoplasmic mean pixel 
intensity ratios for StHdh
Q7/7
 and StHdh
Q111/111 
cells following 0, 5, 15 and 30 minutes of 
stimulation with 100ng/ml EGF following 2 hours incubation with either 1µM MEK 1/2 
inhibitor or the equivalent volume of DMSO. Mean pixel intensities were calculated 
from confocal microscopy images using GNU Image Manipulator (further details of the 
analysis can be found in Section 2.2.1.10). All images were randomised and analysed 
blind to genotype, MEK inhibition and length of time stimulated with EGF. Each 
condition consisted of 9 confocal microscopy images taken from 3 separate coverslips. 
A two-way ANOVA was carried out for main effects analysis, followed by planned one-
way ANOVAs and post-hoc Tukey tests. Error bars = SEM 
* Denotes difference from 0. # Denotes difference from 5 mins + DMSO   
*p<0.05, ** p<0.01, *** p<0.001 
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  4.5.2.4 Immediate-early gene expression changes 
MEK inhibition experiments were carried out in parallel with AKT inhibition, and 
therefore share the same baseline; as such, the data have been presented together 
(Figure 4.18). Inhibition of MEK 1/2 phosphorylation had a greater effect on IE gene 
expression than AKT inhibition, although similar to the patterns of IE gene expression 
following AKT inhibition, there was again a larger response in StHdhQ111/111 cells 
compared to StHdhQ7/7. 
MEK inhibition amplified the effect of EGF on C-fos by reducing its expression below 
baseline in both StHdhQ7/7 (p= 0.015) and StHdhQ111/111 cells (p< 0.001), and further 
below the level of expression following EGF stimulation (StHdhQ7/7 p= 0.44, 
StHdhQ111/111 p= 0.004). There was a strong effect of MEK inhibition on the expression 
of Egr1; in both genotypes, the increased expression due to EGF stimulation was 
inhibited, so that the resulting level of expression was not different from baseline.  
There was no effect of MEK inhibition on Arc expression in StHdhQ7/7 cells, although 
this is likely due to the lack of initial EGF effect. However, the increase in expression 
that was observed in StHdhQ111/111 cells following EGF stimulation did not occur when 
MEK activity was inhibited. A similar pattern occurred for expression of Ngfib; there 
was little effect of EGF or MEK inhibition in StHdhQ7/7 cells, but MEK inhibition 
suppressed the EGF-associated increase of Ngfib expression in StHdhQ111/111 cells.  
 
4.6 Discussion 
We demonstrate that several kinase signalling pathways activated by growth factor 
stimulation are dysregulated in cells carrying mHTT, and that AKT and MEK signalling in 
particular may regulate both the localisation of HTT and downstream transcriptional 
control.  
A panel of ELISA assays exposed differences in kinase signalling activity between 
StHdhQ7/7 and StHdhQ111/111 cells both prior to, and following growth factor stimulation. 
There were consistent baseline differences in phosphorylated AKT1, MEK1 and STAT3; 
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all of which were found to be at an increased concentration in StHdhQ111/111 cells. 
Enhanced AKT activity has been identified in this cell line previously (Ginés et al. 2003; 
Kong et al. 2009; Atwal et al. 2011), as well as in a neural stem cell model of HD (Ritch 
et al. 2012), which may reflect a neuroprotective response to mHTT in these cells 
(Chong et al. 2005). Incubation with EGF elicited a substantial increase in AKT1 
stimulation in both StHdhQ7/7 and StHdhQ111/111 cells, which was significantly larger in 
StHdhQ111/111 cells. This suggests that as well as an increase in baseline AKT activity, 
these cells are also more sensitive to stimulation of this pathway. However, there was 
no effect of NGF stimulation in either genotype, and BDNF elicited a small, but 
significant reduction in phosphorylated AKT1 in StHdhQ111/111 cells. This is surprising, as 
neural stem cells expressing mHTT have been found to be hyper-responsive to BDNF 
stimulation, though this was following an hour of stimulation (Ritch et al. 2012). 
Increased AKT activation is likely to be a neuroprotective, compensatory response; it 
has been suggested that in these cells it counteracts the early excitotoxic effects of 
mHTT (Ginés et al. 2003), and increasing AKT activity reduced neurotoxicity in a 
Drosophila model of HD (Liévens et al. 2008), in addition to reducing the number of 
intranuclear inclusions formed in striatal cells expressing mHTT (Humbert et al. 2002). 
The neuroprotective effects of AKT activity are likely to also be exerted through its 
phosphorylation of HTT on S421 (Humbert et al. 2002; Humbert 2003), which has been 
found to reduce the toxicity of mHTT and the nuclear accumulation of toxic mHTT 
fragments, as well as restoring axonal transport (Liévens et al. 2008; Zala et al. 2008; 
Pineda et al. 2009; Pennuto et al. 2009; Warby et al. 2009). Despite the aberrant 
interaction between mHTT and GRB2 at the EGFR (Liu et al. 1997; Song et al. 2002), 
StHdhQ111/111 cells are still able to respond more sensitively than StHdhQ7/7 cells to EGF 
stimulation, suggesting that there may be an additional mechanism by which EGF 
exerts its effects in the presence of mHTT. For example, EGF is known to play a 
synergistic role with other growth factor signalling pathways, such as the transforming 
growth factor-beta (TGFβ) pathway (Kang et al. 2012; Song et al. 2012), which may 
therefore be more strongly involved in EGF signalling pathways in the context of mHTT 
disruption. mHTT-associated dysregulation at the level of the EGFR may also not be 
sufficient to suppress the normal effect of EGF stimulation, or it is possible that the 
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previously identified aberrant interaction of mHTT with GRB2 (Liu et al. 1997; Song et 
al. 2002) does not occur in this cell model. 
There is currently less information available regarding the role of MEK1 signalling in 
models of HD, however its activation has previously been found to be reduced in 
StHdhQ111 cells (Ginés et al. 2010). In contrast, we found an increased basal level of 
phosphorylated MEK1 in StHdhQ111/111 cells, but its response to both EGF and BDNF 
stimulation was supressed in contrast to StHdhQ7/7 cells, thus providing some support 
for the current literature. It has been reported that HTT can be phosphorylated by 
MEK1 activation (Schilling et al. 2006), although the implications for this mechanism 
are yet to be elucidated. However, it could be hypothesised that as HTT 
phosphorylation by AKT is protective (Thompson et al. 2009; Warby et al. 2009), 
phosphorylation by MEK1 may confer a similar role. For example, a constitutively 
active form of MEK1 was found to be protective against cell death in a mHTT 
expressing PC12 model of HD (Apostol et al. 2006), although in a Drosophila model of 
HD, the induction of MEK1 activity was found to provide no protection against polyQ 
induced lethality (Iijima-ando et al. 2005). ERK1/2 activity has been found to be 
neuroprotective in models of HD (Apostol et al. 2006; Saavedra et al. 2011) and as it 
lies downstream of MEK1, it could be inferred that its action is representative of MEK1 
activity. In StHdhQ111/111 cells, despite an initial baseline increase in MEK1 
phosphorylation, which would be consistent with a protective compensatory 
mechanism, further activation of MEK1 is less efficient following EGF stimulation, 
which may be indicative of mHTT interference at the EGFR. 
Although there was little effect of growth factor stimulation on phosphorylated STAT3 
in this cell model, increased baseline phospho-STAT3 was consistently identified in 
StHdhQ111/111 cells. Increased expression and activation of STAT3 has also been found 
from embryonic day 12.5 in the striata of HdhQ111 mice, where it is likely to play a role 
in brain maturation (Molero et al. 2009). As the immortalised cell model was derived 
from these mice, it is unsurprising that the same hyper-activation was seen, and this 
may be a marker of very early aberrant neuronal development in HD. Conversely, no 
increase in STAT3 mRNA or activity was identified in neural stem cells carrying mHTT 
(Ritch et al. 2012), so differences in its activation may be developmental stage-specific. 
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STAT3 phosphorylation was found to be suppressed in  a MEK1 knock out cell model, 
suggesting that there may be a regulatory interaction between these two pathways (Li 
et al. 2012); as MEK1 activity shows evidence of being enhanced in these StHdhQ111/111 
cells, this may be a mechanism by which STAT3 phosphorylation is also boosted. 
Following EGF stimulation, STAT3 phosphorylation increased in StHdhQ111/111 cells only, 
supporting the potential for increased sensitivity in this pathway, which is likely to 
have downstream effects on transcriptional regulation. 
There were mixed observations for the presence of phosphorylated BAD; in the initial 
BDNF experiment, there was no difference between the genotypes, although there 
was a trend towards a reduction in StHdhQ111/111 cells. In the following experiment, the 
reduction of BAD activation in StHdhQ111/111 cells reached significance. BAD is a pro-
apoptotic signalling kinase, but its activation by phosphorylation inactivates it and 
promotes neuronal survival (Datta et al. 1997; Zala et al. 2008). Reduced activation of 
BAD is therefore consistent with cellular stress due to the presence of mHTT. However, 
as BAD has been found to be phosphorylated in response to the activation of AKT (Zala 
et al. 2008), it could be anticipated that due to higher levels of AKT activation in 
StHdhQ111/111 cells, BAD phosphorylation would also be increased in these cells. The 
variation in basal levels of BAD phosphorylation may reflect a general dysregulation of 
this pathway as opposed to a blanket reduction in its activity. Following EGF 
stimulation, although there were no baseline differences in the levels of BAD 
phosphorylation, there was a significant increase in both genotypes that was 
augmented in StHdhQ111/111 cells. This was in parallel to hyperphosphorylation of AKT in 
these cells, so this may be part of a sensitive pro-survival compensatory mechanism in 
response to EGF stimulation. 
The phosphorylation of P38 MAPK has previously been seen in several models of HD; 
although in general the activity of the MAPK signalling family has been found to be 
reduced in the presence of mHTT (Song et al. 2002; Humbert 2003; Rong et al. 2006), 
increased induction of both JNK and P38 MAPKs have also been found in models of HD. 
For example, there is increased P38 MAPK activity in R6/1 striata from 20 weeks of age 
(Saavedra et al. 2011), and in 10-11 week old R6/2 mice (Gianfriddo et al. 2004). It has 
also been observed in YAC128 striata from only 1 month of age (Fan et al. 2012). 
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Whether increased activation of P38 MAPK is protective or not remains under debate. 
Gianfriddo et al. 2004 suggested that the rise in P38 MAPK correlated with striatal 
damage, and may therefore play a role in apoptosis and reducing neuronal survival. 
Reducing P38 MAPK activation has also been found to improve neuronal survival in a 
rat model of HD (Wang et al. 2010) and in primary neuronal cultures expressing a 
mHTT fragment (Taylor et al. 2013). However, it has also been argued that P38 MAPK 
activation has the potential to be neuroprotective; in R6 mouse models, the lack of 
neuronal loss has been attributed to the anti-apoptotic effects of increased P38 MAPK 
and AKT activity (Mangiarini et al. 1996; Taylor et al. 2013). These pro- or anti-
apoptotic properties of P38 MAPK may be dependent on the activation of downstream 
substrates. In the StHdhQ111 cell line, we also identified increased P38 MAPK activity in 
StHdhQ111/111 cells, but this only reached significance in the final experiment utilising 
EGF stimulation. This may be due to a lack of statistical power, or could be a result of 
instability in P38 MAPK phosphorylation, or biological variation resulting from cell 
passage number. However, following EGF stimulation, there was a significant increase 
in P38 MAPK phosphorylation in StHdhQ111/111 cells, whereas there was no effect in 
StHdhQ7/7 cells. This supports the current literature, as well as the evidence for 
increased sensitivity of several kinase signalling pathways to growth factor stimulation 
that has been observed here.  
There was no effect of growth factor stimulation on cleaved PARP, phosphorylated 
NFκβ or phosphorylated SAPK/JNK, and any genotypic differences were minor and 
variable between the three growth factor experiments, thus making it difficult to draw 
any conclusion about their role in this model of HD. Increased cleaved PARP has been 
previously identified in this cell line, and is thought to potentiate caspase-3 activity 
(Kong et al. 2009), but we did not replicate this effect. Similarly, SAPK/JNK activation is 
usually found to be increased in models of HD, including PC12 cells (Apostol et al. 
2006), YAC128 striata (Fan et al. 2012) and R6/1 striata (Taylor et al. 2013), but despite 
the increase in P38 MAPK observed in StHdhQ111/111 cells, there was no effect for 
phosphorylated SAPK/JNK. The lack of phosphorylation following growth factor 
application may be due to the short period of stimulation, and a longer incubation 
time may be required to see any differential effects. Finally, although NFκβ activity has 
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been identified as being increased in the central nervous system of R6/2 mice 
(Khoshnan & Patterson 2011), no differences in its activity were previously found in 
the same immortalised striatal cell model, although in StHdhQ111/111 cells, NFκβ did 
show increased responsiveness to stimulation by its activator, interleukin-1β (IL-1β) 
(Khoshnan et al. 2004). Although we also found no difference in basal NFκβ activation 
in these cells, none of the growth factors utilised had any effect. This is likely to be due 
to the length of stimulation not being sufficient to alter its activation, as NFκβ has been 
found to be downstream of AKT phosphorylation (Humbert 2003), so should be 
induced in this model. 
The transcription of IE genes is typically activated by growth factors, and so their 
expression could be expected to be affected by dysregulation in upstream kinase 
signalling pathways, as observed in this cell line. There was no difference in the 
expression of C-fos between genotypes, although there was a trend towards higher 
expression in StHdhQ111/111 cells, which is unsurprising, as C-fos is associated with the 
stress response and survival (Zhang et al. 2002).  However, the expression of C-fos in 
both R6/2 and HdhQ111 mice has been found to be downregulated (Luthi-Carter 2000; 
Roze et al. 2008; Liot et al. 2013). In R6/2 mouse striatal neurons, this was correlated 
with the hyperactivation of ERK (Roze et al. 2008), whereas the opposite was found in 
HdhQ111 striatal cells (Liot et al. 2013). There was no effect of EGF stimulation on the 
expression of C-fos in this cell model, despite C-fos previously being associated with 
activation of the EGFR (Haugwitz et al. 2006; Fuentes et al. 2008). This may be due to 
the length of time that cells were stimulated for; mRNA was collected following 2 
hours of EGF stimulation, which may have been too long to detect an increase in C-fos 
activity; C-fos expression has previously been found to be increased immediately 
following EGF stimulation in smooth muscle A-10 cell lines, but this effect was maximal 
following only 30 minutes, and was no longer detectable by 1 hour of stimulation 
(Fuentes et al. 2008). Therefore C-fos expression may be too fast and transient to have 
been detected in this experiment.  
There was no observable effect of AKT inhibition on C-fos expression, although if the 
transient expression increase of C-fos in response to EGF stimulation occurred earlier 
than 2 hours, then any effect of AKT inhibition would also have been missed. Despite 
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this, there was a reduction in C-fos expression below baseline levels in both StHdhQ7/7 
and StHdhQ111/111 cells when MEK was inhibited, which occurred to a larger extent in 
StHdhQ111/111 cells. This suggests that C-fos expression in these cells may be 
downstream of MEK/ERK signalling, as has been previously suggested (Roze et al. 
2008; Liot et al. 2013), although the nature of this association remains to be 
elucidated. However, it has been previously noted that C-fos expression is able to be 
induced independent of both MEK and ERK activation (Fuentes et al. 2008), suggesting 
that C-fos expression may be downstream of several signalling pathways, and thus the 
role of mHTT on its expression is unlikely to be via a single mechanism. 
Baseline expression of Egr1 was similar between genotypes, but there was an 
enhanced response to EGF stimulation in StHdhQ111/111 cells. AKT inhibition had no 
effect on the expression of Egr1 in either cell type, although there was a trend towards 
a reduction in StHdhQ111/111 cells. In contrast, MEK inhibition completely suppressed the 
effects of EGF stimulation on the expression of Egr1. Egr1 is a marker of cellular signal 
transduction and controls the regulation of transcription (Tsai et al. 2000). It has been 
found to be induced by stimulation at the EGFR, and has been associated with both 
AKT and MEK signalling pathways; It was previously found to be dependent on the 
silencing of its transcriptional repressor forkhead box protein 01 (FOXO1) by activated 
AKT (Cabodi et al. 2009), and both inhibitors of phosphatidylinositide 3-kinase (PI3K) 
and MEK have been found to suppress its activity in response to growth factor 
stimulation (Fuentes et al. 2008; Gokce et al. 2009). In StHdhQ111 cells, the MEK 
signalling pathway appears to be more relevant for the control of Egr1 expression. 
However, as MEK activation is slightly suppressed in StHdhQ111/111 cells following EGF 
stimulation, it may be a synergism between MEK signalling and AKT hyperactivation 
that elicits the larger expression response in these cells. There have been mixed 
findings regarding Egr1 expression in models of HD; it has been identified as a 
commonly downregulated gene in R6/2 mice (Luthi-Carter 2000; Macgibbon et al. 
2002; Spektor 2002; Yamanaka et al. 2010), however in a PC12 cell model expressing a 
103 polyQ repeat, the expression of Egr1 was increased x2.4 fold (Apostol et al. 2006). 
Both the R6/2 and PC12 models of HD contain only an N-terminal transgene of Htt, 
whereas the StHdhQ111 cell line is a full length Htt knock-in model. This may therefore 
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have consequences on the involvement of mHTT in aberrant cell signalling and 
downstream control of gene expression. However, aberrant splicing of Htt exon 1 has 
been identified in a full length knock in model of HD (HdhQ150 mouse model), which 
creates a short N-terminal transcript of HTT (Sathasivam et al. 2013). This shorter 
transcript may therefore contribute to HD pathogenesis in the same manner as it does 
in N-terminal transgenic models, and so the abundance and accumulation of the 
pathogenic protein over time may also be contributing to differences in observed gene 
expression changes. In addition, these models all looked at the expression of Egr1 at 
baseline without any cellular input, whereas this dynamic model illustrates the 
importance of taking into account cellular kinase pathway reactivity when assessing 
transcriptional changes in HD models. 
Arc and Ngfib have been less thoroughly characterised than C-fos and Egr1, however 
the induction of both has been found to be downstream of common cell signalling 
pathways, such as following EGF stimulation (Cosgaya & Aranda 1999; Gokce et al. 
2009; Ji et al. 2010). The ARC protein has been found to be increased in R6/2 cortex 
and hippocampus, and was also found to associate with mHTT nuclear aggregates 
(Maheshwari et al. 2012), suggesting that expression of the Arc gene may also be 
increased in this model. We found that although levels of Arc expression were similar 
at baseline in StHdhQ7/7 and StHdhQ111/111 cells, the pattern of activation following EGF 
was similar to that seen for Egr1 expression; there was an enhanced transcriptional 
response in StHdhQ111/111 cells, which is consistent with the finding that there may be 
accumulation of the ARC protein in models of HD (Maheshwari et al. 2012). We also 
find that Arc expression is downstream of MEK signalling in these cells, as inhibition of 
AKT had no effect on its expression. This is also consistent with a previous finding that 
MEK inhibition can diminish Arc expression in response to BDNF in rat striatal cells 
(Gokce et al. 2009). It is currently unknown what the significance of increased Arc 
expression may be in the context of HD, although its association with glutamate 
receptor activity may mean it plays a role in synaptic dysfunction (Maheshwari et al. 
2012).  
Finally, no significant difference in Ngfib expression was observed in these cells, and 
EGF elicited a similar response of Ngfib expression in both StHdhQ7/7 and StHdhQ111/111 
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cells. This was more effectively suppressed by MEK inhibition, although preventing AKT 
activation also reduced its expression so it was no longer significantly higher than 
baseline. Therefore, for the panel of IE genes investigated here, it appears that MEK 
dependent signalling is more relevant for the control of their expression following EGF 
stimulation than AKT signalling, although hyperphosphorylation of the AKT pathway in 
StHdhQ111/111 cells may be a mechanism by which the transcriptional response of these 
genes is augmented. 
Inhibition of both AKT and MEK activation had an effect on the localisation of HTT and 
mHTT in StHdhQ111 cells following EGF stimulation; both elicited an increase in nuclear 
HTT in StHdhQ7/7 cells, as detected by all four N-terminal HTT antibodies. It is therefore 
likely that the localisation of N-terminal fragments of HTT is able to be regulated by 
AKT and MEK activity. Increased nuclear localisation of HTT is usually considered to be 
pathogenic, and is typically associated with transcriptional repression (Reddy et al. 
1999; Crook & Housman 2011), so in StHdhQ7/7 cells following AKT and MEK inhibition, 
this may be a mechanism for the suppression of IE gene expression. Arguably, this 
effect is enhanced following MEK inhibition, as the extent of nuclear filling in StHdhQ7/7 
cells is greater, and for the three primary antibodies that detect amino acids 1-17, 
there appears to be aggregation of HTT to discrete nuclear foci, which have the 
potential to be specific loci of transcription (Osborne et al. 2004).  Mab2166 does not 
show such a large nuclear increase in signal as the other N-terminal antibodies do, and 
this may be due to detection of a different epitope of HTT, as the amino acid sequence 
contributing to the epitope is further down the HTT protein. The nuclear HTT that is 
observed in StHdhQ7/7 cells following EGF may therefore be a smaller N-terminal 
epitope of HTT that is capable of moving across the nuclear membrane by passive 
diffusion (Hackam et al. 1998; Truant 2003; Bauer & Nukina 2009), or it may be 
associating with chaperone-acting TFs that allow HTT to traverse the nuclear pore (Li et 
al. 1995; Faber et al. 1998) in order to regulate transcription. In addition, the non-
classical proline-tyrosine NLS that has been identified on the N-terminus of HTT may 
be altering the nuclear localisation of HTT by mechanisms of active diffusion (Desmond 
et al. 2012; Desmond et al. 2013). 
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Conversely, AKT and MEK inhibition in StHdhQ111/111 cells elicit the opposite effect, as 
there is a dramatic reduction in nuclear mHTT following treatment with EGF when 
these kinase pathways are suppressed.  This suggests that the expanded polyQ in these 
cells is capable of modifying the normal interaction of mHTT with elements 
downstream of kinase signalling pathways, which then alters its activity. Following 
MEK inhibition, although there is a reduction in nuclear mHTT detected using 
Ab109115, the same nuclear foci are apparent as in the StHdhQ7/7 cells that could also 
be areas of transcription. Unfortunately, there was not the opportunity to specifically 
investigate what these foci could be.  The same reduction in nuclear HTT is seen in 
StHdhQ7/7 cells following EGF stimulation when there is no other treatment (see 
Chapter 3), which may suggest that when hyperactivation of the MEK and AKT 
pathways is prevented, StHdhQ111/111 cells look more like StHdhQ7/7 cells. There is little 
change in StHdhQ7/111 cells when either MEK or AKT activities are inhibited, which may 
be an indication of a gene dosage effect; as both HTT and mHTT appear to have 
converse responses to inhibition of these pathways, it could be expected that these 
balance each other out, resulting in an apparent lack of effect. However, when looking 
at Mab2166, these cells more closely resemble their wild type counterparts, which 
may be a reflection of the different epitope of HTT that is being detected with this 
antibody. This may have implications for the mechanism of signalling dysregulation in 
human HD, as the majority of patients are heterozygous for the mutant gene. As these 
cells are an embryonic model, and some dysfunction is already apparent, it may be the 
case that heterozygosity confers a longer developmental period, after which a gene 
dosage effect is no longer apparent. These results implicate MEK and AKT signalling as 
important modulators of mHTT localisation and transcriptional function, although the 
mechanism for how this occurs remains unknown. As both have been identified as 
being able to phosphorylate HTT (Humbert 2003; Schilling et al. 2006; Thompson et al. 
2009), we also looked at the effect of kinase pathway inhibition on the localisation of 
HTT and mHTT phosphorylated on S13 and S16. 
The nuclear localisation of phosphorylated epitopes of HTT and mHTT increased in the 
context of both AKT and MEK inhibition following EGF stimulation. For StHdhQ7/7 cells, 
the same pattern occurred following EGF stimulation with no kinase inhibition, 
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however there was previously no effect in StHdhQ111/111 cells (see Chapter 3). Similar to 
non-phosphorylated epitopes of mHTT detected by the other N-terminal antibodies, 
the inhibition of AKT and MEK signalling in StHdhQ111/111 cells prompts mHTT to behave 
more similarly to wild type HTT following EGF stimulation. Although MEK inhibition had 
a larger effect on the nuclear localisation of phosphorylated HTT epitopes than AKT 
inhibition, AKT inhibition appeared to have a longer lasting effect, as was also the case 
for non-phosphorylated epitopes. However, the localisation of phosphorylated HTT did 
not remain consistent in StHdhQ7/7 cells when AKT was inhibited; there was an initial 
increase at 5 minutes, followed by a reduction before another peak. This may indicate 
that AKT activation is required for the stability of HTT phosphorylation, and therefore 
disruption of this pathway in StHdhQ111/111 cells may elicit aberrant control of this 
mechanism. Interestingly, there is an increase in phosphorylated mHTT in the nuclei of 
StHdhQ111/111 cells following AKT and MEK inhibition, but the non-phosphorylated 
epitopes show a substantial reduction. This could be an indication that the antibodies 
are picking up entirely different epitopes of HTT, and there is a nuclear increase of 
phosphorylated mHTT while non-phosphorylated mHTT reduces, or there may be a 
conformational change in the protein that prevents it being detected by N-terminal 
antibodies following its phosphorylation.  
In conclusion, by using a dynamic model, we have identified several kinase signalling 
pathways that show aberrant activity in StHdhQ111/111 cells following stimulation with 
BDNF, NGF and EGF, which includes hyperphosphorylation as well as suppression of 
activity. We have shown that two of these pathways; AKT and MEK, are both 
important in the regulation of IE genes in both StHdhQ7/7 and StHdhQ111/111 cells, but 
that MEK signalling may be a more relevant pathway for their transcriptional control 
(see Table 4.1 for a summary). However, as MEK activity is suppressed in StHdhQ111/111 
cells, but IE gene expression is enhanced, it is likely that a synergistic mechanism 
between several dysregulated pathways in StHdhQ111/111 cells contribute to aberrant 
transcriptional control. In addition, both AKT and MEK activity modulate the 
localisation of N-terminal epitopes of HTT and mHTT, suggesting that control of HTT 
localisation is downstream of both these pathways. MEK inhibition had the greatest 
magnitude of effect, although this was more transient than AKT inhibition, and 
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inhibition of either pathway led to the localisation of mHTT in StHdhQ111/111 cells more 
closely resembling HTT localisation in StHdhQ7/7 cells. Therefore the increased activity 
in these kinase pathways may be a mechanism for the increased nuclear localisation of 
mHTT seen in StHdhQ111/111 cells and other models of HD. Activity in the AKT pathway 
may be a more important requirement for the localisation and stability of HTT 
phosphorylation than MEK activity, as the nuclear increase of phosphorylated HTT that 
occurs following EGF stimulation (see Chapter 3) still occurred following MEK 
inhibition, but occurred to a lesser extent than when AKT was inhibited. Therefore 
integration of both pathways may be required for the regulation of HTT localisation 
and phosphorylation, which in turn may be a mechanism for transcriptional control 
downstream of growth factor signalling. MEK and AKT signalling may also have effects 
on other post-translational modifications of HTT, which may alter epitope availability 
for antibody binding, as well as HTT localisation; a discussion of this can be found in 
Section 3.5.9. Inhibiting both pathways concurrently would be of interest to determine 
the extent to which synergism between the two modulate the localisation and 
phosphorylation of HTT, and consequent transcriptional control. Unfortunately there 
was not the opportunity to conduct this experiment within the time frame of this 
project.  
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Chapter 5: Comparing differential gene expression changes in an immortalised cell 
model of HD in response to either NGF or EGF stimulation. 
 
5.1 Introduction 
It has been suggested that the increased nuclear localisation of mHTT may interfere 
with gene expression (Zoghbi & Orr 2000; Bauer & Nukina 2009), and that its presence 
can disrupt the organisation and function of the cell nucleus itself (Sun et al. 2007). 
Several mechanisms have been identified by which mHTT may disrupt gene 
expression; for example, several TFs have been found to interact with the 
polyglutamine expansion in the mHTT protein (Kazantsev et al. 1999; Shimohata et al. 
2000; Steffan et al. 2000; Nucifora et al. 2001; Dunah et al. 2002; Li et al. 2002), which 
can compromise TF activity by altering their binding ability, or by sequestration into 
mHTT aggregates (Crook & Housman 2011).  mHTT is also able to bind directly to DNA 
and modulate chromatin structure (Benn et al. 2008; McFarland et al. 2012; 
Seredenina & Luthi-Carter 2012; Ng et al. 2013; Valor et al. 2013). 
The majority of transcriptional changes observed in post-mortem human HD caudate 
and in mouse models of HD are downregulations (Crook & Housman 2011), which may 
be reflective of the reduction in TF activity due to mHTT. There is good correlation in 
the pattern of gene expression changes when mHTT is present, not only between 
mouse models of HD, but also between models and post-mortem human HD brain. A 
meta-analysis of seven mouse models and human HD caudate indicated that the 
transcriptional changes observed in mouse models were similar to those identified in 
human HD (Kuhn et al. 2007). In addition, although the N-terminal HTT models, such as 
the R6/1 and R6/2 mice showed a more rapid progression of transcriptional changes, 
which develop by 6-12 weeks of age, the profiles of the slower developing full-length 
HTT models, such as CHL2Q150/Q150, HdhQ92/Q92 and YAC128 mice, develop similar 
transcriptional profiles to their N-terminal counterparts by 15-24 months, which are 
also comparable to human HD brain (Kuhn et al. 2007). Several other studies 
comparing the transcriptional profiles of HD mouse models have reached similar 
conclusions (Strand et al. 2007; Hodges et al. 2008; Carnemolla et al. 2009; Mazarei et 
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al. 2010), and there is generally good concordance between different gene expression 
microarray platforms (Crocker et al. 2006; Becanovic et al. 2010). This suggests that 
mouse models of HD recapitulate the gene expression changes that occur in human HD 
caudate, and are therefore a useful tool when investigating gene expression. In 
addition, as transgenic mice containing only the pathogenic N-terminal of mHTT 
display a similar pattern of gene expression to the knock in full length models and 
human caudate, it is likely that it is the N-terminal polyglutamine repeat that is 
responsible for alterations in gene expression; whether these changes are entirely 
pathogenic or may also play a compensatory role is yet to be elucidated. 
Mouse and cell models of HD allow the investigation of early, pre-symptomatic striatal 
gene expression changes that are not possible to determine from human HD brain. 
These models indicate that transcriptional dysregulation is identifiable from an early 
age; for example, the expression of several genes associated with RNA regulation were 
found to be disrupted in 3 month old YAC128 mouse striata (Becanovic et al. 2010), 
and genes associated with transcription, translation, protein synthesis and calcium 
homeostasis were altered in R6/2 mice from only 10 weeks of age (Crocker et al. 
2006). In addition, the increased expression of regulator of ribosome synthesis (Rrs1), 
has been identified as an early event in HdhQ111/Q111 mice (15 weeks of age), as well as 
in StHdhQ111/Q111 cells, due to endoplasmic reticular stress (Fossale et al. 2002; 
Carnemolla et al. 2009). Increased expression of Rrs1 was also identified in post-
mortem human HD caudate (Carnemolla et al. 2009). As well as there being 
concordance in gene expression between HD mouse models and human brain, 
StHdhQ111/111 cells have also been found to share similar changes in gene expression to 
human HD caudate (Lee et al. 2007), suggesting that in addition to mouse models, 
these cells are also a relevant model of early transcriptional dysregulation in HD.  
Growth factor signalling can induce the activation of pathways responsible for the 
regulation of gene expression. Both NGF and EGF are known to increase the activity of 
AKT and MAPKs (Humbert 2003), which can either modulate gene expression directly, 
or via activation of transcriptional regulators such as EGR1 (Cabodi et al. 2009), AP1 
(Liu et al. 2011) and NFkβ (Kyriakis & Avruch 2001). Both NGF and EGF have also been 
found to interact with the transforming growth factor-beta (TGFβ) pathway in both a 
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synergistic and antagonistic manner (Lutz et al. 2004; Caja et al. 2011; Jin et al. 2011; 
Kang et al. 2012). The TGFβ pathway is a versatile regulator of cell growth, 
proliferation and apoptosis, and is upstream of the core regulatory mothers against 
decapentaplegic- homologue (SMAD) family of TFs (Massague 2003; Massague 2005). 
A cartoon depicting the mechanism of SMAD TF activity can be found in Figure 5.1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Simplified cartoon depicting the basic mechanism of SMAD TF signalling 
in the TGFβ pathway. TGFβ stimulates its Type I and Type II receptors, creating a 
hetero-tetrameric receptor complex. Here, the Type II receptor phosphorylates the 
Type I receptor, which then allows the phosphorylation of receptor-regulated 
SMADs (RSMADs). The RSMADs are SMADs1-3, 5 and 8, and are constantly shuttling 
between the nucleus and cytoplasm until anchor proteins recruit them to the active 
Type I receptor.  Phosphorylated RSMADs can bind to the common-mediator SMAD 
(CoSMAD). The CoSMAD is SMAD4, which is also consistently shuttling between 
nuclear and cytoplasmic compartments. The resulting RSMAD-CoSMAD complex 
then localises to the nucleus, where it may either bind directly to DNA to stimulate 
transcription, or will incorporate DNA binding cofactors. The process can be 
repressed by the activation of the inhibitory SMADs 6 and 7 in a self-regulatory 
manner (Massague 2003, 2005). A red ‘P’ indicates target phosphorylation.  
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Details of how mHTT may disrupt growth factor signalling, and consequently 
downstream changes in gene expression, were detailed in the previous chapter, and 
several IE genes were identified as being differentially regulated in StHdhQ111/111 cells in 
response to EGF stimulation. In this chapter, microarray analysis is utilised to 
investigate global differential gene expression changes between StHdhQ7/7, StHdhQ7/111 
and StHdhQ111/111 cells in response to growth factor stimulation. This creates a dynamic 
model that allows the identification of additional signalling and transcriptional 
pathways that may be dysregulated due to the presence and mislocalisation of mHTT 
downstream of kinase signal transduction, which would not ordinarily be evident 
without cellular stimulation.  
 
5.2 Microarray experiment 
The EGF experiment used a 3x2 design, which included StHdhQ7/7, StHdhQ7/111 and 
StHdhQ111/111 cells stimulated with 100ng/ml EGF for either 0 or 2 hours, before RNA 
extraction and purification (n= 5 replicates run on individual chips for each group). This 
experiment utilised the Affymetrix GeneChip® Mouse Gene 1.0 ST array system, which 
contains oligonucleotide probes in multiple exons of a gene in order to give whole 
transcript expression information. Each array consists of 770,000 probes to cover 
28,000 genes. 
The NGF experiment was a 2x2 design; StHdhQ7/7 and StHdhQ111/111 cells were 
stimulated with 100ng/ml NGF for either 0 or 2 hours, and were processed in the same 
manner as the EGF samples (n= 4 replicates run on individual chips for each group). 
These samples were run on Affymetrix GeneChip® Mouse Genome 430A 2.0 arrays, 
which contain multiple probes for each transcript in order to increase accuracy and 
reliability. Each array chip has 22,600 probe sets that cover 14,000 genes. 
All samples used in microarray experiments had an RNA integrity number (RIN) of 10. 
Analysis of microarray data was carried out in Partek® Genomics Suite™ unless 
otherwise stated.  
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 5.2.1 Quality control metrics 
Both the NGF and EGF microarray experiments were analysed in the same manner. 
The raw data underwent quantile normalisation to log base 2, and median polish 
probeset summarisation. There was no adjustment for GC content or probe sequence, 
and robust multi-array average (RMA) background correction was applied. 
  5.2.1.1 EGF 
Principal components analysis (PCA) was carried out as an initial exploratory analysis of 
the gene expression data as a whole. PCA mapping of the EGF microarray data 
indicates that the main source of variance in gene expression is attributable to 
genotype, and stimulation with EGF is the second source of variance (Figure 5.2). 
However, it is evident from the PCA map that the StHdhQ7/7 cells are overall more 
responsive to EGF stimulation than StHdhQ111/111 cells, whereas StHdhQ7/111 cells fall in 
between the two. 
Unsupervised hierarchical clustering of genes with a significant interaction term 
following ANOVA analysis (see section 5.2.2) was carried out in Partek to visualise the 
grouping of differentially expressed genes, the results of which can be seen in Figure 
5.3, presented as a Euclidean distance heat map. It is evident from this figure that 
StHdhQ7/7 and StHdhQ7/111 cells cluster more closely together than with StHdhQ111/111 
cells in terms of their gene expression profiles. Cells stimulated with EGF also cluster 
more closely to their control counterparts than to the other EGF stimulated genotypes. 
This reflects the PCA, in that it indicates that growth factor stimulation can distinguish 
the samples within each genotype, and that each genotype is responding to EGF 
stimulation in a differential manner.  
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Figure 5.2 PCA of EGF microarray data. Genotype is the main principle component, 
which accounts for 27.4% of the variance in gene expression. EGF stimulation is the 
second principle component, and accounts for 17.8% of the variance. Each 
genotype clusters together, but there is clear separation between 0 and 2 hours EGF 
stimulation in StHdh
Q7/7
 cells. This separation reduces in the StHdh
Q7/111
 cells, and is 
not apparent in the StHdh
Q111/111
 cells.  
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  5.2.1.2 NGF 
The PCA of the NGF data also showed a very clear separation of gene expression 
profiles between StHdhQ7/7 and StHdhQ111/111 cell types. Genotype was again the main 
source of variance, with NGF stimulation being the second (Figure 5.4). However, in 
contrast to the responses to EGF, there is a greater effect of NGF on gene expression in 
StHdhQ111/111 cells, and a much smaller effect in StHdhQ7/7.  
 
Figure 5.3 Heat map representing unsupervised hierarchical clustering of 
interaction data from the EGF microarray experiment. The data was transformed so 
that the mean expression value for each gene was 0, with a standard deviation of 1. 
Blue depicts a reduction in gene expression, and red depicts an increase. Grey 
indicates no change. The more closely clustered each category is, the more common 
their gene expression profiles. StHdh
Q7/111
 cells (orange) have more similar gene 
expression profiles to StHdh
Q7/7
 cells (yellow) than StHdh
Q111/111
 cells (red). The 
smaller effect of EGF on gene expression compared to genotype is also evident from 
this map. Each genotype clusters closer to its own control following 2 hours of 
100ng/ml EGF stimulation. 
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Hierarchical clustering was performed in the same manner as following EGF 
stimulation. Comparison of the two expression analyses shows that at baseline, there 
is a similar pattern of differential gene expression between the two experiments. As 
seen in the PCA for the NGF microarray data, there is clear separation between the 
genotypes (Figure 5.5); NGF stimulated cells cluster closer to the control of the same 
Figure 5.4 PCA of NGF microarray data. Genotype is the main principle component, 
which accounts for 43.2% of the variance in gene expression. NGF stimulation is the 
second principle component, and accounts for 29.74% of the variance. Each 
genotype clusters together, but there is clear separation between 0 and 2 hours NGF 
stimulation in StHdh
Q111/111
 cells. This separation is reduced in the StHdh
Q7/7
 cells, 
suggesting an augmented gene expression response to NGF in cells containing 
mHTT. 
232 
 
genotype, which is the same pattern observed following EGF. However, in contrast to 
EGF stimulated cells, the NGF heat map illustrates that there is a greater extent of 
gene expression change in NGF treated StHdhQ111/111 cells as compared to StHdhQ7/7 
cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2.2 Differential gene expression 
The data from both EGF and NGF microarrays were analysed separately, but in the 
same manner. All gene expression data were analysed by a 2-way ANOVA with an 
interaction term, plus individual contrasts to identify simple main effects. The focus for 
the following stages of analysis was on the differences between StHdhQ7/7 and 
Figure 5.5 Heat map representing unsupervised hierarchical clustering of interaction 
data from the NGF microarray experiment. The data was transformed so that the 
mean expression value for each gene was 0, with a standard deviation of 1. Blue 
depicts a reduction in gene expression, and red depicts an increase. Grey indicates 
no change.  
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StHdhQ111/111 cell lines only, as this is where the largest differences were expected to 
lie. The following lists of significantly differentially expressed genes were then created 
from the resulting data with the parameters described below: 
- StHdhQ7/7 0 hours vs. StHdhQ111/111 0 hours   Fold change >2 - <-2  
       False discovery rate (FDR) 0.05  
- StHdhQ7/7 0 hours vs. StHdhQ7/7 2 hours  Fold change >1.5 - <-1.5, FDR 0.05 
- StHdhQ111/111 0 hours vs. StHdhQ111/111 2 hours Fold change >1.5 - <-1.5, FDR 0.05 
- Interaction      Fold change >2 - <-2, FDR 0.05 
  5.2.2.1 Differentially expressed genes at baseline 
For the EGF experiment, there were 1394 significantly differentially expressed genes 
between StHdhQ7/7 and StHdhQ111/111 cells at baseline, whereas for the NGF experiment, 
this figure was much higher at 3201. The magnitude of the largest fold change in both 
experiments was drastically different, the largest in the EGF experiment being +59,  
and +496 for the NGF experiment. As this large fold change in the NGF microarray 
experiment was between StHdhQ111/111 cells and StHdhQ7/7 cells at baseline, it is unlikely 
to be an effect of an enhanced response to NGF stimulation compared to EGF 
stimulation. Histograms representing the frequency of particular fold change 
occurrences between StHdhQ7/7 and StHdhQ111/111 cells at baseline (Figure 5.6) indicate 
that there are slightly varied distributions between EGF and NGF microarrays; 
accordingly, the variance of the EGF baseline data was 4.71, whereas the variance for 
the NGF array was much broader at 41.97, which may be a result of the smaller sample 
size utilised in the NGF experiment. However, it may also be due to the nature of the 
different Affymetrix chips used between experiments, or a result of different batches 
of cells used at different times. In addition, although the NGF baseline data has a 
skewness close to a normal distribution (-1.44) the EGF data is skewed further towards 
the upregulated expression of genes in StHdhQ111/111 cells, although two downregulated 
genes with large fold changes give the data a skewness value of -16.49.  Nevertheless, 
despite these variance and expression differences, similar gene ontology (GO) 
categories were identified from the most significant genes in both groups (Section 
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5.2.3), suggesting a degree of homogeneity between the baseline expression profiles 
of the two experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
5.2.2.2 Differentially expressed genes following growth factor 
stimulation 
Both growth factors had roughly equal effects on the magnitude of expression fold 
changes, with the majority of genes being up or downregulated by a fold change of x2. 
Gene expression changes following growth factor stimulation also exhibited a similar 
distribution between genotypes (Figure 5.7). 
The differential effects of the two growth factors on the different genotypes were also 
reflected in the gene lists. Following EGF stimulation, where there was a greater effect 
in StHdhQ7/7 cells, where there were 391 significantly differentially expressed genes, 
whereas there were only 171 following NGF stimulation. In contrast, there were only 
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Figure 5.6 Histograms of the frequency of the magnitude of gene expression fold 
changes between StHdh
Q7/7 
and StHdh
Q111/111 
cells at baseline in A. EGF and B. NGF 
microarray datasets. The NGF data exhibits a distribution closer to normal (skew = -
1.437), but large positive and negative fold changes gives rise to a high kurtosis value 
(2866.68). Although the EGF data is less widely spread (kurtosis = 1582.17), two large 
negative fold changes give the data substantial skew (-16.49). Fold changes are 
indicative of the level of StHdh
Q111/111
 gene expression in comparison to StHdh
Q7/7
 gene 
expression. 
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254 differentially expressed genes in StHdhQ111/111 cells following EGF stimulation, but 
418 following NGF stimulation.  
Despite the larger effect of NGF stimulation in StHdhQ111/111 cells compared to 
StHdhQ7/7, there were only 576 genes that had a significant genotype x growth factor 
interaction effect, whereas there were 2687 that reached significance for an 
interaction following EGF stimulation. This is likely to be a combinatory effect of the 
responses to the different growth factors, as well as the different chips used; there are 
twice as many genes detected on the chips used in the EGF experiment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 Histograms of the frequency of the magnitude of gene expression fold 
changes between 0 and 2 hours stimulation with A. EGF or B. NGF for both StHdh
Q7/7
 
(blue) and StHdh
Q111/111
 (red) cells.  Both StHdh
Q7/7 
and StHdh
Q111/111
 cells exhibit similar 
distributions of gene expression fold changes in response to either growth factor, and 
the majority of changes cluster between -4 and +4. Neither data set deviates markedly 
from the normal distribution;  
NGF skew = -0.11 (StHdh
Q7/7
), 0.5 (StHdh
Q111/111
) & NGF kurtosis = -1.92 (StHdh
Q7/7
), 2.8 
(StHdh
Q111/111
).  
EGF skew = -0.17 (StHdh
Q7/7
), -0.09 (StHdh
Q111/111
) & EGF kurtosis = -1.9 (StHdh
Q7/7
),        
-1.93 (StHdh
Q111/111
). 
More StHdh
Q7/7
 cells have larger positive fold changes following EGF stimulation than 
StHdh
Q111/111 
cells, which is concordant with the PCA data (Figure 5.2). In opposition, 
StHdh
Q111/111
 cells exhibit more genes with higher fold changes than StHdh
Q7/7
 cells 
following NGF stimulation, which is also concordant with the PCA data (Figure 5.4). 
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5.2.3 Pathway analysis 
Either the entire gene list, or the top 500 most significant genes from each gene list 
were put through pathway analyses enriched for the GO categories, using the web 
based gene set analysis toolkit program, WebGestalt V2 
(Http://bioinfo.vanderbilt.edu/webgestalt/) (Zhang et al. 2005; Wang et al. 2013). This 
program uses a hypergeometric statistical method, plus the Benjamini & Hochberg 
multiple test adjustment (Benjamini & Hochberg 1995). The minimum number of 
genes required for a category to be considered was set to 2, and the top 10 most 
significant biological categories were investigated further.  
  5.2.3.1 Baseline differences 
The top 10 most significant biological GO categories and their associated p-values for 
genes differentially expressed between genotypes at baseline can be seen in Table 5.1. 
Seven of the top categories overlap with those identified from the equivalent gene list 
from the NGF microarray experiment, despite differences in the magnitude of fold 
changes. Of the 138 genes that were part of the top 10 GO categories in the EGF data, 
91 of these genes were also in the list of genes that were differentially expressed 
between genotypes at baseline in the NGF data. However, hypergeometric testing 
revealed that the probability of this overlap was not significantly different to chance (p 
(x=138) = 2.35). However, the similarities in GO categories still suggest that there may 
be some homogeneity and reproducibility between different batches of these cells, 
and across different microarray chips on the Affymetrix platform. The identified GO 
categories are largely associated with development, which is likely to be due to the 
derivation of this cell line from embryonic striatal cells that are not yet fully 
differentiated into adult neurons. 
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GO Category P-value
 
EGF NGF 
System development 1.2 x10
13
 5.2 x10
9
 
Anatomical structure development 3.2 x10
13
 5.2 x10
9
 
Multicellular organismal development 3.2 x10
13
 2.7 x10
8
 
Developmental Process 9.5 x10
13
 1.4 x10
8
 
Anatomical structure morphogenesis 1.7 x10
12
 1.4 x10
8
 
Organ development 1.6 x10
10
 1.8 x10
7
 
Organ morphogenesis 4.7 x10
9
 1.6 x10
7
 
Biological adhesion 7.3 x10
8
 - 
Cell adhesion 7.3 x10
8
 - 
Nervous system development 2.5 x10
6
 - 
Positive regulation of biological process - 1.4 x10
7
 
Positive regulation of cellular process - 7.3 x10
7
 
Vasculature development - 8.6 x10
7
 
 
 
 
  5.2.3.2 EGF microarray 
   5.2.3.2a Pathways implicated following EGF stimulation 
Despite substantial differences in gene expression profiles both at baseline and 
following EGF stimulation, pathway analyses of this data suggested very similar GO 
categories as being implicated following EGF stimulation in both StHdhQ7/7 and 
StHdhQ111/111 cell lines (Table 5.2). Although some of the identified pathways were 
associated with developmental processes, the majority of the top 10 pathways were 
related to transcription and transcriptional control. This suggests that EGF stimulation 
in both cell lines initiates expression changes in genes that may regulate transcriptional 
pathways. 
 
 
Table 5.1 Comparison of the top 10 significant biological GO categories identified by 
WebGestalt pathway analysis for genes differentially expressed between StHdh
Q7/7
 
and StHdh
Q111/111
 cells at baseline in both EGF and NGF microarray experiments.  
238 
 
GO Category 
P-value 
StHdh
Q7/7
 StHdh
Q111/111
 Interaction 
Regulation of nitrogen compound 
metabolic process 2.1 x 10
7
 1.2 x 10
7
 
 
Regulation of RNA metabolic 
process 2.0 x 10
7
 1.3 x 10
7
 
 
RNA biosynthetic process 2.0 x 10
7
 1.3 x 10
7
 
 Regulation of transcription, DNA 
dependent 2.0 x 10
7
 1.3 x 10
7
 
 
Regulation of transcription from 
RNA polymerase II 2.0 x 10
7
 1.1 x 10
7
 
 
Transcription, DNA dependent 2.0 x 10
7
 1.3 x 10
8
 
 
Transcription 2.0 x 10
7
 1.3 x 10
8
 2 x 10
11
 
Anatomical structure development 2.0 x 10
7
 1.1 x 10
7
 1.3 x 10
9
 
System development 2.0 x 10
7
 1.4 x 10
7
 
 Regulation of nucleobase, 
nucleoside, nucleotide and nucleic 
acid metabolic process 
2.0 x 10
7
 
  
Regulation of developmental 
processes  
1.0 x 10
7
 
 
Developmental process 
  
1.8 x 10
12
 
Multicellular organismal 
development   
1.8 x 10
12
 
Regulation of cellular metabolic 
process   
7.8 x 10
12
 
Regulation of metabolic process 
  
5.7 x 10
11
 
Blood vessel development 
  
2.8 x 10
10
 
Vasculature development 
  
3.7 x 10
10
 
Regulation of transcription 
  
5.3 x 10
10
 
Organ morphogenesis 
  
5.3 x 10
10
 
 
 
 
 
 
Table 5.2 Comparison of the top 10 significant biological GO categories identified by 
WebGestalt pathway analysis for genes differentially expressed following 2 hours 
100ng/ml EGF stimulation for StHdh
Q7/7
 and StHdh
Q111/111
 cells, as well as for genes 
with a significant genotype x growth factor interaction.  
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   5.2.3.2b Pathways implicated in the EGF x genotype interaction 
The top 10 biological GO pathways identified from the EGF x genotype interaction 
analysis reflects both the differences between these cells found at baseline, and 
following EGF stimulation (Table 5.2). The majority of the pathways are part of various 
developmental processes, and this is likely to be a reflection of genotype as the main 
source of variance. However, the ‘Transcription’ and ‘Regulation of transcription’ 
pathways remain highly significant when looking at the interaction effect, indicating 
that there are significant differential effects between StHdhQ7/7 and StHdhQ111/111 cell 
lines in pathways that may exert some transcriptional control. 
   5.2.3.2c Selecting genes to follow up 
In order to create a smaller list of genes to take forward for further analysis, the genes 
that were in the two GO categories associated with transcription from the interaction 
analysis were cross-referenced with the genes that had a significant effect of EGF in 
either StHdhQ7/7 or StHdhQ111/111 cells. Therefore the genes in the resulting list should 
have the strongest differential expression effects, as well as a strong effect of EGF. This 
means the observed effects in these genes are less likely to be by chance, and are most 
likely to be associated with differences in transcriptional pathways between StHdhQ7/7 
and StHdhQ111/111 cells. This reduced list of genes was then further split into three 
separate lists, depending on the direction of effect; these lists can be found in Table 
5.3. By looking at genes whose expression is changed by EGF stimulation in StHdhQ7/7 
cells only, it should be possible to elucidate the signalling pathways that are generally 
activated by EGF. In contrast, genes that have an augmented response to EGF in the 
StHdhQ111/111 cells are of interest, as the majority of gene expression changes observed 
in this cell line and other HD models are downregulations (Crook & Housman 2011) so 
the genes that are more sensitive to modification of expression may be indicative of 
aberrant signalling pathways in cells that contain mHTT. 
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Gene Name Gene Symbol Ref Sequence
Aryl hydrocarbon receptor nuclear translocator-
like
Arntl NM_007489
Fibroblast growth factor 2 Fgf2 NM_008006
Forkhead box C2 Foxc2 NM_013519
Human immunodeficiency virus type I enhancer 
binding protein 1
Hivep1 NM_007772
Jun oncogene Jun NM_010591
Jun-B oncogene Junb NM_008416
KDM1 lysine (K)-specific demethylase 6B Kdm6b NM_001017426
Kruppel-like factor 5 Klf5 NM_009769
Myelocytomatosis oncogene Myc NM_010849
MAD homolog 7 (Drosophila) Smad7 NM_001042660
SRY-box containing gene 9 Sox9 NM_011448
Sprouty homolog 2 (Drosophila ) Spry2 NM_011897
TEA domain family member 4 Tead4 NM_011567
Teashirt zinc finger family member 1 Tshz1 NM_001081300
Effect of EGF in StHdh Q7/7  only
Gene Name Gene Symbol Ref Sequence
Activating transcription factor 3 Atf3 NM_007498
B-cell CLL/lymphoma 6, member B Bcl6b NM_007528
Basic helix-loop-helix family, member e40 Bhlhe40 NM_011498
Early growth response 1 Egr1 NM_007913
Ets variant gene 5 Etv5 NM_023794
Fos-like antigen 1 Fosl1 NM_010235
High mobility group AT-hook 2 Hmga2 NM_010441
Inhibitor of DNA binding 3 Id3 NM_008321
Interferon regulatory factor 2 binding protein 2 Irf2bp2 NM_001164598
Nuclear receptor subfamily 4, group A, member 
3
Nr4a3 NM_015743
Effect of EGF in both genotypes, enhanced in StHdh Q111/111
Table 5.3 Continued on next page  
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  5.2.3.3 NGF microarray 
   5.2.3.3a Pathways implicated following NGF stimulation 
In contrast to EGF stimulation, NGF stimulation of StHdhQ7/7 and StHdhQ111/111 cells lead 
to the identification of almost entirely different pathways, with only one overlapping 
GO category between the genotypes (Table 5.4). In StHdhQ7/7 cells, these were largely 
regulatory pathways associated with cell growth and metabolic activity.  The GO 
categories identified in StHdhQ111/111 cells were more similar to the categories 
identified following EGF stimulation than to StHdhQ7/7 cells following NGF stimulation; 
three of the categories were associated with transcriptional pathways, and the others 
were regulatory or developmental categories. The implication of more transcriptional-
related pathways in StHdhQ111/111 cells following NGF stimulation may partly explain 
why the extent of gene expression changes is greater in these cells than in StHdhQ7/7 
cells. 
   5.2.3.3b Pathways implicated in the NGF x genotype interaction 
The pathways implicated in the NGF x genotype interaction partially overlap with those 
identified following EGF stimulation, such as ‘Regulation of metabolic processes’ and 
‘Regulation of transcription’ (Table 5.4).  This similarity may be due to the overlapping 
effects of EGF and NGF on StHdhQ111/111 cells. However, by looking at the PCA analyses 
Gene Name Gene Symbol Ref Sequence
Biregional cell adhesion molecule-
related/down-regulated by oncogenes
Boc NM_172506
CDC42 effector protein (Rho GTPase binding) 3 Cdc42ep3 NM_026514
Growth arrest and DNA-damage-inducible, 
gamma interacting protein
Gadd45g NM_183358
Nerve growth factor Ngf NM_013609
RAS p21 protein activator 1 Rasa1 NM_145452
Effect of EGF in StHdh
Q111/111
 only
Table 5.3 Gene lists created by cross-referencing the top genes with a significant 
genotype x EGF interaction with the top genes with a significant effect of EGF in GO 
category transcription related pathways. Arrows indicate the direction of expression 
change following EGF stimulation.  
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for both data sets, it is likely that although similar pathways are involved in these cell 
lines following both EGF and NGF stimulation, the nature of the effect is likely to be 
different. For all the genes with a significant gene expression change in StHdhQ7/7 cells 
following EGF stimulation, only 14.6% of those were downregulations, whereas 
following NGF stimulation, this figure was 49.7%. On the other hand, in StHdhQ111/111 
cells, the percentage of downregulated genes following both NGF and EGF stimulation 
stayed roughly similar (35% and 40%, respectively), suggesting that the response of 
StHdhQ111/111 cells to growth factor stimulation may be less specific to particular 
compounds than in StHdhQ7/7 cells. 
   5.2.3.3c Selecting genes to follow up 
More focused gene lists were created in the same manner as described previously 
(Section 5.2.3.2c), and can be found in Table 5.5. From these lists, there were 5 genes 
that also appeared on the EGF lists. These can be seen in Table 5.6, where the 
magnitude and direction of their expression changes following growth factor 
stimulation are also detailed. The hypergeometric probability of this overlap was 
calculated as p(x=5) = 0.04, thus suggesting that both NGF and EGF are likely to be 
stimulating similar gene expression pathways, but in a differential manner. 
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GO Category 
P-value 
StHdh
Q7/7
 StHdh
Q111/111
 Interaction 
Regulation of cellular process 5.2 x 10
7
 
 
8.6 x 10
7
 
Regulation of cellular metabolic 
process 5.2 x 10
7
 
 
1.1 x 10
6
 
Regulation of metabolic process 1.0 x 10
6
 
 
1.1 x 10
6
 
Regulation of biological process 2.0 x 10
6
 3.9 x 10
7
 2.1 x 10
6
 
Biological regulation 3.9 x 10
6
 
  
Regulation of protein kinase 
activity 1.1 x 10
5
 
  
Regulation of kinase activity 1.2 x 10
5
 
  
Regulation of transferase activity 1.3 x 10
5
 
  
Regulation of cell proliferation 2.5 x 10
5
 
  Negative regulation of cellular 
process 3.0 x 10
5
 
  
Organ development 
 
6.2 x 10
8
 
 
Organ morphogenesis 
 
6.2 x 10
8
 
 Anatomical structure 
morphogenesis  
1.2 x 10
7
 
 
Regulation of transcription, DNA 
dependent  
2.4 x 10
7
 2.2 x 10
6
 
Regulation of RNA metabolic 
process  
3.2x 10
7
 2.1 x 10
6
 
System development 
 
4.0 x 10
7
 
 
RNA biosynthetic process 
 
4.0 x 10
7
 
 
Transcription, DNA dependent 
 
4.0 x 10
7
 2.5 x 10
6
 
Tube morphogenesis 
  
2.1 x 10
6
 
Regulation of primary metabolic 
process   
2.2 x 10
6
 
Regulation of nitrogen compound 
metabolic process   
2.4 x 10
6
 
 
 
 
 
Table 5.4 Comparison of the top 10 significant biological GO categories identified by 
WebGestalt pathway analysis for genes differentially expressed between StHdh
Q7/7
 
and StHdh
Q111/111
 cells, as well as for genes with a significant genotype x growth 
factor interaction following 2 hours 100ng/ml NGF stimulation.  
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 Table 5.5 Continued on next page 
Gene Name Gene Symbol Ref Sequence
A disintegrin-like and metallopeptidase 
(reprolysin type) with thrombospondin 
type 1 motif 5
Adamts5 NM_011782
Aryl-hydrocarbon receptor Ahr NM_013464
ADP-ribosylation factor-like 4C Arl4c NM_177305
Activating transcription factor 3 Atf3 NM_007498
BTB and CNC homology 1 Bach1 NM_007520
BCL2-like 11 (apoptosis facil itator) Bcl2l1 NM_009754 
Bone morphogenetic protein 4 Bmp4 NM_007554
CDC42 effector protein (Rho GTPase 
binding) 3
Cdc42ep3 NM_026514
cAMP responsive element modulator Crem NM_001110850
Chromobox homolog 4 (Drosophila Pc 
class)
Cxb4 NM_007625
DNA-damage-inducible transcript 4 Ddit4 NM_029083
E26 avian leukemia oncogene 2, 3' domain Ets2 NM_011809
Forkhead box A1 Foxa1 NM_008259
Frizzled homolog 8 (Drosophila) Fzd8 NM_008058
Growth arrest and DNA-damage-inducible 
45 gamma
Gadd45g NM_011817
GRP1 (general receptor for 
phosphoinositides 1)-associated scaffold 
protein
Grasp NM_019518
Homeobox A2 Hoxa2 NM_010451
Homeobox A5 Hoxa5 NM_010453
Insulin-like growth factor binding protein 
3
Igfbp3 NM_008343
Jumonji, AT rich interactive domain 2 Jarid2 NM_021878
Ajuba Jub NM_010590
Max interacting protein 1 Mxi1 NM_001008542 
Nuclear receptor subfamily 4, group A, 
member 1
Nr4a1 NM_010444
Nuclear receptor subfamily 4, group A, 
member 2
Nr4a2 NM_001139509 
Paired box gene 9 Pax9 NM_011041
Pyruvate dehydrogenase kinase, 
isoenzyme 4
Pdk4 NM_013743
Peroxisome proliferative activated 
receptor, gamma, coactivator 1 alpha
Ppargc1a NM_008904 
Prostaglandin F receptor Ptgfr NM_008966
Parathyroid hormone-like peptide Pthlh NM_008970
Protein tyrosine phosphatase 4a1 Ptp4a1 NM_011200
Receptor (calcitonin) activity modifying 
protein 3
Ramp3 NM_019511
Regulator of G-protein signaling 2 Rgs2 NM_009061
Effect of NGF in StHdh
Q111/111
 only
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Gene Name Gene Symbol Ref Sequence
Rho family GTPase 3 Rnd3 NM_028810
Sex comb on midleg homolog 1 Scmh1 NM_001159630 
Salt inducible kinase 1 Sik1 NM_010831
Suppressor of cytokine signaling 3 Socs3 NM_007707
Thrombospondin 1 Thbs1 NM_011580
Toll-l ike receptor 2 Tlr2 NM_011905
TSC22 domain family, member 3 Tsc22d3 NM_001077364 
Twist homolog 1 (Drosophila) Twist1 NM_011658
Vitamin D receptor Vdr NM_009504
Vascular endothelial growth factor A Vegfa NM_001025250 
Gene Name Gene Symbol Ref Sequence
Cyclin G2 Ccng2 NM_007635
Cyclin-dependent kinase inhibitor 1A (P21) Cdkn1a NM_007669
Carcinoembryonic antigen-related cell 
adhesion molecule 1
Ceacam1 NM_001039185 
Fos-like antigen 1 Fosl1 NM_010235
Inhibitor of DNA binding 2 Id2 NM_010496
Kit l igand Kitl NM_013598
Myeloblastosis oncogene-like 1 Mybl1 NM_008651
Nuclear factor, interleukin 3, regulated Nfil3 NM_017373
Prolactin family 2, subfamily c, member 2 Prl2c2 NM_011118 
Prostaglandin E receptor 4 (subtype EP4) Ptger4 NM_001136079 
Regulating synaptic membrane exocytosis 
2
Rims2 NM_053271
Effect of NGF in StHdh
Q7/7
 only
Gene Name Gene Symbol Ref Sequence
Connective tissue growth factor Ctgf NM_010217
Colony stimulating factor 1 (macrophage)
Csf1 NM_001113529 
Cysteine rich protein 61 Cyr61 NM_010516
Prostaglandin-endoperoxide synthase 2
Ptgs2 NM_011198
Effect of NGF in both genotypes, enhanced in StHdh Q111/111
Table 5.5 Gene lists created by cross-referencing the top genes with a significant 
genotype x NGF interaction with the top genes with a significant effect of NGF in GO 
category transcription related pathways. Arrows indicate the direction of expression 
change following EGF stimulation 
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EGF NGF 
Gene StHdh
Q7/7
 StHdh
Q111/111
 StHdh
Q7/7
 StHdh
Q111/111
 
Arntl ↑1.64 ↑1.13 ↓ 1.14 ↑1.36 
Atf3 ↑1.56 ↑1.99 ↓ 1.14 ↑2.87 
Fosl1 ↑2.23 ↑2.54 ↓ 2.14 ↓1.26 
Hivep1 ↑1.51 ↑1.41 ↓ 1.03 ↑1.48 
Tshz1 ↑1.74 ↑1.38 ↑1.05 ↑1.47 
 
 
 
5.2.4 Gene expression validation 
Gene expression changes were validated by qRTPCR. A selection of genes from each 
list in Tables 5.3 and 5.5 were chosen for validation. 
  5.2.4.1 EGF 
Reverse transcribed RNA from the same samples used for the microarray experiment 
were used for expression validation by qRTPCR. Eight out of 15 genes tested were fully 
confirmed, and four showed the same pattern of expression, but did not reach 
statistical significance. This is likely due to the small sample of only 5 replicates, and 
the small magnitude of expression changes following EGF stimulation. Only three of 
the 15 genes tested were not validated. A summary of these results can be seen in 
Table 5.7.  On this occasion, Egr1 was one of the genes that were unable to be 
validated; however the same pattern of expression as was seen in the microarray was 
previously identified when using an alternative qRTPCR assay in a previous experiment 
(Chapter 4, Figure 4.9), so it was not excluded from further analysis.  
 
Table 5.6 The genes that appear on the reduced gene lists for both EGF and NGF 
stimulation. Direction of expression change following growth factor stimulation is 
indicated by arrows, alongside the fold change. 
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Genes with higher response in StHdh
Q111/111
 cells 
  
following EGF stimulation  
 
  
Microarray qRTPCR 
Confirmed? 
Gene Genotype Fold change P-value RQ value 
ratio  P-value 
Id3 
StHdh
Q7/7
 -1.75 1.8 x 10
11
 0.3 0.001 
 StHdh
Q7/111
 -1.68 2.5 x 10
10
 0.51 0.035 
StHdh
Q111/111
 -2.18 3.6 x 10
14
 0.21 0.001 
Atf3 
StHdh
Q7/7
 1.56 2.2 x 10
8
 1.86  - 
 StHdh
Q7/111
 1.37 1.2 x 10
5
 3.84 0.003 
StHdh
Q111/111
 1.98 1.0 x 10
11
 3.26 0.058 
Egr1 
StHdh
Q7/7
 1.54 9.2 x 10
13
 1.37  - 
χ StHdh
Q7/111
 1.28 1.8 x 10
7
 1.21 - 
StHdh
Q111/111
 1.56 1.2 x 10
12
 1.25  - 
Fosl1 
StHdh
Q7/7
 2.23 1.6 x 10
22
 3.36 0.002 
 StHdh
Q7/111
 2.5 1.4 x 10
23
 5.61 0.001 
StHdh
Q111/111
 2.54 1.2 x 10
23
 3.37 0.001 
Etv5 
StHdh
Q7/7
 1.52 3.7 x 10
11
 0.69  - 
χ StHdh
Q7/111
 1.35 6.4 x 10
8
 0.95 - 
StHdh
Q111/111
 1.74 2.4 x 10
13
 1.34  - 
   
 
 
 
 
 
 
 
Table 5.7 Continued on next page 
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Genes with higher response in StHdh
Q7/7
 cells 
  
following EGF stimulation  
 
  
Microarray qRTPCR 
Confirmed? 
Gene Genotype Fold change P-value RQ value 
ratio  P-value 
Smad7 
StHdh
Q7/7
 1.69 3.0 x 10
16
 1.53  - 
≈ StHdh
Q7/111
 1.16 2.7 x 10
5
 0.88 - 
StHdh
Q111/111
 1.15 5.1 x 10
5
 0.37  - 
Fgf2 
StHdh
Q7/7
 1.82 1.4 x 10
14
 1.53  - 
≈ StHdh
Q7/111
 1.28 4.9 x 10
9
 2.07 - 
StHdh
Q111/111
 1.4 7.1 x 10
9
 1.4  - 
Myc 
StHdh
Q7/7
 1.64 2.0 x 10
14
 2  - 
≈ StHdh
Q7/111
 1.9 9.6 x 10
17
 3.17 0.024 
StHdh
Q111/111
 1.01 - 0.48  - 
Sox9 
StHdh
Q7/7
 2.16 4.7 x 10
23
 2.3 0.029 
 StHdh
Q7/111
 1.2 1.2 x 10
6
 0.97 - 
StHdh
Q111/111
 -1.04 - 0.74  - 
Junb 
StHdh
Q7/7
 1.52 4.3 x 10
12
 1.5  - 
 StHdh
Q7/111
 1.36 7.9 x 10
9
 2.56 - 
StHdh
Q111/111
 1.21 1.3 x 10
5
 1.78  - 
 
 
 
 
Table 5.7 Continued on next page 
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Genes responsive only in StHdh
Q111/111
 cells 
  
following EGF stimulation  
 
  
Microarray qRTPCR 
Confirmed? 
Gene Genotype Fold change P-value RQ value 
ratio  P-value 
Gadd45g 
StHdh
Q7/7
 -1.24  1.9 x 10
5 
 1.14  - 
 StHdh
Q7/111
 -2.48 4.0 x 10
18
 0.55 - 
StHdh
Q111/111
 -1.89 1.7 x 10
14
  0.65 0.006 
Cdc42ep3 
StHdh
Q7/7
 -1.3  1.7 x 10
10
 0.74  - 
 StHdh
Q7/111
 -1.5 3.6 x 10
14
 0.68 - 
StHdh
Q111/111
 -1.94 8.7 x 10
19
  0.36 0.001 
Ngf 
StHdh
Q7/7
 1.17  1.2 x 10
5
 0.74  - 
≈ StHdh
Q7/111
 1.57 9.3 x 10
14
 1.7 - 
StHdh
Q111/111
 2.01  3.7 x 10
18
 1.26  - 
Rasa1 
StHdh
Q7/7
 1.23 2.12x 10
8
 1.22  - 
 StHdh
Q7/111
 1.20  4.2 x 10
7
 1.4 0.01 
StHdh
Q111/111
 1.53  1.1 x 10
14
 1.96 0.09 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.7 Continued on next page 
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  5.2.4.2 NGF 
To validate the NGF microarray data, qRTPCR was carried out on different cDNA 
samples than those used in the microarray experiment. However, nine of the 14 genes 
investigated were confirmed, three showed the same pattern of expression but did not 
reach statistical significance, and only 2 were unable to be validated. A summary can 
be found in Table 5.8.   
5.2.5 Comparison of gene functions  
As our primary interest is the aberrant control of transcriptional processes in response 
to growth factor stimulation, only the gene lists from the EGF microarray analyses 
were taken forward for further investigation as these were more strongly associated 
with transcriptional regulation for both StHdhQ7/7 and StHdhQ111/111 cell lines. In 
addition, the expression of Ngf was found to be altered in StHdhQ111/111 cells in the EGF 
Genes with no significant change 
  
following EGF stimulation  
 
  
Microarray qRTPCR 
Confirmed? 
Gene Genotype Fold change P-value RQ value 
ratio  P-value 
Usp43 
StHdh
Q7/7
 -1.1  -  0.87  - 
 StHdh
Q7/111
 -1.06  - 1.28 - 
StHdh
Q111/111
 1.01  - 0.64  - 
Table 5.7 Validation of differentially expressed genes by qRTPCR, as identified by 
microarray analyses. The microarray gene expression fold change data from 
StHdh
Q111/111
, StHdh
Q7/111
 and StHdh
Q7/7
 cells following 2 hours 100ng/ml EGF 
stimulation are given with their associated p-values. In comparison is the ratio of 
the qRTPCR RQ value following EGF stimulation with the baseline RQ value, and the 
associated p-value. qRTPCR data was analysed using a two-way ANOVA followed by 
post-hoc Tukey tests. A  ‘‘ indicates that the gene was validated, non-validated 
genes are noted with a ‘,’ and genes that showed the same pattern of expression 
as the microarray data but did not reach significance following qRTPCR analysis are 
given a ‘≈.’ n=5. 
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experiment, so this may prove to be a confounding factor when considering the NGF 
microarray data. 
A literature search was performed in order to determine if any of the identified lists of 
genes had any processes or functions in common. The genes that had a larger 
expression change in StHdhQ7/7 cells were implicated in a range of signalling pathways, 
including P38 MAPK, AKT, MEK and TGFβ. 14 out of the 15 genes identified as having a 
larger effect following EGF stimulation in StHdhQ111/111 cells have also been implicated 
in or associated with the TGFβ pathway and its downstream family of SMAD 
transcription factors. From this we inferred that the altered expression patterns of 
these genes may indicate enhanced activity in this pathway (for details, see Section 
5.4). 
 
Genes with higher response in StHdh
Q111/111
 cells 
  
following NGF stimulation  
 
  
Microarray qRTPCR 
Confirmed? 
Gene Genotype Fold change P-value RQ value 
ratio  P-value 
Csf1 
StHdh
Q7/7
 -1.7 2.6 x 10
12 0.56 0.015 
 
StHdh
Q111/111
 -2.1 3.2 x 10
14 0.57 0.016 
Ctgf 
StHdh
Q7/7
 -1.7 3.4 x 10
6 0.42 - 
 
StHdh
Q111/111
 -3.6 1.4 x 10
10 0.07 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.8 Continued on next page 
252 
 
 
Genes with higher response in StHdh
Q7/7
 cells 
  
following NGF stimulation  
 
  
Microarray qRTPCR 
Confirmed? 
Gene Genotype Fold change P-value RQ value 
ratio  P-value 
Ereg 
StHdh
Q7/7
 -3 4.0 x 10
6 0.43 0.003 
 
StHdh
Q111/111
 1.82 0.0012 1 - 
Rgs16 
StHdh
Q7/7
 -3 7.2 x 10
9 0.26 0.006 
 
StHdh
Q111/111
 -1.2 - - - 
 
 
Genes responsive only in StHdh
Q111/111
 cells 
  
following NGF stimulation  
 
  
Microarray qRTPCR 
Confirmed? 
Gene Genotype Fold change P-value RQ value 
ratio  P-value 
Atf3 
StHdh
Q7/7
 -1.14 - 1.51 - 
 
StHdh
Q111/111
 2.9 8.5 x 10
5 2.1 0.057 
Ppargc1α 
StHdh
Q7/7
 1.1 - 1.43 - 
 
StHdh
Q111/111
 2.4 3.0x 10
7 2.29 0.041 
Nr4a2 
StHdh
Q7/7
 1.24 - 2.13 - 
 
StHdh
Q111/111
 11.9 4.2 x 10
11 6.18 0 
Cdc42ep3 
StHdh
Q7/7
 -1.06 - 0.67 - 
 
StHdh
Q111/111
 -1.8 2.5x 10
9 0.44 0 
Rnd3 
StHdh
Q7/7
 -1.34 7.6 x 10
6 0.79 - 
≈ 
StHdh
Q111/111
 -2.4 4.5 x 10
11 0.7 - 
 
Table 5.8 Continued on next page 
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Genes responsive only in StHdh
Q7/7
 cells 
  
following NGF stimulation  
 
  
Microarray qRTPCR 
Confirmed? 
Gene Genotype Fold change P-value RQ value 
ratio  P-value 
Fosl1 
StHdh
Q7/7
 -2.1 2.8 x 10
8 0.75 - 
≈ 
StHdh
Q111/111
 -1.26 0.001 0.67 - 
Id2 
StHdh
Q7/7
 -1.9 1.2 x 10
4 1.52 - 
 
StHdh
Q111/111
 1.21 - 2.05 - 
Ccng2 
StHdh
Q7/7
 2.3 8.4 x 10
11 2.73 0.004 
 
StHdh
Q111/111
 1.42 1.4 x 10
6 1.6 - 
Mybl1 
StHdh
Q7/7
 -1.9 1.5 x 10
6 0.68 - 
≈ 
StHdh
Q111/111
 -1.28 0.006 1 - 
Prl2c2 
StHdh
Q7/7
 1.5 2.0 x 10
8 0.76 - 
 
StHdh
Q111/111
 1.08 0.04 2.46 0.026 
 
 
 
 
 
 
 
 
 
Table 5.8 Validation of differentially expressed genes by qRTPCR, as identified by 
microarray analyses. The microarray gene expression fold change data from 
StHdh
Q111/111
 and StHdh
Q7/7
 cells following 2 hours 100ng/ml NGF stimulation are 
given with their associated p-values. In comparison is the ratio of the qRTPCR RQ 
value following EGF stimulation with the baseline RQ value, and the associated p-
value. qRTPCR data was analysed using a two-way ANOVA followed by post-hoc 
Tukey tests. A  ‘‘ indicates that the gene was validated, non-validated genes are 
noted with a ‘,’ and genes that showed the same pattern of expression as the 
microarray data but did not reach significance following qRTPCR analysis are given a 
‘≈.’ n=5. 
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5.2.6 Promoter region analysis 
Analysis of promoter regions was carried out in the Genomatix Software Suite v2.6 
(www.genomatix.de). This program compares the promoter regions of a given list of 
genes (500 base pairs upstream of the first transcription start site (TSS) and 100 base 
pairs downstream of the last TSS), and analyses them for potential TF binding sites that 
all of the promoter regions may have in common, by using literature searches and 
sequence analysis. The gene lists identified in Table 5.3 were entered into the program 
and analysed for each group separately. 
All of the genes identified in the three lists from the EGF experiment shared two 
putative TF binding sites; early growth response factors (EGRFs) and SP1s (Figure 5.8). 
These were the only common binding sites for those genes that showed a larger 
expression change in StHdhQ7/7 cells only. However, there were six additional potential 
common TF binding sites in the promoter regions of the genes with a larger expression 
change in StHdhQ111/111 cells. For those genes that were only responsive to EGF 
stimulation in StHdhQ111/111 cells, there were 3 potential TF binding sites in common 
with the previous list, and a further 15 common TF binding sites in their promoter 
regions. However, this gene list was much smaller than the others, and so it would be 
more likely for all genes to share common factors. A summary of common putative TF 
binding sites and their associated p-values can be found in Table 5.9. 
Due to the implication of SMADs and TGFβ signalling during a comparison of gene 
functions in Section 5.2.5, the presence of SMAD TF binding sites in the promoter 
regions of the gene lists was also analysed. It was found that there were no SMAD TF 
binding sites on the promoters of any genes that had a stronger response to EGF in 
StHdhQ7/7 cells. However, there were 6 genes from the remaining two lists combined 
that did have putative SMAD TF binding sites; these were Bhlhe40, Fosl1, Id3, Nr4a2, 
Boc and Ngf  (Figure 5.9), which was significantly higher than chance, as calculated by 
Genomatix (p=0.01). The hypergeometric distribution probability of these genes 
containing a SMAD promoter binding site when StHdhQ7/7-associated genes did not 
was also significant at p(x=6) = 0.01.  
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Table 5.9 TF families identified from the promoter region analysis described in Section 
5.2.6, which are common to all genes in each of the three lists detailed in Table 5.3. P-
values represent the probability to obtain an equal or greater number of sequences 
that all contain a binding site in their promoter region for each defined TF in a randomly 
drawn sample of the same size as the number of input sequences. P-values were 
calculated by the Genomatix Software Suite v2.6 (www.genomatix.de).  
TF name TF symbol
StHdh Q7/7 
only
Larger change in 
StHdh Q111/111
StHdh Q111/111 only 
Early growth response factor EGRF P<0.001 P=0.001 p-=0.02
Stimulating proteins SP1 P=0.01 P=0.003 P=0.03
E-twenty six factors ETSF - P=0.03 P=0.04
Neuron-specific-olfactory factor NOLF - P<0.001 -
RXR heterodimer binding sites RXRF - P=0.03 P>0.05
C2H2 zinc finger transcription 
factors 2
ZF02 - P=0.003 -
Pleiomorphic adenoma gene PLAG - P=0.001 -
Krüppel-like factors KLFS - P=0.03 P>0.05
Twist subfamily of class B bHLH 
transcription factors
HAND - - P>0.05
Nuclear receptor subfamily 2 
factors
NR2F - - P>0.05
MYC-associated zinc finger 
protein
MAZF - - P=0.01
Paired box protein 5 binding 
sites
PAX5 - - P=0.04
Neuron-restrictive silencer 
factor
NRSF - - P=0.01
Oligoadenylate synthetase OAZF - - P<0.001
E2F-homolog cell cycle 
regulators
E2FF - - P=0.04
Nuclear factor kappa B/c-rel NFKB - - P=0.02
MAF and AP1 related factors AP1R - - P>0.05
C2H2 zinc finger transcription 
factors 7
ZF07 - - P=0.002
SOX/SRY-sex/testis determining 
and related HMG box factors
SORY - - P>0.05
CCAAT binding factors CAAT - - P=0.04
Lymphoid enhancer factor-1/T-
cell factor family
LEFF - - P>0.05
Ras-responsive element binding 
protein
RREB - - P=0.003
Homeodomain transcription 
factors
HOMF - - P>0.05
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Atf3 
Bcl6b 
Bhlhe40 
Egr1 
Etv5 
Fosl1 
Hmga2 
Id3 
Irf2bp2 
Nr4a3 
A 
B 
Transcription start site 
Gene promoter region 
 
Gadd45g 
Cdc42ep3 
Rasa1 
Boc 
Ngf 
Figure 5.9 Putative SMAD transcription factor binding sites (represented by blue 
cylinders) on the promoter regions of genes that A. showed a larger gene expression 
response to EGF stimulation in StHdh
Q111/111
 cells compared to StHdh
Q7/7
 cells, and B. 
had a transcriptional response in StHdh
Q111/111 
only. 
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5.3 Investigating TGFβ and SMAD activity   
As SMADs may be playing a role in transcriptional control following EGF stimulation, 
validation of the microarray data for Smad gene expression was carried out.  
5.3.1 Gene expression 
Following EGF microarray analysis, Smads 3, 6 and 9 had significantly higher expression 
in StHdhQ111/111 cells at baseline compared to StHdhQ7/7 cells (Table 5.10). In addition, 
there was also significantly higher expression of Smurf2, and some of the Tgfβ related 
genes (summarised in Table 5.10). There was also small, but significant, 
downregulation of some of the other Smad, Smurf and Tgfβ-related genes, suggesting 
aberrant control of this pathway. 
qRTPCR analysis was carried out on the same samples used in the EGF microarray and 
previous validation experiments in order to confirm expression patterns of Smad and 
Smad-related genes that were identified as being more highly expressed in 
StHdhQ111/111 cells (Figure 5.10). Smad3 was significantly more highly expressed in 
StHdhQ111/111 cells than in both StHdhQ7/7 (p<0.001) and StHdhQ7/111 (p=0.001) cell lines, 
although there was no effect of EGF stimulation on its expression. There was the same 
effect for Smad6 expression (both p<0.003), although EGF stimulation significantly 
downregulated its expression in both StHdhQ7/7 (p=0.004) and StHdhQ111/111 (p=0.023) 
cells. Similarly, Smad9 expression was also higher in StHdhQ111/111 cells than in both 
other genotypes (both p<0.009), but its expression was significantly lower than 
StHdhQ7/7 in StHdhQ7/111 cells (p<0.001). There was only a significant effect of EGF in 
StHdhQ111/111 cells (p=0.03), where expression dropped to similar levels as in StHdhQ7/7 
cells at baseline.  
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Gene 
symbol 
Gene name 
Difference in fold 
change between 
StHdhQ111/111 and 
StHdhQ7/7 cells at 
baseline 
P-value 
Smad1 
Mothers against 
decapentaplegic 
homolog 1 
-1 0.45 
Smad3 
Mothers against 
decapentaplegic 
homolog 3 
1.27 1.2 x 1012 
Smad6 
Mothers against 
decapentaplegic 
homolog 6 
1.6 3.3 x 1015 
Smad9 
Mothers against 
decapentaplegic 
homolog 9 
1.8 3.2 x 1014 
  
 
    
Smurf2 
Smad specific E3 
ubiquitin protein 
ligase 2 
1.74 2.1 x 1013 
  
 
    
Tgfβ1 
Transforming 
growth factor beta 
1 
-1.5 2.4 x 1014 
Tgfβr1 TGF-β receptor 1 -1.2 1.6 x 105 
Tgfβ2 
Transforming 
growth factor beta 
2 
1.5 1.2 x 1014 
Tgfβr2 TGF-β receptor 2 3 5.2 x 1033 
Tgfβ3 
Transforming 
growth factor beta 
3 
3 1.2 x 1025 
Tgfβr3 TGF-β receptor 3 6 2.1 x 1027 
Tgfβi 
TGF-β induced 
protein 
11.4 2.1 x 1030 
 
 
Table 5.10 Expression differences of Smad, Tgfβ and related genes between 
StHdh
Q111/111
 and StHdh
Q7/7 
cells identified from the microarray experiment detailed 
in section 5.2 at 0 minutes EGF stimulation.  
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Figure 5.10 Relative quantification (RQ) values of selected Smad genes following 
qRTPCR to confirm microarray data from StHdh
Q7/7
, StHdh
Q7/111 
and StHdh
Q111/111 
cells prior to, and following 2 hours of 100ng/ml EGF stimulation.  Statistical 
analysis was carried out on ΔCt values, and analysed using a two-way ANOVA, 
followed by post-hoc Tukey tests. (Error bars = SEM, n=5). 
* Denotes a significant difference from StHdh
Q7/7 
cells,    
# Denotes a significant difference from StHdh
Q7/111 
cells. 
* p<0.05  ** p<0.01 *** p<0.001 
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Tgfβ2, Tgfβr2, Tgfβ3 and Smurf2 expression patterns identified in the microarray 
analysis were not able to be confirmed by qRTPCR, and there was no significant effect 
of EGF stimulation on their expression. However, EGF-stimulated StHdhQ7/111 and 
StHdhQ111/111 cells showed higher expression of Tgfβr2 (both p<0.001), and StHdhQ7/111 
cells displayed higher Tgfβ3 expression (p<0.001) compared to StHdhQ7/7 cells, 
indicating a trend towards increased expression of these genes in the presence of 
mHTT. Tgfβr3 and Tgfβi both showed much higher expression in StHdhQ111/111 cells 
compared to both other genotypes (p<0.003), and there was no effect of EGF 
stimulation. However, similar to the effect seen for Smad9, the expression of both 
Tgfβr3 and Tgfβi was significantly lower in StHdhQ7/111 cells compared to StHdhQ7/7 
(p<0.003) (Figure 5.11). Smad1 was identified from the microarray data as not showing 
any difference between genotypes, and no effect of EGF stimulation. This was 
validated by qRTPCR in these cells, as there was no significant difference between 
genotypes or following EGF stimulation (p>0.05).  
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Figure 5.11 Relative quantification (RQ) values of selected Tgfβ-related genes following 
qRTPCR to confirm microarray data from StHdh
Q7/7
, StHdh
Q7/111 
and StHdh
Q111/111 
cells 
prior to (dark grey bars), and following 2 hours (light grey bars) of 100ng/ml EGF 
stimulation. Statistical analysis was carried out on ΔCt values, and analysed using a two-
way ANOVA, followed by post-hoc Tukey tests. (Error bars = SEM, n=5). 
*Denotes a significant difference from StHdh
Q7/7 
cells, # Denotes a significant difference 
from StHdh
Q7/111 
cells.  *p<0.05  ** p<0.01 ***p<0.001 
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5.3.2 Protein analysis 
Western blots and ELISA assays were carried out in order to determine if the increased 
expression of Smad genes was also identifiable in the proteome, and if there was an 
effect of mHTT on their activation by phosphorylation. As SMAD2 and SMAD3 have 
been more thoroughly characterised than the other SMADs, ELISA assays were only 
available for these two proteins. All cells were stimulated with 100ng/ml TGFβ for 
either 0 or 30 minutes after being serum starved overnight. 
  5.3.2.1 SMAD2 
Smad2 was not identified as having differential expression between genotypes from 
the microarray analysis, however investigation by ELISA revealed that there was 
reduced total SMAD2 protein in StHdhQ111/111 cells  in comparison to StHdhQ7/7 
(p=0.017) cells, and StHdhQ7/111 cells lay between these two (Figure 5.12). Cells were 
stimulated with TGFβ in order to phosphorylate the SMAD proteins in order to 
determine if there was an effect of mHTT on their activity. As expected, there was no 
effect of TGFβ stimulation on total SMAD2, however there were significant increases in 
SMAD2 phosphorylated on serines 465/467 in both StHdhQ7/7 (p=0.013) and StHdhQ7/111 
(p<0.001) cell lines following treatment with TGFβ. In contrast, there was no significant 
increase in SMAD2 phosphorylation in StHdhQ111/111 cells following TGFβ stimulation, 
although the level of phosphorylation did not differ from the other genotypes at 
baseline (Figure 5.12).  
Despite the lack of effect in StHdhQ111/111 cells,  StHdhQ7/111 cells showed a strong 
response to TGFβ stimulation, as the level of phospho-SMAD2 detected following TGFβ 
treatment was significantly higher than in the StHdhQ7/7 cells (p=0.023), despite no 
difference in their baseline. This suggests that despite the presence of mHTT, there 
may be increased sensitivity to TGFβ stimulation in these cells, which is reversed with 
increased mHtt gene dosage. As the level of total SMAD2 was reduced in StHdhQ111/111 
cells, the ratio of phosphorylated SMAD2 to total SMAD2 was also calculated in order 
to determine if phosphorylation was hindered or if it reflected reduced total protein. 
The ratio of phosphorylated to total SMAD2 was still significantly lower in StHdhQ111/111 
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cells following TGFβ stimulation, suggesting that SMAD2 activation is inhibited in these 
cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12 Mean absorbance (Abs) read at 450nm following a sandwich ELISA 
protocol in StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111
 cells following 0 and 30mins 
stimulation with TGFβ for A. total SMAD2, B. SMAD2 phosphorylated on serines 
465/467, and C. Ratio of phosphorylated to total SMAD2 mean absorbance. 
Statistical analysis was carried out by using a two-way ANOVA followed by post-hoc 
Tukey tests (Error bars = SEM, n=3). 
* p<0.05 **p<0.01 ***p<0.001  
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Western blots confirmed the ELISA results (Figure 5.13); there was significantly less 
total SMAD2 in StHdhQ111/111 cells compared to StHdhQ7/7 (p=0.013), and there was no 
effect of TGFβ stimulation. In addition, there were significantly increased levels of 
phosphorylated SMAD2 in both the StHdhQ7/7 and StHdhQ7/111 cells following 
stimulation with TGFβ (both p=0.002). However, the larger response in StHdhQ7/111 cells 
was not found by western blot, with the phosphorylation of SMAD2 not being 
significantly different to StHdhQ7/7 cells. There was a detectable increase in phospho-
SMAD2 in StHdhQ111/111 cells following growth factor treatment, but this does not reach 
significance, and is significantly lower than the level of phosphorylation in both 
StHdhQ7/7 and StHdhQ7/111 cells (p<0.01). Analysis of the phosphorylated to total SMAD2 
ratio also yielded the same results as the ELISA assay. Taken together, these results 
suggest that not only is there a reduction in available SMAD2 in StHdhQ111/111 cells 
despite no observable reduction in gene expression, but its activation by 
phosphorylation is also inhibited in these cells.  
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Figure 5.13 A. Western blot analysis of StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111
 cells 
at 0 and 30 minutes of stimulation with 100ng/ml TGFβ. The membrane was 
probed with an antibody against total SMAD2, with α-tubulin utilised as a loading 
control. The membrane was then stripped (see section 2.2.2.8) and reprobed with 
an antibody against SMAD2 phosphorylated on serines 465/467. B-D. Quantification 
of the fluorescence intensity (FI) of A using the Licor Odyssey quantitative 
fluorescent imaging system, with SMAD antibodies normalised to the loading 
control. Statistical analysis was carried out by using a two-way ANOVA followed by 
post-hoc Tukey tests (Error bars = SEM, n=3). 
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  5.3.2.2 SMAD3 
Smad3 was found to have significantly increased expression in StHdhQ111/111 cells 
(Section 5.3.1). However, analysis of the SMAD3 protein by ELISA assay showed that 
there was a significant reduction in total SMAD3 in both StHdhQ7/111 (p<0.001) and 
StHdhQ111/111 (p=0.001) cells compared to StHdhQ7/7 cells; this reduction was roughly 
equal in both heterozygote and homozygote cells carrying mHTT (Figure 5.14).  
Unexpectedly, there was also a significant reduction in total SMAD3 following TGFβ 
stimulation in StHdhQ7/7 cells (p=0.01), although it is possible that this is an artefact of 
reduced antibody binding due to phosphorylation of the targeted epitope.  This 
reduction was also observed in the remaining two genotypes, but did not reach 
significance. 
TGFβ stimulation significantly increased the detection of SMAD3 phosphorylated on 
serines 423/425 in all three genotypes (StHdhQ7/7 p<0.001, StHdhQ7/111 p<0.001, 
StHdhQ111/111 p=0.005) (Figure 5.14). However, the extent of phosphorylation was 
lowered with mHTT load; the level of phospho-SMAD3 at baseline was not significantly 
different between genotypes, however once stimulated with TGFβ, significantly more 
phospho-SMAD3 was detected in StHdhQ7/7 cells than in both StHdhQ7/111 and 
StHdhQ111/111 cells (p<0.001), but StHdhQ7/111 cells still had significantly higher levels of 
phosphorylation than StHdhQ111/111 cells (p<0.001). A ratio of phosphorylated to total 
SMAD3 was calculated, and this revealed that although there is reduced 
phosphorylation of SMAD3 in StHdhQ7/111 cells, the ratio of this to total SMAD3 is not 
significantly different to StHdhQ7/7 cells (p>0.05). However, the ratio of phosphorylated 
to total SMAD3 in StHdhQ111/111 cells was significantly lower than both StHdhQ7/7 and 
StHdhQ7/111 cell lines (both p<0.001). This suggests that although there is less available 
SMAD3 in StHdhQ7/111 cells, it is still phosphorylated to the same extent as in StHdhQ7/7 
cells following TGFβ stimulation, but in StHdhQ111/111 cells, as well as there being less 
SMAD3 present in the cell, the capacity for its phosphorylation is also reduced. 
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Figure 5.14 Mean absorbance (Abs) read at 450nm following a sandwich ELISA 
protocol in StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111
 cells following 0 and 30mins 
stimulation with TGFβ for A. total SMAD3, B. SMAD3 phosphorylated on serines 
423/425, and C. Ratio of phosphorylated to total SMAD3 mean absorbance. 
Statistical analysis was carried out by using a two-way ANOVA followed by post-hoc 
Tukey tests (Error bars = SEM, n=3). 
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Analysis of SMAD3 and its phosphorylation yielded different results when investigated 
by western blot (Figure 5.15). It appeared that there was more total SMAD3 detected 
in StHdhQ111/111 cells both before, and following TGFβ stimulation, which is reflective of 
the gene expression results (Section 5.3.1). However, this difference does not reach 
significance due to large variability in imaging quality between replicates.  
As was observed in the ELISA, there was no significant difference between genotypes 
in the amount of phosphorylated SMAD3 at baseline.  In addition, there was only a 
significant increase in the amount of phospho-SMAD3 detected in StHdhQ7/111 
(p=0.008) and StHdhQ111/111 cells (p=0.001) following TGFβ stimulation. There was an 
increase in StHdhQ7/7 cells, but this did not reach significance, and it remained 
significantly lower than the level detected in StHdhQ111/111 cells (p=0.03). However, 
when the ratio of phosphorylated to total SMAD3 was investigated, there were no 
significant differences between genotypes. This suggests that the observed increase in 
phosphorylated SMAD3 in StHdhQ7/111 and StHdhQ111/111 cells may not be due to an 
increased sensitivity to activation, but due to the increased amount of total SMAD3 
available to be phosphorylated, although StHdhQ7/111 cells appear perhaps more 
sensitive to stimulation than both other genotypes.  However, why the western blot 
data is so dramatically different to the ELISA data is yet to be elucidated, as the 
antibodies used for both techniques were the same. However, these western blots are 
normalised to an α-tubulin loading control, whereas the ELISAs are not, so it is possible 
that the difference in these findings could be reflective of this. The denaturing process 
in preparation for SDS-PAGE gel electrophoresis may also alter the binding capacity of 
the antibody, thus altering the evident levels of SMAD3 and phosphorylated SMAD3. 
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Figure 5.15 A. Western blot analysis of StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111
 cells 
at 0 and 30 minutes of stimulation with 100ng/ml TGFβ. The membrane was probed 
with an antibody against total SMAD3, with α-tubulin utilised as a loading control. 
The membrane was then stripped (see section 2.2.2.8) and reprobed with an 
antibody against SMAD3 phosphorylated on serines 423/425. B-D. Quantification of 
the fluorescence intensity (FI) of A using the Licor Odyssey quantitative fluorescent 
imaging system, with SMAD antibodies normalised to the loading control. Statistical 
analysis was carried out by using a two-way ANOVA followed by post-hoc Tukey 
tests (Error bars = SEM, n=3). 
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  5.3.2.3 Other SMAD TFs and TGFβI 
The following SMAD proteins and TGFβI were only investigated by western blot, as the 
appropriate ELISA kits were not available.  
There was no effect of TGFβ on SMAD1 in all three genotypes, however there was a 
small reduction in StHdhQ7/111 cells compared to StHdhQ7/7 cells, which only just reaches 
significance (p=0.046) (Figure 5.16). However, there is no significant difference 
between the levels of SMAD1 detected in StHdhQ111/111 cells and either StHdhQ7/7 or 
StHdhQ7/111 cells, which is reflective of the qRTPCR and microarray findings on gene 
expression (Section 5.3.1). Two antibodies were available for the detection of 
phosphorylated SMAD1; one was specific to SMAD1 phosphorylation (serine 465), and 
one that detected both phosphorylated SMAD1 and 5 (serines 463/465). There were 
no significant differences in the level of phosphorylated SMAD1 detected with either 
antibody between all three genotypes, and there was also no change in the level of 
phosphorylation following stimulation with TGFβ. This is not unexpected, as although 
SMAD1 is part of the TGFβ signalling pathway, it is mainly a substrate for bone 
morphogenetic protein (BMP) members of the TGFβ family (Massague 2005). 
SMAD5 was significantly reduced in StHdhQ111/111 cell lines in comparison to both 
StHdhQ7/7 (p=0.015) and StHdhQ7/111 cells (p<0.001), although significantly more was 
detected in StHdhQ7/111 cells compared to wild type (p=0.032) (Figure 5.17). As 
expected, there was no difference in total SMAD5 following stimulation with TGFβ in 
any of the genotypes. However, TGFβ treatment did significantly increase SMAD5 
phosphorylated on serines 463/465 in StHdhQ7/7 and StHdhQ7/111 cells (both p<0.003). 
There was an observable increase in phosphorylated SMAD5 in the StHdhQ111/111 cells, 
but surprisingly this did not reach significance. When looking at the phosphorylated to 
total SMAD5 ratio, it initially appears that SMAD5 in StHdhQ111/111 cells is actually 
hyperphosphorylated both prior to, and following TGFβ stimulation than its StHdhQ7/7 
and StHdhQ7/111 counterparts. Although these differences don’t reach significance, this 
may suggest that although there is reduced total SMAD5 in cells homozygote for 
mHTT, its phosphorylation capabilities are equal, and potentially larger, than in 
StHdhQ7/7 and StHdhQ7/111 cells. 
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Figure 5.16 A. Western blot analysis of StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111
 cells 
at 0 and 30 minutes of stimulation with100ng/ml TGFβ. The membrane was probed 
with an antibody against total SMAD1, with α-tubulin utilised as a loading control. 
The membrane was then stripped (see section 2.2.2.8) and reprobed with an 
antibody against SMAD1 phosphorylated on serine 465, then again with an 
antibody against phosphorylated SMAD1/5 (serines 463/465). B-D. Quantification of 
the fluorescence intensity (FI) of A using the Licor Odyssey quantitative fluorescent 
imaging system, with SMAD antibodies normalised to the loading control. Statistical 
analysis was carried out by using a two-way ANOVA followed by post-hoc Tukey 
tests (Error bars = SEM, n=3).    
*p<0.05 **p<0.01 ***p<0.001  
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Figure 5.17 A. Western blot analysis of StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111
 cells 
at 0 and 30 minutes of stimulation with100ng/ml TGFβ. The membrane was probed 
with an antibody against total SMAD5, with α-tubulin utilised as a loading control. 
The membrane was then stripped (see section 2.2.2.8) and reprobed with an 
antibody against SMAD5 phosphorylated on serines 463/465. B-D. Quantification of 
the fluorescence intensity (FI) of A using the Licor Odyssey quantitative fluorescent 
imaging system, with SMAD antibodies normalised to the loading control. Statistical 
analysis was carried out by using a two-way ANOVA followed by post-hoc Tukey 
tests (Error bars = SEM, n=3).  
*p<0.05 **p<0.01 ***p<0.001  
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Phospho-specific antibodies were not available for SMAD4 and SMAD6, so only the 
total protein could be investigated during this project. Although there was increased 
SMAD4 in StHdhQ111/111 cells at 0mins TGFβ stimulation, this did not quite reach 
significance (StHdhQ7/7 p=0.067, StHdhQ7/111 p=0.052). There was also no effect of TGFβ 
on the detection of total SMAD4 (Figure 5.18). In contrast to the gene expression data 
in Section 5.3.1, there were no differences between the genotypes for the detection of 
SMAD6, and there was also no significant effect of TGFβ stimulation (Figure 5.18). 
Due to such large overexpression in StHdhQ111/111 cells identified earlier (Section 5.3.1), 
TGFβI was also investigated. Although there was a visible increase in the TBFβI protein 
in StHdhQ111/111 cells (Figure 5.19), due to variability between replicates and high levels 
of noise in the data, this did not reach significance from StHdhQ7/7 cells, although it was 
significantly higher than in StHdhQ7/111 cells (p=0.003). There was no effect of TGFβ 
stimulation on the level of TGFβI in any of the genotypes. Although not fully reaching 
significance, the trend towards higher levels of TGFβI detection in StHdhQ111/111 cells, 
coupled with the gene expression data, suggest that this may still be a potentially 
interesting target in the TGFβ pathway to follow up. 
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Figure 5.18 A. Western blot analysis of StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111
 cells 
at 0 and 30 minutes of stimulation with100ng/ml TGFβ. The membrane was probed 
with an antibody against total SMAD4, with α-tubulin utilised as a loading control. 
B. Western blot analysis of StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111
 cells at 0 and 30 
minutes of stimulation with 100ng/ml TGFβ. The membrane was probed with an 
antibody against total SMAD6, with α-tubulin utilised as a loading control C-D. 
Quantification of fluorescence intensities (FI) in A and B using the Licor Odyssey 
quantitative fluorescent imaging system, with SMAD antibodies normalised to the 
loading control. Statistical analysis was carried out by using a two-way ANOVA 
followed by post-hoc Tukey tests (Error bars = SEM, n=3).  
276 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.19 A. Western blot analysis of StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111
 cells 
at 0 and 30 minutes of stimulation with 100ng/ml TGFβ. The membrane initially 
probed with total SMAD6 was stripped and reprobed with an antibody against 
TGFβI B. Quantification of the fluorescence intensities (FI) of A using the Licor 
Odyssey quantitative fluorescent imaging system, with the TGFβI antibody 
normalised to the loading control. Statistical analysis was carried out by using a 
two-way ANOVA followed by post-hoc Tukey tests (Error bars = SEM, n=3).  
‘#’ Denotes a significant difference from StHdh
Q7/111
 cells. 
#p<0.05 ##p<0.01 ###p<0.001  
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5.4 Discussion 
We have used a dynamic model to investigate the differential transcriptional effects of 
growth factor stimulation in an immortalised embryonic striatal cell model of HD. The 
comparison of microarray data from both EGF and NGF experiments at baseline 
suggests that the expression changes between genotypes remain relatively 
homogenous and robust between different batches of cells, and the use of different 
Affymetrix chips provide a degree of reproducibility. The top GO categories that were 
associated with these baseline differences were mostly developmental pathways, 
which are likely to be reflective of the embryonic nature of this cell model. As such, the 
focus of further analyses was on genes that were associated with transcriptional 
related pathways, and those that were differentially affected between the genotypes 
following growth factor stimulation.  
 
StHdhQ7/7 cells responded differently to EGF and NGF stimulation in terms of their gene 
expression response. Despite both growth factors sharing similar downstream kinase 
signalling pathways, such as AKT, MEK and P38 MAPK (Song et al. 2002; Humbert 2003; 
Yang et al. 2007; Cabodi et al. 2009; Ji et al. 2010), their subsequent gene expression 
profiles differed. NGF stimulation elicited the expression of genes that were associated 
with the regulation of cellular and metabolic processes, which may be reflective of 
NGF’s association with promoting neurite outgrowth and cellular proliferation (Pang et 
al. 1995; Levkovitz & Baraban 2002; Song et al. 2002). On the other hand, EGF has 
been more closely linked with transcriptional control (Liévens et al. 2008), and the 
EGFR itself has been identified as a potential TF (Lin et al. 2001). In addition, in HeLa 
cells, 46 different transcriptional regulators were identified as being phosphorylated 
within 20 minutes of EGF stimulation (Olsen et al. 2006), thus implicating this as a key 
pathway for the control of gene expression.  EGF and NGF may therefore be 
stimulating similar cellular signalling responses but in a differential manner; it has been 
suggested that the downstream kinetics of kinase signalling pathways in response to 
growth factor stimulation may be the mechanism for differentiation between signals 
that would otherwise share similar cellular responses (Ji et al. 2010). Alternatively, 
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both NGF and EGF may be stimulating separate downstream signalling pathways that 
are then differentially modified by the presence of mHTT. 
StHdhQ111/111 cells do not appear to exhibit such distinct responses to EGF and NGF 
stimulation as StHdhQ7/7 cells do. In both cases, several of the top 10 GO categories 
identified from pathway analysis were associated with the regulation of transcription. 
This may explain why we observed a greater transcriptional response in StHdhQ111/111 
cells compared to the StHdhQ7/7 cells following NGF stimulation, despite evidence 
suggesting that cellular responses to NGF are suppressed in cells containing mHTT 
(Song et al. 2002; Humbert 2003), and that activation of its receptor TRKA is disrupted 
by mHTT associated mechanisms (Rong et al. 2006). The kinase activation data from 
the previous chapter suggests that StHdhQ111 cell lines do not show the same 
phosphorylation response in kinase pathways, such as AKT, MEK and P38 MAPK 
following NGF stimulation as they do following EGF (Figures 4.3-4.6). Therefore, it is 
possible that there are distinct mechanisms by which the transcriptional response 
occurs in response to varying growth factor stimulation. For example, NGF stimulation 
of PC12 cells leads to sustained activation of Map kinase kinase (MAPKK), which 
consequently activates MAPK, whereas EGF stimulation initiates a more rapid 
phosphorylation response that decays after 60 minutes (Traverse et al. 1992). In 
addition, both growth factors have differential effects on the translocation of MAPK to 
the nucleus; this only occurs following NGF (Traverse et al. 1992), and may be a 
mechanism by which transcriptional control differs between two pathways that share 
similar upstream kinases. The differential responses that distinguish the cellular 
reactions to different stimuli may be aberrantly regulated in the presence of mHTT, 
resulting in a homogeneous response when alternate growth factors are presented. As 
NGF stimulation elicited considerable gene expression changes, and is known to 
upregulate the expression of similar IE genes to EGF stimulation (Cosgaya & Aranda 
1999), the lack of an observed phosphorylation response following NGF stimulation in 
the previous chapter may be an artefact of only investigating one time point of growth 
factor stimulation. Therefore to more fully elucidate the upstream kinase signalling 
pathways involved in transcriptional dysregulation in the StHdhQ111 model of HD, a 
more thorough characterisation of kinase phosphorylation kinetics would be required. 
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Comparing the lists of differentially expressed genes between genotypes following EGF 
stimulation was used as a method to identify potentially aberrant pathway signalling in 
StHdhQ111/111 cells. The genes that had significantly increased expression following EGF 
stimulation in StHdhQ7/7 cells are known to encode proteins that perform a range of 
functions and belong to several different classes of TFs. For example, HIVEP1, KLF5 and 
TSHZ1 are all members of the zinc finger family of TFs that are associated with 
functions as broad as embryonic stem cell (ESC) pluripotency, cell growth and 
differentiation, and soft palate development in mice (Ghaleb et al. 2005; Yao et al. 
2006; Coré et al. 2007; Guo et al. 2009; Bourillot & Savatier 2010). Klf5 expression has 
also previously been found to be dependent on EGFR stimulation, and is downstream 
of MEK/ERK signalling (Yang et al. 2007). KDM6B is a histone demethylase; this family 
of TFs is thought to activate gene expression by removing histone H3 lysine 27 
trimethylation marks from chromatin, which are repressive to transcription (Ramadoss 
et al. 2012). 
 
Other genes identified from this analysis, such as Jun and Junb, encode proteins that 
have roles as both transcription activators and repressors, and are IE genes that form 
part of the early growth response (Finch et al. 2002; Cabodi et al. 2009). They also 
form a complex with members of the FOS and ATF TF families to create the activator 
protein 1 (AP1), which is a well-known transcriptional regulator, the composition of 
which can determine differential specificity of DNA binding in order to control gene 
expression (Shaulian & Karin 2002; Eferl & Wagner 2003). As members of both the ATF 
and FOS families (Atf3 and Fosl1) were identified in this study as being dysregulated in 
StHdhQ111/111 cells in response to EGF stimulation, the altered formation of the AP1 
complex may be a mechanism for transcriptional dysregulation in this cell model. In 
addition, both Jun and Junb were identified as having reduced expression in R6/2 
mouse striata at 10-11 weeks of age (Spektor 2002), which supports the differential 
expression pattern following EGF stimulation observed here, and may also indicate 
dysregulation of the AP1 complex. Interestingly, a putative binding site for AP1 has 
also been identified in the Htt gene promoter region (Wang et al. 2012), the disruption 
of which may be a mechanism for the alterations in Htt expression that has been 
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observed in several models of HD (Gutekunst et al. 1995; Persichetti et al. 1996; J. 
Miller et al. 2010; Pouladi et al. 2010). 
 
Several of the remaining genes have also been identified in other models of HD as 
having altered expression; Sox9 is a member of the high mobility group box TF family, 
and is most commonly associated with male sexual development, as well as tumour 
progression (Song et al. 2013). However, it has been found to be increased x0.9 fold in 
post mortem HD human cortex and caudate (Hodges et al. 2006). In this data, Sox9 
was also found to be significantly increased in StHdhQ111/111 cells at baseline (fold 
change x2.4), although following EGF stimulation, its expression is reduced x1 fold. In 
contrast, in StHdhQ7/7 cells, Sox9 expression increases x2.16 fold following EGF 
stimulation. This suggests some concordance between the gene expression profiles of 
this cell model and human HD brain (as has previously been noted, Crook & Housman 
2011), but also highlights the importance of using a dynamic model in order to draw 
conclusions about aberrant cell signalling from gene expression data. In addition, Fgf2 
is a powerful activator of MEK/ERK signalling, and is associated with cellular 
proliferation (Ishii et al. 2012; Li et al. 2012). It was identified as being increased x1 fold 
in human HD cortex and caudate (Hodges et al. 2006), although this was not replicated 
in the current model. Tead4 is a transcriptional enhancer, and has been found to have 
reduced expression in R6/2 mice at 8 weeks of age compared to their wild type 
littermates, but the correct level of expression can be restored with a combination 
treatment of tacrine, maclobemide and creatine (Morton et al. 2005). Although this 
difference was not apparent prior to EGF stimulation in this model, its transcriptional 
response to stimulation was suppressed in StHdhQ111/111 cells compared to StHdhQ7/7s. 
This suggests that interference with transcriptional control is apparent from as early as 
the embryonic stages of development in HD. 
 
Finally, Arntl is a basic helix loop helix (BHLH) TF associated with circadian rhythm 
(Reppert & Weaver 2002), and has been identified as being typically dysregulated in 
models of HD (Seredenina & Luthi-Carter 2012). Its expression was found to be 
reduced x1.38 fold in symptomatic R6/2 mice (Crocker et al. 2006), although no 
significant difference was found in the baseline expression of Arntl in these cells; this 
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may be due to the difference in the developmental stage of each model. However, we 
did find a suppressed response of Arntl expression to growth factor stimulation in 
StHdhQ111/111 cells, which may be an early indicator of progressive downregulation of 
this gene. The implication of Arntl dysregulation in HD is of particular interest, as 
disruption in circadian rhythm is a key clinical feature of HD in humans, and has been 
identified in mouse models of the disease (Morton et al. 2005; Pallier et al. 2007; 
Fedele et al. 2010; Morton 2013). 
 
The genes that were identified as having a stronger transcriptional response in 
StHdhQ111/111 cells also represented a diverse range of functions, predominantly cellular 
survival and proliferation. However, the majority of genes on these lists are responsive 
to TGFβ stimulation, and several have direct associations with SMAD TFs. For example, 
the HMGA2 protein regulates a feed forward mechanism of gene transcription via a 
direct interaction with SMADs 3 and 4 (Thuault et al. 2008). Irf2bp2 encodes a muscle 
enriched TF (Teng et al. 2011) that has been found to be a TGFβ responsive gene 
(Koinuma et al. 2009), as has Cdc42ep3 and Gadd45g (Zawel et al. 2002; Lim et al. 
2005; Gomis et al. 2006), the second of which also mediates the activation of P38 
MAPK (Johnen et al. 2013). Gadd45 was also found to be increased x2.7 fold in an 
inducible PC12 model carrying an N-terminal fragment of mHTT (Apostol et al. 2006), 
which is similar to the x2.45 fold change difference between genotypes observed in 
this cell model. Gadd45g was downregulated in response to EGF stimulation; however 
as a negative regulator of cell growth, downregulation following growth factor 
stimulation is consistent with the predicted growth response. As well as having a 
putative SMAD TF binding site on its promoter, NGF is a mediator of SMAD activity, 
and specifically can enhance the activity of SMAD3 by promoting its complex formation 
with SMAD4 (Lutz et al. 2004). Therefore the enhanced NGF expression observed in 
response to EGF stimulation in StHdhQ111/111 cells may be consistent with heightened 
SMAD activity in this model. In addition, an increased SMAD activity response in these 
cells may explain why there was a much larger transcriptional reaction in StHdhQ111/111 
cells compared to StHdhQ7/7 cells following NGF stimulation. 
 
Bhlhe40 codes for a BHLH transcriptional repressor that can be induced by TGFβ (Ehata 
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et al. 2007; Hsiao et al. 2009), which is consistent with our identification of a putative 
SMAD TF binding site in its promoter region. EGR1 has been found to have a physical 
and functional interaction with SMAD3, which is an association that stimulates 
transcription (Fortin & Bernard 2010). Its increase in expression may be in response to 
increased P38 MAPK or AKT signalling, as identified in the previous chapter. Increased 
expression of Egr1 was also observed in an inducible PC12 model of HD (Liang et al. 
2009), although other studies have consistently identified a downregulation of this 
gene in other models of HD (Luthi-Carter 2000; Spektor 2002; Morton et al. 2005; 
Crocker et al. 2006). No differences in Egr1 expression at baseline were identified in 
this study, so it is possible that this discrepancy is a result of the different stages of 
phenotypic development between these models. However, lower baseline expression 
does not exclude the potential for increased sensitivity to stimulation. 
 
There is currently no literature linking FOSL1 to either SMAD or TGF-β activity, 
however as previously noted, it is known to dimerize with JUN or ATF proteins in order 
to form the AP1 TF complex (Shaulian & Karin 2002; Eferl & Wagner 2003). Combined 
with a potential SMAD TF binding site within its promoter region, it may be indirectly 
associated with aberrant TGFβ signalling. Increased expression of Fosl1 was also found 
in the same inducible N-terminal mHTT PC12 cell model of HD that found increased 
Egr1 expression (Liang et al. 2009). The same authors also found a substantial increase 
in Atf3 expression (x24.6 fold), and suggested that this was a protective effect, as 
knock down of this gene increased mHTT toxicity (Liang et al. 2009). We did not 
identify Atf3 as being different between genotypes at baseline; however regulation of 
its expression was more sensitive in StHdhQ111/111 cells. Atf3 is downstream of P38 
MAPK (Kang et al. 2003; Lu et al. 2007), and is known to be induced following cellular 
stress (Hai et al. 2010). It is a transcriptional repressor (Chen et al. 1994; Hai et al. 
2010), and as a result its overexpression suppresses cell growth (Fan et al. 2002) and 
induces apoptosis by increasing caspase activity (Mashima et al. 2001). Therefore, the 
effects of its overexpression in this and other models of HD are coherent with 
observable phenotypes caused by the mHTT protein. ATF3 is a common target of TGFβ 
signalling, and is activated specifically by SMAD3 (Kang et al. 2003), suggesting that 
there may be enhanced SMAD3 activity in StHdhQ111/111 cells in order to drive increased 
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ATF3 activity. This was supported in the gene expression data, but the evidence for 
increased SMAD3 protein phosphorylation and activity in these cells still requires 
elucidation. 
  
The ATF3/SMAD3 complex is part of the regulatory machinery that controls Id3 
expression; Id3 was identified here as having a putative SMAD TF binding site in its 
promoter region, and the extent of its downregulation in response to EGF stimulation 
was larger in StHdhQ111/111 cells. Id3 is known to be mediated by the EGFR via the 
activation of SMAD5, which is phosphorylated by increased AKT activity (Jin et al. 
2011), and is downregulated by TGFβ stimulation (Kang et al. 2003). It has already 
been demonstrated that there is an increased AKT response in StHdhQ111/111 cells (see 
previous chapter), which is concordant with an exaggerated response in downstream 
gene expression. In this cell model, although there was no difference in SMAD5 gene 
expression, there was reduced SMAD5 protein in StHdhQ111/111 cells, but a trend 
towards its hyperphosphorylation; this may be in part due to the increased AKT 
response in these cells, although more thorough investigation is required to clarify this 
relationship. The pattern of Id3 expression is also consistent with Bcl6b expression in 
this model, as the latter is downstream of activated MEK (Ishii et al. 2012), which is 
phosphorylated in response to EGF stimulation (see previous chapter), and contains an 
Id3 repressive element (Jin et al. 2011).  
 
As a suppressor of RAS function, the increased expression of Rasa1 in StHdhQ111/111 
cells is consistent with previous findings that RAS/MAPK/ERK signalling is impaired in 
this cell model (Ginés et al. 2010), and that its expression was found to be increased 
x1.7 fold in an inducible N-terminal HTT PC12 cell model of HD (Apostol et al. 2006). Its 
protein, RASGAP, is also known to interact with HTT through its SH3 domain, and this 
interaction is mediated through stimulation of the EGFR (Liu et al. 1997). The 
RAS/MAPK and TGFβ pathways interact in both a co-operative and antagonistic 
manner (Massague 2003); for example, RAS hyperactivity is able to inhibit the function 
of SMADs1, 2 and 3 (Kretzschmar et al. 1997; Calonge & Massagué 1999). Therefore 
increased Rasa1 expression and the consequent suppression of RAS could be expected 
to promote enhanced SMAD activity.  
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The association of the TGFβ pathway and SMAD signalling is not exclusive to the genes 
that elicit a stronger response in StHdhQ111/111 cells; several of the genes identified from 
the StHdhQ7/7 list have also been implicated with this pathway, although in contrast to 
the panel of genes just discussed, these are primarily negatively regulated by increased 
TGFβ and SMAD activity. For example, Myc is commonly downregulated in response to 
TGFβ in diverse cell types (Alexandrow & Moses 1995), and Sox9 expression is 
enhanced in the context of repressed TGFβ activity (Song et al. 2013). Spry2 has also 
been found to mediate the crosstalk between EGF and TGFβ pathways; its activation is 
increased by stimulation of the EGFR, where it then propagates the signal by 
preventing degradation of the EGFR. TGFβ suppresses the transcription of Spry2, 
therefore degrading its protein and suppressing EGFR activation (Ding et al. 2007). 
Consequently, its expression in StHdhQ111/111 cells could be expected to be reduced if 
there is enhanced activity in the TGFβ pathway, which would also be consistent with 
their generally suppressed response of transcription following EGF stimulation. Finally, 
Smad7 expression was also enhanced in StHdhQ7/7 cells following EGF stimulation; 
Smad7 is an inhibitor of TGFβ and SMAD signalling by competitively interacting with 
the type 1 TGFβ receptor (Blanchette et al. 2001) and interfering with SMAD-SMAD 
interactions (Massague 2005). It is also expressed in response to EGF stimulation in 
order to act as a negative regulator of the pathway (Kim et al. 2012); in the context of 
this experiment, Smad7 may be enhanced following EGF stimulation in order to 
mediate the response of StHdhQ7/7 cells, but in StHdhQ111/111 cells, lower expression and 
potentially lower activity of its protein may be permissive of enhanced TGFβ pathway 
activity, and consequently prevents normal regulation of cell signalling pathways.  
 
Despite having different roles in specific signalling pathways, all of the genes identified 
as having differential responses to EGF between genotypes share two potential TF 
family binding sites on their promoter regions, suggesting that these are likely to be 
the main regulatory elements controlling their expression. The first of these is the early 
growth response factor family (EGRF), of which one of the StHdhQ111/111 upregulated 
genes, Egr1, is a member. The function of Egr1 has already been discussed, but its 
increased availability in StHdhQ111/111 cells in response to growth factor stimulation may 
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be a mechanism by which the expression change of genes in these cells is enhanced. 
The implication of the SP1 family of TFs in the expression of this panel of genes is also 
of particular interest, as SP1 has been found to bind to the HTT protein, with a higher 
affinity to mHTT (Dunah et al. 2002; Li et al. 2002; Hu et al. 2004), and is also able to 
regulate the transcription of Htt itself (Wang et al. 2012). The potential role of SP1 in 
HD is still under debate; increased expression of it has been observed in 15 week old 
R6/1 mice, where there was also an increase in its DNA binding capacity (Hu et al. 
2004), but in human HD brain this was found to be impaired, which was coupled with 
the downregulation of a variety of SP1-regulated genes (Luthi-Carter et al. 2002; Chen-
Plotkin et al. 2006). Whether SP1 has the capacity to be neuroprotective remains to be 
elucidated; the overexpression and the suppression of Sp1 have both separately been 
found to be neuroprotective (Li et al. 2002; Qiu et al. 2006), which suggests that an 
additional regulatory element may be involved in its effects in HD. Although SP1 is a 
major TF in neuronal cells (Ross 2002), increased Sp1 expression is consistent with 
gene expression changes seen here in the same manner as increased Egr1 expression, 
and the probability of the presence of its binding site in the promoter regions of all of 
the identified genes was found to be significantly unlikely to be due to chance. 
Alterations in the broad activity of SP1 as a neuronal TF may also be a mechanism by 
which global transcriptional dysregulation occurs in HD, and also may explain some of 
the specific susceptibility of neuronal cells to mHTT insult.  
 
The potential roles of the additional TF binding sites on the promoter regions of genes 
with enhanced expression change following EGF stimulation in StHdhQ111/111 cells is 
currently unclear, as they are all associated with a range of different functions and 
signalling pathways. The increased number of TFs in common may simply be due to 
chance, as a shorter gene list is more likely to have more common elements due to 
reduced specificity. Alternatively, being downstream of several kinase signalling 
pathways, they may reflect enhanced activity of these pathways (as observed in the 
previous chapter), therefore promoting a broader range of TF activity in StHdhQ111/111 
cells. The presence of SMAD TF binding sites in the promoter regions of StHdhQ111/111 
related genes is also of interest, as it supports the hypothesis that SMAD activity may 
be augmented in these cell types, and this may be a mechanism for the enhanced 
286 
 
expression response of these genes.  
 
Gene expression data suggested that several members of the TGFβ pathway are 
drastically upregulated in StHdhQ111/111 cells, and as already discussed, this increased 
activity would be concordant with the pattern of gene expression changes observed 
following EGF stimulation in both StHdhQ7/7 and StHdhQ111/111 cells. In order to 
investigate this further, we used a panel of antibodies against several SMAD proteins 
to determine if the observed increases in gene expression were reflected in protein 
levels and their activation. As SMAD9 is one of the least researched members of the 
SMAD TF family, no antibody was available to investigate its activity. A comparison 
between the Smad gene expression data and SMAD protein data can be found in Table 
5.11. Increased expression of the Smad6 gene was not reflected in the level of total 
SMAD6 protein; this may be due to a reduced capacity of StHdhQ111/111 cells to translate 
mRNA into protein, meaning that increased expression of this gene is a compensatory 
response required for normal protein availability. It also was not possible to investigate 
SMAD6 phosphorylation in this project, so it remains to be elucidated whether its 
activity is altered in StHdhQ111/111 cells. SMAD6 is an inhibitory member of the TGFβ 
pathway (Park 2005) that acts by competing with SMAD4 for SMAD1 binding 
(Massague 2005), so it could be expected that its activity will be suppressed in these 
cells. However, its activity is more closely associated with the BMP pathway (Massagué 
1998; Massague 2005), so the significance of its overexpression in this cell model 
remains unclear.  
 
In contrast, there were some mixed results for the activity of SMAD3; the expression of 
the gene was found to be substantially higher in StHdhQ111/111 cells, and there was 
suggestion from western blot data that this also translated into increased presence of 
the protein and its phosphorylation. Several of the genes that had an augmented 
response in StHdhQ111/111 cells are known to be regulated by SMAD3 activity, such as 
Atf3 (Kang et al. 2003), Egr1 (Fortin & Bernard 2010) and Ngf (Lutz et al. 2004). 
Increased expression and phosphorylation of SMAD3 may therefore be a mechanism 
for some of the transcriptional dysregulation apparent in this cell model of HD. 
However, the ELISA data elicited opposing results regarding both total and 
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phosphorylated SMAD3, so its exact role in transcriptional control in StHdhQ111/111 cells 
requires further investigation. There is also a trend towards increased SMAD4 protein 
in StHdhQ111/111 cells, although this did not reach significance. However as SMAD3 is 
required to form a complex with SMAD4 in order to localise to the nucleus and to bind 
with DNA (Massague 2005), increased SMAD4 would be required to accommodate the 
increased activation of SMAD3. 
 
 
  Gene Expression Western Blot ELISA 
  
Microarray 
(Fold 
change) 
qRTPCR                  
(RQ 
Ratio) 
Total 
protein               
(FI 
ratio) 
Phospho-
protein   
(FI ratio) 
Total 
protein 
(Abs 
ratio) 
Phospho-
protein 
(Abs 
ratio) 
SMAD1 ND ND ND ND - - 
SMAD2 -1.20 ↓ - 0.9 ↓ 0.54 ↓ 0.8 ↓ 0.4 ↓ 
SMAD3  1.27 ↑ 4.2 ↑ 1.4 ↑ 2 ↑ 0.78 ↓ 0.3 ↓ 
SMAD4 -1.03 ↓ - ND - - - 
SMAD5 -1.15 ↓ - 0.3 ↓ 0.7 ↓ - - 
SMAD6   1.60 ↑ 3.5 ↑ ND - - - 
SMAD7 
-1.30 ↓ 
0.58 
↓ 
- - - - 
SMAD9  1.80 ↑ 5.6 ↑ - - - - 
 
 
 
 
 
Both Smad2 and Smad5 showed no difference between genotypes in terms of their 
gene expression in the microarray analysis, however both total and phosphorylated 
SMADs2 and 5 were present at lower levels in StHdhQ111/111 cells compared to the 
StHdhQ7/7s, indicating suppression of the TGFβ pathway. This is not entirely 
incompatible with the SMAD3 hypothesis, as TGFβ signalling is a very broad 
mechanism, and the different SMAD proteins are likely to regulate different subsets of 
genes; the suppression of this arm of the pathway may be an additional mechanism for 
some of the transcriptional downregulations commonly seen in models of HD (Crook & 
Housman 2011). Finally, Tgfbi is a key gene associated with corneal dystrophy (El 
Table 5.11 A summary of all Smad gene expression and SMAD protein comparison 
data between StHdhQ111/111 and StHdhQ7/7 cells. Arrows indicate the level of gene 
expression or protein concentration in StHdhQ111/111 cells compared to StHdhQ7/7 cells 
(↑ = higher, ↓ = lower). RQ = relative quantification, FI = fluorescence intensity, 
Abs = absorbance at 450nm.   
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Kochairi et al. 2006), but there is currently no data on its role in TGFβ signalling in 
brain, or in the context of neurodegeneration, so any potential contribution it may 
have to transcriptional control in neurons remains to be seen. 
 
There is currently limited evidence for the implication of TGFβ and SMAD signalling in 
the progression of HD; TGFβ1 is reduced in the peripheral blood of asymptomatic HD 
patients, and its presence had an inverse correlation with CAG repeat length (Battaglia 
et al. 2011). YAC128 and R6/2 mice also had reduced TGFβ1 in the cortex, but there 
was a slight increase in its presence in the striata of symptomatic mice, which was 
thought to be indicative of an inflammatory response in astrocytes and glial cells 
(Battaglia et al. 2011). In contrast, human HD induced pluripotent stem cells (iPSCs) 
were found to have an upregulation of the TGFβ pathway, which could be restored to 
normal levels by replacement of the expanded CAG repeat with a CAG repeat of non-
pathogenic length (An et al. 2012). In addition, increased TGFβ signalling has been 
identified in the hippocampus of a transgenic rat model of HD as well as in the R6/2 
mouse model, where it has an inverse effect on neural stem cell proliferation 
(Kandasamy et al. 2010). Currently, there is no evidence for the association of SMAD 
proteins with either HTT or mHTT. However, evidence is slowly mounting that supports 
dysregulation of this pathway in models of HD, suggesting that it could be a potentially 
interesting new target for research and therapeutics.  
 
In conclusion, we have identified differential gene expression responses to growth 
factor stimulation in StHdhQ111 cell lines, and have identified novel signalling pathways 
that may be implicated in HD-associated transcriptional dysregulation. This study also 
supports the plethora of other work identifying general transcriptional dysregulation in 
various models of HD, and in human HD striata (Crook & Housman 2011), as well as 
replicating some specific gene expression changes. By using an immortalised 
embryonic striatal cell model, we also demonstrate that transcriptional dysregulation 
is a very early event in the development of the HD phenotype. However, we have also 
highlighted the usefulness of utilising a dynamic model in order to investigate the 
effects of aberrant kinase signalling on downstream gene expression, which is 
particularly informative when considering altered mechanisms of transcriptional 
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regulation in models of HD. In this cell model, we have identified a panel of genes that 
exhibit an altered pattern of expression in response to EGF stimulation, the nature of 
which were consistent with the kinase activation responses identified in Chapter 4. 
This implied that there may be potentially aberrant control of TGFβ and SMAD 
signalling pathways in the presence of mHTT, which may prove to be a novel 
mechanism for the transcriptional dysregulation observed in this, and other models of 
HD. There is currently only modest support for the involvement of these pathways in 
HD, however when pooling the vast kinase signalling and transcriptional regulation 
data with these findings, it appears that this pathway may prove to be an interesting 
and worthwhile target for further investigation. 
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Chapter 6: Recapitulating the effects of EGF stimulation on huntingtin localisation,   
   kinase signalling pathways and transcriptional control in primary    
   embryonic striatal cells from the HdhQ111 and HdhQ150 mouse models of 
   HD. 
 
6.1 Introduction 
The HdhQ111 and HdhQ150 knock in mouse models are genetic recapitulations of HD, and 
as such have been thoroughly characterised and investigated (Wheeler 1999; Wheeler 
2000; Fossale et al. 2002; Ginés 2003; Carnemolla et al. 2009; Menalled et al. 2009; 
Molero et al. 2009; Saavedra et al. 2010; Fossale et al. 2011). The HdhQ111 mouse 
model consists of a human/mouse chimeric exon 1 of the Htt gene carrying an 
expanded CAG repeat that ranges between 97-114 CAGs, which is under the 
endogenous murine promoter (Wheeler 2000; Menalled et al. 2009).  
Despite the late onset of motor abnormalities in this model, HdhQ111/111 mice show 
progressive striatal abnormalities that predate any overt behavioural symptomology. 
These abnormalities can occur from a few months of age (Ginés et al. 2006); from 6 
weeks of age, a weak nuclear stain of mHTT can be detected in striatal cell nuclei 
(Wheeler 2000; Fossale et al. 2002), which progressively increases over time until a 
punctate nuclear signal is detectable by only 4.5 months (Wheeler 2000; Wheeler et al. 
2002). Strong nuclear reactivity and dark nuclear puncta are apparent from 10-15 
months in HdhQ111/111 mice (Wheeler 2000; Wheeler et al. 2002), which still predates 
development of the motor phenotype by around a year (Fossale et al. 2002). However, 
correlating with the appearance of nuclear puncta, there has been suggestion of some 
subtle reduction in the startle response in these mice at 52 weeks (Menalled et al. 
2009), which is consistent with the finding of subtle differences in cognition in human 
HD patients prior to motor symptom onset (Hahn-Barma et al. 1998; Lawrence et al. 
1998; Berrios et al. 2002; Snowden et al. 2002). In concordance, the genetically similar 
HdhQ92 mouse model exhibits impairments in operant conditioning learning tasks and 
deficits in visuomotor responding from 4-5 months old (Trueman et al. 2007; Trueman, 
Dunnett, et al. 2012; Trueman, Jones, et al. 2012). Also in accordance with the human 
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HD phenotype, HdhQ111/111 mice show a significant reduction in body weight by 28 
weeks (Menalled et al. 2009; van der Burg et al. 2009).  
Although increased nuclear HTT is associated with the pathogenesis of HD (DiFiglia 
1997; Gutekunst et al. 1999), there are also earlier neuronal changes that can be 
detected in HdhQ111/111 mice that occur prior to nuclear accumulation and aggregation 
of the mutant protein (Fossale et al. 2002; Ginés et al. 2003; Carnemolla et al. 2009; 
Molero et al. 2009; Fossale et al. 2011). For example, gene expression changes have 
been found to occur in HdhQ111/111 mice from 3-10 weeks, and in striatal neurons these 
changes have been associated with pathways such as the regulation of RNA 
metabolism and transcriptional/translational control (Fossale et al. 2011). Increased 
Rrs1 expression can be identified from only 3 weeks in HdhQ111/111 mouse striatum; a 
phenotype that worsens with age (Fossale et al. 2002), and several ER-stress 
associated markers have been found to have increased expression from only 15 weeks 
(Carnemolla et al. 2009), suggesting that prior to both overt motor symptoms and 
neuropathology, mHTT is able to elicit cellular dysregulation from a very early age in 
these mice. 
Neuronal dysfunction in HdhQ111/111 mice has also been identified in embryonic striatal 
primordia. For example, genes associated with embryonic brain maturation were more 
highly expressed between E13.5 and E15.5 in HdhQ111/111 mice (Molero et al. 2009), and 
there were deficits in neurogenesis, such as a delayed exit of the cell cycle. This was 
hypothesised to be due to either abnormal phase lengthening or transient arrest of the 
cell cycle (Molero et al. 2009). Together, these may alter striatal neuronal homeostasis 
and confer increased susceptibility to future insult by mHTT presence. This also 
suggests that mHTT is altering striatal neuronal activity prior to birth, and other 
dysfunctional processes that may also occur at this time point may help explain the 
specificity of striatal degeneration in HD, and the progression of the disease over time. 
The HdhQ150 mouse model of HD is genetically similar to the HdhQ111 model; however it 
does not have a chimeric exon 1, but rather consists of an expanded CAG fragment 
containing 150 CAG repeats knocked into the mouse Htt gene (Lin 2001). Despite their 
genetic similarities, the HdhQ150 model shows a more severe and progressive 
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phenotype (Lin 2001; Heng et al. 2007; Woodman et al. 2007). The original HdhQ150 
model was maintained on a mixed 129/Ola x C57Bl/J6 mouse strain background; in 
contrast to HdhQ111/111 mice, these mice exhibited clasping behaviour, rotarod deficits 
and motor disturbances  from 25-40 weeks in homozygote mice, and 40-65 weeks of 
age in heterozygotes (Lin 2001). These mice also suffered seizures from 25 weeks (Lin 
2001), but subsequent cohorts with altered background strains removed the seizure 
phenotype and delayed the progression of motor symptoms (Heng et al. 2007; 
Woodman et al. 2007; Brooks, Higgs, et al. 2012). In HdhQ150 models with an increased 
percentage of C57Bl/J6 lineage or a replacement of 129/Ola with a CBA background, 
motor abnormalities occurred later from 70-100 weeks (Heng et al. 2007; Woodman et 
al. 2007; Brooks, Higgs, et al. 2012), which is more comparable with the HdhQ111 
phenotype.  
In accordance with cognitive deficits being found to precede motor abnormalities in 
HdhQ111 mice, a similar phenotype has also been uncovered in the HdhQ150 model. 
HdhQ150 mice perform less well in a set-shifting task from 24 weeks, which consists of 
mice being required to switch previously learned cue-reward associations (Brooks et al. 
2006); a cognitive phenotype also observed in human HD patients (Lawrence et al. 
1998). HdhQ150 mice also had an increased latency to finding a hidden platform in the 
Morris water maze task from 4 months old, due to a reduced ability to efficiently 
navigate (Brooks, Higgs, et al. 2012).  
The HdhQ150 model also develops neuropathological features prior to motor and 
cognitive abnormality onset (Woodman et al. 2007; Weiss et al. 2008; Bayram-Weston 
et al. 2012), although to date, earlier neuronal dysfunction in this model has not yet 
been investigated. The transcriptional profile of 15-22 month old HdhQ150/150 mice has 
been found to correlate well with human HD caudate as well as with other transgenic 
mouse models of HD (Kuhn et al. 2007), although earlier developmental time points 
have not yet been investigated. However, as transcriptional changes are concordant 
between mouse models of HD, this suggests that the nature of the changes may be 
mechanistically similar, and therefore early transcriptional changes may also exist in 
HdhQ150/150 mice.  
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Similarities between the immortalised StHdhQ111 and HdhQ111 mouse models have been 
observed previously; both have been found to have decreased cyclic adenosine 
monophosphate (cAMP) responsive element-mediated gene transcription (Ginés 
2003), and display markers of the endoplasmic reticulum stress response (Carnemolla 
et al. 2009). In addition, increased AKT activation has also been identified in both 
models; a phenotype that is present prior to overt motor abnormalities (Ginés et al. 
2003; Saavedra et al. 2010). In this chapter, we aim to replicate the localisation, 
signalling and transcriptional data that was observed in the StHdhQ111 cell model in 
Chapters 3-5 in primary striatal cells from E14 HdhQ111 mice in order to determine 
whether our findings were a result of the nature of the immortalised cell model, or if 
the presence of mHTT can elicit early embryonic changes in striatal neurons. In 
addition, where possible, we have aimed to repeat the experiments in primary E14 
HdhQ150 striatal cells to determine if the results may be generalizable to longer polyQ 
length models of HD.  
 
6.2 The effect of EGF stimulation on the localisation of N-terminal HTT epitopes in 
primary HdhQ111 striatal cells  
Striatal cells were dissected from E14 HdhQ111 and HdhQ150 mouse model embryos, the 
details of which can be found in Section 2.2.1.4. In order to confirm the presence of 
striatal cells in primary cell cultures, a typical selection of cells was immunostained 
with antibodies against striatal cell markers dopamine- and cAMP-regulated neuronal 
phosphoprotein (DARPP-32) and CTIP2 (Figure 6.1), both of which have been identified 
as being expressed specifically in medium spiny neurons, and are commonly used 
markers in the current literature (Slow 2003; Carri et al. 2013; Taylor et al. 2013). The 
proportion of striatal to non-striatal cells was then determined (Table 6.1). The 
majority of cells present in dissections were labelled with striatal markers, and 
therefore the following experiments were considered to reflect the characterisation of 
a striatal cell population. In the images that have been presented representing CTIP2 
and DARPP-32 co-localisation, the HdhQ111/111 cells are considerably smaller than the 
HdhQ150/150 cells. This may be due to the number of surviving cells in culture; 
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HdhQ111/111 cells were more densely plated on this occasion due to reduced cell death. 
In addition, these experiments were separated by a large period of time, and therefore 
variance in batches of serum and media, as well as any uncontrollable environmental 
changes during dissection and culture may have contributed to different cellular 
morphologies. However, in both cell lines, the localisation of both DARPP-32 and CTIP2 
is predominantly nuclear. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hdh
Q111/111
 
DARPP-32 
CTIP2 
Overlay 
 Hdh
Q150/150
 
Figure 6.1 The co-localisation of striatal cell markers DARPP-32 and CTIP2 in primary 
E14 striatal cells cultured from Hdh
Q111/111
 and Hdh
Q150/150
 mice. Scale bar = 20µm. 
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Total no. cells 
No. cells negative for 
striatal markers  
% Striatal cells 
Hdh
Q111
 891 55 93.83 
        
Hdh
Q150
 202 7 96.53 
 
 
 
 
 
 
 6.2.1 Confirming the presence of the EGFR in HdhQ111 cells 
Immunofluorescence analysis revealed that the EGFR was present and had the same 
subcellular localisation in primary striatal cells from all three genotypes; HdhQ7/7, 
HdhQ7/111 and HdhQ111/111 (Figure 6.2).  Western blot analysis suggests that there may 
be a trend towards reduced levels of the EGFR in HdhQ7/111 and HdhQ111/111 cells, 
although this difference does not reach significance.   
 
 
 
 
 
Table 6.1 The percentage of cells immunostained with striatal cell markers DARPP-
32 and CTIP2 from a selection of primary cells dissected from E14 striata of Hdh
Q111 
and Hdh
Q150 
HD knock in mice. Cell numbers were counted from 3 fields of view 
selected at random on 4 individual coverslips representing at least one coverslip 
from each genotype. The majority of cells were stained with the appropriate 
markers, suggesting that dissected cell populations represented mouse striatal 
primordia. 
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 6.2.2 Immunostaining with Ab109115 and Mab2166 
Primary striatal cells were double labelled with Ab109115 and Mab2166, and were 
analysed blind to genotype and time of EGF stimulation in the same manner as 
previously described (Section 2.2.1.10). 
  6.2.2.1 Ab109115 
Ab109115 displayed a similar localisation of HTT in primary embryonic striatal cells as 
in StHdhQ111 cell lines (Section 3.3.5); it was primarily perinuclear in all three 
Figure 6.2 A. Immunofluorescence images of primary E14 striatal cells from the 
Hdh
Q111 
mouse model of HD immunostained for the EGFR. Scale bar = 20μm B. 
Western blot identifying EGFR expression in Hdh
Q7/7
, Hdh
Q7/111
 and Hdh
Q111/111
 
primary embryonic striatal cells. C. Licor Odyssey quantification of fluorescence 
intensity (FI) in B; EGFR is normalised to α-tubulin loading control. (Error bars = 
SEM, n=3) 
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genotypes, although this appeared to be more densely stained in HdhQ111/111 cells, 
despite no apparent increase in nuclear localisation (Figures 6.3 & 6.4). Main effects 
analysis revealed that there was a significant effect of time of EGF stimulation on the 
N/C ratio in HdhQ111 primary embryonic striatal cells (F (3, 571) = 3.526, p=0.015), but 
only a trend towards a significant effect of genotype (p=0.059), and no significant 
interaction between the two (p>0.05). Simple main effects revealed that there were no 
significant differences between individual genotypes for the N/C ratio, and the 
significant effect of EGF stimulation came from a significant difference between 5 and 
30 minutes (p=0.013), and a trend towards a difference between 0 and 30 minutes of 
stimulation (p=0.091).  Post-hoc Tukey tests revealed that there was no difference in 
the N/C ratio for either HdhQ7/111 and HdhQ111/111 cells, however there was a significant 
difference in HdhQ7/7 cells between 5 and 30 minutes (p=0.004) and 15 and 30 minutes 
(p=0.05). These differences arise due to a slight reduction in nuclear HTT in HdhQ7/7 
cells at 5 minutes of EGF stimulation, and an increase in nuclear HTT at 30 minutes. 
However, this is not seen in cells carrying mHTT, suggesting a suppressed response to 
EGF stimulation.  
There was a significant main effect of genotype when analysing the N/P ratio (F (2, 
571) = 12.744, p<0.001), although there was no effect of EGF stimulation, or an 
interaction between the two. Across time points, the N/P ratio was significantly 
different between HdhQ7/7 and HdhQ111/111 cells (p<0.001) and between HdhQ7/111 and 
HdhQ111/111 cells (p=0.012), but there was no difference between HdhQ7/7 and HdhQ7/111 
cells, indicating that for the localisation of nuclear and perinuclear HTT, heterozygote 
cell types are more similar to wild type cells than HdhQ111/111 cells, perhaps suggesting a 
gene dosage effect. Similar to the N/C ratio analyses, there was no effect of EGF 
stimulation on the N/P ratio for HdhQ7/111 or HdhQ111/111 cells; however, there was a 
significant reduction in the N/P ratio in HdhQ7/7 cells at 5 minutes of stimulation 
(p=0.017). There was also a significant difference between 5 and 30 minutes of EGF 
stimulation (p<0.000), which reflects the increase in nuclear HTT that was also 
observed in the N/C ratio. In contrast, there was no significant effect of the P/C ratio at 
any time of EGF stimulation, or for any genotype. 
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Figure 6.4 Quantitative analysis of immunofluorescence images in Figure 6.3. 
Nuclear/Cytoplasmic (N/C),  Nuclear/Perinuclear (N/P) and Perinuclear/Cytoplasmic 
(P/C) mean pixel intensity ratios for Hdh
Q7/7
, Hdh
Q7/111
 and Hdh
Q111/111 
primary 
embryonic striatal cells following 0, 5, 15 and 30 minutes of stimulation with 
100ng/ml EGF. Mean pixel intensities were calculated from confocal microscopy 
images using GNU Image Manipulator (further details of the analysis can be found 
in Section 2.2.1.10). All images were randomised and analysed blind to genotype 
and length of time stimulated with EGF. Each condition consisted of 1 confocal 
microscopy image taken from 4-5 separate embryos of each genotype. A two-way 
ANOVA was carried out for main effects analysis, followed by planned one way 
ANOVAs and post-hoc Tukey tests.  Error bars = SEM 
* p<0.05  ** p<0.01 *** p<0.001 
N
/C
 p
ix
el
 in
te
n
si
ty
 r
at
io
 
Hdh
Q7/7
 Hdh
Q7/111
 Hdh
Q111/111
 
N
/P
 p
ix
el
 in
te
n
si
ty
 r
at
io
 
Hdh
Q7/7
 Hdh
Q7/111
 Hdh
Q111/111
 
* 
0
0.5
1
1.5
2
2.5
P
/C
 p
ix
el
 in
te
n
si
ty
 r
at
io
 
Hdh
Q7/7
 Hdh
Q7/111
 Hdh
Q111/111
 
300 
 
6.2.2.2 Mab2166 
The localisation of the HTT epitope detected by Mab2166 was primarily perinuclear in 
HdhQ7/7, HdhQ7/111 and HdhQ111/111 cells, as observed in immortalised striatal cell lines 
(Section 3.3.4.3), and was less present in the cytoplasm and cell processes in 
HdhQ111/111 cells (Figures 6.5 & 6.6). An overlay of both Ab109115 and Mab2166 can be 
found in Figure 6.7. There was a significant effect of genotype in the N/C ratio (F (2, 
668) = 3.879, p=0.021), which simple main effects analysis revealed to be due to a 
significantly higher N/C ratio over time in HdhQ7/111 compared to HdhQ111/111 cells 
(p=0.016). Post-hoc Tukey tests indicate a significant reduction in the N/C ratio in 
HdhQ7/7 cells after 5 minutes of EGF stimulation (p=0.025), but there were no 
significant effects for either mHTT genotypes. 
In concordance with the epitope of HTT detected by Ab109115, the majority of 
significant effects of EGF stimulation and genotype were apparent in the N/P ratio for 
Mab2166. There was a significant main effect of EGF (F (3, 668) = 2.676, p=0.046), and 
although the genotype effect failed to reach significance, there was a significant 
interaction with EGF stimulation (F (6, 668) = 3.004, p=0.007). This was due to a 
significant reduction in the N/P ratio in HdhQ7/7 cells after 5 minutes (p=0.004) and 15 
minutes (p=0.002) of EGF stimulation, but no effects in either HdhQ7/111 or HdhQ111/111 
cells, suggesting an inhibited response of HTT localisation in the presence of mHTT. 
Similar to Ab109115, there was no significant main effect of either genotype or EGF 
stimulation in the P/C ratio. 
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Figure 6.6 Quantitative analysis of immunofluorescence images in Figure 6.5. 
Nuclear/Cytoplasmic (N/C),  Nuclear/Perinuclear (N/P) and Perinuclear/Cytoplasmic 
(P/C) mean pixel intensity ratios for Hdh
Q7/7
, Hdh
Q7/111
 and Hdh
Q111/111 
primary 
embryonic striatal cells following 0, 5, 15 and 30 minutes of stimulation with 
100ng/ml EGF. Mean pixel intensities were calculated from confocal microscopy 
images using GNU Image Manipulator (further details of the analysis can be found 
in Section 2.2.1.10). All images were randomised and analysed blind to genotype 
and length of time stimulated with EGF. Each condition consisted of 1 confocal 
microscopy images taken from 4-5 separate coverslips. A two-way ANOVA was 
carried out for main effects analysis, followed by planned one way ANOVAs and 
post-hoc Tukey tests.  Error bars = SEM 
* p<0.05  ** p<0.01 *** p<0.001 
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6.2.3 Supporting HTT localisation results using additional N-terminal antibody, 
N17 
As antibody stocks of both Ab675 and N17 were low and the number of available 
HdhQ111 embryos was restricted, it was not possible to immunostain sufficient numbers 
of coverslips for statistical analysis. However, enough reagents were available to 
identify if there may be a qualitative trend towards similar patterns of HTT localisation 
as detected by amino acid 1-17 antibodies in HdhQ111 cells as in StHdhQ111 cell lines.  
Consistent with previous observations when using Ab675 and N17, HTT localisation is 
more nuclear than when it is detected with either Ab109115 or Mab2166 (Section 
3.3.5). Examples of the detection of the localisation of HTT by Ab675 can be found in 
Appendix V. In contrast, there is no obvious effect of EGF stimulation on the epitope of 
HTT detected by N17 (Figure 6.8), but there was stronger nuclear detection with 
increased mHTT load at 0 minutes. Despite the lack of effect, this is in accordance with 
the findings in StHdhQ111 cell lines following EGF stimulation when HTT was detected by 
N17 (Appendix II).  
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6.3 The effect of EGF stimulation on the localisation of N-terminal HTT epitopes in 
primary HdhQ150 cells 
In order to determine whether alterations in HTT localisation in response to EGF 
stimulation only occurred in cells derived from the HdhQ111 mouse model, the 
localisation experiments were repeated in primary embryonic striatal cell cultures 
from E14 HdhQ150 mice. 
 6.3.1 Confirming the presence of the EGFR 
HdhQ7/7, HdhQ7/150 and HdhQ150/150 cells were immunostained for the EGFR in order to 
determine if all three genotypes expressed the receptor to the same extent (Figure 
6.9). All cells expressed the EGFR and there were no qualitative differences between 
genotypes. This was confirmed by western blot; there was no significant difference in 
the quantification of EGFR expression by this method. 
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 6.3.2 Immunostaining with Ab109115 and Mab2166 
HdhQ150 cells were treated in the same manner as described in section 6.2.2. 
  6.3.2.1 Ab109115 
The HTT epitope detected by Ab109115 had a primarily perinuclear localisation in 
HdhQ7/7 cells from the HdhQ150 model (Figures 6.10 & 6.11), in accordance with 
previous observations in wild type cells from the HdhQ111 mouse model and StHdhQ7/7 
cells (Sections 3.3.5 & 6.2.2.1). However, in both HdhQ7/150 and HdhQ150/150 cells, 
detection of this epitope of HTT was more nuclear than in models expressing a shorter 
Figure 6.9 A. Immunofluorescence images of primary E14 striatal cells from the 
Hdh
Q150 
mouse model of HD immunostained for the EGFR. Scale bar = 20μm B. 
Western blot identifying EGFR expression in Hdh
Q7/7
, Hdh
Q7/150
 and Hdh
Q150/150
 
primary embryonic striatal cells. C. Licor Odyssey quantification of fluorescence 
intensity (FI) in B; EGFR is normalised to α-tubulin loading control. (Error bars = 
SEM, n=3) 
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polyQ repeat. This is reflected in the significant main effect of cell type in N/C (F (2, 
772) = 7.966, p<0.001), N/P (F (2, 772) = 46.492, p<0.001) and P/C ratios (F (2, 772) = 
23.831, p<0.001). There were also significant differences in the simple main effects 
between individual genotypes for all three ratios (all p<0.017), with the exception of 
between HdhQ7/150 and HdhQ150/150 cells in the N/C ratio; this suggests that although 
there may be a gene dosage effect in the localisation of HTT as measured by N/P and 
P/C ratios, the increased nuclear localisation is a dominant effect of the expanded 
polyQ.   
There was a main effect of EGF stimulation in the N/C ratio (F (3, 772) = 22.779, 
p<0.001), however there was no interaction with genotype. This is due to all three 
genotypes exhibiting a significant increase in nuclear HTT and a reduction in 
cytoplasmic HTT (HdhQ7/7 (p=0.001), HdhQ7/150 (p=0.005) and HdhQ150/150 (p<0.001)) by 
30 minutes of EGF stimulation. There was also a significant main effect of EGF 
stimulation in the N/P ratio (F (3, 772) = 23.961, p<0.001), and a significant interaction 
with genotype (F (6, 772) = 2.717, p=0.013). Post-hoc Tukey tests revealed that this is 
due to differential patterns of HTT localisation following EGF stimulation in the N/P 
ratio; at 5 minutes of stimulation, there was a significant reduction of nuclear HTT in 
HdhQ7/7 cells (p=0.031), as has been observed previously following EGF stimulation 
(Sections 3.3.5 & 6.2.2.1). In contrast, this does not occur in cells carrying mHTT, but 
there is a significant increase in nuclear HTT compared to the perinucleus by 30 
minutes in both HdhQ7/150 and HdhQ150/150 cells.  Finally, despite a significant main effect 
of EGF stimulation (F (3, 772) = 3.02, p=0.029) and a significant EGF x genotype 
interaction (F (6, 772) = 2.296, p=0.033) in the P/C ratio, there were no significant 
differences between individual time points for any genotype when analysed with post-
hoc Tukey tests, suggesting that in response to EGF stimulation, translocation occurs 
primarily between nuclear and perinuclear regions. 
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Figure 6.11 Quantitative analysis of immunofluorescence images in Figure 6.10. 
Nuclear/Cytoplasmic (N/C),  Nuclear/Perinuclear (N/P) and Perinuclear/Cytoplasmic 
(P/C) mean pixel intensity ratios for Hdh
Q7/7
, Hdh
Q7/150
 and Hdh
Q111/150 
primary 
embryonic striatal cells following 0, 5, 15 and 30 minutes of stimulation with 
100ng/ml EGF. Mean pixel intensities were calculated from confocal microscopy 
images using GNU Image Manipulator (further details of the analysis can be found 
in Section 2.2.1.10). All images were randomised and analysed blind to genotype 
and length of time stimulated with EGF. Each condition consisted of 1 confocal 
microscopy image taken from 4-5 separate embryos of each genotype. A two-way 
ANOVA was carried out for main effects analysis, followed by planned one way 
ANOVAs and post-hoc Tukey tests.  Error bars = SEM 
* p<0.05  ** p<0.01 *** p<0.001 
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  6.3.2.2 Mab2166 
In accordance with previous observations (Sections 3.3.4.3 & 6.2.2.2), Mab2166 labels 
primarily a perinuclear epitope of HTT in HdhQ150 primary cell lines, however in 
contrast to labelling with Ab109115 in Section 6.3.2.1, there was increased nuclear 
localisation of this HTT epitope in HdhQ150/150 cells only (Figures 6.12 & 6.13). 
Accordingly, there was a significant main effect of genotype in the N/C ratio (F (2, 699) 
= 14.106, p<0.001), and simple main effects suggest a trend towards differential HTT 
localisation between HdhQ7/7 and HdhQ7/150 cells (p=0.053), but both HdhQ7/7 and 
HdhQ7/150, and HdhQ7/150 and HdhQ150/150 cells were significantly different from each 
other (p=0.011 & p<0.001, respectively). However, although there was no main effect 
of EGF stimulation, there was a significant interaction with genotype (F (6, 699) = 
3.565, p=0.002). Post-hoc Tukey tests indicate that this was due to a significant 
reduction in nuclear HTT in HdhQ7/7 cells at 15 minutes of EGF stimulation (p=0.013), 
but no effects in the other two genotypes, suggesting a suppressed response in these 
cells due to mHTT. An overlay of both Mab2166 and Ab109115 can be found in Figure 
6.14, where the increased nuclear localisation of the N-terminal epitope detected by 
Ab109115 is particularly evident in comparison to the primarily perinuclear Mab2166. 
There was a significant main effect of genotype (F (2, 699) = 50.882, p<0.001), EGF 
stimulation (F (3, 699) = 3.337, p=0.019), and a significant interaction between the two 
(F (6, 699) = 4.872, p<0.001) for the N/P ratio. Simple main effects analysis showed 
that all three genotypes were significantly different to each other (all p<0.04). There 
was a small reduction in the N/P ratio for HdhQ7/7 cells at 30 minutes from 5 minutes of 
EGF stimulation (p=0.025), but interestingly, the most significant effects were 
observed in HdhQ7/150 cells; there was a significant increase in the N/P ratio at 5 
minutes (p=0.018) and again at 30 minutes (p=0.002), although this appeared to be 
due to a reduction in perinuclear intensity rather than an increase in nuclear HTT. 
Finally, there was a significant effect of genotype for the P/C ratio (F (2, 699) = 4.211, 
p=0.015), although there was only a significant difference between HdhQ7/7 and 
HdhQ150/150 cells when looking at simple main effects, suggesting a gene dosage effect. 
There was no significant effect of EGF stimulation, but there was a significant 
interaction with genotype (F (6, 669) = 2.266, p=0.036); however post-hoc analyses do 
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not identify any individual significant differences in the P/C over time in any of the 
three genotypes. 
6.3.3 Supporting HTT localisation results using additional N-terminal antibodies,   
Ab675 and N17 
A selection of HdhQ150 primary cells were immunostained with two antibodies raised 
against amino acids 1-17 of HTT in order to compare the pattern of localisation in 
response to EGF stimulation with previous observations (Sections 3.3.3.3, 6.2.3 & 
Appendix II). Quantitative analysis could not be carried out for reasons described 
previously (Section 6.2.3). 
The localisation of HTT epitopes detected by Ab675 can be found in Appendix VI. In 
comparison to previous observations when visualising HTT using the N17 antibody 
(Appendix II & 6.2.3), there is a slight reduction the nuclear epitope of HTT detected by 
N17 in both HdhQ7/150 and HdhQ150/150 cells at 30 minutes of stimulation (Figure 6.15). 
However, there is no apparent effect in HdhQ7/7 cells, which is a pattern that is more 
comparable to the previous data. In this case, detection by N17 presents with a 
spotted signal in these images, however as there is no consistent pattern of their 
localisation, and they are apparent in both the cell body and extracellular space, it is 
most likely that these are an artefact of non-specific antibody binding, possibly due to 
minor variations in cell fixation or due to re-use of the primary antibody over several 
samples. 
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Figure 6.13 Quantitative analysis of immunofluorescence images in Figure 6.12. 
Nuclear/Cytoplasmic (N/C),  Nuclear/Perinuclear (N/P) and Perinuclear/Cytoplasmic 
(P/C) mean pixel intensity ratios for Hdh
Q7/7
, Hdh
Q7/150
 and Hdh
Q150/150 
primary 
embryonic striatal cells following 0, 5, 15 and 30 minutes of stimulation with 
100ng/ml EGF. Mean pixel intensities were calculated from confocal microscopy 
images using GNU Image Manipulator (further details of the analysis can be found 
in Section 2.2.1.10). All images were randomised and analysed blind to genotype 
and length of time stimulated with EGF. Each condition consisted of 1 confocal 
microscopy images taken from 4-5 separate coverslips. A two-way ANOVA was 
carried out for main effects analysis, followed by planned one way ANOVAs and 
post-hoc Tukey tests.  Error bars = SEM 
* p<0.05  ** p<0.01 *** p<0.001 
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6.4 The localisation of a double phosphorylated epitope of HTT in response to EGF 
stimulation in HdhQ111 and HdhQ150 primary cells 
In order to determine the effect of EGF stimulation on the localisation of 
phosphorylated HTT epitopes, primary E14 striatal cultures from HdhQ111 and HdhQ150 
models were immunostained with the N17 s1316p antibody (see Table 2.1 and Section 
3.4.3 for further details). The initial single anti-phosphorylated S13p and double anti-
phosphorylated s1316p HTT antibodies were not available in order to try and replicate 
the findings from immortalised striatal cell cultures (Sections 3.4.1.3 &3.4.2.3).  
6.4.1 The localisation of HTT phosphorylated on S13 and S16 in HdhQ111 primary 
cell cultures. 
In HdhQ7/7 cells, phosphorylated HTT is primarily cytoplasmic, whereas in HdhQ7/111 cells 
there is an increased intensity of nuclear staining, and HdhQ111/111 cells have a strong 
perinuclear signal (Figures 6.16 & 6.17), which is a similar pattern of localisation as 
seen in the immortalised striatal cell lines (Section 3.4.3). There is also a strong 
detection signal in the cell processes and at the plasma membrane; this also occurred 
in the StHdhQ111 cells when using the same antibody (Section 3.4.3), although it was 
not apparent to the same extent as in primary cell lines. 
There was a significant main effect of genotype in the N/C (F (2, 415) = 11.794, 
p<0.001), N/P (F (2, 415) = 11.544, p<0.001,) and P/C ratios (F (2, 415) = 5.437, 
p=0.005). However, although there was a significant simple main effect between all 
three individual genotypes in the N/C ratio (all p<0.001), for the N/P and P/C ratios, 
the difference between HdhQ7/111 and HdhQ111/111 cells was not significant, suggesting a 
dominant mutant gene effect. There was a significant main effect of EGF stimulation 
on the N/C ratio (F (3, 415) = 10.795, p<0.001) and a significant interaction with 
genotype (F (6, 415) = 7.87, p<0.001), which was due to an increase in nuclear HTT 
phosphorylated on S13 and S16 in HdhQ7/7 cells at 5 minutes (p<0.001) and 15 minutes 
(p<0.001) of EGF stimulation; this increase in nuclear S1316p HTT was also observed in 
immortalised striatal StHdhQ7/7 cells  (Section 3.4.3), although at a later time point. In 
contrast to the StHdhQ111 cell lines, there was no effect of EGF stimulation on the N/C 
ratio in HdhQ7/111 cells. However, there was a significant increase in nuclear 
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phosphorylated HTT in HdhQ111/111 cells from 5 minutes of EGF stimulation (p=0.005), 
which persisted for up to 30 minutes of EGF stimulation (p=0.002); this was not 
observed in immortalised cell lines.  
The N/P ratio showed the same pattern of localisation as the N/C ratio; there was a 
significant main effect of EGF stimulation (F (3, 415) = 11.276, p<0.001) and a 
significant interaction with genotype (F (6, 415) = 9.452, p<0.001). This was due to the 
same increase in nuclear phosphorylated HTT in HdhQ7/7 cells detected in the N/C ratio 
at 5 (p=0.001) and 15 minutes (p<0.001). Again, there was no effect of EGF stimulation 
in HdhQ7/111 cells, but there was a significant increase in HdhQ111/111 cells at 5 (p=0.001), 
15 (p<0.001) and 30 minutes (p=0.002) of EGF stimulation. Finally, there was no effect 
of EGF on the P/C ratio, or an interaction with genotypes, and there were no significant 
differences between each genotype at individual time points. 
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Figure 6.17 Quantitative analysis of immunofluorescence images in Figure 6.16. 
Nuclear/Cytoplasmic (N/C),  Nuclear/Perinuclear (N/P) and Perinuclear/Cytoplasmic 
(P/C) mean pixel intensity ratios for Hdh
Q7/7
, Hdh
Q7/111
 and Hdh
Q111/111 
primary 
embryonic striatal cells following 0, 5, 15 and 30 minutes of stimulation with 
100ng/ml EGF. Mean pixel intensities were calculated from confocal microscopy 
images using GNU Image Manipulator (further details of the analysis can be found 
in Section 2.2.1.10). All images were randomised and analysed blind to genotype 
and length of time stimulated with EGF. Each condition consisted of 1 confocal 
microscopy images taken from 4-5 separate coverslips. A two-way ANOVA was 
carried out for main effects analysis, followed by planned one way ANOVAs and 
post-hoc Tukey tests.  Error bars = SEM 
* p<0.05  ** p<0.01 *** p<0.001 
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6.4.2 The localisation of HTT phosphorylated on S13 and S16 in HdhQ150 primary 
cell cultures 
The pattern of localisation of phosphorylated HTT epitopes in HdhQ150 primary cultures 
differs substantially from HdhQ111 cultures, and appeared to be considerably more 
variable (Figures 6.18 & 6.19). Initially, the localisation of phosphorylated HTT was 
more nuclear in HdhQ7/7 cells than it was previously in the HdhQ111 model (Section 
6.4.1). However, there is still increased detection of this epitope in the nucleus with 
mHTT load. In concordance with this, there was a significant effect of genotype in the 
N/C (F (2, 462) = 5.276, p=0.005), N/P (F (2, 462) = 2.987, p=0.05), and P/C ratios (F (2, 
462) = 4.171, p=0.016). There was no effect of EGF in the N/C ratio, however there was 
a significant interaction with genotype (F (6, 462) = 2.952, p=0.008), which was a result 
of a significant reduction in the N/C ratio in HdhQ7/150 cells at 15 minutes of stimulation 
(p=0.045), compared with a large increase in the ratio in HdhQ150/Q150 at 30 minutes 
(p=0.006), and no effect in HdhQ7/7 cells.  
In contrast, there was a significant main effect of EGF in the N/P ratio (F (3, 462) = 
4.072, p=0.007), as well as a significant interaction with genotype (F (6, 462) = 3.113, 
p=0.005). There was a gradual increase in nuclear phosphorylated HTT in HdhQ7/7 cells 
over time, but this only reaches significance by 30 minutes of EGF stimulation 
(p=0.045), whereas there was no effect in HdhQ7/150 cells, and a significant increase in 
HdhQ150/150 cultures by only 5 minutes of EGF stimulation (p=0.013). This increase 
appears to be sustained for the full 30 minutes of stimulation, but does not maintain 
significance from baseline.  
For the P/C ratio, there is a significant main effect of EGF stimulation (F (3, 462) = 
2.864, p=0.036), but there is no significant interaction with genotype. Interestingly, 
there is again no significant effect in HdhQ7/7 cells, and there are opposing effects in 
HdhQ7/150 and HdhQ150/150 cells; there is a reduction in the P/C ratio in HdhQ7/150 cells at 
15 minutes (p=0.036) and an increase in HdhQ150/150 cells at 30 minutes (p=0.018).  
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Figure 6.19 Quantitative analysis of immunofluorescence images in Figure 6.18. 
Nuclear/Cytoplasmic (N/C),  Nuclear/Perinuclear (N/P) and Perinuclear/Cytoplasmic 
(P/C) mean pixel intensity ratios for Hdh
Q7/7
, Hdh
Q7/150
 and Hdh
Q150/150 
primary 
embryonic striatal cells following 0, 5, 15 and 30 minutes of stimulation with 
100ng/ml EGF. Mean pixel intensities were calculated from confocal microscopy 
images using GNU Image Manipulator (further details of the analysis can be found 
in Section 2.2.1.10). All images were randomised and analysed blind to genotype 
and length of time stimulated with EGF. Each condition consisted of 1 confocal 
microscopy images taken from 4-5 separate coverslips. A two-way ANOVA was 
carried out for main effects analysis, followed by planned one way ANOVAs and 
post-hoc Tukey tests.  Error bars = SEM 
* p<0.05  ** p<0.01 *** p<0.001 
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6.5 Transcriptional dysregulation in primary embryonic striatal cell cultures 
In order to determine if the transcriptional profile of the StHdhQ111 cell model is 
comparable to primary cell models, the expression of a selection of differentially 
expressed genes that were identified in Chapter 5 were also investigated in primary 
E14 striatal cell cultures from HdhQ111 and HdhQ150 mouse models. 
6.5.1 Transcriptional dysregulation in HdhQ111 primary striatal cells 
6.5.1.1 Genes with increased expression fold changes in StHdhQ7/7 cells 
following EGF stimulation 
Of the list of genes that had a larger transcriptional response following EGF stimulation 
in StHdhQ7/7 cells, four were investigated in HdhQ111 mouse model primary cells; a 
summary of the expression fold changes of these genes in response to EGF are 
presented in Table 6.2, and the full figures can be found in Appendix VII. In accordance 
with the effect seen in StHdhQ7/7 cells (Section 5.2.3.2c), there was a significant effect 
of EGF stimulation on Fgf2 expression (F (1, 24) = 18.514, p<0.001), although this did 
not retain significance following post-hoc analysis .There was a trend towards an 
enhanced Fgf2 expression response in HdhQ7/7 cells compared to both HdhQ7/111 and 
HdhQ111/111, as the increase in expression just failed to reach significance in HdhQ7/7 
cells (p=0.061), but the magnitude of response was smaller in both HdhQ7/111 and 
HdhQ111/111 cells. In contrast to the immortalised cell model, where EGF stimulation 
elicited a significant response of Myc expression in StHdhQ7/7 cells only, there was a 
significant effect of EGF stimulation on the expression of Myc in all three primary cell 
genotypes; HdhQ7/7 (p=0.003), HdhQ7/111 (p=0.009) and HdhQ111/111 cells (p=0.002). There 
was a significant main effect of genotype (F (2,24) = 3.561, p=0.044), suggesting that 
there was a trend towards an increased response in HdhQ7/111 and HdhQ111/111 cells, but 
this did not withstand post-hoc testing.  
There was a significant effect of both genotype (F (2, 24) = 8.251, p=0.002) and EGF 
stimulation (F (1, 24) = 10.719, p=0.003) on the expression of Smad7, as well as a 
significant interaction between the two (F (2, 24) = 5.835, p=0.009). Although there 
was no increase in Smad7 expression following EGF stimulation in HdhQ7/7 cells as there 
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was in StHdhQ7/7 cells (Section 5.2.3.2c), the expression of Smad7 in HdhQ111/111 cells 
was significantly lower than both HdhQ7/7 (p<0.001) and HdhQ7/111 cells (p=0.008) at 
baseline. However, unlike the pattern observed in StHdhQ111 cells, there was a 
significant increase in Smad7 expression in HdhQ111/111 cells following EGF stimulation 
(p=0.001), although this did not bring Smad7 expression up to the same level as in 
HdhQ7/7 and HdhQ7/111 cells. Despite the lack of response to EGF stimulation, the 
suppressed expression of Smad7 in the presence of mHTT in HdhQ111/111 cells is 
consistent with reduced expression also observed in the StHdhQ111 cell model. There 
was no effect of either genotype or EGF stimulation on the expression of Sox9. 
6.5.1.2 Genes with larger expression fold changes in StHdhQ111/111 cells 
following EGF stimulation 
Four genes from the list with a larger expression change in StHdhQ111/111 cells following 
EGF stimulation (Section 5.2.3.2c) were investigated in primary cells from the HdhQ111 
mouse model; a summary of the expression fold changes of these genes in response to 
EGF are presented in Table 6.2, and the full figures can be found in Appendix VII. All 
three genotypes exhibited a significant increase in the expression of Atf3 in response 
to EGF stimulation (all p<0.001), and there was a trend towards higher expression in 
both HdhQ7/111 and HdhQ111/111 cells compared to HdhQ7/7 cells, although this did not 
reach significance. However, when calculating the fold change from each individual 
genotypic baseline, the expression fold change of Atf3 in HdhQ111/111 cells was twice as 
large as in HdhQ7/7 cells following EGF stimulation, suggesting a trend towards a larger 
response in mutant cells. 
Although there was no effect of EGF stimulation on HdhQ111 cells, there was a 
significant effect of genotype (F (2, 24) = 5.021, p=0.015) on Id3 expression, and a 
significant interaction with EGF stimulation (F (2, 24) = 4.74, p=0.018). The baseline 
level of Id3 expression was significantly lower in HdhQ111/111 cells compared to both 
HdhQ7/7 (p=0.005) and HdhQ7/111 cells (p=0.031). This is in contrast to the large 
reduction in Id3 expression following EGF stimulation in StHdhQ111/111 cells (Section 
5.2.3.2c), although is consistent with the phenotype of suppressed Id3 expression in 
the presence of mHTT. 
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The expression of Egr1 was significantly increased in all three genotypes following EGF 
stimulation (all p<0.001), which, similar to Atf3, resulted in a trend towards higher 
expression in HdhQ111/111 cells, although this did not reach significance. Similarly, EGF 
stimulation significantly increased Fosl1 expression in all three genotypes (all p<0.001), 
but despite a trend towards a stronger transcriptional effect in both HdhQ7/111 and 
HdhQ111/111 cells, this was not significantly different to HdhQ7/7 Fosl1 expression. 
The expression of Gadd45g, Cdc42ep3 and Rasa1 were also examined in HdhQ111 
primary cells, as in the StHdhQ111 cell model these exhibited changes in expression 
following EGF stimulation in StHdhQ111/111 cells only (Section 5.2.3.2c). However, there 
was no significant effect of either genotype or EGF stimulation on the expression of 
any of these genes.  
 
 
Fold change following EGF stimulation 
 
Hdh
Q7/7
 Hdh
Q7/111
 Hdh
Q111/111
 
Fgf2 2.17 1.56 1.18 
Myc 1.61 ** 2.43 ** 2 ** 
Smad7 1.08 0.88 1.38 ** 
Sox9 0.85 1.27 0.88 
 
   
Atf3 14 *** 20 *** 30 *** 
Id3 0.31 0.48 1.47 
Fosl1 42.41 *** 61.64 *** 118.93 *** 
Egr1 18.08 *** 14.95 *** 27.4 *** 
 
   
Gadd45g 1.01 0.93 1.91 
Cdc42ep3 0.93 1.2 1.32 
Rasa1 1.35 0.89 0.69 
 
 
 
 
 
 
Table 6.2 A summary of the qRTPCR expression fold changes of a panel of genes in 
Hdh
Q111
 primary embryonic striatal cells following 2 hours stimulation with 
100ng/ml EGF. The genes were previously identified in Chapter 5 as being either A. 
more highly expressed in StHdh
Q7/7
 cells, B. with a larger expression fold change in 
StHdh
Q111/111 
cells or C. having a change in expression in StHdh
Q111/111 
cells only, 
following EGF stimulation. Asterisks represent a significant change in expression 
from 0 mins EGF stimulation. Further details can be found in Appendix VII. 
** p<0.01 *** p<0.001 
A 
B 
C 
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 6.5.2 Transcriptional dysregulation in HdhQ150 primary striatal cells 
6.5.1.1 Genes with larger expression fold changes in StHdhQ7/7 cells 
following EGF stimulation 
A summary of the expression fold changes in response to EGF for these genes, and 
those in the following section are presented in Table 6.3, and the full figures can be 
found in Appendix VIII. Similar to both StHdhQ111 and HdhQ111 models, there was a 
significant effect of EGF stimulation on the expression of Fgf2 (F (1, 24) = 14.822, 
p=0.001) although this did not withstand post-hoc analysis; however there was a trend 
towards a larger increase in Fgf2 expression in HdhQ150/150 cells (p=0.066), which is 
inconsistent with previous observations (Sections 5.2.3.2c & 6.5.1.1). There was also 
no effect of genotype, or an interaction with EGF stimulation. Post-hoc analyses also 
indicated that there were no significant differences in Fgf2 expression between 
individual genotypes. Similarly, there was a significant effect of EGF stimulation on the 
expression of Myc (F (1, 24) = 8.641, p=0.007) that did not withstand post-hoc testing, 
and no effect of genotype or a significant interaction between genotype and EGF 
stimulation. However, similar to the pattern of expression of Fgf2, there is a trend 
towards a larger increase in Myc expression in HdhQ150/150 cells compared to HdhQ7/7 
cells. In addition, there was no effect of either EGF or genotype on the expression of 
Smad7 or Sox9 in the HdhQ150 model. 
6.5.1.2 Genes with a larger expression fold change in StHdhQ111/111 cells 
following EGF stimulation 
In contrast to previous findings on the expression of Atf3 in the immortalised StHdhQ111 
cell model (Section 5.2.3.2c), but in accordance with the expression pattern in HdhQ111 
primary cells (Section 6.5.1.2), there was a significant effect of EGF stimulation on the 
expression of Atf3, which was significant for each individual genotype (all p<0.001). 
However, there was no significant effect of genotype, but there was a trend towards a 
larger fold change in HdhQ150/150 cells following EGF stimulation than in HdhQ7/7 cells. In 
contrast to the lower expression of Id3 observed in mHTT carrying cells in the 
StHdhQ111 and HdhQ111 models, although the relative quantification of Id3 expression 
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was twice as large in HdhQ7/7 cells compared to HdhQ150/150 cells, there was no 
significant effect of either EGF stimulation or genotype. 
Similar to the expression of Atf3 in the HdhQ150 model, there was a significant effect of 
EGF stimulation on the expression of Egr1 (F (1, 24) = 194.965, p<0.001), which 
remained significant following post-hoc analysis (all genotypes p<0.001). However, 
there was no effect of genotype, or a significant interaction between genotype and 
EGF stimulation. Nevertheless, there was still a trend towards an increased 
transcriptional response in HdhQ150/150 cells; the fold change from baseline in HdhQ7/7 
cells was x26, whereas the fold change for HdhQ150/150 cells was x45.  Fosl1 expression 
was also significantly increased in all three genotypes following EGF stimulation (all 
p<0.001), but there was still no significant effect of genotype. In contrast to Atf3 and 
Egr1 expression, there was also no indication within the raw fold change data that 
there was a trend towards differential expression of Fos1 due to genotype.  
In accordance with the expression of Gadd45g, Cdc42ep3 and Rasa1 in HdhQ111 cells 
(Section 6.5.1.2), there was no significant effect of either genotype or EGF stimulation, 
or a significant interaction between the two in HdhQ150 cells. 
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Fold change following EGF stimulation 
 
Hdh
Q7/7
 Hdh
Q7/150
 Hdh
Q150/150
 
Fgf2 1.66 3.86 4.41 
Myc 1.47 2.11 3.08 
Smad7 1.32 1.52 0.96 
Sox9 0.95 1.48 1.51 
 
   
Atf3 24.53 *** 22.7 *** 29 *** 
Id3 0.36 0.49 1.15 
Fosl1 44.1 *** 72.89 *** 44.35 *** 
Egr1 26.4 *** 34.34 *** 45.52 *** 
 
   
Gadd45g 0.82 1.51 1.91 
Cdc42ep3 0.78 1.52 1.17 
Rasa1 1.29 1.4 1.17 
 
 
 
 
 
 
 
6.6 Investigating the activity of kinase signalling pathways previously found to be 
disrupted in StHdhQ111/111 cells 
The phosphorylation of AKT, MEK and P38 MAPK following 10 minutes of 100ng/ml 
EGF stimulation was assayed by ELISA in primary striatal cells from the HdhQ111 mouse 
model of HD, as these pathways were found to be dysregulated in the immortalised 
StHdhQ111 cell model (Section 4.4.1).  
EGF stimulation had a significant effect on AKT1 phosphorylation (F (1, 30) = 42.062, 
p<0.001), as it elicited a substantial increase in the phosphorylation of AKT1 in HdhQ7/7 
(p=0.001) and HdhQ111/111 cells (p<0.001), although there was no significant effect in 
HdhQ7/111 cells (see Figure 6.20). In contrast to the findings in the immortalised cell 
lines, there was no significant difference in the level of AKT1 phosphorylation following 
A 
B 
C 
Table 6.3 A summary of the qRTPCR expression fold changes of a panel of genes in 
Hdh
Q150
 primary embryonic striatal cells following 2 hours stimulation with 
100ng/ml EGF. The genes were previously identified in Chapter 5 as being either A. 
more highly expressed in StHdh
Q7/7
 cells, B. with a larger expression fold change in 
StHdh
Q111/111 
cells or C. having a change in expression in StHdh
Q111/111 
cells only, 
following EGF stimulation. Asterisks represent a significant change in expression 
from 0 mins EGF stimulation. Further details can be found in Appendix VII 
** p<0.01 *** p<0.001   
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EGF stimulation between HdhQ7/7 and HdhQ111/111 cells. However, due to the lack of 
effect in HdhQ7/111 cells, the level of AKT1 phosphorylation in HdhQ7/7 and HdhQ111/111 
cells following EGF stimulation was significantly higher than in HdhQ7/111 cells following 
EGF stimulation (p=0.003 and p=0.004, respectively). In accordance with this, when 
comparing the genotypic specific differences in phosphorylation by taking into account 
the baseline for each genotype, HdhQ7/111 cells had a significantly different 
phosphorylation change compared to both HdhQ7/7 (p=0.011) and HdhQ111/111 cells 
(p=0.016), whereas there was no significant difference in the phosphorylation change 
between HdhQ7/7 and HdhQ111/111 cells. 
There was a significant increase in MEK1 phosphorylation following EGF stimulation in 
all three genotypes (all p<0.001), although there were no significant differences 
between genotypes at baseline. Despite suppressed MEK1 phosphorylation in 
HdhQ7/111 and HdhQ111/111 cells following EGF stimulation, only HdhQ7/111 cells were 
significantly lower than HdhQ7/7 following EGF stimulation (p=0.006), but were not 
significantly different to HdhQ111/111 cells. The same pattern of significance was found 
when analysing the extent of MEK1 phosphorylation when taking baseline 
phosphorylation into account. 
There was no significant effect of EGF on the phosphorylation of P38 MAPK in HdhQ7/7 
or HdhQ7/111 cells, but there was a significant increase in HdhQ111/111 cells (p=0.019), 
which is the same pattern observed in the immortalised cell model (Section 4.4.1). 
Although the resulting level of P38 MAPK was not significantly higher than the level of 
phosphorylated P38 MAPK in HdhQ7/7 or HdhQ111/111 cells following EGF stimulation, 
when taking the baseline levels of phosphorylation into account, the change in P38 
MAPK phosphorylation following EGF stimulation was significantly different in 
HdhQ111/111 cells compared to both HdhQ7/7 (p=0.004) and HdhQ7/111 cells (p=0.021). 
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Figure 6.20  Mean absorbance (Abs) read at 450nm following a sandwich ELISA 
protocol in Hdh
Q7/7
, Hdh
Q7/111
 and Hdh
Q111/111
 cells  for detection of the 
phosphorylation of cell signalling markers A. AKT1 and MEK1, and B.P38 MAPK at 0 
or 10 minutes stimulation with 100ng/ml EGF. Absorbance values were statistically 
analysed by two-way ANOVA for main effects, followed by a priori one-way ANOVAs 
to determine simple main effects, and post-hoc Tukey tests. (Error bars = SEM, 
Hdh
Q7/7
 n = 5, Hdh
Q7/111
 n = 6, Hdh
Q111/111
 n = 7).  
*p<0.05 **p<0.01 ***p<0.001 
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6.7 The expression of Smad genes and the phosphorylation of SMAD proteins in 
primary HdhQ111 cells. 
In order to determine if the dysregulation of the SMAD signalling pathway that was 
suggested to occur in the immortalised StHdhQ111 cell line (Section 5.3)  was also 
present in primary cells from HdhQ111 mice, the expression of Smad and Smad-related 
genes were analysed, and ELISA assays were performed in order to determine the 
levels of SMAD phosphorylation following TGFβ stimulation. 
 6.7.1 Smad gene expression 
In contrast with the expression of Smad and Smad-related genes in StHdhQ111 cell lines, 
there were no significant differences in the expression of Smad3, Smad6, Tgfβi or 
Tgfβr3 between any of the genotypes in HdhQ111 primary striatal cells (Figure 6.21). 
There was a significant effect of EGF on the expression of Smad6 (F (1, 24) = 18.036, 
p<0.001) due to a reduction in Smad6 expression following EGF stimulation. As Smad6 
is an inhibitory member of the Smad family, this is consistent with an increase in Smad-
regulated activity; however, the reduction in Smad6 expression did not withstand post-
hoc testing. 
Similarly, there was also a significant effect of EGF stimulation on Tgfbi expression (F 
(1, 24) = 10.389, p=0.004) by eliciting an increase in expression in all three genotypes; 
despite this, there was no effect of EGF in StHdhQ111 cells on the expression of this 
gene (Section 5.3.1). However, the increase in Tgfbi expression did not remain 
significant during post-hoc testing. Tgfbr3 expression showed a trend towards 
increased expression following EGF stimulation (p=0.057), but there were no 
significant differences in its expression between genotypes or following EGF 
stimulation. 
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Figure 6.21 Relative Quantification (RQ) values representing the fold change in gene 
expression for Smad-related genes in Hdh
Q7/7
, Hdh
Q7/111
 and Hdh
Q111/111 
primary 
embryonic striatal cells at 0 and 2 hours stimulation with 100ng/ml EGF. Delta cycle 
threshold (ΔCt) values were analysed by two-way ANOVA and post-hoc Tukey tests. 
(Error bars = SEM, n=5) 
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 6.7.2 SMAD2 activation 
Due to very restricted numbers of HdhQ111 mice that were available, there was not 
time within the duration of this project to collect substantial numbers of E14 striata for 
use in ELISA assays to accurately determine SMAD2 and SMAD3 phosphorylation 
following TGFβ stimulation in these cells. This restriction also prevented analysis of 
SMAD activation by western blot. 
There was no significant difference in the level of total SMAD2 between genotypes, 
and there was no effect of EGF stimulation (Figure 6.22). However, there was a trend 
towards lower levels of total SMAD2 in HdhQ111/111 cells, but as the n was very low for 
both HdhQ7/7 and HdhQ111/111 cells, there would not have been enough power to detect 
a significant difference. There was a significant effect of TGFβ stimulation on SMAD2 
phosphorylation (F (1, 24) = 9.485, p=0.007), although in contrast to the immortalised 
StHdhQ111 cell line (Section 5.3.2.1), there was no difference in SMAD2 phosphorylation 
between genotypes. There was also no statistical difference in the extent of 
phosphorylation change following TGFβ stimulation when taking baseline 
phosphorylation levels into account, or in the ratio of phosphorylated SMAD2 to total 
SMAD2 between genotypes. 
 
 
 
 
 
 
 
 
 
Figure 6.22 Mean absorbance (Abs) read at 450nm following a sandwich ELISA 
protocol in Hdh
Q7/7
, Hdh
Q7/111
 and Hdh
Q111/111
 cells for the detection of total and 
phosphorylated SMAD2 following 0 and 30 minutes of 100ng/ml TGFβ stimulation. 
Absorbance values were statistically analysed by two-way ANOVA for main effects, 
followed by a priori one-way ANOVAs to determine simple main effects, and post-
hoc Tukey tests. (Error bars = SEM, Hdh
Q7/7
 n = 4, Hdh
Q7/111
 n = 5, Hdh
Q111/111
 n = 2).  
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 6.7.3 SMAD3 activation 
There was also no significant effect of either genotype or TGFβ stimulation between 
genotypes on the level of total SMAD3 (Figure 6.23). There was a significant effect of 
TGFβ stimulation on the phosphorylation of SMAD3 (F (1, 24) = 5.196, p=0.037), 
however this did not remain significant following post-hoc testing. There was no 
significant reduction in the phosphorylation of SMAD3 in HdhQ111/111 cells, as seen in 
StHdhQ111/111 cells by ELISA assay (Section 5.3.2.2), although there was only an n=2 for 
HdhQ111/111 cells in this experiment; one sample exhibited a considerably higher 
phosphorylation response for SMAD3 following TGFβ, whereas the other was 
considerably lower, making any conclusions about SMAD3 phosphorylation in this 
model impossible to draw.  
As expected due to the low n and non-significant results, there was also no difference 
in the ratio of phosphorylated to total SMAD3 between genotypes, and no difference 
in the extent of phosphorylation following TGFβ stimulation between genotypes. 
 
 
 
 
 
 
 
 
 
 
 
Total SMAD3 
Hdh
Q7/7
 Hdh
Q7/111
 Hdh
Q111/111
 
A
b
s 
Hdh
Q7/7
 Hdh
Q7/111
 Hdh
Q111/111
 
A
b
s 
Phosphorylated SMAD3 
Figure 6.23 Mean absorbance (Abs) read at 450nm following a sandwich ELISA 
protocol in Hdh
Q7/7
, Hdh
Q7/111
 and Hdh
Q111/111
 cells for the detection of total and 
phosphorylated SMAD3 following 0 and 30 minutes of 100ng/ml TGFβ stimulation. 
Absorbance values were statistically analysed by two-way ANOVA for main effects, 
followed by a priori one-way ANOVAs to determine simple main effects, and post-
hoc Tukey tests. (Error bars = SEM, Hdh
Q7/7
 n = 4, Hdh
Q7/111
 n = 5, Hdh
Q111/111
 n = 2).  
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6.8 Discussion 
We have used primary embryonic E14 striatal cells from both the HdhQ111 and HdhQ150 
mouse models of HD to repeat a panel of assays that were initially carried out in 
immortalised StHdhQ111 cell lines, in order to determine whether EGF stimulation 
would have a similar effect on gene expression and HTT localisation. We demonstrate 
that HdhQ111 primary cells had a similar, but more subtle response to EGF stimulation 
compared to StHdhQ111 cells, but that the HdhQ150 model exhibited some substantially 
different effects. 
Similar to StHdhQ7/7 cells, the localisation of the HTT epitope detected by Ab109115 
was also primarily perinuclear in HdhQ7/7 cells, possibly reflecting the association of HTT 
with perinuclear organelles (Pal et al. 2006; del Toro et al. 2009; Hilditch-Maguire et al. 
2000). There was also increased nuclear detection of this epitope with increased mHTT 
load in both cell lines, although in primary cells, this was harder to visualise due to 
smaller cell bodies and nuclei. However, EGF stimulation elicited a reduction of the 
nuclear epitope of HTT in HdhQ7/7 cells, an effect that also occurred in the immortalised 
line. In contrast with the immortalised line, there were no significant effects on either 
HdhQ7/111 or HdhQ111/111 cells following EGF stimulation; this suggests a dominant effect 
of mHTT on suppressing the response to EGF stimulation in these cells, whereas a gene 
dosage effect was apparent in StHdhQ111 lines.  This may be due to the transformation 
that occurs in the process of immortalisation of cell lines, which may be altering the 
dominance of the Htt gene or has led to significant divergence between genotypes 
with increasing passage number. The possible mechanisms for the reduced response of 
HTT to EGF stimulation in the context of the expanded polyQ repeat have been 
discussed previously (Section 3.5). 
In accordance with Ab109115, there was also a reduction of the epitope of HTT 
detected by Mab2166 in the nuclei of HdhQ7/7 cells following EGF stimulation, although 
this persisted for longer than the effect observed using Ab109115. This is likely to 
reflect the different epitopes of HTT that each antibody was raised against; Ab109115 
was raised against amino acids 1-30, whereas the Mab2166 immunogen is further 
downstream of HTT between amino acids 118-181. Therefore Ab109115 may be more 
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able to detect shorter HTT N-terminal cleavage products that are enriched within cell 
nuclei (Hilditch-Maguire et al. 2000; Tao & Tartakoff 2001; Kegel et al. 2002), which 
Mab2166 cannot. In addition, the presence of further N-terminal HTT epitopes arising 
from aberrant splicing of exon 1 (Sathasivam et al. 2013) that would only be detectable 
by more N-terminal antibodies such as Ab109115, may also account for the differences 
in apparent HTT localisation detected by these two antibodies. Smaller fragments such 
as these can passively diffuse through the nuclear pore due to their small size (Hackam 
et al. 1998; Truant 2003; Terry et al. 2007; Bauer & Nukina 2009) and may be able to 
return to the nucleus more readily following EGF-stimulated translocation to the 
perinucleus and cytoplasm. Alternatively, the differences observed by each antibody 
may be due to alterations in the conformation of HTT, thus exposing alternate 
epitopes for antibody detection (Trettel et al. 2000; Wheeler 2000).  
Also comparable to the StHdhQ7/7 cells in Chapter 3, is the localisation of the epitope of 
HTT detected by the amino acid 1-17 antibodies N17 and Ab675; there is no effect of 
EGF stimulation on the localisation of the N17 signal, but there is a reduction in the 
nuclear detection of the epitope detected by Ab675 from 5 minutes of EGF stimulation 
in HdhQ7/7 cells. Interestingly, this also occurs in both HdhQ7/111 and HdhQ111/111 
genotypes in the primary cell model, but not in mHTT carrying cells in the immortalised 
model. This could be an effect of the immortalisation process in StHdhQ7/111 and 
StHdhQ111/111 cells; as these lines are maintained in culture for prolonged periods of 
time, it may be expected that with increasing passage number there may also be 
karyotypic instability, as noted in other immortalised cell lines (Mi et al. 2005), which 
may in turn alter the cellular response to EGF stimulation and mHTT presence. 
HdhQ150 cells show a slightly different pattern of HTT localisation in response to EGF 
stimulation than both the immortalised and primary HdhQ111 cells lines. There is a 
similar localisation of the HTT epitope detected by Ab109115 in HdhQ7/7 cells, and as 
has been noted in both StHdhQ111 and HdhQ111 lines, there is increasing nuclear 
localisation of this epitope with mHTT load. However, this is seen to a greater extent in 
HdhQ150 cells than in the HdhQ111 cells, and may reflect the more toxic effect and faster 
pathogenesis of the longer polyQ repeat that has been previously described (Lin 2001; 
Heng et al. 2007; Woodman et al. 2007; Weiss et al. 2008). There is also an evident 
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gene dosage effect, which has also been identified in adult HdhQ150 mouse models 
(Heng et al. 2007). There is a small reduction in the nuclear localisation of Ab109115 
following EGF stimulation in HdhQ7/7 cells only, concurrent with both HdhQ111 and 
StHdhQ111 models. Conversely, all three genotypes exhibit a substantial increase in 
nuclear HTT at 30 minutes of EGF stimulation, which does not occur in the other two 
models; this is unlikely to be an effect of mHTT, as the nuclear filling also occurs in 
HdhQ7/7 cells within the HdhQ150 model.  
Despite the maintenance of both mouse lines in this project on a C57Bl/J6 background, 
the HdhQ111 mouse line was constructed on a different strain background to the 
HdhQ150 line (Wheeler 2000; Lin 2001; Woodman et al. 2007). Therefore there may be 
genetic differences in C57Bl/J6 stock contributing to each mouse line that may account 
for different effects observed in HdhQ7/7 cells from each strain, as substantial strain 
effects have been noted in HD mouse lines before (Lin 2001; Woodman et al. 2007). 
However, the effect of this is likely to be very small, and therefore this could also be a 
result of variation in microdissection and culture conditions. Ideally, this experiment 
would need to be replicated in a new cohort in order to determine if there is an effect 
of variability in strain background or experimental error. The increase in nuclear HTT at 
30 minutes may reflect a stress response in these cells; in cultured HD patient 
lymphoblasts, HTT is released from perinuclear organelles and is translocated to cell 
nuclei in response to apoptotic stimulation (Sawa et al. 2005). A similar stress response 
may also be an effect of EGF stimulation at a concentration considerably higher than is 
found endogenously in these cells, thus eliciting HTT nuclear accumulation. This effect 
is also larger in HdhQ7/150 and HdhQ150/150 cells than in HdhQ7/7, which may be a result of 
an exaggerated stress response due to mHTT presence. In addition, there is a similar 
pattern of an increase of the nuclear epitope of HTT detected by Ab109115 in 
StHdhQ111/111 cells at 30 minutes of EGF stimulation (Section 3.3.5), and an augmented 
stress response is a characteristic phenotype in this model (Trettel et al. 2000). 
A nuclear increase in HTT is not apparent in HdhQ150/150 cells when detected by 
Mab2166, which is consistent with either the enrichment of shorter N-terminal 
fragments in cell nuclei (Hilditch-Maguire et al. 2000; Tao & Tartakoff 2001; Kegel et al. 
2002), the presence of an aberrantly spliced exon 1 variant (Sathasivam et al. 2013) or 
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the altered conformation of HTT to a more amino-terminal accessible conformation, 
both of which Mab2166 may be less able to detect (Wheeler 2000; Thompson et al. 
2009; Di Pardo et al. 2012). Comparable with both StHdhQ111 and HdhQ111 cells, there is 
also a reduction in the nuclear epitope of HTT detected by Mab2166 in HdhQ7/7 cells 
only, although this effect is considerably less marked in the HdhQ150 model. There is a 
slight reduction in nuclear HTT detected by Ab675 in HdhQ7/7 cells, but no effect in 
HdhQ7/150 or HdhQ150/150 lines, although there is also no nuclear filling at 30 minutes as 
was observed when using Ab109115. As these antibodies were previously found to 
exhibit similar patterns of localisation (Sections 3.3.3.3 & 3.3.4.3), the differences in an 
effect at 30 minutes may reflect variability between embryos and primary cell cultures. 
Similarly, N17 immunostaining exhibited a reduction in nuclear HTT in HdhQ150/150 cells 
at 30 minutes, which has not previously been noted. The sample size for the N17 and 
675 experiments was very small, and therefore quantitative statistical analysis was not 
possible; therefore the inconsistency observed in HTT localisation in HdhQ150 cells may 
not be accurately reflecting HTT localisation in response to EGF stimulation in these 
cells.   
EGF stimulation elicits an increase in nuclear HTT phosphorylated on serines 13 and 16 
in HdhQ7/7 cells from the HdhQ111 model, although this occurs at an earlier time point 
than in the immortalised cell line. This also occurs in HdhQ111/111 cells, but interestingly 
not in the HdhQ7/111 cells; at baseline, there is already significantly more nuclear 
phosphorylated HTT in heterozygote cells, which may explain why a further nuclear 
increase of this epitope doesn’t occur following EGF stimulation. This may be due to 
the transient nature of HTT phosphorylation or experimental error, although the same 
increase in nuclear location of this epitope in heterozygote cells was also observed in 
immortalised StHdhQ7/111 cells. Therefore, differential localisation of phosphorylated 
epitopes could be an effect of mHTT presence; it has been found that mHTT is less 
efficiently phosphorylated on both serine 421 (Warby et al. 2009) and serines 13 and 
16 (Thompson et al. 2009; Atwal et al. 2011). This phenotype may be penetrant in 
HdhQ111/111 cells only, thus appearing as though nuclear localisation of mHTT is 
reduced. In contrast, alternate conformations of mHTT may prevent the identification 
of phosphorylated epitopes in HdhQ111/111 cells until stimulation with EGF elicits a 
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response. In order to elucidate whether this was the case, it would have been useful to 
carry out subcellular fractionation and denaturing western blot analysis to determine 
whether the presence of HTT in each cellular compartment and the presence of any 
cleaved fragments may be contributing to the localisation phenotype. However, due to 
the poor sensitivity of the established fractionation protocol used previously (Section 
3.3.6) and restricted availability of E14 striata, these experiments were not carried out. 
However, alterations in phosphorylated HTT localisation in response to EGF stimulation 
suggests that there is a response in HdhQ111 primary cells that is similar to that seen in 
StHdhQ111 cells, and may be a mechanism by which gene expression and nuclear 
organisation are regulated (Holmberg et al. 2002; Ehrnhoefer et al. 2011).  
EGF stimulation also elicited an increase in nuclear phosphorylated HTT over time in 
HdhQ7/7 cells from the HdhQ150 model, but this did not occur until 30 minutes; this is 
likely to be result of variability in culture conditions or some variation in mouse 
background. Increased nuclear HTT in HdhQ7/150 compared to HdhQ150/150 cells was 
observed again, although to a lesser extent. There were also contrary effects of EGF 
stimulation on HdhQ7/150 and HdhQ150/150 cells as seen in the HdhQ111 model; whether 
this is an effect of differing antibody binding efficiency, HTT conformation, or is a true 
representation of phosphorylated HTT localisation remains to be elucidated.  
We have demonstrated that the localisation of HTT detected by N-terminal antibodies 
and anti-phosphorylated antibodies are similar in primary cell models as in the 
immortalised StHdhQ111 cell model, although the process of immortalisation appears to 
have transformed the immortalised cell line so that there is enhanced divergence 
between genotypes. However, there are still some alterations in response to EGF 
stimulation in primary cell lines carrying mHTT, suggesting a very early aberrant effect 
of the mutant protein in cellular signalling responses. There are some differences 
between HdhQ111 and HdhQ150 cells; however these appear to stem largely from 
baseline differences in all three genotypes rather than from a significant effect of a 
larger polyQ repeat. A more thorough discussion of the translocation kinetics and 
regulatory effects of HTT localisation can be found in Chapter 3. 
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As similarities with the immortalised cell line in terms of the localisation and 
phosphorylation of HTT could be identified in primary cells, the expression of several 
genes identified in Chapter 5 were also investigated in both HdhQ111 and HdhQ150 
mouse model E14 striatal cells in order to determine if similar patterns of aberrant 
transcriptional control are present. Transcriptional dysregulation of SRY (sex 
determining region Y)-box 2 (Sox2) and signal transducer and activator of transcription 
3 (Stat3) have been previously described in E13.5-15.5 HdhQ111/111 striatum, and are 
genes associated with embryonic brain maturation and development (Molero et al. 
2009); this indicates that mHTT is initiating alterations in cell signalling from embryonic 
ages, consequently leading to adverse effects on brain development and function that 
may become associated with disease progression. We have also identified some 
evidence for transcriptional dysregulation in primary embryonic cells that may 
contribute to the development of later perturbations in HD mouse models. However, 
these experiments suffered from a low sample size, and consequently high variability, 
resulting in primarily the identification of trends rather than statistical significance.  
Of the four genes that were tested that had a larger response to EGF stimulation in 
StHdhQ7/7 cells in Chapter 5, two showed evidence of having a similar pattern of 
expression in HdhQ111 cells; there was a trend towards increased sensitivity of the 
expression of Fgf2 to EGF stimulation in HdhQ7/7 cells compared to both HdhQ7/111 and 
HdhQ111/111 cells, and there was also a pattern of expression that reflected a gene 
dosage effect. A summary of qRTPCR gene expression data for both primary cell lines 
compared to the original observations in StHdhQ111 cells can be found in Table 6.4. Fgf2 
is an activator of MEK/ERK signalling and regulates neuronal proliferation and 
differentiation (Song & Ghosh 2004; Rudenko et al. 2010; Ishii et al. 2012; Li et al. 
2012), as well as enhancing the differentiation and development of glia, potentially via 
MAPK signalling (Song & Ghosh 2004; Franzdottir et al. 2009; Li et al. 2012). FGF2 has 
been identified as a neuroprotective growth factor (Alzheimer & Werner 2002), and 
treatment of R6/2 mice with FGF2 or an FGF receptor agonist has been found to 
increase the number of proliferating cells in the subventricular zone, recruit new 
neurons to the striatum, reduce neuronal HTT aggregates and increase life span (Jin et 
al. 2005), in addition to alleviating anxiety and deficits in sociability in these mice 
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(Rudenko et al. 2010).  Reduced expression of Fgf2 may therefore be a mechanism by 
which embryonic brain development is impaired, and creates a predisposition to 
neurodegeneration by reducing the availability of neuroprotective factors. 
 
 
StHdh
Q111
 Hdh
Q111
 Hdh
Q150
 
Fgf2 ↑StHdh
Q7/7
 ≈ χ 
Myc  ↑StHdh
Q7/7
 χ χ 
Smad7 ↑StHdh
Q7/7
  χ 
Sox9 ↑StHdh
Q7/7
 χ χ 
  
  
Atf3 ↑StHdh
Q111/111
   
Id3 ↑StHdh
Q111/111
 χ ≈ 
Fosl1 ↑StHdh
Q111/111
  χ 
Egr1 ↑StHdh
Q111/111
   
  
  
Gadd45g ↑StHdh
Q111/111
 χ χ 
Cdc42ep3 ↑StHdh
Q111/111
 χ χ 
Rasa1 ↑StHdh
Q111/111
 χ χ 
 
 
 
 
 
Smad7 expression was also reduced in HdhQ111/111 embryonic striatal cells compared to 
both HdhQ7/7 and HdhQ7/111 cells; in immortalised cell lines, and there was also a 
reduction in Smad7 expression in StHdhQ111/111 cells, although this became evident 
Table 6.4 A summary of the comparisons between both primary embryonic striatal 
cell lines, Hdh
Q111
 and Hdh
Q150, 
against immortalised StHdh
Q111
 cells for the pattern 
of qRTPCR gene expression data following 2 hours stimulation with 100ng/ml EGF. 
Column 2 indicates which genotype had a larger response in StHdh
Q111 
cell lines. ‘’ 
indicates concordance between primary and immortalised cell data, ‘≈’ represents a 
trend in the same direction, and ‘χ’ indicates inconsistent findings.  
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following EGF stimulation. In comparison, the reduction in Smad7 expression in 
primary cell lines was apparent from baseline, and there was only an effect of EGF 
stimulation on Smad7 expression HdhQ111/111 cells. Smad7 is a competitive inhibitor of 
the TGFβ signalling pathway (Blanchette et al. 2001; Massague 2005; Kim et al. 2012); 
for example, its overexpression can prevent EGF-stimulated SMAD3 phosphorylation 
(Kim et al. 2012). In Chapter 5, we identified that there was reduced Smad7 expression 
in StHdhQ111/111 cells, in comparison with enhanced SMAD3 activation; therefore, 
alterations in Smad7 regulation of the TGFβ pathway may be a mechanism for 
aberrant kinase signalling and transcriptional dysregulation in models of HD.  There 
were no differences between genotypes for any of the four genes that were tested in 
the HdhQ150 line, despite a trend towards lower Fgf2 expression at baseline, a 
suppressed response of Smad7 expression to EGF stimulation and increased sensitivity 
of Myc expression following EGF stimulation in HdhQ150/150 cells. However, the high 
variability due to a low signal to noise ratio, and a consequent lack of statistical 
significance makes these results difficult to interpret.  
Those genes with that were identified in Chapter 5 as having increased expression in 
StHdhQ111/111 cells compared to StHdhQ7/7 cells following EGF stimulation had promising 
results in the HdhQ111 primary cells. EGF stimulation elicited an increase in the 
expression of Atf3, Egr1 and Fosl1 in all three genotypes, and the magnitude of 
response compared to baseline expression was greater in HdhQ111/111 cells compared to 
wild type. These three genes are associated with transcription, and in particular Atf3 
and Fosl1 form the AP1 complex that is involved in transcriptional regulation; the 
composition of which alters the control of gene expression by modifying DNA binding 
specificity (Shaulian & Karin 2002; Eferl & Wagner 2003). Early embryonic alterations in 
AP1 composition due to modifications of Atf3 and Fosl1 expression may therefore 
contribute to the transcriptional dysregulation observed in models of HD and human 
HD brain (Ross 2002; Zucker et al. 2005; Crocker et al. 2006; Crook & Housman 2011). 
Egr1 expression was identified as being downstream of MEK signalling in the previous 
chapter, and it has also been associated with P38 MAPK activity (Kang et al. 2003; Lu et 
al. 2007). Therefore, its increased expression in HdhQ111/111 primary cells suggests that 
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there is potentially dysregulation of these kinase signalling pathways, which may be 
occurring as early as during embryonic brain development in HD.  
A significant reduction of Id3 expression following EGF stimulation in StHdhQ111/111 cells 
was seen in the previous chapter; however in the HdhQ111 model, although there is 
significantly lower expression of Id3 in HdhQ111/111 cells compared to both HdhQ7/7 and 
HdhQ7/111 cells, there is no effect of EGF stimulation, whereas there is a trend towards a 
reduction in wild type and heterozygous lines. As Id3 is a transcriptional repressor 
modulated by Atf3/Smad activity (Kang et al. 2003; Jin et al. 2011), it would have been 
expected that the enhanced Atf3 activity in HdhQ111/111 cells following EGF stimulation 
would elicit a consequent reduction in Id3 expression. However, the lack of EGF effect 
in these cells suggests that there may be aberrant activity in other parts of the 
transcriptional machinery that is not maintaining a normal transcriptional equilibrium, 
the effects of which may accumulate over time. 
The trend towards a more sensitive expression response to Atf3 and Egr1 to EGF 
stimulation was also maintained in HdhQ150/150 cells, although there were high levels of 
variability. Id3 expression also showed the same pattern as in the HdhQ111 model; this 
suggests that the expression patterns of Atf3, Egr1 and Id3 may be an effect of the 
mHTT protein independent of polyQ length, and are not likely to be purely a result of 
immortalisation-induced transformation of cells. In contrast, Fosl1 shows the opposite 
pattern of response; there is a gene dosage effect on the extent of Fosl1 expression 
change following EGF stimulation, in which increased mHTT load reduces the response. 
Different polyQ lengths may therefore have differential effects on the expression of 
some genes, and may dictate the point at which cellular function switches from 
compensatory activity to pathogenic loss of function. 
None of the effects observed in the immortalised striatal cell lines for genes that were 
identified as being altered in StHdhQ111/111 cells only following EGF stimulation (Chapter 
5) could be replicated in either HdhQ111 or HdhQ150 primary cells, suggesting that these 
may be an effect of immortalisation; the immortalised cell line has previously been 
identified as having an increased sensitivity to metabolic stress (Ginés 2003), which 
may account for the larger expression effects in these cells. However, the tsA58 SV40 
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large T antigen that was used to immortalise HdhQ111 cell lines has been found to have 
a limited transformation effect on striatal cells (Cattaneo & Conti 1998; Trettel et al. 
2000), and there is a slight trend towards reduced Cdc42ep3 and Gadd45g expression 
in both HdhQ111/111 and HdhQ150/150 cells, which suggests that with increased statistical 
power and reduced variability, an effect similar to that seen in immortalised cells may 
be identified. Unfortunately, the restricted availability of embryos prevented the use 
of a larger n or replication of gene expression experiments. 
We also aimed to determine whether the same kinase signalling pathways that 
showed significant aberrant activity in StHdhQ111 cells were also disrupted in primary 
cells from the HdhQ111 model; a summary of results can be seen in Table 6.5. 
Unfortunately, HdhQ150 cell lines were no longer available for the remaining 
experiments. There was a significant effect of EGF stimulation on the phosphorylation 
of both AKT1 and MEK1 in HdhQ7/7 and HdhQ111/111 cells, although interestingly this was 
not significant in HdhQ7/111 cells. However, in contrast to the immortalised cell line, 
there was not a larger effect in HdhQ111/111 cells for the level of phosphorylated AKT1. 
Increased AKT activation has been identified previously in the HdhQ111 mouse model, 
however these mice were 5-8 months old when this was determined (Ginés et al. 
2003; Saavedra et al. 2010), which may suggest that this is a progressive phenotype 
that is not observable at embryonic stages; the increase in AKT phosphorylation in 
StHdhQ111 cells may be a result of their enhanced sensitivity to stressors (Ginés et al. 
2003) that is exaggerating the phenotype. If the augmentation of AKT activation is 
more subtle in embryonic cells, then this may also be a mechanism by which some of 
the genes downstream of AKT signalling show less of a response in HdhQ111 cells 
compared to the immortalised model. In addition, as AKT activity may regulate HTT 
phosphorylation on S13 and S16 (Thompson et al. 2009), the lack of a differential 
genotype effect in primary cells in response to EGF stimulation may account for 
differences in HTT phosphorylation and localisation between models.  
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StHdh
Q111
 Hdh
Q111
 
 
Gene expression 
Smad3 ↑StHdh
Q111/111
 χ 
Smad6 ↑StHdh
Q111/111
 χ 
Tgfbr3 ↑StHdh
Q111/111
 χ 
Tgfbi ↑StHdh
Q111/111
 χ 
  
 
 
ELISA  
Phospho-AKT1 ↑StHdh
Q111/111
 χ 
Phospho-MEK1 ↑StHdh
Q7/7
 ≈ 
Phospho- P38 
MAPK ↑StHdh
Q111/111
  
  
 
Total SMAD2 ↑StHdh
Q7/7
 ≈ 
Phospho-
SMAD2 ↑StHdh
Q7/7
 χ 
Total SMAD3 ↑StHdh
Q7/7
 χ 
Phospho-
SMAD3 ↑StHdh
Q7/7
 χ 
 
 
 
 
 
There was an equivalent level of MEK1 phosphorylation following EGF stimulation in 
HdhQ7/7 and HdhQ111/111 cells, although similar to the AKT1 assay, this effect was 
suppressed in HdhQ7/111 cells. To date, there is no literature regarding the activation of 
MEK1 in knock in mouse models of HD, however in the StHdhQ111 model, we found a 
suppression of MEK1 activation in response to EGF stimulation when mHTT was 
present. Treatment of a PC12 cell model of HD with a constituently active form of 
Table 6.5 A summary of the comparisons between Hdh
Q111 
primary embryonic 
striatal cells with immortalised StHdh
Q111
 cells for the expression of Smad-related 
genes, and for the activity of kinase signalling pathways as measured by ELISA assay. 
Column 2 indicates which genotype had a larger response in StHdh
Q111 
cell lines. ‘’ 
indicates concordance between primary and immortalised cell data, ‘≈’ represents a 
trend in the same direction, and ‘χ’ indicates inconsistent findings.  
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MEK1 was found to be protective against cell death (Apostol et al. 2006), thus a 
reduction in MEK1 activation may be a mechanism for increased susceptibility to cell 
death in HD. In HdhQ111/111 cells, we see no reduction in MEK1 phosphorylation; 
however, disruption of this signalling pathway may follow a similar course as AKT 
phosphorylation, in that it is undetectable in embryonic cells, but may progressively 
worsen with disease development. It would have been useful to look at the levels of 
total AKT1 and MEK1 in order to calculate an active/total ratio, however, half of each 
embryonic striatum acted as its own baseline control while the other half was 
stimulated with EGF; therefore there was not enough extracted protein available to 
carry out additional ELISA assays with the same samples, and more HdhQ111 embryos 
were not available to carry out these assays separately. Why there was a suppressed 
response in HdhQ7/111 cells would have been interesting to investigate further; a 
replication of this experiment would be required to determine if this was an effect of 
mHTT, or a spurious result due to experimental error. 
The last kinase that was investigated in HdhQ111 cells was P38 MAPK; in the StHdhQ111 
model, we identified enhanced phosphorylation of P38 MAPK in StHdhQ111/111 cells. 
Similarly, there was an increased sensitivity to EGF stimulation in HdhQ111/111 primary 
cells on the phosphorylation of P38 MAPK. Activation of this kinase only occurred in 
the HdhQ111/111 cells, compared to no effect of EGF in either of the other two 
genotypes. Enhanced P38 MAPK signalling has been identified as an early phenotype in 
transgenic mouse models of HD (Gianfriddo et al. 2004; Saavedra et al. 2011; Fan et al. 
2012), although this was noted from 1-3 months of age. Our results suggest that 
increased sensitivity within this pathway may be occurring prior to birth in mouse 
models of HD, but whether this may be a neuroprotective compensatory mechanism 
or not remains to be elucidated.  
As several of the gene expression changes observed in the HdhQ111 model resembled 
those seen in the StHdhQ111 model, we also investigated whether there were similar 
alterations in Smad gene expression and TGFβ-dependent phosphorylation (see Table 
6.5 for a summary of the comparison of Smad expression and SMAD signalling data 
between HdhQ111 and StHdhQ111/111 cell lines). Of the Smad genes that were tested, 
there were no significant differences in expression between genotypes, although EGF 
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stimulation did reduce Smad6 expression and increase the expression of Tgfbi. As the 
TGFβ pathway plays a largely anti-proliferative role in cell regulation (Massague 2003; 
Massague 2005), it may be expected that expression of its associated genes would be 
low in embryonic stages of neuronal development; indeed, it has been found that 
suppression of SMAD2 and 3 signalling enhances conversion of human pluripotent 
stem cells to medium spiny neurons (Chambers et al. 2009; Carri et al. 2013). This may 
be reflected in the low expression values and high variability of Smad-associated genes 
in HdhQ111 cells. The immortalisation of the StHdhQ111 cell line will have altered the 
developmental pathway of these cells, and consequently the expression of Smad and 
Smad-related genes. However, this does not rule out dysregulation of Smad expression 
at later developmental time points, which has not currently been investigated in 
mouse models of HD. It may have also been useful to assay a wider range of Smad 
genes in order to detect any dysregulation in the pathway as a whole, however time 
restrictions prevented this from being carried out, and so only those genes with the 
largest magnitude of effect in StHdhQ111 cells from Chapter 5 were chosen to be 
followed up.  
Finally, the phosphorylation of SMAD2 and SMAD3 were investigated in HdhQ111 cells 
following TGFβ stimulation; this was only able to be carried out by ELISA assay, as 
there was not enough available protein to perform additional western blot analyses. 
There were also very small sample sizes for each ELISA assay due to the limited 
availability of HdhQ111 mouse embryos and the concentration of protein that can be 
extracted per embryonic striata. There was a trend towards reduced total SMAD2 in 
HdhQ111/111 cells, similar to the effect seen in StHdhQ111/111 cells; however due to low 
statistical power, this did not reach significance. There was an effect of TGFβ 
stimulation on the phosphorylation of SMAD2, but there was no evidence of a 
suppression of an effect in mHTT carrying cells as there was in the immortalised cell 
line. This may be due to the restricted role of SMAD2 in neuronal differentiation 
(Chambers et al. 2009; Carri et al. 2013), as the magnitude of response to stimulation 
was also considerably lower in primary cells than in the immortalised model. As the 
extent of the activation change was very small in this case, it would be difficult to 
identify an aberrant response in mutant cells.  
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Total SMAD3 and the phosphorylation of SMAD3 exhibited a similar pattern to SMAD2; 
unlike the immortalised cells, there was not a reduction in total SMAD3 in mHTT 
carrying cells in the HdhQ111 model. Although there was an increase in the 
phosphorylation of SMAD3 following TGFβ stimulation, this did not differ between 
genotypes. However, there was a trend towards increased phosphorylated SMAD3 at 
baseline in HdhQ111/111 cells, but due to an n of only 2, it is not possible to draw any 
conclusions from these findings. The phosphorylated SMAD3 ELISA assay actually 
identified a suppressed phosphorylated SMAD3 response in StHdhQ111/111 cells, 
whereas western blot analysis indicated hyperphosphorylation; therefore it would be 
of interest to investigate the expression and phosphorylation of SMAD proteins in 
primary embryonic striatal cells by alternative methods in order to more thoroughly 
characterise their activity. Nonetheless, these results may provide a starting point that 
suggests there may be a trend towards aberrant activity within the complex TGFβ 
signalling pathway in models of HD. 
In conclusion, the characterisation of primary embryonic striatal cells from two knock-
in mouse models of HD demonstrates some similarities in the localisation and 
phosphorylation of HTT epitopes with the immortalised StHdhQ111 cell model. However, 
differences between wild-type cells from the HdhQ111 and HdhQ150 models make 
conclusions about the effect of polyQ length difficult to draw; replicating these 
experiments would be the best way to determine if these differences were due to 
minor variations within background mouse strains, or due to experimental error and 
technical variation. However, the characterisation of HTT localisation has indicated 
that there is mislocalisation of the mutant protein in both models from embryonic 
development, despite nuclear filling typically being described as a later phenotype 
(Wheeler 2000; Lin 2001; Fossale et al. 2002; Wheeler et al. 2002; Heng et al. 2007; 
Woodman et al. 2007; Menalled et al. 2009), suggesting that aberrant 
neurodevelopment  may contribute to the later development of HD pathogenesis. In 
accordance with this, we have identified the transcriptional dysregulation of several 
genes in both mouse models of HD that are similar in their expression to the StHdhQ111 
cell lines. It has been postulated that transcriptional dysregulation may be the 
initiation point of the pathogenic cascade in HD (Hogel et al. 2012); this has been 
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demonstrated by the contribution of embryonic transcriptional dysregulation to 
altered striatal cell neurogenesis in HdhQ111 mice (Molero et al. 2009), which is likely to 
lead to altered neuronal maturation and may therefore predispose affected cells to 
degeneration (Nguyen et al. 2013). We have identified additional genes that are 
differentially expressed in the presence of mHTT in response to growth factor 
signalling, which may have downstream effects on neuronal development and survival. 
Although we did not identify any differences in AKT1 or MEK1 phosphorylation in 
primary cells, this does not rule out a role for these pathways in disease progression. 
However, there is substantial hyperphosphorylation of P38 MAPK in HdhQ111/111 cells, 
which has been associated with the activity of other kinase signalling pathways, such 
as TGFβ (Massague 2003; Li et al. 2010), and the control of gene expression (Apostol et 
al. 2006; Yang et al. 2007; Martin et al. 2011). As such, aberrant activity in this pathway 
may influence the progression of HD phenotypes. We did not observe any apparent 
alterations in the expression of most Smad related genes, with the exception of 
Smad7. There were also no alterations in SMAD phosphorylation, although this may be 
due to the developmental stage of these cells, as well as this experiment having very 
low power, and therefore a reduced ability to find an effect. This is in addition to only 
being able to investigate a restricted panel of targets in comparison to StHdhQ111 cell 
lines. 
Embryonic primary cells from mouse models of HD have been poorly characterised to 
date, however despite limitations in the availability of HD mouse model embryos, we 
have established that there are already perturbations in cell signalling, transcriptional 
control, and the regulation of HTT activity during the striatal development. This 
provides evidence for the importance of early neurodevelopment in the pathogenesis 
of HD, and may provide a basis for the vulnerability of striatal neurons to mHTT in later 
stages of the disease. However, although there are many similarities between primary 
cells and the immortalised cell line, there was also evidence that transformation of the 
immortalised cells may have made them more sensitive to growth factor stimulation, 
and alteration of their developmental pathways may have had an effect on 
transcriptional control. Therefore, although the StHdhQ111/111 cells are a useful model, 
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characterisation of their phenotypes should be treated with caution when being 
applied to in vivo and primary models of HD, as well as the human disease.  
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Chapter 7: General discussion 
 
7.1 Limitations of HTT localisation experiments 
The determination of antibody specificity was the main limitation of these 
immunofluorescence experiments; we were unable to completely knock down the 
expression of HTT using siRNA transfection for the purposes of antibody validation. 
HTT is a long lived protein, and the half-life of wild type HTT is considerably longer than 
mHTT (J. Miller et al. 2010). It would therefore be difficult to increase the extent of 
siRNA transfection to the level of total HTT knock-down in this model without eliciting 
significant cellular toxicity due to the transfection reagent.  Although there was a 
reduction in signal for the majority of antibodies that were tested following HTT knock-
down, there was still substantial signal detection, particularly within the cytoplasm. 
We are therefore unable to state with any certainty that any of the antibodies that 
were utilised are specific to HTT. However, as there was a reduction in antibody 
detection following Htt siRNA transfection, a substantial proportion of their signal is 
still likely to be due to the detection of HTT.  As the majority of the remaining signal 
following Htt siRNA transfection was cytoplasmic, this could be due to either enhanced 
non-specific binding of these antibodies within the cytoplasm, or may reflect the 
nuclear localisation of protein degradation systems (Thompson et al. 2009). Care 
should be taken when considering the pattern of cytoplasmic staining with these HTT 
antibodies, however as the majority of observable effects were between the nucleus 
and perinuclear area in these experiments, non-specific antibody detection within the 
cytoplasm is not likely to significantly contribute to these patterns. The DharmaFECT-
only control immunofluorescence images differ slightly from the 0 minutes conditions 
in the growth factor experiments in terms of the nuclear staining intensity; this may be 
due to the interference of the transfection reagent within the cells, issues with non-
specific binding, as well as inconsistencies between antibody batches and technical 
variation, as the siRNA experiments and growth factor experiments were conducted 
over a year apart. However, the pattern of increasing nuclear staining with mHTT load 
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was still present following treatment with DharmaFECT, suggesting that these controls 
are still likely to be representative of HTT localisation. 
Despite using a panel of N-terminal HTT antibodies, this methodology is unable to 
determine whether the apparent changes in the subcellular localisation of HTT were 
due to dynamic shuttling of HTT between the nucleus and cytoplasm, or to changes in 
protein conformation and altered epitope availability. However, the differential 
localisation of phosphorylated HTT epitopes in comparison to non-phosphorylated 
epitopes suggests that alterations in apparent localisation may be due to 
conformational changes as a result of post-translational modifications. We only 
investigated phosphorylation of HTT at serines 13 and 16, however many other post-
translational modifications of HTT have been identified that can alter its conformation 
and localisation (Steffan et al. 2004; Bauer & Nukina 2009; Warby et al. 2009), and 
therefore these cannot be ruled out as a mechanism of HTT regulation downstream of 
growth factor stimulation. 
Additional investigation is required to determine whether the differences in antibody 
detection were due to conformation or localisation; the use of antibodies against C-
terminal epitopes of HTT may provide additional information about whether 
conformational alterations are primarily restricted to N-terminal HTT, as the structure 
of this region is particularly flexible (Trettel et al. 2000; Wheeler 2000; Kim et al. 2009; 
Lotz et al. 2010; Seong et al. 2010; Zuccato et al. 2010; Długosz & Trylska 2011), or 
whether shuttling of HTT epitopes between cellular compartments encompasses the 
full length protein or occurs following proteolysis. Additionally, methods that can look 
directly at HTT conformation, such as time resolved fluorescence resonance energy 
transfer (TR-FRET), would be particularly useful to answer this question (Figure 7.1). 
The subcellular fractionation experiments did not prove to be particularly informative; 
no alterations in full length HTT localisation were detectable by western blot, which 
may not be surprising as full length HTT is not able to traverse the nuclear pore in a 
manner as efficient as smaller N-terminal fragments (Hackam et al. 1998; Truant 2003; 
Terry et al. 2007; Bauer & Nukina 2009). Additionally, the majority of effects were 
identified between the perinuclear and nuclear regions; however the subcellular 
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fractionation protocol separated only nuclear and cytoplasmic fractions, therefore 
potentially obscuring these changes. Fractionation protocols that separate cellular 
regions more thoroughly may be a more desirable method of investigating HTT 
localisation by western blot. Conversely, the lack of change in HTT localisation by 
western blot may be reflective of alterations in HTT conformation in response to 
growth factor stimulation, rather than alterations in localisation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No additional bands validated as HTT were detected by any of the antibodies that were 
tested by western blot, other than the full length epitope. Although HTT cleavage has 
been found to occur following DNA damage (Khoshnan et al. 2009), the presence of 
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Figure 7.1 Cartoon depicting the principle behind TR-FRET in order to investigate 
changes in HTT conformation. A. A donor fluorophore is tagged to N-terminal HTT, 
and an acceptor is tagged to the C-terminal end. In an open conformation, following 
excitation from an external source, the two fluorophores are not in close enough 
proximity to each other in order for energy transfer to occur. B. Upon a 
conformation change, the proximity between donor and acceptor is reduced to 
between 1-10nm. Upon excitation of the donor, energy can be transferred to the 
acceptor molecule and a proximity-dependent fluorescent signal is emitted. TR-FRET 
involves the inclusion of a 50-150μs delay between excitation and emission 
measurement to allow for the degradation of short-lived background non-specific 
emissions. Live cell imaging following growth factor stimulation could therefore 
track potential alterations in HTT conformation over time. 
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HTT fragments in the StHdhQ111 model have not been characterised. It is therefore 
unclear whether our failure to detect additional forms of HTT is a result of minimal HTT 
cleavage and proteolysis in these cells, rapid degradation of cleaved products, or a 
methodological effect. As HTT is found to be cleaved as part of its normal function 
(Goldberg et al. 1996; Wellington et al. 1998; Kim et al. 2001; Gafni & Ellerby 2002; 
Graham, Deng, et al. 2006; Landles et al. 2010), it is likely that this may be a 
methodological effect; the protein gel was blotted for a long period of time in order to 
efficiently transfer the large, full length protein, but this process may have lost smaller 
fragments by diffusion through the membrane on to the chromatography paper. 
However, as this cell model does not exhibit mHTT toxicity, and cleavage products 
have not yet been characterised, mHTT cleavage and proteolysis may not be a central 
pathogenic mechanism in these cells, or may not occur at all. 
 
7.2 Subcellular localisation of HTT and mHTT 
The increased nuclear localisation of mHTT that we identify in these cells is consistent 
with other studies using this cell line (Trettel et al. 2000; Truant 2003; Atwal et al. 
2007; Atwal et al. 2011), as well as with other models of HD (Hoogeveen et al. 1993; 
Dorsman et al. 1999; Hilditch-Maguire et al. 2000; Wheeler 2000; Kegel et al. 2002; 
Wheeler et al. 2002; Rockabrand et al. 2007; Seong et al. 2010). However, in mouse 
models of HD and in human HD caudate, HTT nuclear filling is described as a 
progressive phenotype that develops and worsens with disease progression (Gomez-
Tortosa et al. 2001; Menalled et al. 2003; Woodman et al. 2007; Hickey et al. 2008; 
Heng et al. 2010; Bayram-Weston et al. 2012).We have demonstrated that the 
mislocalisation of mHTT is not only an age-associated phenotype, but is a pre-
pathogenic phenotype present from embryonic stages of development. The increased 
nuclear localisation of HTT may affect transcriptional regulation (Zoghbi & Orr 2000; 
Bauer & Nukina 2009), nuclear organisation (Kegel et al. 2002; Sun et al. 2007), as well 
as loss-of-function effects within cytoplasmic-associated mechanisms (Zuccato et al. 
2003; Zuccato et al. 2010). Therefore the mislocalisation of mHTT from embryogenesis 
may have implications for the understanding of HD developmental pathogenesis; 
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increased nuclear localisation of mHTT in striatal neurons may be initially tolerable, as 
its presence during brain development is likely to elicit compensatory mechanisms in 
order to maintain cell survival. The inability for these mechanisms to maintain survival-
associated cell functions with cumulative mHTT insult may then lead to the observable 
pathogenic disease cascade. This underlying dysfunction may have implications for 
informing the development of subtle phenotypes that occur decades before the 
clinically defined age of onset.  
In contrast to the localisation of HTT epitopes, we do not observe HTT 
hypophosphorylation in StHdhQ7/111 and StHdhQ111/111 cells, as has been described 
previously (Atwal et al. 2011). However, we also do not observe changes in the extent 
of phosphorylation following growth factor stimulation, despite previous work 
demonstrating that AKT activation may directly phosphorylate HTT (Thompson et al. 
2009). Therefore, the detection of phosphorylated HTT in these experiments may 
reflect a saturation effect, thus any increase in HTT phosphorylation would not 
correlate with a concomitant increase in antibody detection. The discordance between 
these findings may be a result of high variability in StHdhQ7/111 and StHdhQ111/111 cells 
due to mHTT, the divergence of cell lines between different laboratories, or may be an 
effect of regulation by additional post-translational modifications. Despite the 
contrasting phosphorylated HTT evidence, aberrant phosphorylation has implications 
for the regulation of HTT localisation, cleavage and clearance, therefore contributing to 
cellular dysfunction that is present from embryonic development. 
 
7.3 Effect of growth factor stimulation on HTT subcellular localisation 
The regulation of HTT localisation and phosphorylation has been previously 
investigated following the activation or inhibition of downstream kinases, such as AKT 
and IKKβ (Thompson et al. 2009; Khoshnan et al. 2009; Atwal et al. 2011; Khoshnan & 
Patterson 2011), and the activity within signalling pathways has been investigated in 
the context of mHTT (Liu et al. 1997; Song et al. 2002; Ginés et al. 2003; Humbert 
2003; Apostol et al. 2006; Kong et al. 2009; Liévens et al. 2008; Atwal et al. 2011). 
However, the effect of entire signalling transduction cascades, as elicited by growth 
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factor stimulation, on HTT localisation and phosphorylation has not been previously 
investigated. We demonstrate that stimulation with different growth factors leads to 
differential effects on the localisation of HTT. This suggests that HTT is a general 
downstream target of several kinase signalling pathways, which may regulate HTT 
localisation or conformation, and therefore its function. The differential effects of 
growth factor stimulation on the localisation of HTT may therefore implicate HTT as a 
regulatory mechanism by which cellular responses to diverse stimuli are modulated. 
Transcriptional regulation can be stimulated by growth factor activation of kinase 
signalling pathways (Lin et al. 2001; Apostol et al. 2006; Cabodi et al. 2009; Kong et al. 
2009; Ro et al. 2010), and HTT localisation has been proposed to be a mechanism for 
transcriptional regulation (Zoghbi & Orr 2000; Bauer & Nukina 2009). Therefore, the 
ability for kinase signalling pathways to modulate HTT localisation may be a 
mechanism by which transcription is controlled. All three growth factors were less able 
to modify the apparent localisation of mHTT in StHdhQ111/111 cells, suggesting that the 
expanded polyQ interferes with this process. However, the point in the pathway at 
which this may occur remains to be elucidated; the expanded polyQ may render mHTT 
less able to translocate or alter its conformation in response to kinase signalling, or 
mHTT may be aberrantly modulating signalling mechanisms upstream of 
transcriptional regulation. This may have implications for considering the mechanisms 
of mHTT mislocalisation; increased nuclear accumulation of mHTT is predominantly 
considered to be a result of increased cleavage and aberrant protein-protein 
associations (Bessert et al. 1995; Xia 2003; Truant et al. 2007; Desmond et al. 2013). 
However, if HTT is a regulatory target of signal transduction pathways, then 
mislocalisation of mHTT could also be a result of altered kinase signalling.  
Differential cellular responses to growth factor stimulation in the context of mHTT also 
have implications for the consideration of therapeutic treatments. For example, BDNF 
replacement may have limited therapeutic benefit if cells are unable to appropriately 
respond to stimulation, and transcriptional dysregulation may persist due to continued 
mislocalisation of mHTT. Therefore, targets downstream of the growth factor receptor 
that directly modulate HTT localisation may be a more effective target, although these 
targets are yet to be identified. 
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7.4 Limitations of kinase signalling experiments 
We observed dysregulation in several kinase signalling pathways in StHdhQ111/111 cells, 
which is consistent with altered signalling modulating HTT localisation. However, the 
interpretation of some of the targets was limited by variability in their baseline 
activation. It was therefore difficult to determine the effect of mHTT on several 
kinases, and whether these differences were due to true variability of these pathways 
within this cell line, or were due to technical variation and error. This could be clarified 
by replicating these experiments and increasing statistical power. Non-specific binding 
of the antibodies utilised in the ELISA kits can also not be ruled out. 
An additional limitation of the kinase signalling experiments was the use of only one 
method to assess kinase phosphorylation; ELISA assays are useful for the relative 
quantification of targets within cell populations, however the nature of the assay 
requires removal of the target away from the cellular context. Therefore investigation 
of the localisation of phosphorylated kinase targets would be of use to further 
characterise kinase signalling pathways that may be aberrantly controlled in mHTT 
carrying cells. Our experiment was also limited by only investigating a single time point 
of stimulation prior to collecting cell lysates. As discussed in Chapter 4, this may have 
influenced the observable alterations in kinase phosphorylation in response to each 
growth factor. Although these experiments have indicated which pathways may be 
altered in response to mHTT, they do not clarify how, or at which point in the pathway 
this disruption may occur. Manipulation of several points within a cascade would be 
required to elucidate where mHTT is exerting its effects. 
 
7.5 Dysregulation of kinase signalling pathways 
We demonstrate that in concordance with our HTT localisation data, there are several 
dysregulated kinase signalling pathways in StHdhQ111/111 cells; the nature of which is 
consistent with previous characterisation studies of signalling pathways in HD models 
(Ginés et al. 2003; Kong et al. 2009; Molero et al. 2009; Ginés et al. 2010; Atwal et al. 
2011; Saavedra et al. 2011; Ritch et al. 2012). EGF stimulation elicited the greatest 
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response in the investigated targets, however as the majority of these targets are 
shared between growth factor-induced pathways, the mechanism behind this is 
unclear. It may be a result of the single time point that was investigated; one 
mechanism for differentiating the effects of cellular inputs to similar pathways is by 
altering signalling kinetics (Ji et al. 2010), and therefore we may have looked at the 
time scale most appropriate for EGF signalling. Otherwise, NGF and BDNF stimulation 
may primarily act upon alternate signalling pathways in these cells that were not 
included in these experiments. As NGF and BDNF stimulation elicited a response in the 
apparent localisation of HTT, it is unlikely that the reduced effect observed in these 
signalling pathways is a result of suppressed receptor activation. 
Although the nature of the interference caused by mHTT in these pathways cannot be 
elucidated from these findings, the alteration in both HTT localisation and the 
transcription of IE genes upon AKT1 and MEK1/2 inhibition supports our previous 
assertion that HTT localisation may be regulated by signal transduction pathways, and 
that this is turn may regulate transcription. The nature of this mechanism is likely to be 
complex; the inhibition of both AKT1 and MEK1/2 exerted similar effects on the 
localisation of HTT, suggesting that HTT may be a downstream component of several 
pathways, the synergism of which is required to regulate HTT function. Therefore an 
effective target for therapeutic intervention may be the restoration of the essential 
balance of pro- and anti-apoptotic mechanisms. For example, we identify enhanced 
AKT activation in StHdhQ111/111 cells, which is concordant with the literature (Ginés et 
al. 2003; Kong et al. 2009; Atwal et al. 2011), and is considered to be a compensatory 
response and neuroprotective mechanism (Owada et al. 1997; Noshita et al. 2001; 
Chong et al. 2005). However, by inhibiting AKT1, the localisation of mHTT became less 
nuclear, and the overexpression of IE genes was suppressed. This suggests that despite 
being a neuroprotective anti-apoptotic pathway, the counter-intuitive inhibition of a 
hyper-activated AKT pathway may prove to be beneficial by restoring normal HTT 
localisation and IE gene expression by the re-balancing of pro- and anti-apoptotic 
pathways. As MEK inhibition elicited similar effects, and two pro-apoptotic pathways; 
P38 MAPK and STAT3, were also identified as being hyperphosphorylated in 
StHdhQ111/111 cells, the use of a single kinase as a therapeutic target may prove to be 
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insufficient. Suppressing AKT alone may prove to have beneficial effects, however it 
may ultimately enhance mHTT toxicity by failing to counter pro-apoptotic mechanisms. 
Therefore, a multi-target approach to restore the balance of compensatory and 
synergistic signal transduction mechanisms may be an efficacious therapeutic 
approach. 
Although AKT has been implicated in the phosphorylation of HTT on S13 and S16 
(Thompson et al. 2009), we do not observe any loss of phosphorylation on these 
serines following AKT1 inhibition, and the nuclear localisation of these epitopes 
increased, which is consistent with enhanced phosphorylation. The same effect 
occurred following MEK1/2 inhibition, suggesting that similar to the regulation of HTT 
localisation, the regulation of HTT phosphorylation is likely to be downstream of 
multiple kinases. The phosphorylation of HTT on these serines and consequent nuclear 
translocation is considered to be neuroprotective by enhancing degradation and 
clearance (Thompson et al. 2009), which may be occurring following AKT and MEK 
inhibition. Interestingly, StHdhQ7/7 and StHdhQ111/111 cells exhibit differential responses 
to AKT1 and MEK1/2 inhibition; this may reflect an aberrant association between 
mechanisms regulating mHTT localisation with upstream kinase signalling pathways; 
however these mechanisms are yet to be determined.  
 
7.6 Limitations of differential gene expression experiments 
When considering the microarray data, the effect of NGF and EGF stimulation on gene 
expression was minimal in comparison to the genotype effect; the large genotype 
differences may have masked smaller, but potentially significant growth factor effects. 
In some cases, qRTPCR was not sensitive enough to validate the small expression 
changes of some genes following stimulation. As alterations in expression patterns for 
some genes could not be confirmed, the extent of the effect of growth factor 
stimulation could not be fully verified. Replication of these experiments with increased 
statistical power by increasing the n may allow for verification of small changes in 
expression by qRTPCR, or may definitively rule out the significance of genes that were 
detected by chance in the microarray. There were also extensive differences between 
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the baseline findings for the separate microarray experiments; this variation may have 
been a result of the large period of time between experiments, which may have 
resulted in batch effects, variation in RNA manipulations, or may be an effect of the 
different microarray chips that were used. It may have been advantageous to carry out 
these experiments in parallel to reduce extraneous variation, although this was not 
possible at the time. However, despite the variation, similar GO pathways were 
identified between experiments, indicating a degree of concordance for both NGF and 
EGF microarray experiments. 
Despite potential alterations in SMAD proteins being identified from the EGF 
microarray experiment, the investigation of SMAD activity required stimulation with 
TGFβ to elicit phosphorylation. It could be expected that as potentially aberrant TGFβ 
pathway activity was highlighted following stimulation with EGF, then alterations in 
the downstream SMADs would also be identified following EGF stimulation, as these 
pathways can work synergistically (Jin et al. 2011; Kang et al. 2012). Baseline 
dysregulation of the TGFβ pathway in StHdhQ111/111 cells may therefore have 
contributed to the alterations in gene expression observed following EGF stimulation; 
therefore EGF stimulation may be modulated by TGFβ activity, but did not activate the 
TGFβ pathway itself, and would therefore not enhance SMAD activity.  
 
7.7 Differential gene expression 
The differential effects of NGF and EGF stimulation on gene expression are consistent 
with the differential kinase signalling responses previously observed, and may reflect 
the diverse functions of these growth factors. Despite the dissimilar effects of NGF and 
EGF stimulation on gene expression in these cells, the transcriptional response was 
altered by mHTT for both growth factors. This suggests that mHTT interference is not 
specific to a particular pathway, but the nature of this interference remains unclear; 
however, influencing chromatin modification is the mechanism by which the broadest 
alterations to transcriptional regulation may occur. As HTT is a large and 
multifunctional protein, it is likely that several mechanisms contribute to 
transcriptional dysregulation following growth factor stimulation.  
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These findings have implications for the consideration of gene expression changes in 
models of HD; we demonstrate that by investigating the minority of upregulated 
genes, alternative, novel mechanisms for transcriptional dysregulation in HD may be 
identified, such as the TGFβ pathway and SMAD transcription factors. The genes that 
we identify as being differentially expressed in StHdhQ111/111 cells have more putative 
TF binding sites in common than the genes identified in StHdhQ7/7 cells; the increased 
responsiveness of these genes may therefore be due to compensatory responses. If 
the binding of some regulatory TFs is inhibited by mHTT, there is increased availability 
for binding by alternative TFs in the gene promoter region, which when not 
appropriately regulated, may lead to increased reactivity to transcriptional stimulation. 
As the genes associated with StHdhQ7/7 cells had two TFs in common, Egrf and Sp1, 
which also had putative binding sites on the genes associated with StHdhQ111/111 cells, 
these may be key TFs downstream of EGF signalling that had increased availability in 
StHdhQ111/111 cells. Increased TF binding is inconsistent with the majority of the 
literature, where TFs are proposed to be sequestered by mHTT (Kazantsev et al. 1999; 
Steffan et al. 2000; Nucifora et al. 2001), or their binding is inhibited (Shimohata et al. 
2000; Dunah et al. 2002; Li et al. 2002). However, our results suggest that altered 
transcriptional dysregulation in HD may not be as simple as a loss of TF function, but is 
more likely to be dysfunction of the regulatory mechanisms resulting from a 
combination of loss- and gain-of-function events. These events may be reflective of the 
loss of balance and coordination between signal transduction pathways.  
There is currently limited and mixed evidence for the role of the TGFβ pathway in HD 
(Kandasamy et al. 2010; Battaglia et al. 2011; An et al. 2012), and to date there is no 
data regarding SMAD activity in the context of HD, or any potential associations with 
HTT. Therefore, our demonstration of SMAD expression and activation in this model 
implicates a novel pathway in the pathogenesis of HD. The TGFβ pathway is associated 
with immune reactivity and inflammation (Kandasamy et al. 2011), and these 
processes tend to be enhanced in mouse models and human HD (Dalrymple et al. 
2007; Bjorkqvist et al. 2008; Hsiao et al. 2013), thus implicating a potential role for 
TGFβ in the development of HD phenotypes. TGFβ signalling plays a role within 
multiple cell types (Hata et al. 1998), and it would therefore be of interest to 
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investigate whether peripheral TGFβ and SMAD activation correlated with striatal 
dysfunction. If there was an association, these novel targets may be useful biomarkers 
for the development of HD pathology. In addition, the identification of additional 
pathways that may contribute to the HD phenotype also provides the potential for the 
development of new therapeutic targets.  
 
7.8 Limitations of cell models 
One of the main limitations of this project is the use of an immortalised cell model of 
HD to unearth potentially aberrant mechanisms that may play a role in the human 
disease. Although this model was derived from the knock-in HdhQ111 mouse model, 
which is genetically similar to human HD, the immortalisation process elicits 
substantial modifications to these cells that may confer additional phenotypes to these 
cell lines that are not present in other models of HD. However, the StHdhQ111 cell line 
remains a useful and informative model, as previously its transcriptional profile has 
been found to be similar to that in mouse models and human HD caudate (Lee et al. 
2007), and many of the signalling mechanisms identified in these cells have also been 
replicated in other models (Ginés et al. 2003; Kong et al. 2009; Molero et al. 2009; 
Ginés et al. 2010; Atwal et al. 2011; Saavedra et al. 2011; Ritch et al. 2012). This 
provides evidence that the transformation of these cells has not had a substantial 
effect so as to distance their molecular phenotype too far from mouse models and 
human HD. This cell line can also be grown at the non-permissive temperature of 39˚C, 
where the immortalising virus becomes inactive, and cell death can be assayed. 
However, this modification of the model was not appropriate for this project, as our 
focus was on the interference of mHTT within pre-pathogenic cellular processes rather 
than on modifications of its toxicity.  
In order to determine whether the effects we observed in StHdhQ111 cells were a result 
of the immortalisation process, we aimed to replicate key experiments in primary 
embryonic striatal cells from both the HdhQ111 and HdhQ150 mouse models of HD. 
However, neither mouse model fully recapitulates the human disease, so any findings 
from primary cell cultures from these models will still require validation in human 
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derived cell lines, and potentially human post-mortem HD caudate. By using striatal 
dissections from embryonic mouse brain, the developing neurons are removed from 
their cellular context, which may potentially alter their signalling and transcriptional 
phenotypes. However, for the purposes of recapitulating aberrant signalling pathways 
and transcriptional mechanisms from immortalised striatal StHdhQ111 cells, the 
isolation of striatal neurons was not inappropriate. Cortical-striatal co-cultures may be 
of interest for future research, as connectivity between these two regions plays a large 
role in the functioning of the striatum and in HD pathogenesis.  
One of the most restricting elements of the primary culture work was a lack of power; 
in order to gain sufficient numbers of each genotype for each experiment, a large 
cohort of mice was required. However, timed mating was restricted by factors such as 
colony size, and mating was not always successful. Therefore, many of the primary 
culture experiments carried out in this project were underpowered. It is therefore 
difficult to determine whether any differences that were observed between the mouse 
models and the immortalised cell model were due to model-specific effects (i.e. 
immortalisation or CAG repeat length), or were due to high variability in primary cells. 
The homozygous cells in the primary cultures tended to have less extreme phenotypes 
than StHdhQ111/111 cells; this is likely due to the effect of divergence and transformation 
in the immortalised cells over many passages. It is therefore possible that the 
differences between wild type cells and homozygous cells in primary cultures may 
become more apparent with differentiation and age.   
 
7.9 Replicating results in primary cell cultures 
We demonstrate that some of the signalling and transcriptional effects observed in 
StHdhQ111 cell lines following growth factor stimulation can be replicated in HdhQ111 
primary cell cultures. Although we were unable to replicate several of the gene 
expression and kinase signalling events, the lack of power and high variability in the 
data means that these targets may not be immediately ruled out. Similarities between 
the models have been observed previously (Fossale et al. 2002; Ginés et al. 2003; 
Carnemolla et al. 2009; Sinha et al. 2010), and therefore support the use of 
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immortalised cell lines as a more accessible model for investigating molecular 
mechanisms of HD. However, we demonstrate that there are substantial differences 
between HdhQ111 and HdhQ150 primary cell lines in terms of HTT localisation; 
interestingly, these differences are also apparent in wild type cells from baseline, 
which suggests that some of the variation in HTT localisation may be due to either 
differences in mouse background strain, or to technical variation rather than CAG 
repeat length. The housing of mouse models changed during the course of the project 
due to infection; HdhQ150 microdissections were carried out while mice were housed in 
the presence of the infection, and HdhQ111 dissections were carried out later after 
colonies were transferred to a barrier unit. The infection may therefore have had 
implications for embryonic development or the establishment of dissections into 
culture. However, despite baseline differences, there is a differential effect of EGF 
stimulation between genotypes in both mouse models, suggesting that mHTT 
mislocalisation, and therefore dysregulation of HTT-associated functions, is a pre-
pathogenic phenotype that is present from embryonic development. Nonetheless, this 
experiment will need to be replicated for both mouse models under similar conditions 
in order to determine the most likely source of variation between models. 
When considering the gene expression data, HdhQ150 cells exhibit a trend towards 
some similar transcriptional differences to the HdhQ111 and StHdhQ111 models. 
However, there are also some variations in the pattern of gene expression changes 
following growth factor stimulation, such as for Fosl1. This may be an effect of the 
longer polyQ on the regulation of gene expression; different polyQ lengths may exert 
differential effects on the expression of some genes, and may therefore influence the 
point at which compensatory activity is overcome by pathogenic processes. The 
similarities that do exist between both models suggest that there is still a degree of 
reproducibility of the effect of mHTT during embryonic development, regardless of 
CAG repeat length. 
Our findings have implications for the comparison of the developmental trajectories of 
mouse models of HD; knock-in models with longer CAG repeat lengths develop motor 
abnormalities and neuropathological features earlier than those with shorter repeat 
lengths (Heng et al. 2007; Woodman et al. 2007; Heng et al. 2010). These alterations in 
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pathogenic development may not be due exclusively to hastened and more severe 
pathology as a result of a longer polyQ, but may also be due to differential 
transcriptional events during embryogenesis and development that may alter the 
pathogenic trajectory. Mouse models of HD have similar transcriptional profiles by the 
late stages of disease development (Kuhn et al. 2007), which suggests that the 
endpoint of mHTT disruption is the same regardless of CAG length and genetic context. 
However, if the developmental pathogenesis differs with CAG length, this may have 
implications for early therapeutic interventions that target transcriptional 
dysregulation, as different targets may be more appropriate for different CAG repeat 
lengths.  
 
7.10 Conclusion 
We created a dynamic cell model in order to investigate the signalling and 
transcriptional changes that may be present in the immortalised striatal cell model of 
HD, but which may be too subtle to be identified in a static cell culture. The use of 
growth factor stimulation at levels much higher than would be found endogenously 
initiated a cellular response and exacerbated minor alterations between cell lines. 
These differences in responding may be not be apparent during disease development 
due to their subtlety, but may be part of a cumulative process of cellular dysfunction 
that ultimately contributes to disease progression. From this model, we have 
demonstrated that; 
 Cellular dysfunction is not solely a degenerative process in models of HD, but is 
a pre-pathogenic mechanism that is present during embryogenesis and may 
play a role in aberrant development;  
 This dysfunction includes mislocalisation of mHTT and phosphorylated mHTT, 
which may be a result of aberrant control of signal transduction pathways. In 
turn, the mislocalisation of mHTT epitopes may contribute to the 
transcriptional dysregulation observed in HD. Several pathogenic mechanisms 
are likely to contribute to these effects;   
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 The dysregulation of HTT localisation may be a result of aberrant kinase 
signalling pathways, which is a novel mechanism for transcriptional 
dysregulation in HD, and also implies that HTT could be a transcriptional 
regulator that is a downstream substrate of several major signalling pathways;  
 By focusing on a subset of genes with a larger transcriptional response in 
StHdhQ111/111 cells, we have implicated a novel pathway in the pathogenesis of 
HD; dysregulation of SMAD transcription factors may contribute to the 
transcriptional effects observed in HD, and involvement of this pathway may 
also account for some of the inflammatory and immune system HD 
phenotypes;  
 Much of this evidence could be replicated in HdhQ111 primary cell cultures, 
although a lack of power prevented clear conclusions from being drawn;  
 Alterations in gene expression phenotypes suggest that polyQ length may lead 
to differential gene expression effects, which may contribute to the speed and 
nature of phenotypic development.  
Although signalling pathways may therefore be efficient targets for therapeutic 
intervention, the nature of the complex network of pro- and anti-apoptotic pathways, 
including compensatory and pathogenic responses, means that the targeting of a 
single kinase may not be sufficient. The restoration of a balance between these 
pathways may be a more efficacious approach, and may involve counter-intuitive 
interventions, such the suppression of compensatory anti-apoptotic signalling 
pathways. However, the efficiency of these compensatory responses during 
development may be a mechanism that contributes to variability in the age of disease 
onset. TGFβ and the SMADs also have the potential to be new targets of interest, and 
may be useful therapeutic targets and possibly biomarkers. However, the nature of the 
association between HTT and this pathway has not yet been investigated. 
In the future, it would be of interest to determine whether the apparent changes in 
HTT localisation were due to the dynamic shuttling of HTT, or to alterations in its 
conformation, as this could not be ascertained in this project. Alternative C-terminal 
antibodies may be of use, and TR-FRET may be particularly informative. In addition, 
assaying additional post-translational modifications of HTT in response to growth 
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factor stimulation, such as alternate phosphorylation sites, SUMOylation and 
ubiquitination, would further characterise this model.  
The validation of these results in additional models would also be of interest; it is 
important to see if replication of these results occurs in human-derived cell lines, such 
as patient HD fibroblasts and iPSCs, as these more closely mimic the human disease. 
Studying these changes directly in animal models without exogenous stimulation may 
be limiting, as alterations in signalling pathways may be too small to detect in the early 
stages of development; however a longitudinal study to investigate their progression 
may be of use. In human patients, investigation would be limited to peripheral or post-
mortem tissue. However, if any subtle changes in kinase activation can be detected 
peripherally, these may become useful biomarkers to track disease progression and 
therapeutic efficiency.  
The involvement of the TGFβ pathway and SMAD TFs in HD requires characterisation, 
as little work has currently been done concerning their role in HD pathogenesis. As TFs, 
the SMADs may interact directly with HTT; an association that may be altered by the 
presence of an expanded polyQ in order to disrupt transcriptional regulation. 
Alternatively, TGFβ signalling may also alter the localisation of HTT in the same manner 
as EGF, NGF and BDNF signalling, and mislocalisation of mHTT may be responsible for 
the altered activity of SMAD TFs.  
In conclusion; 
 We have identified a potential mechanism for transcriptional dysregulation in 
models of HD that stems from aberrant cellular responses to stimulation, and 
we have implicated a novel signalling pathway in the pathogenesis of HD.  
 Cellular dysfunction is present from embryogenesis, and therefore confers a 
developmental aspect in the consideration of HD progression, which may have 
implications for the development of therapeutic interventions and the 
development of biomarkers.  
 Although the mechanisms behind these findings require further elucidation and 
validation in additional models of HD, they contribute to our understanding of 
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HD molecular pathogenesis, and provide a new perspective from which to 
consider mechanisms of transcriptional dysregulation in HD.     
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Appendices 
 
Appendix I - StHdh
Q111
 cell lines immunostained with Ab109115 following EGF 
  stimulation 
 
Consistent with Ab675 (Section 3.3.3.3), there was a significant effect of both time (F 
(3,856) = 6.08, p<0.001) and cell type (F (2, 856) = 132.21, p<0.001) in the N/C ratio, as 
well as a significant interaction between the two (F (6, 856) = 3.81, p=0.001) when cells 
were stained with Ab109115 following EGF stimulation (Figures AI.1 & AI.2). This was 
also the case for both the N/P and P/C ratios (p<0.05 in all cases). Similar to the 
observations with Ab675 following EGF stimulation, there was also a reduction in 
nuclear HTT using this antibody in both StHdh
Q7/7 
and StHdh
Q7/111 
cells, although this 
was significant after 15 minutes of stimulation rather than 5, and was only apparent in 
the N/P ratio rather than the N/C ratio (StHdh
Q7/7 
p=0.04, StHdh
Q7/111 
p=0.018). This 
may be because this antibody detects an epitope of HTT that is more perinuclear than 
the epitope detected by Ab675. Although there is no significant reduction in nuclear 
mHTT in StHdh
Q111/111 
cells, there is a trend towards it. However, the high variability 
suggests that the nuclear reduction of the N-terminal epitope of mHTT in response to 
growth factor stimulation is impaired due to the expanded polyQ. Although there was a 
significant effect of both cell type and time in the P/C ratio, further investigation 
revealed that there were no individual significant differences in any of the cell lines at 
any time point. Simple main effects analyses indicated that this difference is due to 
StHdh
Q111/111 
cells having significantly higher P/C ratios than StHdh
Q7/7 
cells (p=0.006), 
while the StHdh
Q7/111
 cells lie between the two other genotypes, which is the same 
pattern of localisation seen with other N-terminal HTT antibodies. 
 
 
 
425 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
5
 m
in
u
te
s 
0
 m
in
u
te
s 
1
5
 m
in
u
te
s 
3
0
 m
in
u
te
s 
St
H
d
h
Q
7
/7
 
St
H
d
h
Q
7
/1
11
 
St
H
d
h
Q
1
11
/1
1
1
 
Fi
gu
re
 A
I.
1
 S
u
b
ce
llu
la
r 
lo
ca
lis
at
io
n
 o
f 
an
 N
-t
er
m
in
al
 e
p
it
o
p
e 
o
f 
H
TT
 a
n
d
 m
H
TT
 i
n
 S
tH
d
h
Q
7
/7
, 
St
H
d
h
Q
7
/1
1
1
 a
n
d
 S
tH
d
h
Q
1
1
1
/1
1
1
 c
el
l 
lin
es
. 
C
el
ls
 w
er
e 
fi
xe
d
 f
o
llo
w
in
g 
0
, 
5
, 
1
5
 a
n
d
 3
0
 m
in
u
te
s 
o
f 
st
im
u
la
ti
o
n
 w
it
h
 1
0
0n
g/
m
l 
EG
F,
 l
ab
el
le
d
 w
it
h
 A
b
1
0
91
1
5
 a
ga
in
st
 a
m
in
o
 a
ci
d
s 
1
-3
0
 o
f 
H
TT
, 
th
en
 
an
al
ys
ed
 b
y 
co
n
fo
ca
l m
ic
ro
sc
o
p
y 
(s
ee
 S
ec
ti
o
n
s 
2
.2
.1
.8
 a
n
d
 2
.2
.1
.9
 f
o
r 
fu
rt
h
er
 d
et
ai
ls
).
 S
ca
le
 b
ar
 =
 2
0
µ
m
 
426 
 
 
 
 
 
 
 
 
N
/C
 p
ix
el
 in
te
n
si
ty
 r
at
io
 
StHdh
Q7/7
 StHdh
Q7/111
 StHdh
Q111/111
 
#
#
 
N
/P
 p
ix
el
 in
te
n
si
ty
 r
at
io
 
# 
* 
* 
# 
P/
C
 p
ix
el
 in
te
n
si
ty
 r
at
io
 
Figure AI.2 Quantitative analysis of immunofluorescence images in Figure AI.1. 
Nuclear/Cytoplasmic (N/C),  Nuclear/Perinuclear (N/P) and Perinuclear/Cytoplasmic 
(P/C) mean pixel intensity ratios for StHdh
Q7/7
, StHdh
Q7/111
 and StHdh
Q111/111 
cells 
following 0, 5, 15 and 30 minutes of stimulation with 100ng/ml EGF. Mean pixel 
intensities were calculated from confocal microscopy images using GNU Image 
Manipulator (further details of the analysis can be found in Section 2.2.1.10). All 
images were randomised and analysed blind to genotype and length of time 
stimulated with EGF. Each condition consisted of 9 confocal microscopy images 
taken from 3 separate coverslips. A 3x2 ANOVA was carried out for main effects 
analysis, followed by planned one way ANOVAs and post-hoc Tukey tests.  Error bars 
= SEM. 
* Denotes a significant difference from 0mins 
# Denotes a significant difference from 5mins 
* p<0.05  ** p<0.01  *** p<0.001 
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Appendix II -  StHdh
Q111
 cell lines immunostained with N17 following EGF  
  stimulation, and a replicate   of Ab675 immunostaining carried out in 
  parallel 
 
The N17 antibody was a kind gift from Ray Truant (McMaster University, Canada). It is a 
rabbit polyclonal antibody against the first 17 amino acids of the HTT protein, and 
would therefore be expected to yield similar results to Ab675 and Ab109115. 
Quantitative image analysis was not carried out with this antibody, as we did not have 
enough of it to carry out a sufficient number of replicates. However, it was still used to 
determine if it gave qualitatively comparable results. In comparison to the other N-
terminal antibodies that were used here, N17 detects mostly nuclear HTT in all three 
genotypes (Figure AII.1). There is a slight increase in the amount of perinuclear HTT 
detected in StHdh
Q111/111 
cells as compared to StHdh
Q7/111 
and StHdh
Q7/7 
cells, but 
otherwise there is no qualitative difference. In addition, there is no observable effect of 
EGF stimulation for any of the genotypes. Additional coverslips from the same 
experiment were probed with Ab675 to determine if the effect of EGF was replicated, 
and there was reduced detection of this epitope of HTT in the nucleus by 15 minutes of 
stimulation in the StHdh
Q7/7 
cells, a small effect in the StHdh
Q7/111 
cells, and no 
observable difference in StHdh
Q111/111 
cells (Figure AII.2). This is similar to previous 
findings with the same antibody, Mab2166 and Ab109115 (Sections 3.3.3.3, 3.3.4.3 & 
3.3.5). The lack of a visible effect when using N17 may therefore reflect the detection 
of a different epitope of HTT that either does not relocalise following EGF stimulation, 
or can be detected regardless of any changes in protein conformation. As the detection 
of this antibody was reduced in all three genotypes following Htt siRNA treatment 
(Section 3.3.2.3), the lack of response to EGF treatment is unlikely to be due to binding 
of N17 to non-specific targets.  
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Appendix III - Subcellular fractionation following stimulation with NGF and EGF  
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Figure AIII.1 A. Western blots of cytoplasmic fractions of StHdh
Q7/7
, StHdh
Q7/111 
and 
StHdh
Q111/111
 cells  stimulated with 100ng/ml NGF for 0, 5, 15 and 30 minutes before 
cell lysis and subcellular fractionation (see Section 2.2.2.3 for more details), and a 
whole cell lysate control (W). Blots were probed with Mab2166, stripped and re-
probed with Ab109115, followed by MW1. Fractions were normalised to  α-tubulin 
loading control, and purity of the fraction was assessed by the presence of 
cytoplasmic marker MEK and lack of the nuclear marker Lamin A/C. B. Licor Odyssey 
quantification of fluorescence intensities (FI) in A normalised to the loading control, 
and expressed as a percentage of 0 mins NGF stimulation (%0). Percentages were 
analysed by genotype individually by a one way ANOVA due to differences in band 
intensity between cell types, followed by post-hoc Tukey tests. (Error bars = SEM, 
n=3). 
B 
A 
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Figure AIII.2 A. Western blots of nuclear fractions of StHdh
Q7/7
, StHdh
Q7/111 
and 
StHdh
Q111/111
 cells  stimulated with 100ng/ml NGF for 0, 5, 15 and 30 minutes 
before cell lysis and subcellular fractionation (see Section 2.2.2.3 for more details), 
and a whole cell lysate control (W). Blots were probed with Mab2166, stripped and 
re-probed with Ab109115, followed by MW1. Fractions were normalised to α-
tubulin loading control, and purity of the fraction was assessed by the presence of 
nuclear marker Lamin A/C and lack of the cytoplasmic marker MEK. B. Licor 
Odyssey quantification of fluorescence intensities (FI) in A normalised to the 
loading control, and expressed as a percentage of 0 mins NGF stimulation (%0). 
Percentages were analysed by genotype individually  by a one way ANOVA due to 
differences in band intensity  between cell types, followed by post-hoc Tukey tests 
(Error bars = SEM, n=3). 
B 
A 
432 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
StHdh 
Q7/7
 
StHdh
Q7/7
 
StHdh
Q7/111
 
StHdh
Q7/111
 
StHdh
Q7/111
 
StHdh 
Q111/111
 
StHdh 
Q111/111
 
StHdh 
Q111/111
 
Mab2166 Ab109115 MW1 
%
0
 
%
0
 
%
0
 
Figure AIII.3 A. Western blots of cytoplasmic fractions of StHdh
Q7/7
, StHdh
Q7/111 
and 
StHdh
Q111/111
 cells  stimulated with 100ng/ml EGF for 0, 5, 15 and 30 minutes 
before cell lysis and subcellular fractionation (see Section 2.2.2.3 for more details), 
and a whole cell lysate control (W). Blots were probed with Mab2166, stripped 
and re-probed with Ab109115, followed by MW1. Fractions were normalised to  α-
tubulin loading control, and purity of the fraction was assessed by the presence of 
cytoplasmic marker MEK and lack of the nuclear marker Lamin A/C. B. Licor 
Odyssey quantification of fluorescence intensities (FI) in A normalised to the 
loading control, and expressed as a percentage of 0 mins EGF stimulation (%0). 
Percentages were analysed by genotype individually by a one way ANOVA due to 
differences in band intensity between cell types, followed by post-hoc Tukey tests. 
(Error bars = SEM, n=3). 
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Figure AIII.4 A. Western blots of nuclear fractions of StHdh
Q7/7
, StHdh
Q7/111 
and 
StHdh
Q111/111
 cells  stimulated with 100ng/ml EGF for 0, 5, 15 and 30 minutes 
before cell lysis and subcellular fractionation (see Section 2.2.2.3 for more details), 
and a whole cell lysate control (W). Blots were probed with Mab2166, stripped 
and re-probed with Ab109115, followed by MW1. Fractions were normalised to α-
tubulin loading control, and purity of the fraction was assessed by the presence of 
nuclear marker Lamin A/C and lack of the cytoplasmic marker MEK. B. Licor 
Odyssey quantification of fluorescence intensities (FI) in A normalised to the 
loading control, and expressed as a percentage of 0 mins EGF stimulation (%0). 
Percentages were analysed by genotype individually  by a one way ANOVA due to 
differences in band intensity  between cell types, followed by post-hoc Tukey tests 
(Error bars = SEM, n=3). 
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Appendix IV - Examples of full western blots from the StHdh
Q111
 cell line 
 
Figure AIV.1 provides several examples of the full western blot membranes used in the 
StHdh
Q111
 cell line fractionation experiments (Chapter 3). The blots indicate that in 
these cells, only full length HTT was detected by both Ab109115 and Mab2166, thus 
making the presence of smaller N-terminal fragments in these cells difficult to 
ascertain.  
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Appendix V -  Hdh
Q111
 primary embryonic striatal cell lines immunostained with 
  Ab675 following EGF stimulation 
 
Consistent with previous observations when using Ab675 (Sections 3.3.3.3 & 6.2.3), 
HTT localisation is more nuclear than when it is detected with either Ab109115 or 
Mab2166. When looking at Ab675, there is a reduction in nuclear HTT following 5 
minutes of EGF stimulation in embryonic striatal cells from all three genotypes from 
the Hdh
Q111
 model, although this only persists to 15 minutes in Hdh
Q7/7 
cells (Figure 
AV.1). This is a similar pattern of response to EGF stimulation as was observed in 
StHdh
Q111 
cell lines (Section 3.3.3.3), and also suggests a reduced response to growth 
factor stimulation in mHTT cells. However, there are no apparent differences in the 
nuclear localisation of HTT at baseline.  
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Appendix VI -  Hdh
Q150
 primary embryonic striatal cell lines immunostained with 
  Ab675 following EGF stimulation 
 
Hdh
Q150
 primary cells exhibited an increased nuclear localisation of the HTT epitope 
detected by Ab675 with increasing mHTT gene dosage (Figure AVI.1). There was a slight 
reduction in nuclear HTT from 5 minutes following EGF stimulation in Hdh
Q7/7 
cells, but 
there was no apparent effect in Hdh
Q7/150 
or Hdh
Q150/150 
cells until a slight reduction in 
nuclear localisation of this epitope at 30 minutes of EGF stimulation. 
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Appendix VII - qRTPCR gene expression data for Hdh
Q111
 cell lines following EGF  
  stimulation  
 
Full expression data for a panel of genes in Hdh
Q111
 cells that were previously identified 
in StHdh
Q111
 cell lines (Chapter 5) as having either a larger fold change in StHdh
Q7/7
 cells 
(Figure AVII.1), or a larger fold change in StHdh
Q111/111
 cells (Figure AVII.2) , as well as 
genes that showed a significant response in  StHdh
Q111/111
 cells only (Figure AVII.3) 
following 2 hours 100ng/ml EGF stimulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure AVII.1 Relative Quantification (RQ) values representing the fold change in 
gene expression for four genes in Hdh
Q7/7
, Hdh
Q7/111
 and Hdh
Q111/111 
primary 
embryonic striatal cells at 0 and 2 hours stimulation with 100ng/ml EGF. The genes 
had been previously identified in Chapter 5 as having a larger change in expression 
following EGF stimulation in StHdh
Q7/7
 cells than in StHdh
Q111/111 
cells. Delta cycle 
threshold (ΔCt) values were analysed by 3x2 ANOVA and post-hoc Tukey tests. (Error 
bars = SEM, n=5) 
*p<0.05 **p<0.01 ***p<0.001  
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Figure AVII.2 Relative Quantification (RQ) values representing the fold change in 
gene expression for four genes in Hdh
Q7/7
, Hdh
Q7/111
 and Hdh
Q111/111 
primary 
embryonic striatal cells at 0 and 2 hours stimulation with 100ng/ml EGF. The genes 
had been previously identified in Chapter 5 as having a larger change in expression 
following EGF stimulation in StHdh
Q111/111
 cells than in StHdh
Q7/7 
cells. Delta cycle 
threshold (ΔCt) values were analysed by 3x2 ANOVA and post-hoc Tukey tests. (Error 
bars = SEM, n=5) 
*p<0.05 **p<0.01 ***p<0.001  
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Figure AVII.3 Relative Quantification (RQ) values representing the fold change in 
gene expression for three genes in Hdh
Q7/7
, Hdh
Q7/111
 and Hdh
Q111/111 
primary 
embryonic striatal cells at 0 and 2 hours stimulation with 100ng/ml EGF. The genes 
had been previously identified in Chapter 5 as having a change in expression 
following EGF stimulation in StHdh
Q111/111
 cells only. Delta cycle threshold (ΔCt) 
values were analysed by 3x2 ANOVA and post-hoc Tukey tests. (Error bars = SEM, 
n=5) 
*p<0.05 **p<0.01 ***p<0.001  
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Appendix VIII-  qRTPCR gene expression data for Hdh
Q150
 cell lines following EGF 
  stimulation  
 
Full expression data for a panel of genes in Hdh
Q150
 cells that were previously identified 
in StHdh
Q111
 cell lines (Chapter 5) as having either a larger fold change in StHdh
Q7/7
 cells 
(Figure AVIII.1),  or a larger fold change in StHdh
Q111/111
 cells (Figure AVIII.2) , as well as 
genes that showed a significant response in  StHdh
Q111/111
 cells only (Figure AVIII.3) 
following 2 hours 100ng/ml EGF stimulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure AVIII.1 Relative Quantification (RQ) values representing the fold change in 
gene expression for four genes in Hdh
Q7/7
, Hdh
Q7/150
 and Hdh
Q150/150 
primary 
embryonic striatal cells at 0 and 2 hours stimulation with 100ng/ml EGF. The genes 
had been previously identified in Chapter 5 as having a larger change in expression 
following EGF stimulation in StHdh
Q7/7
 cells than in StHdh
Q111/111 
cells. Delta cycle 
threshold (ΔCt) values were analysed by 3x2 ANOVA and post-hoc Tukey tests. (Error 
bars = SEM, n=5) 
*p<0.05 **p<0.01 ***p<0.001  
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Figure AVIII.2 Relative Quantification (RQ) values representing the fold change in 
gene expression for four genes in Hdh
Q7/7
, Hdh
Q7/150
 and Hdh
Q150/150 
primary 
embryonic striatal cells at 0 and 2 hours stimulation with 100ng/ml EGF. The genes 
had been previously identified in Chapter 5 as having a larger change in expression 
following EGF stimulation in StHdh
Q111/111
 cells than in StHdh
Q7/7 
cells. Delta cycle 
threshold (ΔCt) values were analysed by 3x2 ANOVA and post-hoc Tukey tests. (Error 
bars = SEM, n=5) 
*p<0.05 **p<0.01 ***p<0.001  
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Figure AVIII.3 Relative Quantification (RQ) values representing the fold change in 
gene expression for three genes in Hdh
Q7/7
, Hdh
Q7/150
 and Hdh
Q150/150 
primary 
embryonic striatal cells at 0 and 2 hours stimulation with 100ng/ml EGF. The genes 
had been previously identified in Chapter 5 as having a change in expression 
following EGF stimulation in StHdh
Q111/111
 cells only. Delta cycle threshold (ΔCt) 
values were analysed by 3x2 ANOVA and post-hoc Tukey tests. (Error bars = SEM, 
n=5) 
*p<0.05 **p<0.01 ***p<0.001  
